TO ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	1417

6. パーキンソン病

---

臨床試験数 : 2,307 /  薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05094011 (ClinicalTrials.gov)	March 1, 2023	20/7/2021	Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease	A Phase I Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Autologous MitoCell (Adipose-Derived Mesenchymal Stem Cells) Transplantation in Subjects With Idiopathic Parkinson's Disease	Idiopathic Parkinson's Disease	Biological: Aadipose-Derived Mesenchymal Stem Cells	Taiwan Mitochondrion Applied Technology Co., Ltd.	NULL	Not yet recruiting	45 Years	70 Years	All	9	Phase 1	NULL
2	NCT05766813 (ClinicalTrials.gov)	March 2023	24/2/2023	Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease	A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease	Parkinson Disease	Drug: Lenrispodun;Drug: Placebo	Intra-Cellular Therapies, Inc.	NULL	Recruiting	40 Years	80 Years	All	132	Phase 2	United States
3	NCT05611372 (ClinicalTrials.gov)	January 1, 2023	6/11/2022	Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease	Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease	REM Sleep Behavior Disorder;Parkinson Disease;Synucleinopathies	Drug: Rasagiline	Second Affiliated Hospital, School of Medicine, Zhejiang University	Beijing Tiantan Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Jiangsu Province Nanjing Brain Hospital;The First Affiliated Hospital of Anhui Medical University;Huashan Hospital;Second Affiliated Hospital of Soochow University;Guizhou Medical University;The First Affiliated Hospital of Guangzhou Medical University;West China Hospital;Sir Run Run Shaw Hospital;The Affiliated Hospital of Hangzhou Normal University;The First Affiliated Hospital of Dalian Medical University;Qilu Hospital of Shandong University;Fujian Medical University Union Hospital	Not yet recruiting	30 Years	75 Years	All	732	Phase 2/Phase 3	NULL
4	NCT05610189 (ClinicalTrials.gov)	December 15, 2022	2/11/2022	Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease	A Phase 1, Randomized, Multiple-dose, Crossover Trial in Participants With Parkinson's Disease to Evaluate the Clinical Bioequivalence Between Tavapadon Tablets	Parkinson Disease	Drug: Tavapadon	Cerevel Therapeutics, LLC	NULL	Recruiting	45 Years	80 Years	All	24	Phase 1	United States
5	EUCTR2021-004849-20-AT (EUCTR)	13/12/2022	05/08/2022	A Study to Assess the Safety of BIIB122 Tablets and if it can Slow the Worsening of Early-Stage Parkinson’s Disease in Participants Between the Ages of 30 and 80	A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BIIB122 Product Code: DNL151, DN0001575, DN1575 INN or Proposed INN: NA Other descriptive name: DNL151, DN0001575, DN1575	Biogen Idec Research Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	640	Phase 2	United States;Spain;Austria;Israel;Italy;United Kingdom;France;Canada;Poland;Netherlands;Germany;China;Japan
6	NCT05642442 (ClinicalTrials.gov)	December 1, 2022	30/11/2022	A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease	A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Severe Residual Tremor in Participants With Parkinson's Disease	Parkinson Disease;Tremor	Drug: Placebo;Drug: Suvecaltamide	Jazz Pharmaceuticals	NULL	Recruiting	40 Years	80 Years	All	160	Phase 2	United States
7	NCT05635409 (ClinicalTrials.gov)	November 30, 2022	15/11/2021	A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease	STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the Safety and Tolerability of Intraputamenal Transplantation of Human Embryonic Stem Cell Derived Dopaminergic Cells for Parkinson's Disease (STEM-PD Product)	Parkinson Disease	Biological: STEM-PD	Region Skane	Lund University;Cambridge University Hospitals NHS Foundation Trust;University of Cambridge	Recruiting	50 Years	75 Years	All	8	Phase 1	Sweden;United Kingdom
8	NCT05581823 (ClinicalTrials.gov)	October 19, 2022	12/10/2022	Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants	A Phase 1, Open-label, Fixed-sequence, Crossover Trial to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Induction by Carbamazepine on the Steady-state Pharmacokinetics of Tavapadon in Healthy Adult Participants	Parkinson Disease	Drug: Tavapadon;Drug: Carbamazepine	Cerevel Therapeutics, LLC	NULL	Active, not recruiting	18 Years	55 Years	All	16	Phase 1	United States
9	NCT05635461 (ClinicalTrials.gov)	October 9, 2022	7/11/2022	Relative Bioavailability and Food Effect Study of CVN424	A Randomized, Open-Label, Single Oral Dose, Three-Way Cross-Over Trial to Evaluate the Relative Bioavailability of CVN424 Suspension &Tablet Formulations Including an Assessment of the Effect of Food on the Tablet Formulation in Healthy Adult Volunteers	Parkinson Disease	Drug: CVN424	Cerevance Beta, Inc.	NULL	Completed	18 Years	55 Years	All	32	Phase 1	United States
10	NCT05603312 (ClinicalTrials.gov)	October 5, 2022	12/10/2022	A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants	A Randomized, Double-Blind, Sham-Controlled Study to Evaluate the Safety and Tolerability of Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Participants With Parkinson's Disease	Parkinson Disease	Genetic: AAV-GAD Dose 1;Genetic: AAV-GAD Dose 2;Procedure: Sham Surgery	MeiraGTx, LLC	NULL	Recruiting	25 Years	85 Years	All	14	Phase 1/Phase 2	United States
11	NCT05543252 (ClinicalTrials.gov)	August 29, 2022	13/9/2022	An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of UCB0599 in Study Participants With Parkinson's Disease	A Dose-Blinded Extension Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of UCB0599 in Study Participants With Parkinson's Disease	Parkinson's Disease	Drug: UCB0599	UCB Biopharma SRL	NULL	Enrolling by invitation	40 Years	78 Years	All	270	Phase 2	United States;France;Germany;Netherlands;Poland
12	NCT05418673 (ClinicalTrials.gov)	August 26, 2022	10/6/2022	A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants With Parkinson's Disease and Pathogenic LRRK2 Variants	Parkinson Disease	Drug: BIIB122;Drug: BIIB122-Matching Placebo	Biogen	Denali Therapeutics Inc.	Recruiting	30 Years	80 Years	All	400	Phase 3	United States;France;Spain
13	NCT05523570 (ClinicalTrials.gov)	August 22, 2022	24/8/2022	A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension	Phase 1, Non-randomized, Single Ascending Doses (SAD) Study Following Single Injection in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HNC364 Injectable Suspension	Parkinson's Disease	Drug: HNC364	Guangzhou Henovcom Bioscience Co. Ltd.	NULL	Recruiting	18 Years	45 Years	All	18	Phase 1	United States
14	NCT05357989 (ClinicalTrials.gov)	August 3, 2022	19/4/2022	A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD	A 6-month Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Efficacy, Safety, and Tolerability of Two Different Doses of Buntanetap or Placebo in Patients With Early Parkinson's Disease	Parkinson's Disease, Idiopathic	Drug: Buntanetap;Drug: Placebo	Annovis Bio Inc.	TFS Trial Form Support	Recruiting	40 Years	85 Years	All	450	Phase 3	United States;Germany;Hungary;Italy;Poland;Spain
15	NCT04147949 (ClinicalTrials.gov)	August 2022	27/10/2019	AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia	Randomized, Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Phase 2 Study to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia	Parkinson Disease;Dyskinesia, Medication-Induced;L-Dopa Causing Adverse Effects in Therapeutic Use	Drug: AV-101;Drug: Placebo	VistaGen Therapeutics, Inc.	NULL	Not yet recruiting	30 Years	80 Years	All	20	Phase 2	NULL
16	NCT05670782 (ClinicalTrials.gov)	July 19, 2022	21/12/2022	A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants With Parkinson's Disease	A Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KM-819 in Healthy Older Adults and Participants With Parkinson's Disease	Parkinson Disease	Drug: KM-819;Drug: Placebo	FAScinate Therapeutics Inc.	Parexel	Recruiting	40 Years	N/A	All	330	Phase 2	United States
17	NCT03903549 (ClinicalTrials.gov)	July 15, 2022	3/4/2019	Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers	A Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2)	Parkinson Disease	Drug: [18F]P17-059	Five Eleven Pharma, Inc.	NULL	Completed	45 Years	90 Years	All	4	Phase 1	United States
18	NCT05318937 (ClinicalTrials.gov)	July 6, 2022	1/4/2022	A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Parkinson's Disease Cognitive Impairment	Parkinson Disease;Cognitive Dysfunction	Drug: SAGE-718;Drug: SAGE-718-matching placebo	Sage Therapeutics	NULL	Recruiting	50 Years	75 Years	All	76	Phase 2	United States
19	JPRN-UMIN000047341	2022/07/01	31/03/2022	Randomized controlled trial of the efficacy and feasibility of a mHealth-type dance program for people with Parkinson's disease.	Randomized controlled trial of the efficacy and feasibility of a mHealth-type dance program for people with Parkinson's disease. - Randomized controlled trial of the efficacy and feasibility of a mHealth-type dance program for people with Parkinson's disease.	Parkinson's disease	The dance exercise group will have one online lesson per week with a coach, 60 minutes (see Appendix for details) and 30 minutes of video dance (movement review and lesson) as a home trainer to perform the exercises. The active control group was instructed to perform stretching, flexibility, and relaxation exercises (excluding strength, balance, aerobic, and functional training) three times a week for 30 minutes per session. These exercises were selected from several physical therapy programs created for persons with Parkinson's disease.	Department of Neurology, Fukuoka university	NULL	Pending	30years-old	75years-old	Male and Female	60	Not selected	Japan
20	NCT05344365 (ClinicalTrials.gov)	June 2022	18/4/2022	A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis	An Open-label, Sequential Cohorts, Flexible Dose Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Iloperidone in Elderly Patients With Parkinson's Disease Psychosis (PDP)	Parkinson Disease Psychosis	Drug: Iloperidone	Vanda Pharmaceuticals	NULL	Recruiting	65 Years	N/A	All	24	Phase 2	United States
21	NCT05348785 (ClinicalTrials.gov)	April 19, 2022	4/4/2022	A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80	A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease	Parkinson Disease	Drug: BIIB122;Drug: BIIB122-Matching Placebo	Biogen	Denali Therapeutics Inc.	Recruiting	30 Years	80 Years	All	640	Phase 2	United States;France;Germany;Netherlands;Poland;Spain
22	NCT05312632 (ClinicalTrials.gov)	April 5, 2022	28/3/2022	A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea	A Multi-center, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Patients With Motor Fluctuation in South Korea	Parkinson Disease	Drug: Safinamide Mesilate	Eisai Korea Inc.	NULL	Recruiting	19 Years	N/A	All	199	Phase 4	Korea, Republic of
23	JPRN-jRCTs052220012	01/04/2022	22/04/2022	A study of the short-term gait improvement effect using a biological signal reaction type motor function improvement device in patients withParkinson's disease.	A study of the short-term gait improvement effect using a biological signal reaction type motor function improvement device for gait instability in patients with Parkinson's disease. a randomized controlled trial	Parkinson's disease Parkinson's disease	The normal rehabilitation group and the HAL grou p are assigned 1: 1 and the normal rehabilitation g roup is subjected to normal walking training, and t he HAL group is subjected to walking training by H AL.	Kohara Nobuo	NULL	Recruiting	>= 20age old	Not applicable	Both	30	N/A	Japan
24	EUCTR2021-000041-40-NL (EUCTR)	22/02/2022	10/11/2021	A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action	A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action - Microdosing and Parkinson’s disease	Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Psilocybin INN or Proposed INN: Psilocybine Product Name: Ketamine INN or Proposed INN: KETAMINE	Maastricht University	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	34	Phase 2	Netherlands
25	NCT05287503 (ClinicalTrials.gov)	February 15, 2022	28/1/2022	Ambroxol as a Disease-modifying Treatment in GBA-PD	Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial	Parkinson Disease;GBA Gene Mutation	Drug: Ambroxol Hydrochloride;Drug: Placebo	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	University of Campania Luigi Vanvitelli;IRCCS National Neurological Institute C. Mondino Foundation	Recruiting	21 Years	80 Years	All	60	Phase 2	Italy
26	NCT05266417 (ClinicalTrials.gov)	February 7, 2022	23/2/2022	Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Insulin and Glutathione as an Add-On Therapy in Subjects With Parkinson's Disease (NOSE-PD)	Parkinson Disease	Drug: INS-GSH;Drug: Matched Placebos	Gateway Institute for Brain Research	NULL	Recruiting	30 Years	85 Years	All	56	Phase 2	United States
27	NCT05274568 (ClinicalTrials.gov)	January 31, 2022	1/2/2022	Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein	Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein by [18F]UCB-2897 in Participants With Parkinson's Disease or Multi-system Atrophy	Parkinson Disease;Multisystem Atrophy;Healthy Volunteer	Drug: [18F]UCB-2897	Invicro	NULL	Recruiting	18 Years	N/A	All	14	Phase 1	United States
28	EUCTR2021-005024-37-NL (EUCTR)	24/01/2022	19/01/2022	Evaluation of a novel PET tracer [18F]MC225 to measure the function of P-glycoprotein, a transporter at the blood brain barrier, in neurodegenerative disease	Evaluation of [18F]MC225 to measure P-glycoprotein function in neurodegenerative disease	- Alzheimer's disease - Mild Cognitive Impairment - Parkinson's disease;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]	Product Name: [18F]MC225 INN or Proposed INN: [18F]MC225 Other descriptive name: [18F]MC225	University Medical Center Groningen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	Netherlands
29	EUCTR2020-002754-24-DE (EUCTR)	19/01/2022	14/06/2021	Clinical study in early PD patients to investigate the effect of Opicapone 50mg or Levodopa 100 mg in the treatment of motor fluctuations.	A randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study to evaluate the add-on effect of opicapone 50 mg or levodopa 100 mg as first strategy for the treatment of wearing-off in patients with Parkinson’s Disease. - ADOPTION: eArly levoDopa with Opicapone in Parkinson’s paTients wIth motOr fluctuatioNs	Parkinson's Disease (PD) MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ongentys 50 mg hard capsules INN or Proposed INN: Ongentys 50 mg hard capsules Other descriptive name: OPICAPONE Trade Name: Madopar 125 mg T, tablets INN or Proposed INN: BENSERAZIDE HYDROCHLORIDE INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA Trade Name: SINEMET 100 mg + 25 mg tablets INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA INN or Proposed INN: CARBIDOPA Other descriptive name: CARBIDOPA	Bial - Portela & Ca, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 4	Portugal;Spain;Germany;United Kingdom;Italy
30	NCT05094050 (ClinicalTrials.gov)	January 18, 2022	20/10/2021	Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease	Parkinson's Disease: A Comparative Study of Levodopa and Carbidopa Bioavailability Following Foslevodopa/Foscarbidopa Infusion at Different Subcutaneous Sites in Parkinson's Disease Patients	Parkinson's Disease	Drug: ABBV-951	AbbVie	NULL	Active, not recruiting	30 Years	N/A	All	16	Phase 1	United States
31	NCT05083260 (ClinicalTrials.gov)	January 4, 2022	23/9/2021	NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa	A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's Disease (PD) Participants Treated With Carbidopa/Levodopa and NE3107	Parkinson Disease	Drug: NE3107;Drug: placebo	BioVie Inc.	NULL	Completed	30 Years	80 Years	All	46	Phase 1/Phase 2	United States
32	NCT04858074 (ClinicalTrials.gov)	January 3, 2022	7/4/2021	Study to Investigate the Effect of Hypoestes Rosea Powder in Parkinson's Disease	A Proof of Concept (POC) Study to Investigate the Effect of 100% Hypoestes Rosea Powder in Parkinson's Disease Using ActiGraph Wearable as a Quantitative Assessment Tool.	Parkinson Disease	Drug: Hypoestoxide	University of Ibadan	NULL	Enrolling by invitation	30 Years	85 Years	All	30	Phase 1/Phase 2	Nigeria
33	NCT04265209 (ClinicalTrials.gov)	December 1, 2021	6/2/2020	[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor	Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor.	Parkinson Disease;Essential Tremor	Drug: SPECT;Drug: PET	Zionexa	NULL	Recruiting	35 Years	80 Years	All	112	Phase 3	France
34	NCT04990284 (ClinicalTrials.gov)	November 29, 2021	27/7/2021	eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.	A Randomized, Parallel Group, Multicentre, Multinational, Prospective, Open-label Exploratory Study to Evaluate the add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease.	Parkinson Disease	Drug: Opicapone;Drug: L-DOPA/DDCI	Bial - Portela C S.A.	NULL	Recruiting	30 Years	N/A	All	100	Phase 4	Germany;Italy;Portugal;Spain;United Kingdom
35	EUCTR2019-004235-23-SE (EUCTR)	13/11/2021	24/08/2021	Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-951 in subjects with Parkinson's disease.	An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Foscarbidopa and Foslevodopa Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa-4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa-4'-Monophosphate	Abbvie Deutschland GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Denmark;Australia;Russian Federation;Germany;Netherlands;Italy;United Kingdom;Japan;Sweden
36	NCT04871464 (ClinicalTrials.gov)	November 11, 2021	29/4/2021	Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease	Role and Mechanism of Bifidobacterium Triple Viable Capsules in Improving Motor Symptoms in Patients With Mild to Moderate Parkinson's Disease: a Multicenter Randomized Clinical Study	Parkinson Disease;Parkinsonian Disorders;Basal Ganglia Diseases;Brain Diseases;Movement Disorders;Neurodegenerative Diseases;Central Nervous System Diseases;Nervous System Diseases	Drug: Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules;Other: Placebo	Beijing Friendship Hospital	NULL	Recruiting	40 Years	85 Years	All	240	Phase 4	China
37	NCT05297201 (ClinicalTrials.gov)	November 2, 2021	17/2/2022	Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia	Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A Inhibitor) in Patients With Parkinson's Disease Suffering From Levodopa Induced Dyskinesia	Parkinson Disease;Dyskinesia, Medication-Induced	Drug: CPL500036 - low dose;Drug: CPL500036 - high dose;Drug: Placebo	Celon Pharma SA	National Center for Research and Development, Poland	Recruiting	50 Years	80 Years	All	108	Phase 2	Poland
38	NCT04983290 (ClinicalTrials.gov)	November 1, 2021	9/6/2021	Outcomes to the Nutritional Need of Patients With Parkinson's Disease	Clinical Trial to Assess the Effectiveness of the Food Plan Consisting of Products With Modified Consistency Called (Weancare-Domus) in Changing the Quality of Life in Patients With Parkinson's Disease	Deglutition Disorders;Parkinson Disease;Nursing;Quality of Life	Dietary Supplement: weancare-domus	Milko Zanini	Azienda Sanitaria Locale 3 Genovese	Not yet recruiting	18 Years	N/A	All	140	N/A	Italy
39	NCT05056194 (ClinicalTrials.gov)	November 1, 2021	17/9/2021	Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study	A Double-blind, Randomized, Placebo-controlled, Parallel, Study to Assess the Efficacy and Safety of XW10172 MR for the Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease	Parkinson Disease;Excessive Daytime Somnolence	Drug: Valiloxybate;Other: Placebo	XWPharma	NULL	Not yet recruiting	40 Years	75 Years	All	70	Phase 2	NULL
40	NCT05699161 (ClinicalTrials.gov)	October 14, 2021	7/12/2022	Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson	Treatment of Parkinson Disease With Transplantation of SVF Cells of Adipose Origin: Safety and Exploratory Efficacy Study	Idiopathic Parkinson Disease;Parkinson's Disease and Parkinsonism	Genetic: Adipose-derived stromal vascular fraction cells	Samuel Vilchez, PhD	Wake Forest University;Ministerio de Salud, Nicaragua;GID BIO, Inc.;National Autonomous University of Nicaragua	Completed	18 Years	80 Years	All	10	Phase 1/Phase 2	Nicaragua
41	NCT05084365 (ClinicalTrials.gov)	October 10, 2021	7/10/2021	A 6-month Study to Evaluate Sulforaphane Effects in PD Patients	A 6-month Study to Evaluate Sulforaphane Effects in Treatment of Cognition Impairment of PD Patients	Parkinson Disease	Drug: Sulforaphane;Drug: Placebo	Central South University	NULL	Not yet recruiting	40 Years	75 Years	All	100	Phase 2	NULL
42	NCT04912115 (ClinicalTrials.gov)	October 5, 2021	25/5/2021	Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia	A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects With Parkinson's Disease	Dyskinesias;Movement Disorders;Central Nervous System Diseases;Nervous System Diseases;Neurologic Manifestations	Drug: Ketamine;Drug: Midazolam	PharmaTher Inc.	NULL	Suspended	30 Years	85 Years	All	30	Phase 2	United States
43	EUCTR2020-006053-22-SE (EUCTR)	22/09/2021	26/07/2021	A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson’s Disease	A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson’s Disease	Parkinson´s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: NLX-112 INN or Proposed INN: BEFIRADOL	Neurolixis SAS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	24	Phase 2	Sweden
44	NCT04887467 (ClinicalTrials.gov)	September 16, 2021	26/4/2021	Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease	Pharmacokinetic Study of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease Under Stabilized Treatment.	Parkinson Disease	Drug: Apomorphine	Rennes University Hospital	NULL	Recruiting	50 Years	70 Years	Male	20	Phase 4	France
45	NCT04691661 (ClinicalTrials.gov)	September 9, 2021	16/12/2020	Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease	A Randomized Double-blind Placebo-controlled Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Radotinib in Parkinson's Disease	Parkinson Disease	Drug: Radotinib HCl 50 mg;Drug: Placebo	Il-Yang Pharm. Co., Ltd.	NULL	Recruiting	40 Years	80 Years	All	40	Phase 2	France
46	EUCTR2020-002754-24-IT (EUCTR)	09/09/2021	30/08/2021	Clinical study in early PD patients to investigate the effect of Opicapone 50mg or Levodopa 100 mg in the treatment of motor fluctuations.	A randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study to evaluate the add-on effect of opicapone 50 mg or levodopa 100 mg as first strategy for the treatment of wearing-off in patients with Parkinson's Disease. - ADOPTION: eArly levoDopa with Opicapone in Parkinson's paTients wIth motOr fluctuatioNs	Parkinson's Disease (PD) MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SINEMET 100 mg + 25 mg tablets Product Name: SINEMET 100 mg + 25 mg compresse Product Code: [023145028] INN or Proposed INN: Levodopa Other descriptive name: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: Carbidopa Trade Name: Madopar 125 mg T, tablets Product Name: Madopar® 125 mg T Tablets Levodopa 100 mg Benserazide 25 mg (as benserazide hydrochloride) Product Code: [6036937.00.01] INN or Proposed INN: BENSERAZIDE HYDROCHLORIDE INN or Proposed INN: Levodopa Other descriptive name: Levodopa Trade Name: Ongentys 50 mg hard capsules Product Name: Ongentys 50 mg capsule rigide Product Code: [BIA 9-1067] INN or Proposed INN: Opicapone Other descriptive name: Opicapone	BIAL-Portela & Ca, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 4	Portugal;Spain;Germany;United Kingdom;Italy
47	EUCTR2020-005011-52-PT (EUCTR)	03/09/2021	29/03/2021	Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopathic Parkinson’s Disease Patients: The EPSILON Study	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson’s Disease Patients, with an Open-Label ExtensionThe EPSILON Study: Early Parkinson wIth L-DOPA/DDCI and Opicapone - EPSILON	Early Idiopathic Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Opicapone Product Code: BIA 9-1067 INN or Proposed INN: OPICAPONE	BIAL – Portela & Cª, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	324	Phase 3	Portugal;Serbia;Czechia;Spain;Ukraine;Turkey;Italy;United Kingdom;France;Czech Republic;Belgium;Poland;Bulgaria;Germany
48	NCT05220072 (ClinicalTrials.gov)	August 28, 2021	18/11/2021	Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156	An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of Carbon-14 BIA 28-6156 in Healthy Male Subjects	Parkinson Disease	Drug: Carbon-14 BIA 28-6156	Bial R&D Investments, S.A.	NULL	Completed	30 Years	65 Years	Male	6	Phase 1	United Kingdom
49	NCT04857359 (ClinicalTrials.gov)	August 6, 2021	21/4/2021	Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy	Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients With Parkinson's Disease Receiving Levodopa-based Therapy	Parkinson Disease;Dyskinesia, Drug-Induced;Dyskinesias	Drug: Dipraglurant;Drug: Placebo	Addex Pharma S.A.	NULL	Recruiting	30 Years	85 Years	All	140	Phase 2/Phase 3	United States
50	EUCTR2020-003372-41-ES (EUCTR)	27/07/2021	09/06/2021	Investigating the DopaFuse® Delivery System in Parkinson’s Disease Patients. Assessing safety, effectiveness, how well it is tolerated, and how the drug is processed by the body.	Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa via the DopaFuse Delivery System in Parkinson’s Disease Patients - Study of Continuous Oral Levodopa: SCOL	Motor symptoms in Parkinson’s Disease. MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: DopaFuse Delivery System INN or Proposed INN: levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA	SynAgile Corporation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	24	Phase 1;Phase 2	Spain;Luxembourg;Italy
51	EUCTR2020-005011-52-BE (EUCTR)	19/07/2021	07/04/2021	Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopathic Parkinson’s Disease Patients: The EPSILON Study	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson’s Disease Patients, with an Open-Label ExtensionThe EPSILON Study: Early Parkinson wIth L-DOPA/DDCI and Opicapone - EPSILON	Early Idiopathic Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ongentys Product Name: Opicapone Product Code: BIA 9-1067 INN or Proposed INN: OPICAPONE	BIAL – Portela & Cª, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	324	Phase 3	Serbia;Portugal;Czechia;Spain;Ukraine;Turkey;Italy;United Kingdom;France;Czech Republic;Belgium;Poland;Bulgaria;Germany
52	EUCTR2020-006004-16-PL (EUCTR)	16/07/2021	23/04/2021	Phase II clinical trial to assess anti-dyskinetic efficacy of CPL500036, in patients with levodopa-induced dyskinesia in Parkinson's disease	Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A inhibitor) in Patients with Parkinson's Disease Suffering from Levodopa Induced Dyskinesia	Levodopa-induced dyskinesia in Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: PG203 INN or Proposed INN: CPL500036 Other descriptive name: CPL500036	Celon Pharma S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	108	Phase 2	Poland
53	EUCTR2020-003265-19-IT (EUCTR)	15/07/2021	07/06/2021	A 18-month study to evaluate the efficacy, safety, tolerability and pharmacokinetics of oral UCB0599 in study participants with early-stage Parkinson's Disease	A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease - -	Early-stage Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: UCB0599 Product Code: [UCB0599] Trade Name: DaTSCAN Product Name: DaTSCAN Product Code: [DaTSCAN] INN or Proposed INN: IODIO IOFLUPANO-123I	UCB Biopharma SRL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	France;United States;Canada;Spain;Poland;Netherlands;Germany;United Kingdom;Italy
54	EUCTR2020-002754-24-ES (EUCTR)	06/07/2021	09/06/2021	Clinical study in early PD patients to investigate the effect of Opicapone 50mg or Levodopa 100 mg in the treatment of motor fluctuations.	A randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study to evaluate the add-on effect of opicapone 50 mg or levodopa 100 mg as first strategy for the treatment of wearing-off in patients with Parkinson’s Disease. - ADOPTION: eArly levoDopa with Opicapone in Parkinson’s paTients wIth motOr fluctuatioNs	Parkinson's Disease (PD) MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ongentys 50 mg hard capsules INN or Proposed INN: Ongentys 50 mg hard capsules Other descriptive name: OPICAPONE Trade Name: Madopar 125 mg T, tablets INN or Proposed INN: BENSERAZIDE HYDROCHLORIDE INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA Trade Name: SINEMET 100 mg + 25 mg tablets INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA INN or Proposed INN: CARBIDOPA Other descriptive name: CARBIDOPA	Bial - Portela & Ca, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 4	Portugal;Spain;Germany;United Kingdom;Italy
55	EUCTR2020-005011-52-FR (EUCTR)	23/06/2021	01/04/2021	Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopathic Parkinson’s Disease Patients: The EPSILON Study	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson’s Disease Patients, with an Open-Label ExtensionThe EPSILON Study: Early Parkinson wIth L-DOPA/DDCI and Opicapone - EPSILON	Early Idiopathic Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ongentys Product Name: Opicapone Product Code: BIA 9-1067 INN or Proposed INN: OPICAPONE	BIAL – Portela & Cª, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	324	Phase 3	Serbia;Portugal;Czechia;Spain;Ukraine;Turkey;Italy;United Kingdom;France;Czech Republic;Belgium;Poland;Bulgaria;Germany
56	NCT04821687 (ClinicalTrials.gov)	June 17, 2021	25/3/2021	A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD	A Randomized, Parallel Group, Multicenter, Prospective, Open-label, Exploratory, Phase 4 Study to Evaluate the Add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease	Parkinson Disease	Drug: Ongentys 50mg;Drug: Madopar Tab. 125 or Perkin Tab. 25-100mg	SK Chemicals Co., Ltd.	NULL	Recruiting	30 Years	N/A	All	200	Phase 4	Korea, Republic of
57	NCT04986995 (ClinicalTrials.gov)	June 9, 2021	27/7/2021	OpicApone Sleep dISorder	Open-label, Single-arm, Pilot Study to Evaluate the Effect of Opicapone 50 mg on Parkinson's Disease Patients With End-of-dose Motor Fluctuations and Associated Sleep Disorders	Parkinson Disease	Drug: Opicapone	Bial - Portela C S.A.	NULL	Recruiting	30 Years	N/A	All	30	Phase 4	Portugal
58	EUCTR2020-004997-23-PL (EUCTR)	09/06/2021	03/09/2021	A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease	A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE	Early Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: RO7046015 INN or Proposed INN: Prasinezumab Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	575	Phase 2	France;United States;Canada;Spain;Poland;Austria;United Kingdom;Italy
59	EUCTR2020-003265-19-DE (EUCTR)	07/06/2021	01/12/2020	A 18-month study to evaluate the efficacy, safety, tolerability and pharmacokinetics of oral UCB0599 in study participants with early-stage Parkinson’s Disease	A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson’s Disease	Early-stage Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: UCB0599 Product Code: UCB0599	UCB Biopharma SRL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 2	France;United States;Canada;Spain;Poland;Netherlands;Germany;Italy;United Kingdom
60	NCT04978597 (ClinicalTrials.gov)	May 31, 2021	5/7/2021	Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel-Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add-on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson's Disease Patients, With an Open-Label Extension	Parkinson	Drug: Opicapone 50 mg;Drug: Placebo	Bial - Portela C S.A.	NULL	Recruiting	30 Years	80 Years	All	324	Phase 3	Bulgaria
61	EUCTR2019-002952-17-BG (EUCTR)	31/05/2021	21/05/2021	A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product (TAVAPADON) for patients diagnosed with Parkinson's Disease	58-Week Open-label Trial of Tavapadon in Parkinson’s Disease (TEMPO-4 Trial) - TEMPO-4	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	854	Phase 3	Serbia;United States;Czechia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany
62	EUCTR2020-005011-52-IT (EUCTR)	28/05/2021	04/06/2021	Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopathic Parkinson's Disease Patients: The EPSILON Study	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson's Disease Patients, with an Open- Label ExtensionThe EPSILON Study: Early Parkinson wIth L-DOPA/DDCI and Opicapone - EPSILON	Early Idiopathic Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ongentys Product Name: Opicapone Product Code: [BIA 9-1067] INN or Proposed INN: OPICAPONE	BIAL-Portela & Ca, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	324	Phase 3	Serbia;Portugal;Czechia;Spain;Ukraine;Turkey;Italy;United Kingdom;France;Czech Republic;Belgium;Poland;Bulgaria;Germany
63	EUCTR2020-004997-23-AT (EUCTR)	27/05/2021	16/03/2021	A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease	A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE	Early Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: RO7046015 INN or Proposed INN: Prasinezumab Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	575	Phase 2	Austria;United Kingdom;Italy;France;United States;Canada;Spain;Poland
64	EUCTR2020-003265-19-ES (EUCTR)	26/05/2021	09/02/2021	A 18-month study to evaluate the efficacy, safety, tolerability and pharmacokinetics of oral UCB0599 in study participants with early-stage Parkinson’s Disease	A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson’s Disease	Early-stage Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: UCB0599 Product Code: UCB0599 INN or Proposed INN: -	UCB Biopharma SRL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	France;United States;Canada;Poland;Spain;Netherlands;Germany;United Kingdom;Italy
65	EUCTR2020-004997-23-ES (EUCTR)	25/05/2021	01/09/2021	A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease	A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE	Early Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: RO7046015 INN or Proposed INN: Prasinezumab Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	575	Phase 2	France;United States;Canada;Poland;Spain;Austria;United Kingdom;Italy
66	EUCTR2019-004235-23-DE (EUCTR)	19/05/2021	25/02/2021	Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-951 in subjects with Parkinson's disease.	An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Foscarbidopa and Foslevodopa Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa-4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa-4'-Monophosphate	Abbvie Deutschland GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Denmark;Australia;Russian Federation;Netherlands;Germany;Italy;United Kingdom;Japan;Sweden
67	EUCTR2020-005011-52-BG (EUCTR)	17/05/2021	22/03/2021	Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopathic Parkinson’s Disease Patients: The EPSILON Study	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson’s Disease Patients, with an Open-Label ExtensionThe EPSILON Study: Early Parkinson wIth L-DOPA/DDCI and Opicapone - EPSILON	Early Idiopathic Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Opicapone Product Code: BIA 9-1067 INN or Proposed INN: OPICAPONE	BIAL – Portela & Cª, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	324	Phase 3	Serbia;Portugal;Czechia;Spain;Ukraine;Turkey;Italy;United Kingdom;France;Czech Republic;Belgium;Poland;Bulgaria;Germany
68	EUCTR2020-005011-52-CZ (EUCTR)	12/05/2021	04/03/2021	Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopathic Parkinson’s Disease Patients: The EPSILON Study	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson’s Disease Patients, with an Open-Label ExtensionThe EPSILON Study: Early Parkinson wIth L-DOPA/DDCI and Opicapone - EPSILON	Early Idiopathic Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Opicapone Product Code: BIA 9-1067 INN or Proposed INN: OPICAPONE	BIAL – Portela & Cª, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	324	Phase 3	Serbia;Portugal;Czechia;Spain;Ukraine;Turkey;Italy;United Kingdom;France;Czech Republic;Belgium;Poland;Bulgaria;Germany
69	EUCTR2020-004997-23-FR (EUCTR)	11/05/2021	02/03/2021	A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease	A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE	Early Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: RO7046015 INN or Proposed INN: Prasinezumab Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	575	Phase 2	United States;France;Canada;Spain;Poland;Austria;United Kingdom;Italy
70	EUCTR2020-001176-15-DE (EUCTR)	07/05/2021	17/12/2020	Clinical study to investigate if Opicapone 50mg can reduce sleep disorders associated to Parkinson's disease.	Open-label, single-arm, pilot study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated sleep disorders. - OpicApone Sleep dISorder (OASIS)	Parkinson's disease patients with wearing-off motor fluctuations and associated sleep disorders. MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ongentys Product Name: Ongentys 50 mg hard capsules INN or Proposed INN: OPICAPONE Other descriptive name: OPICAPONE	Bial - Portela & Ca, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 4	Portugal;Germany
71	NCT04777331 (ClinicalTrials.gov)	May 5, 2021	26/2/2021	A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease	A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease	Parkinsons Disease	Drug: Prasinezumab;Drug: Placebo	Hoffmann-La Roche	Prothena Biosciences Limited	Recruiting	50 Years	85 Years	All	575	Phase 2	United States;Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;Germany
72	EUCTR2020-003265-19-NL (EUCTR)	04/05/2021	24/02/2021	A 18-month study to evaluate the efficacy, safety, tolerability and pharmacokinetics of oral UCB0599 in study participants with early-stage Parkinson’s Disease	A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson’s Disease	Early-stage Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: UCB0599 Product Code: UCB0599 INN or Proposed INN: - Other descriptive name: -	UCB Biopharma SRL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 2	United States;France;Canada;Spain;Poland;Germany;Netherlands;United Kingdom;Italy
73	NCT04802733 (ClinicalTrials.gov)	May 3, 2021	12/3/2021	Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease	Phase 1 Study To Assess the Safety and Tolerability of Human Embryonic Stem Cell-Derived Midbrain Dopamine Neuron Cell Therapy (MSK-DA01) For Advanced Parkinson's Disease	Advanced Parkinson's Disease	Biological: MSK-DA01;Device: MSK-DA01 Cell Delivery Device	BlueRock Therapeutics	Memorial Sloan Kettering Cancer Center	Active, not recruiting	50 Years	78 Years	All	12	Phase 1	United States;Canada
74	EUCTR2020-003265-19-PL (EUCTR)	30/04/2021	18/01/2021	A 18-month study to evaluate the efficacy, safety, tolerability and pharmacokinetics of oral UCB0599 in study participants with early-stage Parkinson’s Disease	A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson’s Disease	Early-stage Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: UCB0599 Product Code: UCB0599	UCB Biopharma SRL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 2	France;United States;Canada;Spain;Poland;Germany;Netherlands;United Kingdom;Italy
75	NCT04867642 (ClinicalTrials.gov)	April 29, 2021	27/4/2021	A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease	A First-In-Human, Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled, Single- and Multiple-Dose, Dose-Escalating Study Evaluating the Safety, Tolerability, and Pharmacokinetics of UCB0022 in Healthy Participants and Participants With Parkinson's Disease	Healthy Study Participants;Parkinson's Disease	Drug: UCB0022;Other: Placebo	UCB Biopharma SRL	NULL	Active, not recruiting	18 Years	75 Years	All	100	Phase 1	United Kingdom
76	NCT04377945 (ClinicalTrials.gov)	April 28, 2021	4/5/2020	Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components	A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components	Dyskinesias;Parkinson Disease	Drug: Part 1, JM-010 component Group A;Drug: Part 1, JM-010 component Group B;Drug: Part 1, JM-010 component Group C;Drug: Part 1, Placebo Group;Drug: Part 2, JM-010 combination Group A;Drug: Part 2, JM-010 combination Group B;Drug: Part 2, JM-010 component Group C;Drug: Part 2, Placebo Group	Bukwang Pharmaceutical	NULL	Recruiting	18 Years	85 Years	All	188	Phase 2	United States
77	EUCTR2020-003265-19-FR (EUCTR)	28/04/2021	04/12/2020	A 18-month study to evaluate the efficacy, safety, tolerability and pharmacokinetics of oral UCB0599 in study participants with early-stage Parkinson’s Disease	A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson’s Disease	Early-stage Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: UCB0599 Product Code: UCB0599	UCB Biopharma SRL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	United States;France;Canada;Spain;Poland;Netherlands;Germany;United Kingdom;Italy
78	EUCTR2018-004892-11-IT (EUCTR)	22/04/2021	07/10/2020	A randomized, double-blind, placebo controlled, multicentre study to evaluate the effect of safinamide on freezing of gait (FOG) in mid- to late-stage fluctuating PD patients	A randomized, double-blind, placebo controlled, multicentre study to evaluate the effect of safinamide on freezing of gait (FOG) in mid- to late-stage fluctuating PD patients - SteP-on	•Subjects of both genders over 18 years of age, with a clinical diagnosis of idiopathic PD•A Modified Hoehn and Yahr stage of = 4 in the off” state;•A stable (4 weeks since last modification) anti-parkinsonian therapy; •The presence of FOG (defined as the persistence of gait hesitation and failure in starting the gait or the reported sensation of having the legs frozen” or glued to the ground”) even on an optimized dopaminergic treatment (patients with FOG item 3 score >0) MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: XADAGO - 100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE Product Name: Xadago Product Code: [043906039] INN or Proposed INN: SAFINAMIDE METANSOLFONATO Trade Name: XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE Product Name: Xadago Product Code: [043906039] INN or Proposed INN: SAFINAMIDE METANSOLFONATO	OSPEDALE SANTA MARIA DELLA MISERICORDIA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	128	Phase 3	Italy
79	EUCTR2020-004997-23-IT (EUCTR)	19/04/2021	08/06/2021	A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease	A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE - NA	Early Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: [RO7046015] INN or Proposed INN: Prasinezumab Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	F. HOFFMANN - LA ROCHE LTD.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	575	Phase 2	France;United States;Canada;Spain;Poland;Austria;United Kingdom;Italy
80	ChiCTR2100045506	2021-04-19	2021-04-18	The immediate effects of rhythmic auditory stimulation on upper-limb movements in patients with Parkinson’s disease	The immediate effects of rhythmic auditory stimulation on upper-limb movements in patients with Parkinson’s disease	Parkinson Disease	Healthy people group:Different frequency of RAS;Parkinson's disease group:Different frequency of RAS;	Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology	NULL	Recruiting			Male	Healthy people group:36;Parkinson's disease group:36;		China
81	EUCTR2021-000867-65-DE (EUCTR)	19/04/2021	16/03/2021	Investigation of the adhesion properties of a newly developed rotigotine-containing patch in patients with Parkinson's disease	Comparative, randomized, open, crossover clinical trial to investigate adhesiveness of a newly developed rotigotine-containing transdermal patch in patients with Parkinson's disease	Idiopathic Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]	Product Name: ROT-TDS 8 mg/24 h INN or Proposed INN: ROTIGOTINE Trade Name: Neupro® 8 mg/24 h Product Name: Neupro® 8 mg/24 h INN or Proposed INN: ROTIGOTINE	Luye Pharma Switzerland AG	NULL	Not Recruiting			Female: yes Male: yes	38	Phase 2	Germany
82	ChiCTR2100044662	2021-04-01	2021-03-25	Study on exosome biomarkers in Parkinson's disease	Study on exosome biomarkers in Parkinson's disease	Parkinson’s disease	Gold Standard:Clinically established Parkinson's disease conforming to China Diagnostic Criteria for Parkinson's Disease (2016);Index test:Exosome biomarkers (miRNA and a-synuclein);	The First Affiliated Hospital, Sun Yat-sen University	NULL	Recruiting	21	100	Both	Target condition:1200;Difficult condition:0		China
83	NCT04491383 (ClinicalTrials.gov)	April 1, 2021	22/7/2020	Tocotrienols in Parkinson's Disease (PD)	Tocotrienols in Parkinson's Disease (PD): A Pilot, Randomised, Placebo-controlled Trial	Neuro-Degenerative Disease;Parkinson Disease	Drug: Tocovid Suprabio (HOV-12020);Other: Placebo	National Neuroscience Institute	Hovid Berhad	Recruiting	40 Years	90 Years	All	100	Phase 2	Singapore
84	EUCTR2019-000247-27-FR (EUCTR)	31/03/2021	05/03/2019	Study to demonstrate an at least equivalent performance of a new test in brain imaging test compared to the reference examination to establish the differential diagnosis between Parkinson's Disease and Essential Tremor.	Non-inferiority study of the molecular imaging of dopamine transporters using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to distinguish between Parkinson’s Disease and Essential Tremor. - DATTEP	Patients suffering from an essential tremor or with Parkinson's disease. MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Classification code 10015496;Term: Essential tremor;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]	Trade Name: DaTSCAN 74 MBq/ml solution for injection Product Code: [18F] LBT-999	ZIONEXA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	112	Phase 3	France
85	EUCTR2019-002952-17-DE (EUCTR)	30/03/2021	18/09/2020	A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product (TAVAPADON) for patients diagnosed with Parkinson's Disease	58-Week Open-label Trial of Tavapadon in Parkinson’s Disease (TEMPO-4 Trial) - TEMPO-4	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	854	Phase 3	Serbia;United States;Czechia;Spain;Ukraine;Israel;Italy;France;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Czech Republic
86	JPRN-jRCTs051200160	24/03/2021	24/03/2021	ZEAL study	Zonisamide for the Efficacy of Sleep Abnormality in Parkinson's Disease: A Randomized Single-Blind Placebo-Controlled Trial - ZEAL	Parkinson's disease Parkinson's disease,Somnipathy;D010300	70 patients with Parkinson's disease were allocated to Zonisamide tablets (Trelief OD tablets) 1T (25mg) or placebo 1T at a time before going to bed by randomizing soft, and the efficacy of zonisamide tablet (Trelief OD tablets) for sleep is investigated comparing the parallel-group before and after administration	Hiroshi Kataoka	NULL	Recruiting	>= 41age old	Not applicable	Both	70	Phase 2-3	Japan
87	EUCTR2020-001176-15-PT (EUCTR)	19/03/2021	04/01/2021	Clinical study to investigate if Opicapone 50mg can reduce sleep disorders associated to Parkinson's disease.	Open-label, single-arm, pilot study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated sleep disorders. - OpicApone Sleep dISorder (OASIS)	Parkinson's disease patients with wearing-off motor fluctuations and associated sleep disorders. MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ongentys Product Name: Ongentys 50 mg hard capsules INN or Proposed INN: OPICAPONE Other descriptive name: OPICAPONE	Bial - Portela & Ca, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 4	Portugal;Germany
88	NCT04986982 (ClinicalTrials.gov)	February 25, 2021	27/7/2021	OpiCapone Effect on Motor Fluctuations and pAiN	Randomised, Double-blind, Placebo-controlled, Clinical Study to Evaluate the Effect of Opicapone 50 mg on Parkinson's Disease Patients With End-of-dose Motor Fluctuations and Associated Pain.	Parkinson Disease	Drug: Opicapone 50 mg;Other: Matching placebo	Bial - Portela C S.A.	NULL	Recruiting	30 Years	N/A	All	140	Phase 4	United Kingdom
89	NCT04764669 (ClinicalTrials.gov)	February 25, 2021	19/2/2021	A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology	An Open-Label Study To Evaluate the Pharmacodynamic Effects, Efficacy, Safety, and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies or Parkinson's Disease Dementia With or Without Amyloid Copathology	Lewy Body Disease;Parkinson Disease	Drug: E2027	Eisai Inc.	NULL	Completed	50 Years	85 Years	All	34	Phase 2	United States;Canada
90	EUCTR2019-002952-17-IT (EUCTR)	19/02/2021	25/01/2021	A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product (TAVAPADON) for patients diagnosed with Parkinson's Disease	58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4Trial) - TEMPO-4	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5 mg Product Code: [CVL-751] INN or Proposed INN: TAVAPADON Other descriptive name: TAVAPADON Product Name: Tavapadon 1mg Product Code: [CVL-751] INN or Proposed INN: TAVAPADON Other descriptive name: TAVAPADON Product Name: Tavapadon 0.25 mg Product Code: [CVL-751] INN or Proposed INN: TAVAPADON Other descriptive name: TAVAPADON	Cerevel Therapeutics LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	854	Phase 3	Serbia;United States;Czechia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany
91	NCT04750226 (ClinicalTrials.gov)	February 18, 2021	10/2/2021	Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease	An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson's Disease	Parkinson's Disease (PD)	Drug: ABBV-951	AbbVie	NULL	Enrolling by invitation	30 Years	N/A	All	130	Phase 3	United States;Australia
92	NCT04350177 (ClinicalTrials.gov)	February 16, 2021	26/12/2019	A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients	A Phase I, Randomized Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Determine the Safety, Tolerability and Pharmacokinetics (PK) of IkT-148009 in Older Adult and Elderly Healthy Volunteers With Extension Into Parkinson's Patients	Healthy Elderly;Parkinson Disease	Drug: IkT-148009;Drug: Placebo	Inhibikase Therapeutics, Inc.	NULL	Completed	55 Years	70 Years	All	101	Phase 1	United States
93	NCT04643327 (ClinicalTrials.gov)	February 9, 2021	18/11/2020	Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease	Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept Study	Parkinson Disease;Mild Cognitive Impairment;Memory Impairment	Drug: Levetiracetam;Drug: Placebo	The University of Queensland	Johns Hopkins University;Cleveland Clinic Lou Ruvo Center for Brain Health;Royal Brisbane and Women's Hospital;Queensland University of Technology	Recruiting	N/A	N/A	All	28	Phase 2	Australia
94	NCT04593511 (ClinicalTrials.gov)	February 2, 2021	21/9/2020	to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers	An Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 After a Single Intramuscular Injection	Parkinson's Disease	Drug: LY03009 F1;Drug: LY03009 F2;Drug: LY03009 F3;Drug: LY03009 F4	Luye Pharma Group Ltd.	NULL	Enrolling by invitation	18 Years	65 Years	All	40	Phase 1	Australia
95	EUCTR2020-003372-41-IT (EUCTR)	27/01/2021	15/06/2021	Investigating the DopaFuse® Delivery System in Parkinson's Disease Patients. Assessing safety, effectiveness, how well it is tolerated, and how the drug is processed by the body.	Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa via the DopaFuse® Delivery System in Parkinson’s Disease Patients - Study of Continuous Oral Levodopa: SCOL	Motor symptoms in Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: DopaFuse Delivery System Product Code: [N04BA] INN or Proposed INN: LEVODOPA Other descriptive name: Levodopa INN or Proposed INN: CARBIDOPA Other descriptive name: Carbidopa	SynAgile Corporation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	24	Phase 2	Spain;Luxembourg;Italy
96	NCT04625361 (ClinicalTrials.gov)	January 20, 2021	9/11/2020	Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects	A Single Center, Randomized, Double-Blind, Placebo-Controlled Study of Single/Multiple Ascending Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, and Single Center, Randomized, Double-Blind, Two Periods, Crossover, Food Effect Study of HEC122505MsOH Tablets in Healthy Chinese Subjects	Parkinson Disease	Drug: HEC122505MsOH	Sunshine Lake Pharma Co., Ltd.	NULL	Recruiting	18 Years	45 Years	All	102	Phase 1	China
97	EUCTR2020-001175-32-PT (EUCTR)	15/01/2021	30/09/2020	Clinical study to investigate if Opicapone 50mg can reduce pain associated to Parkinson’s disease	Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain. - OpiCapone Effect on motor fluctuations and pAiN (OCEAN)	Parkinson's disease patients with wearing-off motor fluctuations and associated pain. MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ongentys Product Name: Opicapone 50 mg hard capsules INN or Proposed INN: Opicapone	Bial - Portela & Ca, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	176	Phase 4	Portugal;Spain;Germany;United Kingdom;Italy
98	EUCTR2019-002949-38-BG (EUCTR)	13/01/2021	21/12/2020	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	522	Phase 3	United States;Czechia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany
99	NCT04277247 (ClinicalTrials.gov)	January 12, 2021	10/2/2020	Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease	Botulinum Toxin A (Onabotulinumtoxin A) for Foot Dystonia-associated Pain in Parkinson's Disease: A Randomized, Double-blind Placebo Control Study	Dystonia Disorder;Parkinson Disease	Drug: Botulinum toxin type A;Drug: Placebo	University of Calgary	Allergan	Recruiting	30 Years	100 Years	All	40	Phase 2/Phase 3	Canada
100	EUCTR2019-002951-40-BG (EUCTR)	11/01/2021	05/01/2021	A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease with Motor Fluctuations	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease with Motor Fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	368	Phase 3	Serbia;United States;Czechia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany
101	EUCTR2019-002952-17-HU (EUCTR)	30/12/2020	19/10/2020	A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product (TAVAPADON) for patients diagnosed with Parkinson's Disease	58-Week Open-label Trial of Tavapadon in Parkinson’s Disease (TEMPO-4 Trial) - TEMPO-4	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	854	Phase 3	United States;Serbia;Spain;Ukraine;Israel;Italy;France;Hungary;Czech Republic;Canada;Poland;Australia;Bulgaria;Germany
102	NCT04658186 (ClinicalTrials.gov)	December 30, 2020	1/12/2020	A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease	A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease	Early-stage Parkinson's Disease	Drug: UCB0599;Drug: Placebo	UCB Biopharma SRL	NULL	Active, not recruiting	40 Years	75 Years	All	490	Phase 2	United States;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
103	NCT04685265 (ClinicalTrials.gov)	December 22, 2020	17/12/2020	A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease	A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of anle138b, and to Characterise the Effect of Food of anle138b in Mild to Moderate Parkinson's Disease	Parkinson Disease	Drug: anle138b;Drug: Placebo	MODAG GmbH	Aptuit (Verona) Srl, an Evotec Company;Quotient Sciences;Nottingham University Hospitals NHS Trust	Active, not recruiting	40 Years	80 Years	All	72	Phase 1	United Kingdom
104	EUCTR2020-001175-32-IT (EUCTR)	17/12/2020	15/06/2021	Clinical study to investigate if Opicapone 50mg can reduce pain associated to Parkinson's disease	Randomized, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson's disease patients with end-of-dose motor fluctuations and associated pain. - OpiCapone Effect on motor fluctuations and pAiN (OCEAN)	Parkinson's disease patients with wearing-off motor fluctuations and associated pain. MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ongentys Product Name: Ongentys 50 mg capsule rigide Product Code: [BIA 9-1067] INN or Proposed INN: Opicapone	BIAL-Portela & Ca, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	176	Phase 4	Portugal;Spain;Germany;United Kingdom;Italy
105	NCT04651153 (ClinicalTrials.gov)	December 14, 2020	25/11/2020	A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)	A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease	Parkinson's Disease	Drug: UCB7853;Other: Placebo	UCB Biopharma SRL	NULL	Active, not recruiting	18 Years	80 Years	All	57	Phase 1	Netherlands;United Kingdom
106	EUCTR2019-004235-23-DK (EUCTR)	18/11/2020	22/06/2020	Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-951 in subjects with Parkinson's disease.	An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Foscarbidopa and Foslevodopa Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa-4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa-4'-Monophosphate	Abbvie Deutschland GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Australia;Denmark;Russian Federation;Germany;Netherlands;Italy;United Kingdom;Japan;Sweden
107	EUCTR2019-004235-23-NL (EUCTR)	09/11/2020	26/05/2020	Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-951 in subjects with Parkinson's disease.	An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Foscarbidopa and Foslevodopa Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa-4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa-4'-Monophosphate	Abbvie Deutschland GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Denmark;Australia;Russian Federation;Germany;Netherlands;Italy;United Kingdom;Japan;Sweden
108	EUCTR2019-002952-17-CZ (EUCTR)	04/11/2020	12/10/2020	A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product (TAVAPADON) for patients diagnosed with Parkinson's Disease	58-Week Open-label Trial of Tavapadon in Parkinson’s Disease (TEMPO-4 Trial) - TEMPO-4	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	854	Phase 3	Serbia;United States;Czechia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany
109	ChiCTR2000038937	2020-11-01	2020-10-10	Clinical study of early diagnosis of Parkinson's disease based on substantia nigra-striatal axis multimodal imaging	Clinical study of early diagnosis of Parkinson's disease based on substantia nigra-striatal axis multimodal imaging	Parkinson's disease	Gold Standard:Clinical diagnosis by experienced movement disorder specialists after 2 years of follow-up.;Index test:Including traditional imaging feature algorithms (SUVR value, total cortical volume, bilateral cortical surface area, cortical thickness, etc.), high-dimensional imaging omics feature algorithms (energy entropy, gray-level co-occurrence matrix, and mutual information, etc.), and brain connection group Learning feature algorithm.;	Huashan Hospital, Fudan University	NULL	Recruiting	45	80	Both	Target condition:105;Difficult condition:0		China
110	EUCTR2019-002951-40-IT (EUCTR)	30/10/2020	21/01/2021	A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease with Motor Fluctuations	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease with Motor Fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: [CVL-751] INN or Proposed INN: Tavapadon Product Name: Tavapadon 1mg Product Code: [CVL-751] INN or Proposed INN: TAVAPADON Product Name: Tavapadon 0.25mg Product Code: [CVL-751] INN or Proposed INN: TAVAPADON	Cerevel Therapeutics LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	368	Phase 3	Serbia;United States;Czechia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden
111	NCT04542499 (ClinicalTrials.gov)	October 27, 2020	2/9/2020	Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial)	Parkinson Disease	Drug: Tavapadon;Drug: Placebo	Cerevel Therapeutics, LLC	NULL	Recruiting	40 Years	80 Years	All	368	Phase 3	United States;Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine
112	NCT03947216 (ClinicalTrials.gov)	October 23, 2020	7/5/2019	Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.	Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease	Parkinson Disease	Drug: Active drug: pimavanserin 17mg (2 strength tablets);Drug: Placebo: 2 tablets containing same excipients except active compound;Behavioral: Assessment of severity of ICD (impulse control disorders);Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors;Behavioral: Assessment of quality of life;Behavioral: Assessment of depression;Behavioral: Assessment of cognition;Behavioral: Assessment of severity of Parkinson Disease;Procedure: Blood analysis;Procedure: Cardiac monitoring	University Hospital, Strasbourg, France	NS-PARK;EUCLID Clinical Trial Platform;F-CRIN	Recruiting	35 Years	75 Years	All	130	Phase 2	France
113	EUCTR2020-003796-17-GB (EUCTR)	22/10/2020	01/09/2020	A study to look at the effect of CST-103 or CST-139 on blood flow in the brain and on memory.	An Open-Label Brain Imaging and Cognition Study to Determine Changes in Cerebral Perfusion and Cognition After Oral Administration of CST-103 or CST-139	Patients with Mild Cognitive Impairment or Parkinson’s Disease MedDRA version: 21.1;Level: LLT;Classification code 10009846;Term: Cognitive impairment;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Spiropent Product Name: Clenbuterol HCl Product Code: CST-103 INN or Proposed INN: CLENBUTEROL HYDROCHLORIDE Trade Name: Berachin Product Name: Tulobuterol Product Code: CST-139 INN or Proposed INN: Tolubuterol Hydrochloride Other descriptive name: TULOBUTEROL HYDROCHLORIDE	CuraSen Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	32	Phase 2	United Kingdom
114	NCT04334317 (ClinicalTrials.gov)	October 21, 2020	30/3/2020	A Study of TAK-071 in People With Parkinson Disease	A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls	Parkinson Disease;Healthy Participants	Drug: TAK-071;Drug: Placebo	Takeda	Michael J. Fox Foundation for Parkinson's Research	Completed	40 Years	85 Years	All	64	Phase 2	United States
115	NCT04380142 (ClinicalTrials.gov)	October 19, 2020	6/5/2020	Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease	A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients	Parkinson's Disease (PD)	Drug: ABBV-951;Drug: Placebo for Levodopa/Carbidopa (LD/CD);Drug: Levodopa/Carbidopa (LD/CD);Drug: Placebo for ABBV-951	AbbVie	NULL	Completed	30 Years	N/A	All	174	Phase 3	United States;Australia
116	ChiCTR2000037239	2020-10-01	2020-08-27	Construction and application of a diagnostic marker for Parkinson's disease based on gut microbiomics	Construction and application of a diagnostic marker for Parkinson's disease based on gut microbiomics	Parkinson's disease	Gold Standard:All patients satisfied the United Kingdom Parkinson's Disease Society Brain Bank criteria;Index test:Microbial gene detection chip;	Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	NULL	Recruiting	55	80	Both	Target condition:500;Difficult condition:600		China
117	ChiCTR2000036137	2020-10-01	2020-08-21	Clinical study of 18F-FDG combined with 18F-AV-133 PET/CT imaging in the diagnosis and differentiation of primary Parkinson's disease	Clinical study of 18F-FDG combined with 18F-AV-133 PET/CT imaging in the diagnosis and differentiation of primary Parkinson's disease	Parkinson’s disease	Gold Standard:UK Parkinson's disease Society Brain Bank Clinical Diagnosis Criteria;Index test:18F-FDG combined with 18F-AV-133 PET/CT imaging;	Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University	NULL	Pending			Both	Target condition:50;Difficult condition:0		China
118	ChiCTR2000037856	2020-10-01	2020-09-02	Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)	Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)	Parkinson's Disease	Gold Standard:DAT-PET and 18F-FDG PET ;Index test:a-synuclein protein misfolding cyclic amplification;	Huashan Hospital Affiliated to Fudan University	NULL	Recruiting	50	75	Both	Target condition:150;Difficult condition:76		China
119	NCT04338997 (ClinicalTrials.gov)	October 2020	3/4/2020	PK Study in Patients With Parkinson's Disease With IZD174	An Open-label Phase 1b Study to Evaluate the Pharmacokinetics and Pharmacodynamics in Plasma and Cerebrospinal Fluid (CSF), Safety and Tolerability of Oral IZD174 in Patients With Parkinson's Disease	Parkinson Disease	Drug: IZD174	Inflazome UK Ltd	NULL	Withdrawn	45 Years	75 Years	All	0	Phase 1	NULL
120	EUCTR2020-001175-32-GB (EUCTR)	29/09/2020	07/08/2020	Clinical study to evaluate the effect of opicapone 50 mg in the pain associated to Parkinson’s disease.	Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain. - OpiCapone Effect on motor fluctuations and pAiN (OCEAN)	Parkinson's disease patients with wearing-off motor fluctuations andassociated pain. MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ongentys Product Name: Ongentys INN or Proposed INN: Opicapone	Bial - Portela & Ca, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	176	Phase 4	Portugal;Spain;Germany;Italy;United Kingdom
121	EUCTR2019-004235-23-GB (EUCTR)	15/09/2020	28/05/2020	Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-951 in subjects with Parkinson's disease.	An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Foscarbidopa and Foslevodopa Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa-4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa-4'-Monophosphate	Abbvie Deutschland GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Australia;Russian Federation;Japan;United Kingdom
122	NCT04476017 (ClinicalTrials.gov)	September 11, 2020	15/7/2020	A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)	An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment	Parkinson Disease;Cognitive Dysfunction	Drug: SAGE-718	Sage Therapeutics	NULL	Completed	50 Years	75 Years	All	18	Phase 2	United States
123	EUCTR2019-002949-38-DE (EUCTR)	07/09/2020	21/01/2020	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	552	Phase 3	Serbia;United States;Czechia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden
124	ChiCTR2000037828	2020-09-01	2020-09-02	Clinical study of Wuqinxi combined with selegilan in improving frozen gait of Parkinson's disease	Clinical study of Wuqinxi combined with selegilan in improving frozen gait of Parkinson's disease	Parkinson's disease	Group 1:Routine anti PD treatment + stretching training;Group 2:Routine anti PD treatment + stretching training + selegiline;Group 3:Routine anti PD treatment + Wuqinxi training;Group 4:Routine anti PD treatment + Wuqinxi training + selegiline;	Union Medical College Affiliated Hospital of Tongji Medical College, Huazhong University of science and technology	NULL	Recruiting	40	80	Male	Group 1:30;Group 2:30;Group 3:30;Group 4:30;		China
125	EUCTR2019-004235-23-IT (EUCTR)	26/08/2020	22/10/2020	Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-951 in subjects with Parkinson's disease.	An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease. - na	Parkinson's Disease MedDRA version: 21.1;Level: PT;Classification code 10068100;Term: Vascular parkinsonism;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Foscarbidopa and Foslevodopa Product Code: [ABBV-951] INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa-4'-Monophosphate	ABBVIE DEUTSCHLAND GMBH & CO. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Australia;Russian Federation;Netherlands;United Kingdom;Japan;Italy
126	NCT04524351 (ClinicalTrials.gov)	August 14, 2020	11/8/2020	Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD) or Early Parkinson's Disease (PD)	Alzheimer Disease;Parkinson Disease	Drug: Posiphen	Annovis Bio Inc.	Parexel	Completed	45 Years	N/A	All	75	Phase 1/Phase 2	United States
127	NCT04449484 (ClinicalTrials.gov)	August 4, 2020	23/4/2019	Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease	A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: MEDI1341;Other: Placebo	AstraZeneca	Takeda	Completed	40 Years	85 Years	All	25	Phase 1	United States
128	NCT04483479 (ClinicalTrials.gov)	July 30, 2020	20/7/2020	Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety Roll-over Study (Rollover)	A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period	Parkinson Disease;Constipation	Drug: Active Investigational Treatment ENT-01	Enterin Inc.	NULL	Completed	30 Years	90 Years	All	28	Phase 2	United States
129	EUCTR2019-002951-40-DE (EUCTR)	29/07/2020	12/02/2020	A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease with Motor Fluctuations	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease with Motor Fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	368	Phase 3	Serbia;United States;Czechia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany
130	NCT04630860 (ClinicalTrials.gov)	July 7, 2020	5/11/2020	A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD	A Randomized, Open-label, Multiple Ascending Dose Study in Patients With Advanced-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections	Parkinson Disease	Drug: LY03003	Luye Pharma Group Ltd.	NULL	Recruiting	18 Years	80 Years	All	30	Phase 1	China
131	EUCTR2019-002951-40-HU (EUCTR)	02/07/2020	29/04/2020	A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease with Motor Fluctuations	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease with Motor Fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	368	Phase 3	United States;Serbia;Spain;Ukraine;Israel;Italy;France;Hungary;Czech Republic;Canada;Poland;Australia;Bulgaria;Germany;Sweden
132	EUCTR2018-004156-37-PT (EUCTR)	16/06/2020	09/12/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD/CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	482	Phase 3	Portugal;Serbia;United States;Czechia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Poland;Belgium;Netherlands;Sweden;Korea, Republic of
133	EUCTR2018-004156-37-NL (EUCTR)	14/06/2020	13/01/2020	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD / CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	482	Phase 3	Serbia;United States;Portugal;Czechia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden
134	NCT04379050 (ClinicalTrials.gov)	June 8, 2020	1/5/2020	Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease	An Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease	Parkinson's Disease (PD)	Drug: ABBV-951	AbbVie	NULL	Active, not recruiting	30 Years	N/A	All	130	Phase 3	United States;Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
135	EUCTR2019-002951-40-CZ (EUCTR)	03/06/2020	25/02/2020	A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease with Motor Fluctuations	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease with Motor Fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	368	Phase 3	Serbia;United States;Czechia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany
136	NCT04384666 (ClinicalTrials.gov)	June 2, 2020	8/5/2020	A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers	A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers	Parkinson Disease	Drug: LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection);Other: Neupro 4 mg / 24 Hr. Transdermal Patch	Luye Pharma Group Ltd.	NULL	Completed	18 Years	45 Years	All	56	Phase 1	United States
137	ChiCTR2000032616	2020-05-30	2020-05-04	Assistant diagnosis machinery system development based on speech and movement sensitive device for Parkinson's disease	Parkinson's disease, Assistant diagnosis machinery system, speech, movement sensitive device	Parkinson's disease	Gold Standard:clinical outcome meet 2015 MDS-probable PD criteria;Index test:Acoustic receptive and analysis device,Wearable movement sensor;	Shanghai Jiao Tong University School of Medicine affiliated Shanghai General Hospital	NULL	Pending			Both	Target condition:20;Difficult condition:80		China
138	EUCTR2019-002950-22-IT (EUCTR)	21/05/2020	15/06/2021	A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease	A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Flexible-Dose, 27 Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO 2 Trial) - TEMPO-2 Trial	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: [CVL-751] INN or Proposed INN: Tavapadon Other descriptive name: TAVAPADON Product Name: Tavapadon 1mg Product Code: [CVL-751] INN or Proposed INN: Tavapadon Other descriptive name: TAVAPADON Product Name: Tavapadon 0.25mg Product Code: [CVL-751] INN or Proposed INN: Tavapadon Other descriptive name: TAVAPADON	Cerevel Therapeutics LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	296	Phase 3	Serbia;United States;Czechia;Spain;Ukraine;Israel;Italy;France;Hungary;Canada;Poland;Australia;Bulgaria;Germany
139	EUCTR2019-002949-38-IT (EUCTR)	21/05/2020	21/01/2021	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY,AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON'S DISEASE (TEMPO-1 TRIAL)	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY,AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON'S DISEASE (TEMPO-1 TRIAL) - TEMPO-1 TRIAL	Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: [CVL-751] INN or Proposed INN: TAVAPADON Product Name: Tavapadon 0.25mg Product Code: [CVL-751] INN or Proposed INN: Tavapadon Product Name: Tavapadon 1mg Product Code: [CVL-751] INN or Proposed INN: TAVAPADON	Cerevel Therapeutics LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	522	Phase 3	Serbia;United States;Czechia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden
140	EUCTR2018-004156-37-SE (EUCTR)	18/05/2020	10/09/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD / CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350	Phase 3	United States;Serbia;Portugal;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Belgium;Poland;Netherlands;Sweden;Korea, Republic of
141	EUCTR2019-002949-38-PL (EUCTR)	13/05/2020	20/02/2020	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	522	Phase 3	Serbia;United States;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden
142	NCT04571164 (ClinicalTrials.gov)	May 11, 2020	21/9/2020	A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD	A Multi-centre,Randomized,Double-blind,Placebo Parallel Controlled Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD	Parkinson Disease	Drug: LY03003(Rotigotine,extended-release microspheres);Drug: Placebo,extended-release microspheres	Luye Pharma Group Ltd.	Parexel	Recruiting	30 Years	N/A	All	294	Phase 3	China
143	EUCTR2018-002144-85-DE (EUCTR)	07/05/2020	06/06/2019	Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study	A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa-4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa-4'-Monophosphate	AbbVie Deutschland	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Canada;Belgium;Spain;Denmark;Australia;Netherlands;Germany;Italy;United Kingdom;Japan
144	EUCTR2019-002950-22-HU (EUCTR)	06/05/2020	12/03/2020	A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease	A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Flexible-Dose, 27 Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson’s Disease (TEMPO 2 Trial)	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	296	Phase 3	United States;Serbia;Spain;Ukraine;Israel;Italy;France;Hungary;Czech Republic;Canada;Poland;Australia;Bulgaria;Germany
145	EUCTR2018-004156-37-IT (EUCTR)	04/05/2020	17/06/2021	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson's disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson's disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: IR LD / CD Product Name: Carbidopa and Levodopa tablets, USP Product Code: [NA] INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Product Name: levodopa/carbidopa solution Product Code: [ND0612] INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA	NEURODERM LTD.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	482	Phase 3	Portugal;Serbia;United States;Czechia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden;Korea, Republic of
146	EUCTR2018-004156-37-SK (EUCTR)	30/04/2020	13/02/2020	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Levodopa/Carbidopa Solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD / CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	482	Phase 3	United States;Portugal;Serbia;Czechia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden
147	NCT03959540 (ClinicalTrials.gov)	April 28, 2020	23/4/2019	Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease	A Multinational, Multicentre, Prospective Non-interventional Study to Assess Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease	Parkinson Disease	Drug: Opicapone;Drug: Levodopa (L-DOPA) + Standard care	Bial - Portela C S.A.	NULL	Completed	75 Years	N/A	All	39		United Kingdom
148	EUCTR2018-004156-37-BE (EUCTR)	27/04/2020	03/03/2020	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD / CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	482	Phase 3	Serbia;United States;Portugal;Czechia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden
149	EUCTR2018-002233-37-PL (EUCTR)	23/04/2020	24/01/2020	Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.	A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations.	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA Trade Name: Carbidopa and Levodopa Tablets, USP Product Name: IR CD-LD (carbidopa-levodopa) tablets Product Code: IR CD-LD INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA	Impax Laboratories, LLC	NULL	Not Recruiting			Female: yes Male: yes	510	Phase 3	United States;France;Czech Republic;Canada;Spain;Poland;Germany;United Kingdom;Italy
150	EUCTR2019-002951-40-ES (EUCTR)	14/04/2020	06/03/2020	A clinical trial which runs in multiple countries and aims to analyse how efficient, safe and tolerable the investigational product (TAVAPADON) is compared with placebo treatment when given in multiple doses for patients diagnosed with Parkinson's Disease with Motor Fluctuations	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial) - TEMPO-3	Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease with Motor Fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	368	Phase 3	United States;Serbia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden
151	EUCTR2019-002949-38-ES (EUCTR)	07/04/2020	28/02/2020	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	522	Phase 3	United States;Serbia;Spain;Ukraine;Israel;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Bulgaria;Germany;Sweden
152	NCT02967250 (ClinicalTrials.gov)	April 1, 2020	13/9/2016	Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment	7T Magnetic Resonance Spectroscopy Monitoring Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment	Parkinson Disease	Drug: ursodeoxycholic acid	University of Minnesota	NULL	Not yet recruiting	18 Years	N/A	All	20	Phase 1	United States
153	EUCTR2020-000686-16-NL (EUCTR)	26/03/2020	09/03/2020	Validation of finger tapping in PD patients	Randomized, double-blind, placebo-controlled crossover study to validate finger tapping tasks for the quantification of levodopa/carbidopa effects in Parkinson’s Disease patients.	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SINEMET 125 Product Name: SINEMET Product Code: RVG 08740 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopamonohydraat Other descriptive name: CARBIDOPA MONOHYDRATE	Centre for Human Drug Research	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	Netherlands
154	EUCTR2019-003962-41-GB (EUCTR)	23/03/2020	06/02/2020	Trial of Ondansetron as a Parkinson's HAllucinations Treatment: TOP HAT	Trial of Ondansetron as a Parkinson’s HAllucinations Treatment - TOP HAT	Adults aged over 18 years with Parkinson's disease and visual hallucinations MedDRA version: 21.1;Level: LLT;Classification code 10047570;Term: Visual hallucinations;System Organ Class: 100000004873;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]	Trade Name: Ondansetron 8 mg film-coated tablets Product Name: Ondansetron 8 mg film-coated tablets INN or Proposed INN: Ondansetron hydrochloride dihydrate	University College London	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	216	Phase 2	United Kingdom
155	NCT04269642 (ClinicalTrials.gov)	March 19, 2020	13/1/2020	SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease	Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease	Early Parkinson's Disease	Drug: PT320 2.0mg Placebo;Drug: PT320 2.0 mg;Drug: PT320 2.5 mg	Peptron, Inc.	NULL	Active, not recruiting	40 Years	75 Years	All	99	Phase 2	Korea, Republic of
156	EUCTR2017-003415-19-IT (EUCTR)	10/03/2020	19/05/2021	A Clinical Study in Parkinson’s Disease Patients With Moderate to Severe Abnormal Movements to See If JM-010 is Effective and Safe/Tolerable.	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010	Parkinson’s Disease Patients With Moderate to Severe Dyskinesia MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: JM-010 Product Code: JM-010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan Product Name: JM-010 Product Code: JM-010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan	Contera Pharma	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	81	Phase 2	France;Spain;Germany;Italy
157	EUCTR2018-003941-41-AT (EUCTR)	05/03/2020	19/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Not Recruiting			Female: yes Male: yes	258	Phase 3	United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
158	EUCTR2019-002949-38-CZ (EUCTR)	04/03/2020	19/12/2019	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL) - TEMPO-1 Trial	Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	522	Phase 3	United States;Czechia;Spain;Ukraine;Israel;Italy;France;Hungary;Czech Republic;Canada;Poland;Australia;Bulgaria;Germany
159	NCT04127695 (ClinicalTrials.gov)	March 3, 2020	9/10/2019	A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease	A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients With Parkinson's Disease	Parkinson's Disease	Drug: ABBV-0805;Drug: Placebo ABBV-0805	AbbVie	NULL	Withdrawn	N/A	85 Years	All	0	Phase 1	United States;Puerto Rico
160	EUCTR2018-004156-37-AT (EUCTR)	02/03/2020	05/11/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD / CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	482	Phase 3	United States;Portugal;Serbia;Czechia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden
161	NCT04870372 (ClinicalTrials.gov)	March 1, 2020	15/1/2020	Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease	A Multi-center, Open-Label Study to Evaluate the Efficacy and Safety of Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease	Parkinson Disease	Drug: Selegiline	Second Affiliated Hospital of Soochow University	NULL	Completed	30 Years	80 Years	All	141	Phase 4	China
162	NCT04154072 (ClinicalTrials.gov)	February 27, 2020	4/11/2019	A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease	Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease	Parkinson Disease	Drug: NLY01;Drug: Vehicle	Neuraly, Inc.	NULL	Active, not recruiting	30 Years	80 Years	All	255	Phase 2	United States;Canada
163	NCT04291859 (ClinicalTrials.gov)	February 26, 2020	28/2/2020	Lu AF28996 in Participants With Parkinson's Disease (PD)	Interventional, Open-label, Exploratory Study, Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AF28996 in Patients With Parkinson's Disease	Parkinson Disease	Drug: Lu AF28996	H. Lundbeck A/S	NULL	Recruiting	45 Years	75 Years	All	37	Phase 1	United States;Netherlands
164	EUCTR2018-004156-37-ES (EUCTR)	11/02/2020	06/11/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350	Phase 3	Russian Federation;Hungary;United States;Ukraine;United Kingdom;Portugal;Spain;Canada;Austria;Czech Republic;Netherlands;Sweden;Belgium;Korea, Republic of;Poland;Italy;Israel;Slovakia;France;Serbia
165	EUCTR2019-002949-38-HU (EUCTR)	06/02/2020	17/12/2019	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)	Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease	Product Name: Tavapadon 0.25mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 1mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751 Product Name: Tavapadon 5mg Product Code: CVL-751 INN or Proposed INN: TAVAPADON Other descriptive name: PF-06649751	Cerevel Therapeutics, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	522	Phase 3	Hungary;United States;Ukraine;Spain;Canada;Czech Republic;Sweden;Poland;Italy;Israel;Australia;Bulgaria;France;Serbia;Germany
166	NCT04251585 (ClinicalTrials.gov)	February 4, 2020	28/1/2020	Intranasal Insulin in Parkinson's Disease	Single Center Safety and Tolerability Trial of Intranasal Insulin in Parkinson's Disease	Parkinson Disease	Drug: Regular Novolin R;Drug: Placebo	HealthPartners Institute	NULL	Recruiting	41 Years	89 Years	All	30	Phase 2	United States
167	EUCTR2018-003941-41-PT (EUCTR)	03/02/2020	21/08/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure MedDRA version: 20.0;Level: LLT;Classification code 10021102;Term: Hypotension orthostatic symptomatic;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	Portugal;United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
168	NCT04220762 (ClinicalTrials.gov)	January 21, 2020	17/12/2019	A Study to Determine the Dose of WIN-1001X by Evaluating Efficacy and Safety in Early Parkinson's Disease Patients	A Clinical Study to Determine the Optimal Dose of WIN-1001X by Evaluating Its Efficacy and Safety in Patients With Early Parkinson's Disease: Double-blind, Randomized, Placebo-controlled, Multicenter, Phase II Study	Parkinson Disease	Drug: WIN-1001X;Drug: Placebo	Medi Help Line	NULL	Recruiting	30 Years	N/A	All	188	Phase 2	Korea, Republic of
169	NCT04369430 (ClinicalTrials.gov)	January 16, 2020	13/4/2020	Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment	Parkinson Disease	Drug: AKST4290;Drug: Placebo	Alkahest, Inc.	NULL	Completed	50 Years	80 Years	All	110	Phase 2	United States;Estonia;Germany;Poland;Slovakia;Hungary
170	EUCTR2018-004156-37-GB (EUCTR)	14/01/2020	13/09/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350	Phase 3	Russian Federation;Hungary;United States;Ukraine;United Kingdom;Portugal;Spain;Canada;Austria;Czech Republic;Netherlands;Sweden;Belgium;Korea, Republic of;Poland;Italy;Israel;Slovakia;France;Serbia
171	EUCTR2019-001657-42-SK (EUCTR)	14/01/2020	01/10/2019	A study to learn how well the drug AKST4290 works and how safeAKST4290 is in people who have Parkinson's disease that are takingdopamine based medication.	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate theEfficacy and Safety of AKST4290 in Subjects with Parkinson's Disease onStable Dopaminergic Treatment. - N/A	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AKST4290 Product Code: AKST4290 INN or Proposed INN: AKST4290 Other descriptive name: 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE	Alkahest, Inc.	NULL	Not Recruiting			Female: yes Male: yes	120	Phase 2	United States;Hungary;Estonia;Slovakia;Poland;Germany
172	NCT04295642 (ClinicalTrials.gov)	January 8, 2020	24/1/2020	A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease	A 2-Part, Open Label, Adaptive, Single and/or Multiple Oral Dose, Safety, Tolerability, and Food Effect Trial of CVL-751 in Subjects With Parkinson's Disease	Parkinson Disease	Drug: CVL-751	Cerevel Therapeutics, LLC	NULL	Completed	45 Years	75 Years	All	24	Phase 1	United States
173	NCT04223193 (ClinicalTrials.gov)	January 6, 2020	7/1/2020	Flexible-Dose Trial in Early Parkinson's Disease (PD)	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)	Parkinson Disease	Drug: Tavapadon;Drug: Placebo	Cerevel Therapeutics, LLC	NULL	Recruiting	40 Years	80 Years	All	296	Phase 3	United States;Australia;France;Germany;Hungary;Italy;Poland;Serbia;Spain;Ukraine
174	NCT04226248 (ClinicalTrials.gov)	January 2, 2020	5/12/2019	CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)	CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease: A Phase 3 Randomised, Double-blind Placebo-controlled Trial of Rivastigmine to Prevent Falls in Parkinson's Disease.	Parkinson Disease	Drug: Rivastigmine Transdermal System;Other: Placebo Transdermal System	University of Bristol	Royal United Hospitals Bath NHS Foundation Trust	Recruiting	18 Years	N/A	All	600	Phase 3	United Kingdom
175	NCT04152655 (ClinicalTrials.gov)	January 1, 2020	7/10/2019	A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease	A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD)	REM Sleep Behavior Disorder;Parkinson Disease	Drug: Idebenone;Drug: Placebo oral tablet	Second Affiliated Hospital, School of Medicine, Zhejiang University	Peking Union Medical College Hospital;Beijing Hospital;Beijing Tiantan Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Jiangsu Province Nanjing Brain Hospital;The First Affiliated Hospital of Anhui Medical University;Huashan Hospital;Tongji Hospital;Second Affiliated Hospital of Soochow University;Guizhou Medical University;The First Affiliated Hospital of Guangzhou Medical University;Peking University Shenzhen Hospital;West China Hospital;Wuhan Union Hospital, China;Sir Run Run Shaw Hospital;The Affiliated Hospital of Hangzhou Normal University;The First Affiliated Hospital of Dalian Medical University;Qilu Hospital of Shandong University	Recruiting	18 Years	N/A	All	180	Phase 2/Phase 3	China
176	EUCTR2018-004156-37-HU (EUCTR)	19/12/2019	18/10/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Not Recruiting			Female: yes Male: yes	350	Phase 3	United States;Serbia;Portugal;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Belgium;Poland;Netherlands;Sweden;Korea, Republic of
177	NCT03815916 (ClinicalTrials.gov)	December 19, 2019	18/1/2019	31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease	A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Parkinson's Disease	Parkinson's Disease	Drug: Gold Nanocrystals	Clene Nanomedicine	University of Texas Southwestern Medical Center	Completed	30 Years	80 Years	All	13	Phase 2	United States
178	NCT04164121 (ClinicalTrials.gov)	December 17, 2019	12/11/2019	A Randomized, Double-blind, Placebo-controlled, Single-dose, Multiple-dose, Incremental Tolerance and Pharmacokinetics Study of Phenlarmide Tablets in Chinese Healthy Adult Volunteers	A Randomized, Double-blind, Placebo-controlled, Single-dose, Multiple-dose, Incremental Tolerance and Pharmacokinetics Study of Phenlarmide Tablets in Chinese Healthy Adult Volunteers	Parkinson Disease	Drug: Phenlarmide Tablets;Drug: Placebos	Yiling Pharmaceutical Inc.	NULL	Completed	18 Years	65 Years	All	36	Phase 1	China
179	NCT04201093 (ClinicalTrials.gov)	December 13, 2019	13/12/2019	Fixed-Dose Trial in Early Parkinson's Disease (PD)	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)	Parkinson Disease	Drug: Tavapadon;Drug: Placebo	Cerevel Therapeutics, LLC	NULL	Recruiting	40 Years	80 Years	All	522	Phase 3	United States;Australia;Bulgaria;Canada;Czechia;France;Germany;Israel;Italy;Poland;Spain;Ukraine
180	EUCTR2018-004156-37-CZ (EUCTR)	26/11/2019	26/09/2019	A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations (BouNDless) - BouNDless	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: IR LD / CD Product Name: Carbidopa and Levodopa tablets, USP INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	482	Phase 3	Portugal;Serbia;United States;Czechia;Slovakia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Netherlands;Sweden
181	NCT04301492 (ClinicalTrials.gov)	November 20, 2019	17/2/2020	Tolerability, Safety and Efficacy of Vortioxetine	Tolerability, Safety and Efficacy of Vortioxetine for Treatment od Depression in Parkinson's Disease: a 16 Week Open Label Study	Depression	Drug: Vortioxetine	IRCCS San Raffaele Roma	NULL	Recruiting	30 Years	80 Years	All	20	Phase 4	Italy
182	ChiCTR1900027306	2019-11-15	2019-11-08	Application of optical coherence tomography and detection of a-synuclein in tears in the diagnosis of Parkinson's disease	Morphological changes of retina in patients with Parkinson's disease and the role of a-synuclein in retinal damage	Parkinson's disease	Gold Standard:British brain bank Parkinson's disease diagnostic criteria;Index test:Application of optical coherence tomography to observe the retinal structure of the macular area, optic disc area and the expression level of a-synuclein in tears in the diagnosis of Parkinson's disease.;	The First Affiliated Hospital of Chengdu Medical College	NULL	Recruiting			Both	Target condition:85;Difficult condition:85		China
183	NCT03924414 (ClinicalTrials.gov)	November 15, 2019	2/4/2019	Trial of Parkinson's And Zoledronic Acid	TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease	Parkinson Disease;Osteoporosis;Parkinsonism;Parkinson's Disease and Parkinsonism;Atypical Parkinsonism;Progressive Supranuclear Palsy;Multiple System Atrophy;Vascular Parkinsonism;Dementia With Lewy Bodies	Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: Placebo	California Pacific Medical Center Research Institute	National Institute on Aging (NIA);University of California, San Francisco;Duke University;University of Pittsburgh;Parkinson's Foundation	Recruiting	60 Years	N/A	All	3500	Phase 4	United States
184	NCT04148391 (ClinicalTrials.gov)	November 14, 2019	30/10/2019	NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)	A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia	Mild Cognitive Impairment;Mild Dementia;Parkinson Disease;Lewy Body Disease	Drug: Placebo Oral Capsule;Drug: NYX-458	Aptinyx	CogState Ltd.;Worldwide Clinical Trials	Active, not recruiting	50 Years	80 Years	All	99	Phase 2	United States
185	NCT04175132 (ClinicalTrials.gov)	November 12, 2019	12/11/2019	Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)	Interventional, Open-label, Positron Emission Tomography (PET) Study With [11C]-PXT012253 Investigating the Brain mGlu4 Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of Foliglurax in Healthy Subjects and Patients With Parkinson's Disease	Healthy;Parkinson Disease	Drug: foliglurax	H. Lundbeck A/S	NULL	Terminated	50 Years	70 Years	All	6	Phase 1	Sweden
186	ChiCTR1900027210	2019-11-01	2019-11-05	Effects of different anesthesia methods on postoperative delirium in patients with Parkinson's disease and biological markers of postoperative delirium in patients with Parkinson's disease	Effects of different anesthesia methods on postoperative delirium in patients with Parkinson's disease and biological markers of postoperative delirium in patients with Parkinson's disease	Delirium	1:Total Intravenous Anesthesia;2:Balance Anesthesia;	Tsinghua University Yuquan Hospital	NULL	Recruiting			Female	1:60;2:60;		China
187	NCT04164758 (ClinicalTrials.gov)	October 23, 2019	13/11/2019	Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine	A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine	Parkinson's Disease	Drug: Pimavanserin;Other: Placebo;Drug: Quetiapine	ACADIA Pharmaceuticals Inc.	NULL	Terminated	50 Years	85 Years	All	11	Phase 2	United States
188	EUCTR2019-001657-42-DE (EUCTR)	22/10/2019	11/06/2019	A study to learn how well the drug AKST4290 works and how safe AKST4290 is in people who have Parkinson's disease that are taking dopamine based medication.	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson's Disease on Stable Dopaminergic Treatment - N/A	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AKST4290 Product Code: AKST4290 INN or Proposed INN: AKST4290 Other descriptive name: 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE	Alkahest, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Phase 2	United States;Hungary;Estonia;Slovakia;Poland;Germany
189	EUCTR2018-003337-15-ES (EUCTR)	17/10/2019	30/04/2019	A study to look at how safe, and effective the study drug K0706 is in patients with early Parkinson's Disease.	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease	Early Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: K0706 INN or Proposed INN: K0706 Other descriptive name: K0706	Sun Pharma Advanced Research Company (SPARC) Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	504	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United States;Hungary;Czech Republic;Slovakia;Poland;Spain;India
190	NCT04157933 (ClinicalTrials.gov)	October 16, 2019	1/11/2019	Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease	A Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Profile of AZ-009 in Subjects With Established Parkinson's Disease	Parkinson's Disease	Drug: 009-A1;Drug: 009-A2;Drug: 009-A3;Drug: 009-A0;Drug: 009-B1 (active --> placebo) crossover;Drug: 009-B2 (placebo --> active) crossover	Alexza Pharmaceuticals, Inc.	NULL	Completed	30 Years	85 Years	All	35	Phase 1	Netherlands
191	NCT04165837 (ClinicalTrials.gov)	October 14, 2019	13/11/2019	Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects	Parkinson's Disease	Drug: FB-101;Drug: Placebo	1ST Biotherapeutics, Inc.	NULL	Completed	19 Years	55 Years	All	24	Phase 1	United States
192	EUCTR2018-002233-37-GB (EUCTR)	11/10/2019	14/02/2019	Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.	A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations.	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA Trade Name: Carbidopa and Levodopa Tablets, USP Product Name: IR CD-LD (carbidopa-levodopa) tablets Product Code: IR CD-LD INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA	Impax Laboratories, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	510	Phase 3	United States;France;Czech Republic;Poland;Spain;Germany;Italy;United Kingdom
193	EUCTR2018-003941-41-BG (EUCTR)	10/10/2019	26/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Not Recruiting			Female: yes Male: yes	258	Phase 3	United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
194	NCT03987750 (ClinicalTrials.gov)	October 2019	12/6/2019	Safinamide for Levodopa-induced Dyskinesia (PD-LID)	A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations	Dyskinesia, Drug-Induced;Parkinson Disease	Drug: Safinamide Methanesulfonate 150mg;Drug: Safinamide Methanesulfonate 100mg;Drug: Safinamide Methanesulfonate matching placebo	Zambon SpA	NULL	Withdrawn	30 Years	N/A	All	0	Phase 3	NULL
195	EUCTR2018-003941-41-IT (EUCTR)	17/09/2019	18/01/2021	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure MedDRA version: 20.0;Level: LLT;Classification code 10021102;Term: Hypotension orthostatic symptomatic;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: NA Product Code: [TD-9855] INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Not Recruiting			Female: yes Male: yes	258	Phase 3	Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand;Estonia;Spain;Ukraine;Portugal;United States
196	EUCTR2018-002144-85-NL (EUCTR)	11/09/2019	27/03/2019	Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study	A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa-4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa-4'-Monophosphate	AbbVie Deutschland	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Belgium;Spain;Denmark;Australia;Germany;Netherlands;United Kingdom;Japan
197	NCT04075318 (ClinicalTrials.gov)	August 29, 2019	5/8/2019	Study of UB-312 in Healthy Participants and Parkinson's Disease Patients	A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease	Parkinson's Disease;Parkinsonism	Biological: UB-312;Biological: Placebo	United Neuroscience Ltd.	Centre for Human Drug Research, Netherlands;Worldwide Clinical Trials;Vaxxinity, Inc.	Active, not recruiting	40 Years	85 Years	All	70	Phase 1	Netherlands
198	NCT04006210 (ClinicalTrials.gov)	August 27, 2019	30/6/2019	Efficacy, Safety and Tolerability Study of ND0612 vs. Oral IR-LD/CD in Subjects With PD Experiencing Motor Fluctuations	A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Study of the Efficacy, Safety, and Tolerability of Continuous SC ND0612 Infusion vs. Oral IR-LD/CD in Subjects With PD Experiencing Motor Fluctuations	Parkinson's Disease	Combination Product: ND0612 Solution for SC infusion;Combination Product: Placebo for SC infusion;Drug: Carbidopa and Levodopa 25mg/100mg;Drug: Placebo for Carbidopa and Levodopa 25mg/100mg	NeuroDerm Ltd.	NULL	Active, not recruiting	30 Years	80 Years	All	381	Phase 3	United States;Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom
199	EUCTR2018-003941-41-PL (EUCTR)	23/08/2019	03/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Not Recruiting			Female: yes Male: yes	258	Phase 3	Portugal;United States;Estonia;Spain;Ukraine;Austria;Chile;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Denmark;Australia;Peru;Bulgaria;Germany;New Zealand
200	EUCTR2018-002144-85-BE (EUCTR)	20/08/2019	24/04/2019	Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study	A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa-4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa-4'-Monophosphate	AbbVie Deutschland	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United States;Canada;Spain;Belgium;Denmark;Australia;Germany;Netherlands;United Kingdom;Japan
201	EUCTR2018-003941-41-ES (EUCTR)	13/08/2019	11/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
202	NCT03976349 (ClinicalTrials.gov)	August 12, 2019	4/6/2019	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease	A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's Disease	Parkinson's Disease	Drug: BIIB094;Drug: Placebo	Biogen	Ionis Pharmaceuticals, Inc.	Recruiting	35 Years	80 Years	All	82	Phase 1	United States;Canada;Israel;Norway;Spain;United Kingdom
203	NCT04043338 (ClinicalTrials.gov)	August 11, 2019	24/7/2019	Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of XC130-A10H in Healthy Adult Subjects	Parkinson's Disease	Drug: XC130-A10H;Drug: Placebo	Xoc Pharmaceuticals	Celerion	Active, not recruiting	18 Years	75 Years	All	56	Phase 1	United States
204	EUCTR2018-003941-41-GB (EUCTR)	09/08/2019	16/05/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;Italy;United Kingdom;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
205	NCT03881371 (ClinicalTrials.gov)	August 1, 2019	18/3/2019	A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa	A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa	Parkinson Disease	Drug: Safinamide;Other: Placebo	Zambon SpA	NULL	Completed	18 Years	N/A	All	307	Phase 3	China
206	JPRN-UMIN000037421	2019/08/01	01/08/2019	A study on improvement of cognitive function by istradefylline for parkinson disease	An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease - A study on improvement of cognitive function by istradefylline for parkinson disease	Parkinson disease	Prescription istradefylline 20 mg for 1 month. If there are no side effects, We increase to 40 mg and prescribe for 2 months. The assessments will be made in all patients participating the study, patients with MMSE scores of 26 or more, patients with MMSE score of less than 26.	Ichinomiya Nishi Hospital	NULL	Complete: follow-up continuing	40years-old	85years-old	Male and Female	25	Not selected	Japan
207	JPRN-UMIN000037422	2019/08/01	01/08/2019	An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease	An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease - An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease	Parkinson disease	Prescription istradefylline 20 mg for 1 month, and if there are no side effects, increase to 40 mg and prescribe for 2 months.	Ichinomiya Nishi Hospital	NULL	Complete: follow-up continuing	40years-old	85years-old	Male and Female	25	Not selected	Japan
208	EUCTR2018-003941-41-HU (EUCTR)	30/07/2019	01/08/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Not Recruiting			Female: yes Male: yes	258	Phase 3	Portugal;United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
209	EUCTR2018-002144-85-GB (EUCTR)	29/07/2019	13/03/2019	Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study	A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa-4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa-4'-Monophosphate	AbbVie Deutschland	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Belgium;Spain;Denmark;Australia;Germany;Netherlands;Japan;United Kingdom
210	NCT04056689 (ClinicalTrials.gov)	July 23, 2019	12/8/2019	Study to Evaluate DNL151 in Subjects With Parkinson's Disease	A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: DNL151;Drug: Placebo	Biogen	NULL	Completed	30 Years	75 Years	All	36	Phase 1	United States;Belgium;Netherlands;United Kingdom
211	NCT03575195 (ClinicalTrials.gov)	July 15, 2019	21/6/2018	Microbiota Intervention to Change the Response of Parkinson's Disease	Microbiota Intervention to Change the Response of Parkinson's Disease	Parkinson Disease	Drug: Rifaximin;Other: Placebo	University of California, San Francisco	Nova Southeastern University;Gateway Institute for Brain Research	Recruiting	30 Years	N/A	All	86	Phase 1/Phase 2	United States
212	EUCTR2018-002144-85-ES (EUCTR)	11/07/2019	12/04/2019	Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study	A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa-4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa-4'-Monophosphate	AbbVie Deutschland	NULL	Not Recruiting			Female: yes Male: yes	130	Phase 3	United States;Canada;Belgium;Spain;Denmark;Australia;Germany;Netherlands;Italy;United Kingdom;Japan
213	EUCTR2018-002144-85-DK (EUCTR)	08/07/2019	14/03/2019	Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study	A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa-4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa-4'-Monophosphate	AbbVie Deutschland	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	United States;Canada;Belgium;Spain;Australia;Denmark;Germany;Netherlands;Italy;United Kingdom;Japan
214	EUCTR2018-003941-41-EE (EUCTR)	04/07/2019	29/05/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood Study	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Not Recruiting			Female: yes Male: yes	258	Phase 3	Portugal;United States;Estonia;Spain;Ukraine;Austria;Chile;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Denmark;Australia;Peru;Bulgaria;Germany;New Zealand
215	JPRN-UMIN000037390	2019/07/01	16/07/2019	An exploratory study to optimize the administration of COMT inhibitor on LCIG therapy	An exploratory study to optimize the administration of COMT inhibitor on LCIG therapy - Levodopa pharmacokinetics on concomitant use of LCIG therapy and COMT inhibitor	Parkinson's disease	Entacapone 100mg	Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine	Saiseikai Matsuyama Hospital	Pending	20years-old	Not applicable	Male and Female	10	Not selected	Japan
216	ChiCTR1900021708	2019-07-01	2019-03-05	Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphi	Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphism	Parkinson's Disease	Healthy control group:No;tremor-dominant phenotype PD patients group:pramipexole;	Department of Neurology, Brain Hospital Affiliated to Nanjing Medical University	NULL	Pending	50	70	Both	Healthy control group:80;tremor-dominant phenotype PD patients group:80;		China
217	EUCTR2018-003219-23-GB (EUCTR)	28/06/2019	04/06/2019	CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease)	CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease): A phase 3 randomised double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease - CHIEF-PD	This trial will investigate the effectiveness of Rivastigmine on prevention of falls in patients with Parkinson's disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rivastigmin Luye Transdermal Patches - 4.6mg/24h Product Name: Rivastigmin Luye Transdermal Patches - 4.6mg/24h Product Code: N/A INN or Proposed INN: Rivastigmine Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below) Trade Name: Rivastigmine Luye Transdermal Patch- 9.5mg/24h Product Name: Rivastigmine Luye Transdermal Patch- 9.5mg/24h INN or Proposed INN: Rivastigmine Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below) Product Name: Rivastigmine transdermal system 13.3 mg/24 h Product Code: RIV-TDS 13.3 mg/24 h INN or Proposed INN: Rivastigmine Other descriptive name: Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)	University of Bristol	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	United Kingdom
218	EUCTR2018-002144-85-IT (EUCTR)	21/06/2019	15/06/2021	Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion study	A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde	Parkinson's Disease MedDRA version: 21.1;Level: PT;Classification code 10068100;Term: Vascular parkinsonism;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ABBV-951 Product Code: [ABBV-951] INN or Proposed INN: Foslevodopa Other descriptive name: Levodopa-4'-Monophosphate INN or Proposed INN: Foscarbidopa Other descriptive name: Carbidopa-4'-Monophosphate	ABBVIE DEUTSCHLAND GMBH & CO. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Belgium;Spain;Denmark;Australia;Germany;Netherlands;United Kingdom;Japan;Italy
219	EUCTR2018-003337-15-HU (EUCTR)	18/06/2019	12/04/2019	A study to look at how safe, and effective the study drug K0706 is in patients with early Parkinson's Disease.	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease	Early Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: K0706 INN or Proposed INN: K0706 Other descriptive name: K0706 Product Code: K0706 INN or Proposed INN: K0706 Other descriptive name: K0706 Product Code: K0706 INN or Proposed INN: K0706 Other descriptive name: K0706	Sun Pharma Advanced Research Company (SPARC) Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	504	Phase 2	United States;Hungary;Slovakia;Spain;Poland;India
220	NCT03938922 (ClinicalTrials.gov)	June 13, 2019	18/4/2019	A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia	A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.	Parkinson Disease;Dementia	Drug: Active Investigational Treatment ENT-01	Enterin Inc.	NULL	Active, not recruiting	30 Years	90 Years	All	40	Phase 1	United States
221	EUCTR2018-003337-15-SK (EUCTR)	05/06/2019	26/04/2019	A study to look at how safe, and effective the study drug K0706 is in patients with early Parkinson's Disease.	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease	Early Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: K0706 INN or Proposed INN: K0706 Other descriptive name: K0706 Product Code: K0706 INN or Proposed INN: K0706 Other descriptive name: K0706 Product Code: K0706 INN or Proposed INN: K0706 Other descriptive name: K0706	Sun Pharma Advanced Research Company (SPARC) Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	504	Phase 2	United States;Hungary;Slovakia;Spain;Poland;India
222	JPRN-jRCTs031180248	29/05/2019	12/03/2019	N/A	Intervention study for the effect of Istradefylline on adjustment of Levodopa in Parkinson's Disease - Istra adjust PD	Parkinson's disease	Arm with treatment of Istradefylline and levodopa Treatment with Istradefylline will be started at a dose of 20 mg administered once daily at Week 0. The dose of Istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 1. Dose reduction is possible if the patient has tolerability issues. Patients will visit every 4 weeks from the following day of Week0, and 50mg levodopa will be added of if CGI-S score >=4 every time. Dose reduction is possible if the patient has tolerability issues. Arm without treatment of Istradefylline 50mg levodopa will be added at Week 0. Patients will visit every 4 weeks from the following day of Week0, and 50mg levodopa will be added of if CGI-S score >=4 every time. Dose reduction is possible if the patient has tolerability issues.	Hatano Taku	Kyowa Kirin Co., Ltd	Complete	>= 30age old	<= 84age old	Both	111	N/A	Japan
223	NCT03971617 (ClinicalTrials.gov)	May 29, 2019	30/5/2019	Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease	A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson's Disease	Parkinson Disease	Drug: Hydrogen;Drug: Placebo oral tablet	Stony Brook University	NULL	Terminated	40 Years	80 Years	All	2	Phase 2/Phase 3	United States
224	NCT03671785 (ClinicalTrials.gov)	May 15, 2019	12/9/2018	Study of the Fecal Microbiome in Patients With Parkinson's Disease	A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Parkinson's Disease	Parkinson Disease	Drug: PRIM-DJ2727;Drug: Placebo oral capsule	The University of Texas Health Science Center, Houston	Kelsey Research Foundation	Active, not recruiting	55 Years	75 Years	All	12	Phase 1	United States
225	NCT03693872 (ClinicalTrials.gov)	May 15, 2019	1/10/2018	Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals	Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals	Parkinson Disease	Drug: Apomorphine;Drug: Dopaminergic Agonist + Apomorphine	Rennes University Hospital	NULL	Recruiting	18 Years	N/A	All	42	N/A	France
226	NCT03970239 (ClinicalTrials.gov)	May 13, 2019	6/5/2019	Serotonin in Impulse Control Disorders in Parkinson's Disease	Role of the Serotoninergic System in Impulse Control Disorders in Parkinson's Disease	Parkinson Disease;Impulse Control Disorders	Drug: Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin);Drug: Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)	Hospices Civils de Lyon	NULL	Recruiting	30 Years	80 Years	All	45	N/A	France
227	NCT04875962 (ClinicalTrials.gov)	May 6, 2019	3/5/2021	A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)	A Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)	Parkinson's Disease	Drug: UCB0599;Drug: Placebo	UCB Biopharma S.P.R.L.	NULL	Completed	40 Years	80 Years	All	31	Phase 1	United States
228	EUCTR2018-002233-37-IT (EUCTR)	03/05/2019	07/01/2021	Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson's with motor fluctuations.	A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations. - NA	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IPX203 Product Code: [IPX203] INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA INN or Proposed INN: CARBIDOPA Other descriptive name: ANHYDROUS CARBIDOPA Trade Name: Carbidopa and Levodopa Tablets, USP Product Name: IR CD-LD (carbidopa-levodopa) tablets Product Code: [IR CD-LD] INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Other descriptive name: ANHYDROUS CARBIDOPA	Impax Laboratories, LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	510	Phase 3	France;United States;Czechia;Poland;Spain;Germany;United Kingdom;Italy
229	NCT03781167 (ClinicalTrials.gov)	April 29, 2019	18/12/2018	A Study to Evaluate the Safety and Tolerability of ABBV-951 in Participants With Parkinson's Disease (PD)	A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease	Parkinson's Disease (PD)	Drug: ABBV-951	AbbVie	NULL	Completed	30 Years	N/A	All	244	Phase 3	United States;Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;France
230	NCT03899324 (ClinicalTrials.gov)	April 26, 2019	29/3/2019	Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease	A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease	Parkinson Disease	Drug: Bumetanide white, oblong, scored tablet;Drug: Placebo white, oblong, scored tablet	B&A Therapeutics	NULL	Recruiting	40 Years	80 Years	All	40	Phase 2	France
231	JPRN-JapicCTI-194763	22/4/2019	20/05/2019	Safety and PK study of LY03003	An open-label study in Japanese patients with Parkinson's disease to evaluate the safety, pharmacokinetics and preliminary efficacy of LY03003 following intramuscular injections and its comparative bioavailability to Rotigotine transdermal patch.	Parkinson's Disease	Intervention name : Rotigotine INN of the intervention : Rotigotine Dosage And administration of the intervention : LY03003 IM injections 14, 28 and 56 mg/week. Control intervention name : Rotigotine INN of the control intervention : Rotigotine Dosage And administration of the control intervention : Rotigotine transdermal patch applications 4.5, 9 and 18 mg/day.	Shandong Luye Pharmaceutical Co., Ltd./CMIC Co., Ltd.	NULL	complete	20		BOTH	32	Phase 1	Japan
232	EUCTR2018-002233-37-DE (EUCTR)	17/04/2019	08/01/2019	Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.	A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations.	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA Trade Name: Carbidopa and Levodopa Tablets, USP Product Name: IR CD-LD (carbidopa-levodopa) tablets Product Code: IR CD-LD INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA	Impax Laboratories, LLC	NULL	Not Recruiting			Female: yes Male: yes	510	Phase 3	United States;France;Czechia;Poland;Spain;Germany;United Kingdom;Italy
233	NCT03661125 (ClinicalTrials.gov)	April 11, 2019	4/9/2018	SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis	A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.	Parkinson Disease Psychosis	Drug: Saracatinib;Drug: Placebo Oral Tablet	King's College London	AstraZeneca;King's College Hospital NHS Trust	Recruiting	40 Years	N/A	All	30	Early Phase 1	United Kingdom
234	NCT03841604 (ClinicalTrials.gov)	April 9, 2019	30/1/2019	Effect of Safinamide on Parkinson's Disease Related Chronic Pain	A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide 100mg Once Daily, as add-on Therapy, in Idiopathic Parkinson's Disease (PD) Patients With Motor Fluctuations and PD Related Chronic Pain	Idiopathic Parkinson Disease	Drug: Safinamide Methanesulfonate;Drug: Safinamide methanesulfonate matching placebo	Zambon SpA	NULL	Completed	30 Years	N/A	All	71	Phase 4	Austria;France;Germany;Italy;Spain
235	EUCTR2017-002426-20-FR (EUCTR)	05/04/2019	26/11/2018	Effect of Safinamide on Parkinson’s Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson’s Disease (IPD) patients with motor fluctuations and PD related chronic pain - Pain study	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON” phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain. MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descriptive name: SAFINAMIDE METHANESULFONATE Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descriptive name: SAFINAMIDE METHANESULFONATE	Zambon SpA	NULL	Not Recruiting			Female: yes Male: yes	177	Phase 4	France;Spain;Austria
236	EUCTR2016-000657-12-GR (EUCTR)	04/04/2019	11/01/2019	A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation	Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant - MOVES-PD	Parkinson's disease (PD) carrying a GBA mutation MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: - Other descriptive name: Genz-682452-AU Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: - Other descriptive name: Genz-682452-AU	Genzyme Corporation	NULL	Not Recruiting			Female: yes Male: yes	290	Phase 2	Taiwan;United States;Portugal;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Germany;Norway;Japan;Sweden
237	ChiCTR1800015757	2019-04-01	2018-04-18	Value of 131I-MIBG salivary gland imaging in the early diagnosis of Parkinson's disease	Value of 131I-MIBG salivary gland imaging in the early diagnosis of Parkinson's disease	Parkinson's Disease	Gold Standard:PD diagnostic criteria made by MDS in 2016;Index test:reduced uptake in salivery gland and myocardium in I-131-MIBG scintigraphic imaging;	Tongji hospital, Tongji University	NULL	Pending			Both	Target condition:30;Difficult condition:30		China
238	NCT03922711 (ClinicalTrials.gov)	March 26, 2019	17/4/2019	A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease	A Double-Blind, Randomized, Three-Arm, Parallel-Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease (gLIDe)	Parkinson Disease	Drug: Pridopidine;Drug: Placebo	Prilenia	NULL	Terminated	30 Years	85 Years	All	23	Phase 2	United States
239	EUCTR2018-002233-37-CZ (EUCTR)	18/03/2019	11/12/2018	Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.	A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations.	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Classification code 10028035;Term: Movement disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IPX203 Product Code: IPX203 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA Trade Name: Carbidopa and Levodopa Tablets, USP Product Name: IR CD-LD (carbidopa-levodopa) tablets Product Code: IR CD-LD INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: ANHYDROUS CARBIDOPA	Impax Laboratories, LLC	NULL	Not Recruiting			Female: yes Male: yes	510	Phase 3	United States;France;Czech Republic;Poland;Spain;Germany;United Kingdom;Italy
240	NCT03716570 (ClinicalTrials.gov)	March 12, 2019	22/10/2018	A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease	A Multicenter, Blinded, Placebo-Controlled, Randomized, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Subjects With Parkinson's Disease	Parkinson's Disease	Drug: BIIB054;Drug: Placebo	Biogen	NULL	Terminated	40 Years	80 Years	All	24	Phase 1	Japan
241	NCT03820037 (ClinicalTrials.gov)	March 2019	25/1/2019	Relative Bioavailability and Bioequivalence of Opicapone	A Phase I, Open-Label, Randomised, Three-Period, Three-Sequence, Partial Replicate Crossover Study to Investigate the Relative Bioavailability and Bioequivalence of Opicapone Obtained From Two Different Sources, Under Fasting Conditions After Single-dose Administration in Healthy Subjects	Parkinson Disease	Drug: Ongentys;Drug: BIA 9-1067 (test)	Bial - Portela C S.A.	NULL	Not yet recruiting	18 Years	55 Years	All	45	Phase 1	United Kingdom
242	EUCTR2017-002426-20-IT (EUCTR)	21/02/2019	07/10/2020	Effect of Safinamide on Parkinson's Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson's Disease (IPD) patients with motor fluctuations and PD related chronic pain - Pain study	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain. MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xadago Product Name: Xadago Product Code: [-] INN or Proposed INN: SAFINAMIDE METANSOLFONATO Other descriptive name: SAFINAMIDE METHANESULFONATE Trade Name: Xadago Product Name: Xadago Product Code: [-] INN or Proposed INN: SAFINAMIDE METANSOLFONATO Other descriptive name: SAFINAMIDE METHANESULFONATE	ZAMBON SPA	NULL	Not Recruiting			Female: yes Male: yes	177	Phase 4	Germany;Italy;France;Spain;Austria
243	NCT03968744 (ClinicalTrials.gov)	February 18, 2019	19/4/2019	Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease	A Prospective, Open Label, Single Arm, Clinical Study to Evaluate the Effect of Safinamide on Sleep Quality and Polysomnographic Parameters in Patients With Parkinson's Disease: the Safe Sleep Study	Idiopathic Parkinson's Disease (at Later Stage)	Drug: Safinamide	Alain Kaelin	Clinical Trial Unit Ente Ospedaliero Cantonale	Recruiting	18 Years	N/A	All	23	Phase 4	Switzerland
244	NCT03413384 (ClinicalTrials.gov)	February 15, 2019	8/1/2018	To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia	A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia	Parkinson's Disease Dementia	Drug: Ceftriaxone;Other: Placebo	BrainX Corporation	Virginia Contract Research Organization Co., Ltd.	Recruiting	50 Years	80 Years	All	106	Phase 2	Taiwan
245	NCT04510922 (ClinicalTrials.gov)	February 11, 2019	9/7/2020	Lundbeck TOMs Orthostatic Hypotension	Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients With Orthostatic Hypotension: Feasibility and Effect-Size Finding Study	Orthostatic Hypotension;Idiopathic Parkinson Disease	Drug: Droxidopa 100 MG [Northera]	Alberto Espay, MD, MSc	Lundbeck LLC	Completed	30 Years	80 Years	All	10	Phase 4	United States
246	NCT03790670 (ClinicalTrials.gov)	January 30, 2019	18/12/2018	Biomarker Assessments of Leukine During Treatment of Parkinson's Disease	Safety, Tolerability and Biomarker Assessments of Leukine (Sargramostim) During Extended Timed Treatment for Parkinson's Disease: A Phase I Pilot Study	Parkinson Disease	Drug: sargramostim	University of Nebraska	NULL	Active, not recruiting	35 Years	85 Years	All	7	Phase 1	United States
247	EUCTR2017-003458-18-SE (EUCTR)	23/01/2019	10/12/2018	A clinical trial to study the effects of IRL790 in Parkinson's disease dyskinesia	A randomised, double-blind, placebo-controlled, phase IIA study evaluating the efficacy and tolerability of IRL790 in Parkinson's disease dyskinesia	Parkinson's disease dyskinesia MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IRL790 Product Code: IRL790 INN or Proposed INN: IRL790	Integrative Research Laboratories AB (IRLAB)	NULL	Not Recruiting			Female: yes Male: yes	74	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Sweden
248	EUCTR2017-002426-20-AT (EUCTR)	22/01/2019	03/12/2018	Effect of Safinamide on Parkinson’s Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson’s Disease (IPD) patients with motor fluctuations and PD related chronic pain - Pain study	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON” phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain. MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descriptive name: SAFINAMIDE METHANESULFONATE Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descriptive name: SAFINAMIDE METHANESULFONATE	Zambon SpA	NULL	Not Recruiting			Female: yes Male: yes	105	Phase 4	Spain;Austria
249	NCT03826134 (ClinicalTrials.gov)	January 17, 2019	30/1/2019	A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects	Interventional, Phase I, Open-label, First in Human, Single-center Positron Emission Tomography (PET) Study Investigating Test-retest Properties of [11C]-PXT012253 as a Radiotracer in Healthy Subjects	Parkinson Disease	Drug: [11C]PXT012253	H. Lundbeck A/S	NULL	Completed	20 Years	50 Years	All	7	Early Phase 1	Sweden
250	NCT03391882 (ClinicalTrials.gov)	December 19, 2018	2/1/2018	A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)	An Open-Label, Randomized, Crossover Trial Utilizing a Single-Blinded Rater to Evaluate APL-130277 Compared to Subcutaneous Apomorphine in Levodopa Responsive Subjects With Parkinson's Disease Complicated by Motor Fluctuations	Motor OFF Episodes Associated With Parkinson's Disease	Drug: APL-130277;Drug: subcutaneous apomorphine	Sunovion	NULL	Completed	18 Years	N/A	All	113	Phase 3	Austria;France;Germany;Italy;Spain;United Kingdom
251	NCT03840005 (ClinicalTrials.gov)	December 18, 2018	11/2/2019	Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The UP Study	A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)	Parkinson's Disease	Drug: Ursonorm	Sheffield Teaching Hospitals NHS Foundation Trust	JP Moulton Charitable Foundation;PRO.MED.CS Praha a.s.;Clinical Trials Research Unit, University of Sheffield	Completed	18 Years	75 Years	All	31	Phase 2	United Kingdom
252	NCT03781791 (ClinicalTrials.gov)	December 10, 2018	27/11/2018	Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)	Constipation;Parkinson Disease	Drug: Active Investigational Treatment ENT-01;Drug: Placebo Treatment	Enterin Inc.	NULL	Completed	30 Years	90 Years	All	144	Phase 2	United States
253	NCT03710707 (ClinicalTrials.gov)	December 4, 2018	15/10/2018	Study to Evaluate DNL201 in Subjects With Parkinson's Disease	A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease	Parkinson Disease	Drug: DNL201;Drug: Placebo	Denali Therapeutics Inc.	NULL	Completed	30 Years	80 Years	All	29	Phase 1	United States
254	NCT03944447 (ClinicalTrials.gov)	December 1, 2018	3/5/2019	Outcomes Mandate National Integration With Cannabis as Medicine	Outcomes Mandate National Integration With Cannabis as Medicine	Chronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar Disorder;Covid19;SARS-CoV Infection;COVID-19;Corona Virus Infection;Coronavirus	Drug: Cannabis, Medical;Device: RYAH-Medtech Inhaler	OMNI Medical Services, LLC	OMNI Medical Services Inc	Recruiting	7 Years	N/A	All	200000	Phase 2	United States
255	NCT03639064 (ClinicalTrials.gov)	December 2018	4/7/2018	Cannabis Oil for Pain in Parkinson's Disease	A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease	Parkinson Disease	Drug: Cannabis Oil	University Health Network, Toronto	Parkinson Society Canada	Unknown status	18 Years	N/A	All	15	Phase 2	NULL
256	NCT03822364 (ClinicalTrials.gov)	November 26, 2018	18/12/2018	Staccato Apomorphine Single and Multi Dose PK	A Randomized Study of the Safety, Tolerability, and Pharmacokinetics of AZ-009 (Staccato Apomorphine) in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZ-009 in Subjects With Parkinson's Disease	Parkinson Disease	Drug: 009-1;Drug: active comparator;Drug: 009-0;Drug: 009-2;Drug: 009-3;Drug: 009-4;Drug: 009-5	Alexza Pharmaceuticals, Inc.	NULL	Completed	18 Years	60 Years	All	56	Phase 1	Netherlands
257	NCT03823638 (ClinicalTrials.gov)	November 20, 2018	20/11/2018	Safety, Tolerability and Effects of Mannitol in Parkinson's Disease	A Phase II Single Center, Randomized, Double Blind and Placebo Controlled Study Assessing the Safety, Tolerability and Effects of Progressively Increased Dose of Oral Mannitol in Parkinson's Disease	Parkinson Disease	Dietary Supplement: Oral D-Mannitol of Placebo	Hadassah Medical Organization	NULL	Recruiting	40 Years	75 Years	All	60	Phase 2	Israel
258	NCT03713957 (ClinicalTrials.gov)	November 12, 2018	18/10/2018	A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment	Parkinson Disease	Drug: GRF6021;Other: Placebo	Alkahest, Inc.	Michael J. Fox Foundation for Parkinson's Research	Completed	40 Years	85 Years	All	79	Phase 2	United States;Australia;France
259	NCT03733561 (ClinicalTrials.gov)	November 9, 2018	6/11/2018	A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro	A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers	Parkinson Disease	Drug: LY03003;Drug: Neupro 4Mg/24Hr Transdermal Patch	Luye Pharma Group Ltd.	NULL	Completed	18 Years	45 Years	All	40	Phase 1	United States
260	EUCTR2018-001887-46-GB (EUCTR)	08/11/2018	19/06/2019	Trial of Ursodeoxycholic Acid (UDCA) for PD. The 'UP-study'	A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial to assess the safety and tolerability Of 30mg/kg daily Ursodeoxycholic Acid (UDCA) in Patients with Parkinson’s Disease (PD) - Trial of Ursodeoxycholic Acid (UDCA) for PD. The 'UP-study'	Parkinson’s disease (PD) MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ursonorm Product Name: Ursonorm INN or Proposed INN: Ursodeoxycholic acid	Sheffield Teaching Hospitals NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
261	NCT03667404 (ClinicalTrials.gov)	November 6, 2018	10/9/2018	Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study	Gut Microbial Remodeling With Resistant Maltodextrin for Motor and Non-motor Symptoms in Parkinson's Disease: Safety and Tolerability Study	Parkinson Disease;Intestinal Bacteria Flora Disturbance;Dietary Modification	Dietary Supplement: maltodextrin;Dietary Supplement: Resistant maltodextrin	Northwestern University	University of Illinois at Chicago	Active, not recruiting	60 Years	N/A	All	30	Phase 2	United States
262	NCT03670953 (ClinicalTrials.gov)	November 6, 2018	12/9/2018	A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor Fluctuations	A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations	Parkinson's Disease (Disorder)	Drug: IR CD-LD;Drug: IPX203 ER CD-LD;Other: IPX203 placebo;Other: IR CD-LD placebo	Impax Laboratories, LLC	NULL	Completed	40 Years	N/A	All	631	Phase 3	United States;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom
263	NCT04629404 (ClinicalTrials.gov)	November 5, 2018	5/11/2020	A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of Multiple Intramuscular Doses of LY03003 in Patients With Early Parkinson's Disease	Parkinson Disease	Drug: LY03003;Drug: Placebo	Luye Pharma Group Ltd.	NULL	Completed	30 Years	N/A	All	32	Phase 1	China
264	JPRN-JapicCTI-184181	01/11/2018	30/10/2018	Rasagiline Tablets Special Drug Use-Results Survey Survey on Long-term Safety	AZILECT Tablets Special Drug Use-Results Survey Survey on Long-term Safety	Parkinson's disease	Intervention name : Rasagiline INN of the intervention : rasagiline Dosage And administration of the intervention : Rasagiline 1 milligram (mg), orally, once daily for up to 24 months. Participants received interventions as part of routine medical care. Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -	TAKEDA PHARMACEUTICAL COMPANY LTD.	NULL	complete			BOTH	1021	NA	Japan
265	EUCTR2016-002033-30-NL (EUCTR)	31/10/2018	15/11/2017	A clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuations	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO) - iNDiGO	Subjects with Parkinson’s Disease with motor fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Serbia;Portugal;United States;Spain;Ukraine;Russian Federation;Chile;Israel;Italy;United Kingdom;France;Czech Republic;Hungary;Poland;Belgium;Denmark;Netherlands;Germany
266	EUCTR2017-003415-19-ES (EUCTR)	31/10/2018	20/08/2018	A Clinical Study in Parkinson’s Disease Patients With Moderate to Severe Abnormal Movements to See If JM-010 is Effective and Safe/Tolerable.	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations Of JM-010	Parkinson’s Disease Patients With Moderate to Severe Dyskinesia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: JM-010 Product Code: JM-010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan Product Name: JM-010 Product Code: JM-010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan	Contera Pharma	NULL	Not Recruiting			Female: yes Male: yes	81	Phase 2	France;Spain;Germany
267	EUCTR2017-002426-20-ES (EUCTR)	19/10/2018	20/08/2018	Effect of Safinamide on Parkinson’s Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson’s Disease (IPD) patients with motor fluctuations and PD related chronic pain - Pain study	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON” phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain. MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descriptive name: SAFINAMIDE METHANESULFONATE Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descriptive name: SAFINAMIDE METHANESULFONATE	Zambon SpA	NULL	Not Recruiting			Female: yes Male: yes	177	Phase 4	France;Spain;Austria;Italy
268	EUCTR2018-000346-19-FI (EUCTR)	03/10/2018	09/07/2018	An extended clinical study to test the safety of Cerebral Dopamine Neurotrophic Factor (CDNF) by brain infusion via Drug Delivery System (DDS) in patients with Parkinson's disease.	A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002. - Extension Study	Idiopathic Parkinson's Disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cerebral Dopamine Neurotrophic Factor Product Code: CDNF INN or Proposed INN: Not Applicable Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor	Herantis Pharma Plc	NULL	Not Recruiting			Female: yes Male: yes	18	Phase 1;Phase 2	Finland;Sweden
269	EUCTR2016-004610-95-DE (EUCTR)	01/10/2018	27/02/2018	Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: BIIB054 INN or Proposed INN: n/a Other descriptive name: BIIB054	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	357	Phase 2	France;United States;Canada;Spain;Austria;Israel;Germany;United Kingdom;Italy
270	NCT03665454 (ClinicalTrials.gov)	September 24, 2018	1/8/2018	PF 06412562 in Subjects With Advanced Stage Parkinson's Disease	A Phase Ib Safety, Tolerability, and Efficacy Study of Two Days of Oral Split Dose (25/20 mg) Administration of PF 06412562 in Subjects With Advanced Stage Parkinson's Disease	Parkinson Disease	Drug: PF-06412562;Drug: Standard of Care Placebo	Milton S. Hershey Medical Center	Pfizer	Completed	N/A	N/A	All	8	Phase 1	United States
271	NCT03582137 (ClinicalTrials.gov)	September 17, 2018	17/4/2018	A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease	A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease	Parkinson Disease	Drug: Cannabidiol;Other: Placebo	University of Colorado, Denver	Colorado Department of Public Health and Environment	Completed	40 Years	85 Years	All	74	Phase 2	United States
272	NCT03608371 (ClinicalTrials.gov)	August 31, 2018	9/5/2018	BTRX-246040 Study in Subjects With Parkinson's Disease With Motor Fluctuations	Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations	Parkinson Disease;Motor Disorder	Drug: BTRX-246040;Drug: Placebo	BlackThorn Therapeutics, Inc.	NULL	Completed	30 Years	76 Years	All	24	Phase 2	United States
273	EUCTR2016-004610-95-FR (EUCTR)	08/08/2018	01/03/2018	Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: BIIB054 INN or Proposed INN: n/a Other descriptive name: BIIB054	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	311	Phase 2	United States;France;Canada;Spain;Austria;Israel;Germany;United Kingdom;Italy;Sweden
274	NCT03773796 (ClinicalTrials.gov)	August 6, 2018	19/7/2018	Nabilone for Non-motor Symptoms in Parkinson's Disease	Nabilone for Non-motor Symptoms in Parkinson's Disease: An Open-label Study to Evaluate Long-term Safety and Efficacy	Parkinson Disease	Drug: Nabilone 0.25 mg	Medical University Innsbruck	NULL	Recruiting	30 Years	100 Years	All	48	Phase 3	Austria
275	ChiCTR1800017084	2018-08-01	2018-07-11	Investigation of new approaches and technologies in the management of Parkinson's disease	The efficacy of Butylphthalide on cognitive impairment of patients with idiopathic PD and DBS patients: A Randomized, double-blind, placebo-controlled, multicenter trial	Parkinson's disease	Butylphthalide group:Butylphthalide, 2 capsules/time, 3 times/day, for 48 weeks;Control group:Placebo, 2 capsules/time, 3 times/day, for 48 weeks;	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	NULL	Recruiting	18	80	Both	Butylphthalide group:140;Control group:140;	Phase 4	China
276	JPRN-JMA-IIA00385	01/08/2018	12/09/2018	Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease	Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease	Parkinson's disease	Intervention type:DRUG. Intervention1:TACROLIMUS TABLETS, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:In the early phase, the immunosuppressant is orally administered 0.03 to 0.15 mg/kg, twice a day, and the targeted blood concentration is within a range of 5-10 ng/mL as a trough value..	Kyoto University Hospital	NULL	Completed	>=50 YEARS	<70 YEARS	BOTH	7	Phase 3	Japan
277	JPRN-UMIN000033409	2018/07/30	17/07/2018	Prevention of local skin reaction by heparinoid due to rotigotine transdermal patch: a pilot randomized clinical trial.	Prevention of local skin reaction by heparinoid due to rotigotine transdermal patch: a pilot randomized clinical trial. - SkinHeRo	Parkinson's disease	Pretreatment by heparinoid In the pretreatment group, heparinoid is applied daily to the sites (shoulder, upper arm, abdomen, thigh, buttocks on both sides) to be applied rotigotine transdermal patch from the beginning of 1 week before. The dose is one finger tip unit (about 0.5 g) for two palms. The period is 8 weeks. Non-pretreatment by heparinoid. The non-pretreatment group use rotigotine without using heparinoid. The period is 8 weeks.	Wakayama Medical University	NULL	Complete: follow-up complete	20years-old	85years-old	Male and Female	20	Phase 1	Japan
278	NCT03611569 (ClinicalTrials.gov)	July 25, 2018	26/7/2018	Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease	Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease	Healthy;Parkinson Disease	Drug: Lu AF82422;Drug: Placebo	H. Lundbeck A/S	NULL	Completed	18 Years	80 Years	All	74	Phase 1	United States
279	NCT03774459 (ClinicalTrials.gov)	July 9, 2018	8/12/2018	ANAVEX2-73 Study in Parkinson's Disease Dementia	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia	Parkinsons Disease With Dementia	Drug: High dose ANAVEX2-73;Drug: Mid dose ANAVEX2-73;Drug: Placebo oral capsule	Anavex Life Sciences Corp.	Anavex Germany GmbH	Completed	50 Years	85 Years	All	132	Phase 2	Australia;Spain
280	NCT03775538 (ClinicalTrials.gov)	July 5, 2018	11/10/2018	Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study	A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients With Idiopathic Parkinson's Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002	Parkinson Disease;Movement Disorders;Neuro-Degenerative Disease;Nervous System Diseases;Brain Diseases	Drug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery System	Herantis Pharma Plc.	Renishaw plc.	Completed	35 Years	75 Years	All	15	Phase 1/Phase 2	Finland;Sweden
281	EUCTR2018-001209-95-IT (EUCTR)	05/07/2018	03/08/2021	An open-label Phase 2 study to assess the pharmacokinetics of Accordion Pill¿ Carbidopa-Levodopa compared to immediate release carbidopa-levodopa in patients with Parkinson¿s disease	An open-label Phase 2 study to assess the pharmacokinetics of Accordion Pill¿ Carbidopa-Levodopa compared to immediate release carbidopa-levodopa in patients with Parkinson¿s disease - IN 18001	Parkinson's Disease (PD) MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Accordion Pill¿ Carbidopa/levodopa Product Code: N.A. INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA INN or Proposed INN: CARBIDOPA Other descriptive name: CARBIDOPA Trade Name: SINEMET - 100 MG + 25 MG COMPRESSE 50 COMPRESSE DIVISIBILI Product Name: Sinemet Product Code: N.A. INN or Proposed INN: LEVODOPA Other descriptive name: Levodopa INN or Proposed INN: CARBIDOPA Other descriptive name: CARBIDOPA	INTEC PHARMA LTD	NULL	Not Recruiting			Female: yes Male: yes	12	Phase 2	Spain;Italy
282	EUCTR2017-004335-36-ES (EUCTR)	04/07/2018	11/04/2018	A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients.	A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients. - A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73	Cognition in Parkinson’s Disease with dementia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ANAVEX2-73 INN or Proposed INN: ANAVEX2-73 Product Name: ANAVEX2-73 INN or Proposed INN: ANAVEX2-73	Anavex Life Sciences Corp.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Phase 2	Spain
283	JPRN-UMIN000033454	2018/07/01	20/07/2018	A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient.	A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient. - A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient.	Parkinson's Disease	robot assisted balance training (RABT) The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16. traditional balance training (TBT) The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16.	Hyogo College of Medicine	NULL	Complete: follow-up complete	40years-old	80years-old	Male and Female	50	Not selected	Japan
284	NCT03576638 (ClinicalTrials.gov)	July 2018	25/6/2018	Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients	An Open Label Phase 2 Study to Assess the Pharmacokinetics of the Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Patients With Parkinson's Disease	Parkinson Disease	Drug: Accordion Pill Carbidopa/Levodopa;Drug: Sinemet CR 25Mg-100Mg Extended-Release Tablet	Intec Pharma Ltd.	NULL	Unknown status	30 Years	N/A	All	12	Phase 2	NULL
285	NCT03562494 (ClinicalTrials.gov)	June 28, 2018	16/5/2018	VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)	A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations	Parkinson's Disease	Biological: VY-AADC02;Other: Sham (Placebo) Surgery	Neurocrine Biosciences	Voyager Therapeutics	Active, not recruiting	40 Years	75 Years	All	85	Phase 2	United States
286	NCT03407378 (ClinicalTrials.gov)	June 26, 2018	15/1/2018	A Study to Investigate a New Treatment in Patients With Parkinson's Disease	A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson's Disease	Parkinson Disease	Drug: IPT803;Genetic: Optional pharmacogenetic assessment;Other: Questionnaires;Other: Optional Blood-Oxygen-level Dependent functionalMRI;Other: Motor Assessments before taking regular PD treatment;Other: Motor Assessments on regular PD treatment	Tools4Patient	NULL	Completed	35 Years	N/A	All	110	Phase 1/Phase 2	United States;Belgium;France
287	EUCTR2017-001420-21-DE (EUCTR)	18/06/2018	16/02/2018	Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's Disease	A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER.	Early Parkinson's Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: P2B001 INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Product Name: Pramipexole dihydrochloride INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE Product Name: Rasagiline INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Trade Name: Pramipexole dihydrochloride extended-release tablets Product Name: Pramipexole dihydrochloride extended-release tablets INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE	Pharma Two B Ltd	NULL	Not Recruiting			Female: yes Male: yes	525	Phase 3	France;United States;Canada;Spain;Germany
288	NCT03439943 (ClinicalTrials.gov)	June 13, 2018	13/2/2018	Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease	Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease	Parkinson Disease	Drug: Lixisenatide;Drug: placebo	University Hospital, Toulouse	Cure Parkinson;Réseau NS-Park;EUCLID;Sanofi	Active, not recruiting	40 Years	75 Years	All	156	Phase 2	France
289	EUCTR2017-001420-21-ES (EUCTR)	13/06/2018	15/03/2018	Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's Disease	A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER.	Early Parkinson's Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: P2B001 INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Product Name: Pramipexole dihydrochloride INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE Product Name: Rasagiline INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Trade Name: Pramipexole dihydrochloride extended-release tablets Product Name: Pramipexole dihydrochloride extended-release tablets INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE	Pharma Two B Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	525	Phase 3	United States;France;Canada;Spain;Germany
290	EUCTR2017-004006-18-NL (EUCTR)	07/06/2018	15/11/2017	The effect of inhaled levodopa on the recovery from off periods in patients with Parkinson's disease	Therapeutic effects of an inhaled levodopa dry powder formulation on the recovery from off periods in patients with Parkinson's disease - Effectiveness of inhaled levodopa in Parkinson's disease	Parkinson's disease is a progressive neurodegenerative disorder characterized by a lack of dopamine production due to the loss of dopamine producing cells in the substantia nigra. This lack of dopamine causes disruption of motor circuits in the brain resulting in motor function impairments like tremor, rigidity and bradykinesia. MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Levodopa powder for inhalation Product Code: Levodopa Cyclops INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Trade Name: Madopar 125 mg, orodispersible tablet	Pharmaceutical Technology and Biopharmacy, University of Groningen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	8	Phase 2	Netherlands
291	NCT03510572 (ClinicalTrials.gov)	June 4, 2018	17/4/2018	Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain	Clinical Evaluation of [18F]PI-2620 Positron Emission Computed Tomography for Imaging Tau Protein in Patients With Tauopathies and Healthy Volunteers: Phase 0 Study	Healthy Volunteer;Alzheimer Disease;Frontotemporal Dementia;Parkinson Disease	Drug: [18F]PI-2620	Asan Medical Center	Korea Health Industry Development Institute	Completed	40 Years	80 Years	All	20	Early Phase 1	Korea, Republic of
292	EUCTR2018-000346-19-SE (EUCTR)	04/06/2018	09/04/2018	An extended clinical study to test the safety of Cerebral Dopamine Neurotrophic Factor (CDNF) by brain infusion via Drug Delivery System (DDS) in patients with Parkinson's disease.	A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002. - Extension Study	Idiopathic Parkinson's Disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cerebral Dopamine Neurotrophic Factor Product Code: CDNF INN or Proposed INN: Not Applicable Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor	Herantis Pharma Plc	NULL	Not Recruiting			Female: yes Male: yes	18	Phase 1;Phase 2	Finland;Sweden
293	NCT04730245 (ClinicalTrials.gov)	June 1, 2018	25/1/2021	Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease	Targeting Gut Microbiota for Motor Complications in Parkinson´s Disease	Parkinson's Disease Aggravated	Drug: sodium phosphate enema, oral rifaximin and polyethylene glycol	Torre Médica Santé	NULL	Completed	18 Years	N/A	All	14	Phase 1	Mexico
294	EUCTR2017-002780-17-ES (EUCTR)	21/05/2018	12/02/2018	Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the blood levels of Levodopa Administered as ND0612 via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Duodopa.	A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension	Parkinson’s Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ND0612 Product Code: ND0612 INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Trade Name: SINEMET Plus Product Name: SINEMET INN or Proposed INN: levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: Duodopa LD/CD 20/5 mg/mL Product Name: Duodopa LD/CD 20/5 mg/mL INN or Proposed INN: levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 3	France;United States;Spain;Austria;Netherlands;Italy
295	EUCTR2016-004610-95-ES (EUCTR)	18/05/2018	07/03/2018	Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: BIIB054 INN or Proposed INN: n/a Other descriptive name: BIIB054	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	311	Phase 2	United States;France;Canada;Spain;Austria;Israel;Germany;United Kingdom;Italy;Sweden
296	NCT03589066 (ClinicalTrials.gov)	May 15, 2018	8/6/2018	Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease	An Open-label, Randomized, Parallel-group Trial to Evaluate the Pharmacokinetics of Two Formulations of LY03003 After a Single Intramuscular Injection Administered to Patients With Parkinson's Disease	Parkinson Disease	Drug: LY03003	Luye Pharma Group Ltd.	NULL	Completed	18 Years	N/A	All	24	Phase 1	United States
297	EUCTR2017-004475-31-CZ (EUCTR)	09/05/2018	09/05/2018	Safety and efficacy study of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease.	Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease	Excessive daytime sleepiness associated with Parkinson’s disease MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: PT;Classification code 10041349;Term: Somnolence;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Flecainide acetate Product Code: THN02 INN or Proposed INN: Flecainidum Other descriptive name: FLECAINIDE ACETATE Product Name: Flecainide acetate Product Code: THN02 INN or Proposed INN: Flecainidum Other descriptive name: FLECAINIDE ACETATE Trade Name: Modiodal Product Name: over-encapsulated Modafinil INN or Proposed INN: MODAFINIL	Theranexus S.A.	NULL	Not Recruiting			Female: yes Male: yes	60	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	France;United States;Hungary;Czech Republic;Germany
298	NCT03541356 (ClinicalTrials.gov)	May 8, 2018	5/4/2018	Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal	A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Ascending Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of DCI to L-dopa Responsive Parkinson's Disease Patients	Parkinson's Disease	Combination Product: Placebo;Combination Product: L-dopa 35 mg;Combination Product: L-dopa 70mg;Combination Product: L-dopa 140 mg;Combination Product: L-dopa 70mg/carbidopa 7mg	Impel NeuroPharma Inc.	NULL	Completed	40 Years	80 Years	All	32	Phase 2	Australia
299	NCT03587649 (ClinicalTrials.gov)	May 7, 2018	3/7/2018	Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss	Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).	Alzheimer Disease;Parkinson Disease;Healthy Volunteers	Drug: [18F]MNI-1126	Invicro	NULL	Completed	18 Years	55 Years	All	12	Phase 1	United States
300	EUCTR2016-003456-70-IT (EUCTR)	04/05/2018	02/02/2021	A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson¿s Disease patients	An Open-Label Randomized Crossover Trial, utilizing a Single-Blinded Rater to evaluate APL- 130277 compared to S.C. Apomorphine in Levodopa Responsive Subjects with Parkinson¿s Disease Complicated by Motor Fluctuations - A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson¿s Di	Levodopa Responsive Patients with Parkinson¿s Disease Complicated by Motor Fluctuations (OFF episodes) MedDRA version: 22.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: APOMORFINA CLORIDRATO Other descriptive name: APOMORPHINE HYDROCHLORIDE Trade Name: APO-go Product Name: s.c. apomorphine Product Code: n/a INN or Proposed INN: APOMORFINA CLORIDRATO Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: APOMORFINA CLORIDRATO Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: APOMORFINA CLORIDRATO Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277	SUNOVION PHARMACEUTICALS INC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	106	Phase 3	France;Spain;Austria;Germany;United Kingdom;Italy
301	NCT03843944 (ClinicalTrials.gov)	May 1, 2018	12/2/2019	Overnight Switch From Rasagiline To Safinamide	Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study	Parkinson Disease	Drug: Safinamide	IRCCS San Raffaele Roma	NULL	Completed	30 Years	80 Years	All	20	Phase 4	Italy
302	EUCTR2016-004610-95-GB (EUCTR)	01/05/2018	27/12/2017	Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: BIIB054 INN or Proposed INN: n/a Other descriptive name: BIIB054	Biogen Idec Research Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	357	Phase 2	United States;France;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom
303	EUCTR2017-002780-17-FR (EUCTR)	26/04/2018	27/02/2018	-	A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension	Parkinson’s Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ND0612 Product Code: ND0612 INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Trade Name: SINEMET Plus Product Name: SINEMET INN or Proposed INN: levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa Other descriptive name: CARBIDOPA Trade Name: Duodopa LD/CD 20/5 mg/mL Product Name: Duodopa LD/CD 20/5 mg/mL INN or Proposed INN: levodopa Other descriptive name: LEVODOPA INN or Proposed INN: carbidopa	NeuroDerm Ltd.	NULL	Not Recruiting			Female: yes Male: yes	50	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;France;Spain;Austria;Netherlands;Italy
304	NCT03374917 (ClinicalTrials.gov)	April 18, 2018	8/12/2017	A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment	An Open-Label Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment	Parkinson's Disease (PD)	Drug: ABBV-951	AbbVie	NULL	Completed	30 Years	85 Years	All	20	Phase 1	United States
305	EUCTR2017-004475-31-HU (EUCTR)	17/04/2018	09/02/2018	Safety and efficacy study of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease.	Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease	Excessive daytime sleepiness associated with Parkinson’s disease MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: PT;Classification code 10041349;Term: Somnolence;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Flecainide acetate Product Code: THN02 INN or Proposed INN: Flecainidum Other descriptive name: FLECAINIDE ACETATE Product Name: Flecainide acetate Product Code: THN02 INN or Proposed INN: Flecainidum Other descriptive name: FLECAINIDE ACETATE Trade Name: Modiodal Product Name: over-encapsulated Modafinil INN or Proposed INN: MODAFINIL	Theranexus S.A.	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	Czech Republic;Hungary;United States;France;Germany
306	EUCTR2017-004253-16-AT (EUCTR)	13/04/2018	27/02/2018	Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-Motor symptoms (e.g.sleeping dirsorders, cognitive dysfunction, hallucinations, autonomic dysfunction,...)	Nabilone for non-motor symptoms in Parkinson’s disease: An open-label study to evaluate long-term safety and efficacy	Subject with non-Motor symptoms of Parkinson´s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Nabilone INN or Proposed INN: NABILONE	Medizinische Universität Innsbruck, Universitätsklinik für Neurologie	NULL	Not Recruiting			Female: yes Male: yes	48	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Austria
307	NCT03368170 (ClinicalTrials.gov)	April 12, 2018	5/12/2017	Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia	A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia	Parkinson Disease	Drug: Mesdopetam (IRL790)	Integrative Research Laboratories AB	The Clinical Trial Company	Completed	18 Years	79 Years	All	75	Phase 2	Sweden;United Kingdom
308	EUCTR2016-002033-30-IT (EUCTR)	10/04/2018	20/01/2021	A clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuations	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO) - iNDiGO	Subjects with Parkinson’s Disease with motor fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa / carbidopa solution Product Code: ND0612 INN or Proposed INN: LEVODOPA Other descriptive name: levodopa INN or Proposed INN: CARBIDOPA Other descriptive name: carbidopa Product Name: levodopa / carbidopa solution Product Code: ND0612 INN or Proposed INN: LEVODOPA Other descriptive name: Levodopa INN or Proposed INN: CARBIDOPA Other descriptive name: Carbidopa	NEURODERM LTD.	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	France;Hungary;Belgium;Spain;Netherlands;United Kingdom;Italy
309	EUCTR2017-002780-17-IT (EUCTR)	10/04/2018	04/11/2020	study in patients with Parkinson's disease to evaluate the bioavailability of levodopa administered as subcutaneous infusion	A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson¿s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension - study in patients with Parkinson's disease to evaluate the bioavailability of levodopa administered	Parkinson¿s Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SINEMET Plus Product Name: SINEMET INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Trade Name: Duodopa LD/CD 20/5 mg/mL Product Name: Duodopa LD/CD 20/5 mg/mL INN or Proposed INN: LEVODOPA Other descriptive name: levodopa INN or Proposed INN: CARBIDOPA Other descriptive name: carbidopa Product Name: ND0612 Product Code: ND0612 INN or Proposed INN: CARBIDOPA Other descriptive name: carbidopa INN or Proposed INN: LEVODOPA Other descriptive name: levodopa	NEURODERM LTD.	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 3	United States;France;Spain;Austria;Netherlands;Italy
310	EUCTR2017-002707-10-DK (EUCTR)	10/04/2018	03/11/2017	Measurements of drug concentration in the blood for anti-dementia drugs, in order to improve efficacy and reduce side-effects	Serum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance	Dementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies MedDRA version: 20.0;Level: PT;Classification code 10012271;Term: Dementia Alzheimer's type;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10075174;Term: Mixed dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Memantin Orion INN or Proposed INN: MEMANTINE Product Name: Donepezil Sandoz Product Code: 25330 INN or Proposed INN: DONEPEZIL	Regional Dementia Research Centre, Dept of Neurology	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	110	Phase 4	Denmark
311	ChiCTR2200057135	2018-04-04	2022-03-01	Use of Wii Sports based training to reduce the falls and improve quality of life in people diagnosed as Parkinson's disease	Effectiveness of Wii Sports Training on Postural Stability, Fall and Quality of Life in Idiopathic Parkinson’s Disease.	Parkinson's Disease	Experimental:Wii Sports based training;Control:Traditional Balance training;	Alagumoorthi Gandhisubramanian	NULL	Completed	40	90	Both	Experimental:96;Control:96;	N/A	India
312	EUCTR2016-003456-70-DE (EUCTR)	04/04/2018	03/04/2017	A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients	An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor Fluctuations	Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes) MedDRA version: 22.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Trade Name: APO-go Product Name: s.c. apomorphine INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomor	Sunovion Pharmaceuticals Inc.	NULL	Not Recruiting			Female: yes Male: yes	106	Phase 3	France;Spain;Austria;Germany;United Kingdom;Italy
313	EUCTR2016-000657-12-AT (EUCTR)	03/04/2018	17/10/2016	A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation	Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant - MOVES-PD	Parkinson's disease (PD) carrying a GBA mutation MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Venglustat Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: venglustat malate Other descriptive name: Genz-682452-AU Product Name: Venglustat Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: venglustat malate Other descriptive name: Genz-682452-AU	Genzyme Corporation	NULL	Not Recruiting			Female: yes Male: yes	290	Phase 2	United States;Portugal;Taiwan;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Australia;Germany;Norway;Japan;Sweden
314	EUCTR2018-000405-23-FI (EUCTR)	27/03/2018	21/02/2018	Postitron emission tomography imaging of neuroinflammation in Parkinson´s disease	In vivo PET imaging of neuroinflammation in Parkinson’s disease using the purinergic P2X7 receptor ligand [11C]SMW139 (PRI-PD) - PRI-PD	Parkinson´s disease MedDRA version: 20.0;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) Product Code: [11C]SMW139	Juha Rinne / PET Centre	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	14	Phase 2	Finland
315	EUCTR2016-004610-95-AT (EUCTR)	23/03/2018	04/01/2018	Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARK	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: BIIB054 INN or Proposed INN: n/a Other descriptive name: BIIB054	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	357	Phase 2	United States;France;Canada;Spain;Austria;Israel;Germany;United Kingdom;Italy
316	NCT03457493 (ClinicalTrials.gov)	March 22, 2018	23/2/2018	The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy	UAB Neuroinflammation in Parkinson's Disease - TSPO-PET Substudy	Parkinson Disease	Drug: DPA-714-PET/MRI	University of Alabama at Birmingham	NULL	Recruiting	30 Years	N/A	All	20	Phase 1/Phase 2	United States
317	EUCTR2016-004610-95-IT (EUCTR)	22/03/2018	14/01/2021	Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson¿s Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson¿s Disease - SPARK	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: nd Product Code: [BIIB054] INN or Proposed INN: HA 1A ANTICORPO MONOCLONALE UMANO CLASSE IGM	BIOGEN IDEC RESEARCH LIMITED	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	311	Phase 2	France;United States;Canada;Spain;Austria;Australia;Israel;Germany;United Kingdom;Italy;Sweden
318	EUCTR2016-000637-43-IT (EUCTR)	05/03/2018	21/01/2021	Safety, tolerability and efficacy study to examine APL-130277 in patients with Parkinson's Disease.	An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patientswith Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes). - Safety, tolerability and efficacy study to examine APL-130277 in patients with Parkinson's Disease.	Levodopa Responsive Patients with Parkinson's Disease complicated by Motor Fluctuations (OFF Episodes) MedDRA version: 22.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: [APL-130277] INN or Proposed INN: APOMORFINA CLORIDRATO Other descriptive name: Apomorphine hydrochloride Product Name: Apomorfina cloridrato Product Code: [APL-130277] INN or Proposed INN: APOMORFINA CLORIDRATO Other descriptive name: Apomorphine hydrochloride Product Name: Apomorfina cloridrato Product Code: [APL-130277] INN or Proposed INN: APOMORFINA CLORIDRATO Other descriptive name: Apomorphine hydrochloride Product Name: Apomorfina cloridrato Product Code: [APL-130277] INN or Proposed INN: APOMORFINA CLORIDRATO Other descriptive name: Apomorphine hydrochloride	SUNOVION PHARMACEUTICALS INC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 3	France;United States;Canada;Spain;Austria;Germany;United Kingdom;Italy
319	NCT04265027 (ClinicalTrials.gov)	February 20, 2018	7/2/2020	Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)	An Open Label, Randomised, Two Period, Crossover Study to Assess Bioavailability, Bioequivalence and S COMT Activity Between Two Active Pharmaceutical Ingredient Sources of Opicapone at Two Different Dosage Strengths (50 mg and 25 mg) After Single and Multiple Dose Administrations Under Fasting Conditions in Healthy Volunteers.	Parkinson Disease	Drug: 50 mg BIA 9 1067;Drug: 25 mg BIA9 1067;Drug: 50 mg Ongentys;Drug: 25 mg Ongentys	Bial - Portela C S.A.	NULL	Completed	18 Years	55 Years	All	72	Phase 1	United Kingdom
320	NCT03496870 (ClinicalTrials.gov)	February 8, 2018	1/3/2018	A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.	A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease	Parkinson Disease	Drug: Opicapone;Drug: Carbidopa Levodopa	Neurocrine Biosciences	NULL	Completed	18 Years	85 Years	All	16	Phase 1	United States
321	NCT03189563 (ClinicalTrials.gov)	February 6, 2018	12/6/2017	Safety and Efficacy of DA-9805 for Parkinson's Disease	A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: DA-9805 45mg;Drug: DA-9805 90mg;Other: Placebo	Dong-A ST Co., Ltd.	NULL	Completed	30 Years	79 Years	All	60	Phase 2	United States
322	EUCTR2016-000637-43-ES (EUCTR)	06/02/2018	07/12/2017	Safety, tolerability and efficacy study to examine APL-130277 in patients with Parkinson’s Disease.	An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF” Episodes).	Levodopa Responsive Patients with Parkinson’s Disease complicated by Motor Fluctuations (OFF” Episodes) MedDRA version: 20.0;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride	Sunovion Pharmaceuticals Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 3	France;United States;Canada;Spain;Austria;Germany;Italy;United Kingdom
323	EUCTR2016-003456-70-ES (EUCTR)	06/02/2018	07/12/2017	A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients	An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor Fluctuations	Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes) MedDRA version: 20.0;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Trade Name: APO-go Product Name: s.c. apomorphine INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE	Sunovion Pharmaceuticals Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	85	Phase 3	Spain;Austria;United Kingdom
324	EUCTR2016-000637-43-AT (EUCTR)	01/02/2018	15/12/2017	Safety, tolerability and efficacy study to examine APL-130277 in patients with Parkinson’s Disease.	An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF” Episodes).	Levodopa Responsive Patients with Parkinson’s Disease complicated by Motor Fluctuations (OFF” Episodes) MedDRA version: 22.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE	Sunovion Pharmaceuticals Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 3	France;United States;Canada;Spain;Austria;Germany;United Kingdom;Italy
325	NCT02940912 (ClinicalTrials.gov)	January 31, 2018	14/10/2016	Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease	Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease	Parkinson Disease	Drug: Apomorphine;Drug: Placebo	Clinique Beau Soleil	NULL	Active, not recruiting	35 Years	90 Years	All	45	Phase 4	France
326	NCT03329508 (ClinicalTrials.gov)	January 29, 2018	30/10/2017	A Phase 3 Study With P2B001 in Subjects With Early Parkinson's	A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.	Parkinson Disease;Early Parkinson's Disease	Drug: P2B001;Drug: Rasagiline;Drug: Pramipexole;Drug: Pramipexole ER	Pharma Two B Ltd.	NULL	Active, not recruiting	35 Years	80 Years	All	525	Phase 3	United States;Canada;Germany;Spain
327	EUCTR2016-001403-23-HU (EUCTR)	23/01/2018	22/01/2018	12-Week study comparing Levodopa-Carbidopa Intestinal Gel / Levodopa Carbidopa Enteral Suspension to Optimized Medical Treatment on dyskinesia in subjects with advanced Parkinson's disease	An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with Advanced Parkinson's Disease - DYSCOVER (DYSkinesia COmparative interventional trial on Duodopa VERsus oral medication) - DYSCOVER Study	Dyskinesia in advanced Parkinson's disease MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA MONOHYDRATE	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 3	United States;Hungary;Slovakia;European Union;Greece;Finland;Spain
328	NCT03531086 (ClinicalTrials.gov)	January 19, 2018	8/5/2018	Idiopathic Parkinson's Progression and Dopamine Transporter SPECT	Exploring Dopamine Transporter Single-photon Emission Computer Tomography Quantification as a Measure of Disease Progression in Idiopathic Parkinson's Disease	Parkinson Disease	Drug: Ioflupane I 123	Julie Gurwell	NULL	Completed	40 Years	75 Years	All	12		United States
329	NCT03331848 (ClinicalTrials.gov)	January 15, 2018	1/11/2017	Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)	A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety, and Tolerability of 8-week Oral Treatment With PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)	Parkinson Disease	Drug: Placebo oral capsule;Drug: PXT002331 - 20mg	Prexton Therapeutics	NULL	Withdrawn	35 Years	85 Years	All	0	Phase 2	NULL
330	NCT03318523 (ClinicalTrials.gov)	January 10, 2018	19/10/2017	Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: Placebo;Drug: BIIB054	Biogen	NULL	Terminated	40 Years	80 Years	All	357	Phase 2	United States;Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom
331	EUCTR2016-003456-70-AT (EUCTR)	04/01/2018	16/11/2017	A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients	An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor Fluctuations	Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes) MedDRA version: 22.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Trade Name: APO-go Product Name: s.c. apomorphine INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomor	Sunovion Pharmaceuticals Inc.	NULL	Not Recruiting			Female: yes Male: yes	106	Phase 3	France;Spain;Austria;Germany;United Kingdom;Italy
332	EUCTR2017-003254-17-ES (EUCTR)	21/12/2017	22/11/2017	Safety and efficacy of Safinamide (Xadago®) in apathy associated with Parkinson's disease	A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Safinamide on Apathy in Patients With Parkinson's Disease	Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xadago INN or Proposed INN: SAFINAMIDE Other descriptive name: SAFINAMIDE	Institut de Recerca Hospital de la Santa Creu i Sant Pau	NULL	Not Recruiting			Female: yes Male: yes	36	Phase 4	Spain
333	EUCTR2017-000087-15-DE (EUCTR)	21/12/2017	17/05/2017	A Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants with Early Parkinson's Disease with A 6-Year all- Participants-on-Treatment Extension (Pasadena)	A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015/PRASINEZUMAB (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE WITH A 6-YEAR ALL-PARTICIPANTSON-TREATMENT EXTENSION (PASADENA)	Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: RO7046015/PRASINEZUMAB INN or Proposed INN: N/A Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	United States;France;Spain;Austria;Germany
334	EUCTR2017-003458-18-GB (EUCTR)	19/12/2017	27/09/2017	A clinical trial to study the effects of IRL790 in Parkinson's disease dyskinesia	A randomised, double-blind, placebo-controlled, phase IIA study evaluating the efficacy and tolerability of IRL790 in Parkinson's disease dyskinesia	Parkinson's disease dyskinesia MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IRL790 Product Code: IRL790 INN or Proposed INN: IRL790	Integrative Research Laboratories AB (IRLAB)	NULL	Not Recruiting			Female: yes Male: yes	74	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom;Sweden
335	EUCTR2017-000877-35-IT (EUCTR)	04/12/2017	10/11/2020	A phase IIb, randomized, double blind, parallel group, placebo control, multicentre, 6-week dose-finding study to assess the efficacy and safety of Bavisant for the treatment of excessive daytime sleepiness in subjects with Parkinson's disease.	Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in parkinson's Disease (PD). - Treatment of excessive daytime sleepiness with Bavisant in Parkinson's Disease Patients (CASPAR)	Excessive daytime sleepiness with Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Bavisant Product Code: JNJ31-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Product Name: Bavisant Product Code: [JNJ31-31001074] INN or Proposed INN: Bavisant dihydrochloride monohydrate Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate	BENEVOLENTAI BIO	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 2	United States;Czechia;Czech Republic;Spain;Poland;Germany;United Kingdom;Italy
336	NCT03944785 (ClinicalTrials.gov)	November 30, 2017	1/5/2019	Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)	A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and Other Clinical Outcome Assessments of Parkinson's Disease Patients Treated With XADAGO (Safinamide)Tablets	Idiopathic Parkinson Disease	Drug: XADAGO (safinamide)	Supernus Pharmaceuticals, Inc.	NULL	Completed	30 Years	80 Years	All	164		United States
337	EUCTR2016-002033-30-GB (EUCTR)	27/11/2017	05/09/2017	A clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuations	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO) - iNDiGO	Subjects with Parkinson’s Disease with motor fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Not Recruiting			Female: yes Male: yes	240	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Serbia;Portugal;United States;Spain;Ukraine;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Poland;Belgium;Denmark;Netherlands;Germany
338	NCT03194217 (ClinicalTrials.gov)	November 10, 2017	19/6/2017	BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness	Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD).	Excessive Daytime Sleepiness;Parkinson Disease	Drug: BEN-2001;Drug: Placebo	BenevolentAI Bio	NULL	Completed	50 Years	80 Years	All	244	Phase 2	United States
339	NCT03305809 (ClinicalTrials.gov)	November 9, 2017	4/10/2017	A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)	Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)	Lewy Body Dementia	Drug: LY3154207;Drug: Placebo	Eli Lilly and Company	NULL	Completed	40 Years	85 Years	All	344	Phase 2	United States;Canada;Puerto Rico;China
340	EUCTR2016-002033-30-HU (EUCTR)	08/11/2017	19/09/2017	A clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuations	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO) - iNDiGO	Subjects with Parkinson’s Disease with motor fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	Serbia;Portugal;United States;Spain;Ukraine;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Poland;Belgium;Denmark;Netherlands;Germany
341	EUCTR2017-000877-35-DE (EUCTR)	19/10/2017	04/09/2017	A phase IIb, randomized, double blind, parallel group, placebo control, multicentre, 6-week dose-finding study to assess the efficacy and safety of Bavisant for the treatment of excessive daytime sleepiness in subjects with Parkinson's disease.	Dose finding phase IIb study of Bavisant to evaluate its safety and effiCacy in treAtment of exceSsive daytime sleePiness (EDS) in PARkinson’s Disease (PD). CASPAR study. - Treatment of excessive daytime sleepiness with Bavisant in Parkinson’s Disease Patients (CASPAR)	Excessive daytime sleepiness with Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE	BenevolentAI Bio	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 2	United States;Czech Republic;Spain;Poland;Germany;United Kingdom;Italy
342	NCT03272165 (ClinicalTrials.gov)	October 17, 2017	29/6/2017	Single Ascending Dose Study of MEDI1341 in Healthy Volunteers	A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers	Parkinson's Disease	Drug: MEDI1341;Drug: Placebo	AstraZeneca	Covance;MMS Holdings, Inc;Catalent;Takeda	Completed	18 Years	80 Years	All	50	Phase 1	United States;United Kingdom
343	NCT03205488 (ClinicalTrials.gov)	October 16, 2017	28/6/2017	Nilotinib in Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease	Parkinson Disease	Drug: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg);Drug: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1);Drug: Placebo	Northwestern University	University of Rochester;University of Iowa;Michael J. Fox Foundation for Parkinson's Research	Completed	40 Years	79 Years	All	76	Phase 2	United States
344	NCT04045678 (ClinicalTrials.gov)	October 10, 2017	30/7/2019	A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease	A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections	Parkinson Disease	Drug: LY03003 ( Rotigotine, extended-release microspheres);Drug: Placebo, extended-release microspheres	Luye Pharma Group Ltd.	Beijing Bozhiyin T&S Co., Ltd.	Completed	18 Years	75 Years	All	30	Phase 1	China
345	NCT03250117 (ClinicalTrials.gov)	October 10, 2017	11/8/2017	Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole	An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa	Parkinson Disease	Drug: Ropinirole oral product;Drug: Ropinirole Implant	Titan Pharmaceuticals	NULL	Terminated	30 Years	80 Years	All	3	Phase 1/Phase 2	United States
346	EUCTR2017-001673-17-FI (EUCTR)	03/10/2017	29/08/2017	A study to evaluate the safety and tolerability of IRL752 treatment inpatients with Parkinson's disease dementia.	A randomized, double-blind, placebo-controlled, multi-centre phase IIastudy evaluating the safety and tolerability of IRL752 in patients withParkinson's Disease Dementia	Dementia in Parkinson's disease MedDRA version: 20.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;System Organ Class: 100000014717;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: IRL752 INN or Proposed INN: IRL752	Integrative Research Laboratories AB	NULL	Not Recruiting			Female: yes Male: yes	40	Phase 2	Finland;Sweden
347	NCT03257046 (ClinicalTrials.gov)	September 28, 2017	14/8/2017	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease	A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease	Parkinson Disease	Drug: ITI-214;Other: Placebo	Intra-Cellular Therapies, Inc.	NULL	Completed	50 Years	N/A	All	40	Phase 1/Phase 2	United States
348	EUCTR2015-004175-73-FI (EUCTR)	27/09/2017	07/07/2016	A clinical study to test the safety of CDNF by brain infusion in patients with Parkinson's disease.	A Phase I-II, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intermittent Bilateral Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Administered via an Investigational Drug Delivery System to Patients with Idiopathic Parkinson’s Disease (PD) of Moderate Severity.	Idiopathic Parkinson's Disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: CDNF INN or Proposed INN: Not Applicable Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor	Herantis Pharma Plc	NULL	Not Recruiting			Female: yes Male: yes	17	Phase 1;Phase 2	Finland
349	NCT03295786 (ClinicalTrials.gov)	September 26, 2017	14/9/2017	Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease	Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's Disease	Parkinson Disease;Movement Disorders;Neurodegenerative Diseases;Nervous System Diseases;Brain Diseases	Drug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery System	Herantis Pharma Plc.	Renishaw plc.	Completed	35 Years	75 Years	All	17	Phase 1/Phase 2	Finland;Sweden
350	EUCTR2017-000128-81-DE (EUCTR)	20/09/2017	06/07/2017	PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITHMOTOR FLUCTUATIONS DUE TO PARKINSON’S DISEASE	PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITHMOTOR FLUCTUATIONS DUE TO PARKINSON’S DISEASE	Parkinson’s disease MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000014025;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: PF-06649751 - 1mg INN or Proposed INN: Not yet assigned Other descriptive name: PF-06649751 Product Code: PF-06649751 - 5mg INN or Proposed INN: Not yet assigned Other descriptive name: PF-06649751 Product Code: PF-06649751 - 15mg INN or Proposed INN: Not yet assigned Other descriptive name: PF-06649751	Pfizer Inc., 235 East 42nd Street, New York, New York	NULL	Not Recruiting			Female: yes Male: yes	198	Phase 2	France;United States;Canada;Spain;Germany
351	NCT03306329 (ClinicalTrials.gov)	September 13, 2017	25/9/2017	DNS-7801 vs. Placebo in Parkinson's Disease	A Phase 2a, Double-Blind, Placebo-Controlled Two-Part Study To Investigate the Safety and Efficacy of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor Fluctuations	Parkinson's Disease	Drug: DNS-7801 (low-dose);Drug: DNS-7801 (high dose);Drug: Placebo	Dart NeuroScience, LLC	NULL	Terminated	30 Years	N/A	All	5	Phase 2	United States
352	EUCTR2016-003961-25-CZ (EUCTR)	07/09/2017	15/05/2017	A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing wearing off	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose Wearing-Off”	Parkinson's Disease MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: tozadenant Product Code: TOZ INN or Proposed INN: tozadenant Other descriptive name: TOZADENANT	Biotie Therapies	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Hungary;Czech Republic;European Union;Canada;Spain;Australia;Germany;Italy;United Kingdom
353	JPRN-jRCTs041180018	04/09/2017	20/12/2018	Pupillary autonomic dysfunction and visual hallucination in Parkinson's disease	Association between pupillary autonomic dysfunction and visual hallucination in Parkinson's disease - Pupillary autonomic dysfunction and visual hallucination in Parkinson's disease	Parkinson's disease and related diseases	Two drops of 0.05% pilocarpine hydrochloride, which is a parasympathomimetic agent, on the right eye, 2 drops of 0.04% dipivefrin hydrochloride, which is a sympathomimetic agent, to the left eye	katsuno Masahisa	NULL	Complete	>= 40age old	Not applicable	Both	40	Phase 2	Japan
354	ChiCTR-INR-17012013	2017-09-01	2017-07-17	Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's disease	Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's disease	Parkinson‘s disease, Depression	BTX-A:BOTOX Allergan;Placebo:0.9% Sodium Chloride Injection;	Shanghai Tongji Hospital, Tongji University	NULL	Pending	18	80	Both	BTX-A:40;Placebo:40;		China
355	EUCTR2017-000128-81-ES (EUCTR)	28/08/2017	12/07/2017	PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITHMOTOR FLUCTUATIONS DUE TO PARKINSON’S DISEASE	PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITHMOTOR FLUCTUATIONS DUE TO PARKINSON’S DISEASE	Parkinson’s disease MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000014025;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: PF-06649751 - 1mg INN or Proposed INN: Not yet assigned Other descriptive name: PF-06649751 Product Code: PF-06649751 - 5mg INN or Proposed INN: Not yet assigned Other descriptive name: PF-06649751 Product Code: PF-06649751 - 15mg INN or Proposed INN: Not yet assigned Other descriptive name: PF-06649751	Pfizer Inc., 235 East 42nd Street, New York, New York	NULL	Not Recruiting			Female: yes Male: yes	198	Phase 2	France;United States;Canada;Spain;Germany
356	NCT03292016 (ClinicalTrials.gov)	August 22, 2017	11/9/2017	A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by OFF Episodes	A Comparative Bioavailability Study to Evaluate the Single Dose Pharmacokinetic Properties of APL-130277 With Two Different Formulations of Subcutaneous Apomorphine in a Randomized, 3-Period Crossover Design in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)	Parkinson Disease	Drug: APL-130277;Drug: APO-go;Drug: Apokyn	Sunovion	NULL	Completed	18 Years	N/A	All	8	Phase 2	United States
357	EUCTR2017-000087-15-AT (EUCTR)	17/08/2017	18/05/2017	A Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab(PRX002) in Participants with Early Parkinson's Disease with A 6-Year all-Participants-on-Treatment Extension (Pasadena)	A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015/PRASINEZUMAB (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE WITH A 6-YEAR ALL-PARTICIPANTSONTREATMENT EXTENSION (PASADENA)	Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: RO7046015 INN or Proposed INN: N/A Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	France;United States;Spain;Austria;Germany
358	NCT04162275 (ClinicalTrials.gov)	August 15, 2017	22/9/2019	A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Tolerance and Pharmacokinetics Study of Oral Taking Finamine Tablets in Chinese Healthy-adult Subjects	A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Tolerance and Pharmacokinetics Study of Oral Taking Finamine Tablets in Chinese Healthy-adult Subjects	Parkinson Disease	Drug: Finamine tablets;Drug: Placebo tablets	Yiling Pharmaceutical Inc.	NULL	Completed	18 Years	65 Years	All	34	Phase 1	China
359	NCT03204929 (ClinicalTrials.gov)	August 14, 2017	28/6/2017	Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease	A Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's Disease	Parkinson Disease	Drug: Cu(II)ATSM	Collaborative Medicinal Development Pty Limited	NULL	Completed	30 Years	N/A	All	31	Phase 1	Australia
360	EUCTR2017-000877-35-CZ (EUCTR)	09/08/2017	05/06/2017	A phase IIb, randomized, double blind, parallel group, placebo control, multicentre, 6-week dose-finding study to assess the efficacy and safety of Bavisant for the treatment of excessive daytime sleepiness in subjects with Parkinson's disease.	Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in parkinson’s Disease (PD). - Treatment of excessive daytime sleepiness with Bavisant in Parkinson’s Disease Patients (CASPAR)	Excessive daytime sleepiness with Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE	BenevolentAI Bio	NULL	Not Recruiting			Female: yes Male: yes	240	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United States;Czech Republic;Poland;Spain;Germany;Italy;United Kingdom
361	EUCTR2017-000877-35-GB (EUCTR)	08/08/2017	17/07/2017	A phase IIb, randomized, double blind, parallel group, placebo control, multicentre, 6-week dose-finding study to assess the efficacy and safety of Bavisant for the treatment of excessive daytime sleepiness in subjects with Parkinson's disease.	Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in parkinson’s Disease (PD). - Treatment of excessive daytime sleepiness with Bavisant in Parkinson’s Disease Patients (CASPAR)	Excessive daytime sleepiness with Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE	BenevolentAI Bio	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 2	United States;Czech Republic;Poland;Spain;Germany;Italy;United Kingdom
362	NCT03187301 (ClinicalTrials.gov)	August 3, 2017	7/6/2017	A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations OFF Episodes	A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)	Parkinson's Disease;Off Episodes of Parkinson Disease	Drug: APL-130277;Drug: Placebo;Drug: Moxifloxacin	Sunovion	NULL	Completed	18 Years	N/A	All	48	Phase 2	United States;Italy
363	EUCTR2017-000877-35-ES (EUCTR)	03/08/2017	09/06/2017	A phase IIb, randomized, double blind, parallel group, placebo control, multicentre, 6-week dose-finding study to assess the efficacy and safety of Bavisant for the treatment of excessive daytime sleepiness in subjects with Parkinson's disease.	Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in parkinson’s Disease (PD). - Treatment of excessive daytime sleepiness with Bavisant in Parkinson’s Disease Patients (CASPAR)	Excessive daytime sleepiness with Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE Product Name: Bavisant Product Code: JNJ-31001074 INN or Proposed INN: Bavisant dihydrochloride monohydrate Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE	BenevolentAI Bio	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 2	United Kingdom;United States;Czech Republic;Poland;Spain;Germany;Italy
364	EUCTR2014-004865-26-GR (EUCTR)	01/08/2017	25/04/2017	26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease	An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkinson's Disease – INSIGHTS Study - INSIGHTS Study	Non-motor symptoms in advanced Parkinson's disease MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA MONOHYDRATE	AbbVie Deutschland GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	88	Phase 3	United States;European Union;Canada;Greece;Spain;Australia;Germany;Italy;Sweden
365	EUCTR2017-000087-15-FR (EUCTR)	27/07/2017	30/10/2017	A Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson’s Disease with A 52-Week Blinded Extension (Pasadena)	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON’S DISEASE WITH A 52 WEEK BLINDED EXTENSION (PASADENA)	Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: RO7046015 INN or Proposed INN: N/A Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	United States;France;Spain;Austria;Germany
366	EUCTR2017-000087-15-ES (EUCTR)	26/07/2017	08/06/2017	A Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson’s Disease with A 52-Week Blinded Extension (Pasadena)	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON’S DISEASE WITH A 52 WEEK BLINDED EXTENSION (PASADENA)	Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: RO7046015 INN or Proposed INN: N/A Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	France;United States;Spain;Austria;Germany
367	NCT03026231 (ClinicalTrials.gov)	July 15, 2017	11/1/2017	Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients	A Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's Disease	Parkinson's Disease	Biological: PRIM-DJ2727;Drug: Placebo (for PRIM-DJ2727)	The University of Texas Health Science Center, Houston	Kelsey Research Foundation	Withdrawn	45 Years	70 Years	All	0	Phase 1/Phase 2	United States
368	EUCTR2017-000262-30-IT (EUCTR)	10/07/2017	04/11/2020	Efficacy, Safety, Tolerability and Pharmacokinetics of EXN-32 and EXN-44 in patients with Parkinson¿s Disease experiencing motor fluctuations	Efficacy, Safety, Tolerability and Pharmacokinetics of EXN-32 and EXN-44 in patients with Parkinson¿s Disease experiencing motor fluctuations - NA	Parkinson's Desease (PD) MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: EXN-44(LEVODOPA) Product Code: EXN-44 Trade Name: Sinemet Product Name: EXN-32 (CARBIDOPA E LEVODOPA) Product Code: EXN-32	DR. REDDY’S LABORATORIES LIMITED	NULL	Not Recruiting			Female: yes Male: yes	18	Phase 2	Italy
369	EUCTR2017-000135-14-ES (EUCTR)	07/07/2017	09/06/2017	A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) - AMBLED Study	Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E	Prexton Therapeutics B.V.	NULL	Not Recruiting			Female: yes Male: yes	165	Phase 2	Spain;Austria;Germany;Italy;United Kingdom
370	NCT03185481 (ClinicalTrials.gov)	July 6, 2017	9/6/2017	Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations	A PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE	Parkinson's Disease With Motor Fluctuations	Drug: 1 mg QD to 15 mg QD PF-06649751;Drug: 3 mg QD to 15 mg QD PF-06649751;Drug: 7 mg QD to 15 mg QD PF-06649751;Drug: 15 mg QD PF-06649751;Drug: 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study);Drug: 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD	Pfizer	NULL	Terminated	40 Years	87 Years	All	5	Phase 2	United States
371	NCT03162874 (ClinicalTrials.gov)	July 4, 2017	19/5/2017	Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment With PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects With Parkinson's Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED)	Parkinson Disease	Drug: Placebo oral capsule;Drug: PXT002331 - dose 1;Drug: PXT002331 - dose 2	Prexton Therapeutics	NULL	Completed	35 Years	85 Years	All	157	Phase 2	Austria;France;Germany;Italy;Spain;United Kingdom
372	NCT03288155 (ClinicalTrials.gov)	July 1, 2017	15/9/2017	Can a Flavonoid-rich Pure Cocoa Reduce Fatigue in People With Parkinson's (PD)	A Study to Determine Whether the Daily Consumption of Flavonoid-rich Pure Cocoa Can Reduce Fatigue in People With Parkinson's (PD)	Parkinson Disease;Fatigue	Dietary Supplement: Cocoa	Oxford Brookes University	European Parkinson Therapy Centre	Completed	18 Years	N/A	All	30	N/A	Italy
373	EUCTR2016-003961-25-DE (EUCTR)	30/06/2017	01/02/2017	A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing wearing off	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose Wearing-Off”	Parkinson's Disease MedDRA version: 19.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: tozadenant Product Code: TOZ INN or Proposed INN: tozadenant Other descriptive name: TOZADENANT	Biotie Therapies	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Czech Republic;Hungary;European Union;Canada;Spain;Australia;Germany;Italy;United Kingdom
374	NCT03100149 (ClinicalTrials.gov)	June 27, 2017	29/3/2017	A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 6-Year All-Participants-on-Treatment Extension	Parkinson's Disease	Drug: RO7046015;Drug: Placebo	Hoffmann-La Roche	Prothena Biosciences Limited	Active, not recruiting	40 Years	80 Years	All	316	Phase 2	United States;Austria;France;Germany;Spain
375	NCT03195231 (ClinicalTrials.gov)	June 25, 2017	20/6/2017	Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease	Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease: a Randomised, Double-blind, Placebo-controlled Trial.	Antidepressive Agents	Drug: Wuling Powder;Drug: Placebo	Beijing Hospital	Tongji Hospital;Shanghai Tong Ren Hospital;The First Hospital of Hebei Medical University	Not yet recruiting	40 Years	N/A	All	120	Phase 4	NULL
376	EUCTR2017-000135-14-GB (EUCTR)	15/06/2017	17/03/2017	A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) - AMBLED Study	Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E	Prexton Therapeutics B.V.	NULL	Not Recruiting			Female: yes Male: yes	165	Phase 2	Spain;Austria;Germany;United Kingdom
377	EUCTR2016-003961-25-ES (EUCTR)	08/06/2017	27/04/2017	A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing wearing off	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose Wearing-Off”	Parkinson's Disease MedDRA version: 19.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: tozadenant Product Code: TOZ INN or Proposed INN: tozadenant Other descriptive name: TOZADENANT	Biotie Therapies	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Czech Republic;Hungary;European Union;Canada;Spain;Australia;Germany;United Kingdom
378	EUCTR2017-000135-14-DE (EUCTR)	06/06/2017	10/03/2017	A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) - AMBLED Study	Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E	Prexton Therapeutics B.V.	NULL	Not Recruiting			Female: yes Male: yes	165	Phase 2	Spain;Austria;Germany;Italy;United Kingdom
379	EUCTR2016-003961-25-HU (EUCTR)	31/05/2017	03/04/2017	A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing wearing off	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose Wearing-Off”	Parkinson's Disease MedDRA version: 19.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: tozadenant Product Code: TOZ INN or Proposed INN: tozadenant Other descriptive name: TOZADENANT	Biotie Therapies	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Czech Republic;Hungary;European Union;Canada;Spain;Australia;Germany;United Kingdom
380	EUCTR2017-000135-14-IT (EUCTR)	30/05/2017	04/11/2020	A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa	Studio di fase IIa, multicentrico, in doppio cieco, randomizzato, controllato verso placebo, a gruppi paralleli per valutare l'efficacia, la sicurezza e la tollerabilit¿ del trattamento orale con PXT002331 (foliglurax) della durata di 28 giorni nella riduzione delle complicazioni motorie dovute alla terapia con levodopa nei pazienti affetti da malattia di Parkinson che manifestano deterioramento da fine dose e discinesia indotta da levodopa (AMBLED) - AMBLED Study	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax	PREXTON THERAPEUTICS B.V.	NULL	Not Recruiting			Female: yes Male: yes	165	Phase 2	France;Spain;Austria;Germany;United Kingdom;Italy
381	EUCTR2017-000135-14-AT (EUCTR)	26/05/2017	08/03/2017	A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) - AMBLED Study	Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E	Prexton Therapeutics B.V.	NULL	Not Recruiting			Female: yes Male: yes	165	Phase 2	Spain;Austria;Germany;United Kingdom
382	NCT03033498 (ClinicalTrials.gov)	May 17, 2017	25/1/2017	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease	A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease	Parkinson's Disease (PD)	Drug: ABBV-951	AbbVie	NULL	Completed	45 Years	85 Years	All	29	Phase 1	United States
383	NCT03047629 (ClinicalTrials.gov)	May 11, 2017	3/2/2017	Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation	A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation	Parkinson's Disease;Constipation	Drug: ENT-01;Other: Placebo	Enterin Inc.	NULL	Completed	30 Years	86 Years	All	50	Phase 1/Phase 2	United States
384	NCT03065192 (ClinicalTrials.gov)	May 11, 2017	10/2/2017	Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease	An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa	Idiopathic Parkinson's Disease;Parkinson's Disease;Basal Ganglia Disease;Brain Diseases;Central Nervous System Diseases;Movement Disorders;Nervous System Diseases;Neurodegenerative Diseases;Parkinsonian Disorders	Drug: VY-AADC01	Neurocrine Biosciences	Voyager Therapeutics	Completed	40 Years	75 Years	All	16	Phase 1	United States
385	EUCTR2015-004507-23-FI (EUCTR)	08/05/2017	30/03/2017	Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.	Efficacy and safety of ODM-104 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson’s disease and end-of-dose wearing-off. - COMPOC	Parkinson’s disease (PD) patients with end-of-dose wearing-off (motor fluctuations);Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]	Product Name: Levodopa 75 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Levodopa 100 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Levodopa 125 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Levodopa 150 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Carbidopa 65 mg capsule INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA Product Name: ODM-104 INN or Proposed INN: na Other descriptive name: ODM-104	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	80	Phase 2	Hungary;Finland;Latvia;Germany
386	NCT02702076 (ClinicalTrials.gov)	May 2017	2/3/2016	Apomorphine in Parkinson's Disease Patients With Visual Hallucinations	Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Continuous Subcutaneous Infusion in Parkinson's Disease Patients With Refractory Visual Hallucinations	Parkinson's Disease;Hallucinations, Visual	Drug: Apomorphine;Drug: Placebo	University Medical Center Groningen	NULL	Recruiting	30 Years	N/A	All	35	Phase 2	Netherlands
387	NCT03119636 (ClinicalTrials.gov)	May 2017	6/4/2017	Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease	A Phase I/II, Open-Label Study to Assess the Safety and Efficacy of Striatum Transplantation of Human Embryonic Stem Cells-derived Neural Precursor Cells in Patients With Parkinson's Disease	Parkinson's Disease	Biological: NPC transplantation;Drug: Levodopa	Chinese Academy of Sciences	The First Affiliated Hospital of Zhengzhou University	Recruiting	50 Years	80 Years	All	50	Phase 1/Phase 2	China
388	ChiCTR-IPR-17011155	2017-04-20	2017-04-16	Dihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's disease	Dihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's disease	Parkinson’s disease	treatment group:dihydroergotoxine mesylate 2.5 mg, twice daily, two weeks;intervention group:identical placebo 2.5 mg, twice daily, two weeks;	Nanjing First Hospital Affiliated to Nanjing Medical University	NULL	Recruiting	18	80	Both	treatment group:10;intervention group:10;		China
389	NCT03128450 (ClinicalTrials.gov)	April 15, 2017	9/2/2017	A Study To Evaluate the Safety and Efficacy of Human Neural Stem Cells for Parkinson's Disease Patient	A Single Arm, Open-Label,Pilot Study to Evaluate the Safety and Efficacy of Human Neural Stem Cells Injection (ANGE-S003) Through Nasal Way Delivery to Patients With Parkinson's Disease	Parkinson Disease	Biological: human neural stem cell	Second Affiliated Hospital of Soochow University	NULL	Enrolling by invitation	35 Years	70 Years	All	12	Phase 2/Phase 3	China
390	NCT03051607 (ClinicalTrials.gov)	April 10, 2017	9/2/2017	Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off	Idiopathic Parkinson Disease	Drug: Tozadenant	Biotie Therapies Inc.	Acorda Therapeutics	Terminated	30 Years	80 Years	All	66	Phase 3	United States;Canada;United Kingdom
391	JPRN-jRCTs051180185	07/04/2017	26/03/2019	APISJ Study	Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease - APISJ Study	Parkinson's disease Parkinson's disease	In this research, the duration of evaluation will be 24 weeks. Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by Istradefylline.	Takahashi Makio	Kyowa Kirin Co., Ltd.	Complete	>= 30age old	Not applicable	Both	30	N/A	Japan
392	EUCTR2016-003961-25-GB (EUCTR)	04/04/2017	16/02/2017	A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing wearing off	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose Wearing-Off”	Parkinson's Disease MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: tozadenant Product Code: TOZ INN or Proposed INN: tozadenant Other descriptive name: TOZADENANT	Biotie Therapies	NULL	Not Recruiting			Female: yes Male: yes	450	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Czech Republic;Hungary;European Union;Canada;Spain;Australia;Germany;Italy;United Kingdom
393	EUCTR2016-001403-23-GR (EUCTR)	31/03/2017	14/10/2016	12-Week study comparing Levodopa-Carbidopa Intestinal Gel / Levodopa Carbidopa Enteral Suspension to Optimized Medical Treatment on dyskinesia in subjects with advanced Parkinson's disease	An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with Advanced Parkinson's Disease - DYSCOVER (DYSkinesia COmparative interventional trial on Duodopa VERsus oral medication) - DYSCOVER Study	Dyskinesia in advanced Parkinson's disease MedDRA version: 19.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA MONOHYDRATE	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	60	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Hungary;Slovakia;European Union;Greece;Finland;Spain
394	NCT02970019 (ClinicalTrials.gov)	March 30, 2017	18/11/2016	Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease	A Double-blind, Placebo-controlled Study to Determine Safety, Tolerability, Pharmacokinetic of K0706.	Parkinson Disease	Drug: K0706;Drug: Placebo	Sun Pharma Advanced Research Company Limited	NULL	Completed	18 Years	65 Years	All	60	Phase 1	United States
395	EUCTR2016-003456-70-GB (EUCTR)	22/03/2017	26/01/2017	A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients	An Open-Label, Randomized, Crossover Trial utilizing a Single-BlindedRater to evaluate APL-130277 compared to s.c. Apomorphine in LevodopaResponsive Subjects with Parkinson's Disease Complicated by MotorFluctuations	Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes) MedDRA version: 21.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Trade Name: APO-go Product Name: s.c. apomorphine INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorp	Sunovion Pharmaceuticals Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	106	Phase 3	France;Spain;Austria;Germany;Italy;United Kingdom
396	EUCTR2016-001575-71-ES (EUCTR)	16/03/2017	17/01/2017	A 15-WEEK CLINICAL STUDY TO DETERMINE THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF PF-06649751 IN PATIENTS WITH EARLY PARKINSON’S DISEASE	A 15 WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, FLEXIBLE DOSE STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH EARLY STAGE PARKINSON’S DISEASE	Parkinson's Disease MedDRA version: 19.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PF-06649751 Product Code: PF-06649751 INN or Proposed INN: PF-06649751 Other descriptive name: PF-06649751 Product Name: PF-06649751 Product Code: PF-06649751 INN or Proposed INN: PF-06649751 Other descriptive name: PF-06649751 Product Name: PF-06649751 Product Code: PF-06649751 INN or Proposed INN: PF-06649751 Other descriptive name: PF-06649751	Pfizer, Inc.	NULL	Not Recruiting			Female: yes Male: yes	88	Phase 2	France;United States;Spain;Israel;Germany
397	JPRN-UMIN000026492	2017/03/15	15/03/2017	Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease	Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease - Intervention Study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease.	Parkinson's disease	In this research, the duration of evaluation will be 24 weeks. Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by istradefylline.	Osaka Red Cross Hospital	Clinical Research Center, Wakayama Medical University	Complete: follow-up complete	30years-old	Not applicable	Male and Female	30	Not selected	Japan
398	EUCTR2015-003513-24-SK (EUCTR)	14/03/2017	04/03/2016	OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004	MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill™ Carbidopa/Levodopa 50/500 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA	Intec Pharma, Ltd.	NULL	Not Recruiting			Female: yes Male: yes	266	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Hungary;Slovakia;Poland;Spain;Ukraine;Israel;Bulgaria;Germany;Italy;United Kingdom
399	JPRN-jRCTs071180014	08/03/2017	29/01/2019	ODYSSEI Study	Intervention Study for the effect of Istradefylline on onset of Dyskinesia in Patients with Parkinson's Disease - ODYSSEI Study	Parkinson's disease Parkinson's disease	Arm A: Treatment with Istradefylline combined with optimal medical therapy. Treatment with Istradefylline will be started at a dose of 20 mg administered once daily at Week 0. The dose of Istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. From the following day of Week 4, Optimal medical therapy including Istradefylline will be applied to each patient. Arm B: Optimal medical therapy without Istradefylline. Treatment with increased dose of previously used antiparkinson drugs or addition of new antiparkinson drug other than Istradefylline will be started at Week 0. After Week 4, Optimal medical therapy without Istradefylline will be applied to each patient.	Tsuboi Yoshio	Kyowa Kirin Co., Ltd.	Not Recruiting	>= 30age old	< 80age old	Both	280	N/A	N A;Japan
400	EUCTR2015-004507-23-HU (EUCTR)	24/02/2017	04/01/2017	Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.	Efficacy and safety of ODM-104 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson’s disease and end-of-dose wearing-off. - COMPOC	Parkinson’s disease (PD) patients with end-of-dose wearing-off (motor fluctuations);Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]	Product Name: Levodopa 75 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Levodopa 100 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Levodopa 125 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Levodopa 150 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Carbidopa 65 mg capsule INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA Product Name: ODM-104 INN or Proposed INN: na Other descriptive name: ODM-104	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	80	Phase 2	Hungary;Finland;Latvia;Germany
401	EUCTR2016-001403-23-FI (EUCTR)	22/02/2017	31/08/2016	12-Week study comparing Levodopa-Carbidopa Intestinal Gel / Levodopa Carbidopa Enteral Suspension to Optimized Medical Treatment on dyskinesia in subjects with advanced Parkinson's disease	An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with Advanced Parkinson's Disease - DYSCOVER (DYSkinesia COmparative interventional trial on Duodopa VERsus oral medication) - DYSCOVER Study	Dyskinesia in advanced Parkinson's disease MedDRA version: 19.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA MONOHYDRATE	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	60	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Hungary;Slovakia;European Union;Greece;Finland;Spain
402	EUCTR2016-000657-12-IT (EUCTR)	16/02/2017	08/02/2017	A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation	Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant - MOVES-PD	Parkinson's disease (PD) carrying a GBA mutation MedDRA version: 19.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: 000000 Other descriptive name: Genz-682452-AU Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: 00000 Other descriptive name: Genz-682452-AU	Genzyme Corporation	NULL	Not Recruiting			Female: yes Male: yes	276	Phase 2	United States;Portugal;Taiwan;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Australia;Germany;Norway;Japan;Sweden
403	NCT03119194 (ClinicalTrials.gov)	January 27, 2017	13/4/2017	Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067	An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067 in Healthy Male Subjects	Parkinson Disease	Drug: [14C]-BIA 9-1067	Bial - Portela C S.A.	NULL	Completed	30 Years	65 Years	Male	7	Phase 1	United Kingdom
404	EUCTR2016-000657-12-DE (EUCTR)	26/01/2017	17/10/2016	A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation	Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant - MOVES-PD	Parkinson's disease (PD) carrying a GBA mutation MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Venglustat Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: venglustat malate Other descriptive name: Genz-682452-AU Product Name: Venglustat Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: venglustat malate Other descriptive name: Genz-682452-AU	Genzyme Corporation	NULL	Not Recruiting			Female: yes Male: yes	290	Phase 2	United States;Portugal;Taiwan;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Australia;Germany;Norway;Japan;Sweden
405	EUCTR2016-000657-12-PT (EUCTR)	09/01/2017	25/10/2016	A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation	Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant - MOVES-PD	Parkinson's disease (PD) carrying a GBA mutation MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Venglustat Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: venglustat malate Other descriptive name: Genz-682452-AU Product Name: Venglustat Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: venglustat malate Other descriptive name: Genz-682452-AU	Genzyme Corporation	NULL	Not Recruiting			Female: yes Male: yes	290	Phase 2	Germany;Norway;Japan;Portugal;United States;Taiwan;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Sweden
406	ChiCTR-DDD-16009569	2017-01-01	2016-10-24	Differential diagnosis of primary Parkinson's disease by 18F-FDG combined with 11C-ß-CFT PET / CT imaging	Differential diagnosis of primary Parkinson's disease by 18F-FDG combined with 11C-ß-CFT PET / CT imaging	Parkinson's Disease	Gold Standard:;Index test:;	Renji hospital, School of Medicine, Shanghai Jiao Tong University	NULL	Pending	20	80	Both	Target condition:0;Difficult condition:0		China
407	NCT02954978 (ClinicalTrials.gov)	January 2017	1/11/2016	Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease	A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease	Parkinson Disease;Parkinsons Disease With Dementia	Drug: Placebo Oral Capsule;Drug: Nilotinib 150mg oral capsule [Tasigna];Drug: Nilotinib 300mg oral capsule [Tasigna]	Georgetown University	NULL	Active, not recruiting	40 Years	90 Years	All	75	Phase 2	United States
408	NCT02969369 (ClinicalTrials.gov)	December 31, 2016	17/11/2016	A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis	A Multicenter Randomized Double-blind Followed by an Open-label Extension Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis	Parkinson Disease Psychosis	Drug: SEP-363856;Drug: Placebo capsule	Sunovion	NULL	Completed	55 Years	105 Years	All	39	Phase 2	United States
409	EUCTR2016-001575-71-DE (EUCTR)	23/12/2016	26/09/2016	A 15-WEEK CLINICAL STUDY TO DETERMINE THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF PF-06649751 IN PATIENTS WITH EARLY PARKINSON’S DISEASE	A 15 WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, FLEXIBLE DOSE STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH EARLY STAGE PARKINSON’S DISEASE	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PF-06649751 Product Code: PF-06649751 INN or Proposed INN: PF-06649751 Other descriptive name: PF-06649751 Product Name: PF-06649751 Product Code: PF-06649751 INN or Proposed INN: PF-06649751 Other descriptive name: PF-06649751 Product Name: PF-06649751 Product Code: PF-06649751 INN or Proposed INN: PF-06649751 Other descriptive name: PF-06649751	Pfizer, Inc.	NULL	Not Recruiting			Female: yes Male: yes	88	Phase 2	France;United States;Spain;Israel;Germany
410	EUCTR2016-002033-30-BE (EUCTR)	19/12/2016	21/11/2016	A clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuations	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO) - iNDiGO	Subjects with Parkinson’s Disease with motor fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 3	Serbia;Portugal;United States;Spain;Ukraine;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Poland;Belgium;Denmark;Netherlands;Germany
411	NCT02906020 (ClinicalTrials.gov)	December 15, 2016	14/9/2016	A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation	Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.	Parkinson's Disease	Drug: venglustat GZ/SAR402671;Drug: Placebo	Genzyme, a Sanofi Company	NULL	Terminated	18 Years	80 Years	All	270	Phase 2	United States;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom
412	JPRN-UMIN000024859	2016/12/14	16/11/2016	The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide.	The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide. - The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide.	Parkinson's disease	Switching from Dopamine agonist to Zonisamide. Intervention period of 12 weeks.	Medical Corporation Abe Neurology Clinic	NULL	Complete: follow-up continuing	30years-old	Not applicable	Male and Female	50	Not applicable	Japan
413	NCT02941822 (ClinicalTrials.gov)	December 2016	5/9/2016	Ambroxol in Disease Modification in Parkinson Disease	A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease	Parkinson Disease	Drug: Ambroxol	University College, London	The Cure Parkinson's Trust	Completed	40 Years	80 Years	All	23	Phase 2	United Kingdom
414	NCT02879136 (ClinicalTrials.gov)	December 2016	23/6/2016	TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease	TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot Study	Parkinson's Disease, Idiopathic	Drug: Methylphenidate;Other: Physical Therapy;Drug: Atomoxetine	Hubert Fernandez	NULL	Recruiting	18 Years	90 Years	All	42	Early Phase 1	United States
415	NCT03000569 (ClinicalTrials.gov)	November 30, 2016	28/11/2016	A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease	A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's Disease	Parkinson Disease	Drug: SAGE-217;Drug: Levodopa;Drug: Antiparkinsonian Agent(s)	Sage Therapeutics	NULL	Completed	40 Years	75 Years	All	29	Phase 2	United States
416	EUCTR2016-002033-30-FR (EUCTR)	29/11/2016	12/01/2017	A clinical study investigating the efficacy, tolerability, and safety of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuations	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO) - iNDiGO	Subjects with Parkinson’s Disease with motor fluctuations MedDRA version: 19.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Not Recruiting			Female: yes Male: yes	150	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;France;Hungary;Canada;Belgium;Spain;Denmark;Israel;Netherlands;United Kingdom;Sweden
417	EUCTR2016-001403-23-SK (EUCTR)	29/11/2016	07/09/2016	12-Week study comparing Levodopa-Carbidopa Intestinal Gel / Levodopa Carbidopa Enteral Suspension to Optimized Medical Treatment on dyskinesia in subjects with advanced Parkinson's disease	An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with Advanced Parkinson's Disease - DYSCOVER (DYSkinesia COmparative interventional trial on Duodopa VERsus oral medication) - DYSCOVER Study	Dyskinesia in advanced Parkinson's disease MedDRA version: 20.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA MONOHYDRATE	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	60	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Hungary;European Union;Slovakia;Greece;Finland;Spain
418	JPRN-UMIN000024536	2016/11/28	25/10/2016	Intervention Study for the effect of Istradefylline on onset of Dyskinesia in Patients with Parkinson's Disease.	Intervention Study for the effect of Istradefylline on onset of Dyskinesia in Patients with Parkinson's Disease. - ODYSSEI Study(Onset of Dyskinesia and Safety/Efficacy of Istradefylline)	Parkinson's disease	Treatment with istradefylline combined with optimal medical therapy. Treatment with istradefylline will be started at a dose of 20 mg administered once daily at Week 0. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. From the following day of Week 4, Optimal medical therapy including istradefylline will be applied to each patient. Optimal medical therapy without istradefylline. Treatment with increased dose of previously used antiparkinson drugs or addition of new antiparkinson drug other than istradefylline will be started at Week 0. After Week 4, Optimal medical therapy without istradefylline will be applied to each patient.	Fukuoka University	NULL	Complete: follow-up complete	30years-old	80years-old	Male and Female	280	Not applicable	Japan
419	EUCTR2015-004912-39-ES (EUCTR)	25/11/2016	17/05/2016	A 15-WEEK CLINICAL STUDY TO DETERMINE THEEFFECTIVENESS, SAFETY AND TOLERABILITY OF PF-06649751 IN PATIENTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE	A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THEEFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE	Parkinson's Disease MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PF-06649751 Product Code: PF-06649751 INN or Proposed INN: PF-06649751 Other descriptive name: PF-06649751 Product Name: PF-06649751 Product Code: PF-06649751 INN or Proposed INN: PF-06649751 Other descriptive name: PF-06649751	Pfizer, Inc.	NULL	Not Recruiting			Female: yes Male: yes	198	Phase 2	France;United States;Spain;Germany;Japan;United Kingdom
420	EUCTR2016-000102-11-NL (EUCTR)	23/11/2016	08/11/2016	Trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with refractory visual hallucinations.	Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with refractory visual hallucinations. - Apomorphine in PD patients with visual hallucinations: a RCT	Parkinson's disease patients with refractory visual hallucinations MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: APO-go Product Name: Apomorphine	University Medical Center Groningen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2;Phase 3	Netherlands
421	EUCTR2016-001403-23-ES (EUCTR)	14/11/2016	15/11/2016	12-Week study comparing Levodopa-Carbidopa Intestinal Gel / Levodopa Carbidopa Enteral Suspension to Optimized Medical Treatment on dyskinesia in subjects with advanced Parkinson's disease	An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with Advanced Parkinson's Disease - DYSCOVER (DYSkinesia COmparative interventional trial on Duodopa VERsus oral medication) - DYSCOVER Study	Dyskinesia in advanced Parkinson's disease MedDRA version: 19.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA MONOHYDRATE	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 3	United States;Hungary;Slovakia;European Union;Greece;Finland;Spain
422	NCT03007888 (ClinicalTrials.gov)	November 14, 2016	6/12/2016	A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease	A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease	Advanced Parkinson's Disease	Drug: IR CD-LD;Drug: ER CD-LD	Impax Laboratories, LLC	NULL	Completed	40 Years	100 Years	All	28	Phase 2	United States
423	EUCTR2016-000657-12-SE (EUCTR)	09/11/2016	12/10/2016	A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation	Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant - MOVES-PD	Parkinson's disease (PD) carrying a GBA mutation MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Venglustat Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: venglustat malate Other descriptive name: Genz-682452-AU Product Name: Venglustat Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: venglustat malate Other descriptive name: Genz-682452-AU	Genzyme Corporation	NULL	Not Recruiting			Female: yes Male: yes	290	Phase 2	United States;Portugal;Taiwan;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Germany;Norway;Japan;Sweden
424	NCT03531060 (ClinicalTrials.gov)	November 8, 2016	10/4/2018	A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia	A Randomised, Double-blind, Placebo-controlled, Phase Ib Study Evaluating the Safety and Tolerability of IRL790 in Patients With Parkinson's Disease (PD) Experiencing Levodopa (L-Dopa) Induced Dyskinesia (LID).	Parkinson Disease	Drug: IRL790;Drug: Placebo	Integrative Research Laboratories AB	NULL	Completed	50 Years	85 Years	All	15	Phase 1/Phase 2	NULL
425	EUCTR2016-002033-30-ES (EUCTR)	03/11/2016	25/08/2016	A clinical study investigating the efficacy, tolerability, and safety of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuations	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO) - iNDiGO	Subjects with Parkinson’s Disease with motor fluctuations MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: Levodopa INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 3	United States;France;Canada;Belgium;Spain;Denmark;Israel;Netherlands;Sweden
426	JPRN-UMIN000025638	2016/11/01	16/01/2017	Adenosine A2A receptors in Parkinson's disease	Adenosine A2A receptors in Parkinson's disease - Adenosine A2A receptors in Parkinson's disease	Parkinson's disease	11C-preladenant-PET scanning	Tokyo Metropolitan Institute of Gerontology	NULL	Complete: follow-up complete	40years-old	89years-old	Male and Female	40	Not selected	Japan
427	NCT03022799 (ClinicalTrials.gov)	November 2016	27/12/2016	Phase I, KM-819 in Healthy Subjects for Parkinson's Disease	A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects	Parkinson's Disease	Drug: KM-819;Drug: Placebo	Kainos Medicine Inc.	NULL	Completed	19 Years	45 Years	All	88	Phase 1	Korea, Republic of
428	NCT02857244 (ClinicalTrials.gov)	November 2016	25/7/2016	A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients	A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients	Parkinson's Disease	Drug: Duloxetine;Drug: Donepezil;Drug: Modafinil	University of Chicago	NULL	Withdrawn	18 Years	100 Years	All	0	Phase 2	United States
429	EUCTR2016-000657-12-ES (EUCTR)	20/10/2016	24/10/2016	A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation	Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant - MOVES-PD	Parkinson's disease (PD) carrying a GBA mutation MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: NA Other descriptive name: Genz-682452-AU Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: NA Other descriptive name: Genz-682452-AU	Genzyme Corporation	NULL	Not Recruiting			Female: yes Male: yes	276	Phase 2	United States;Portugal;Taiwan;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapore;Australia;Germany;Norway;Japan;Sweden
430	NCT02847650 (ClinicalTrials.gov)	October 17, 2016	25/7/2016	Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease	A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FLEXIBLE DOSE STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH EARLY STAGE PARKINSON'S DISEASE	Parkinson Disease	Drug: Placebo;Drug: PF-06649751	Pfizer	NULL	Terminated	45 Years	80 Years	All	57	Phase 2	United States;France;Germany;Israel
431	EUCTR2015-002571-24-GB (EUCTR)	14/10/2016	12/02/2019	A Pilot Study to Evaluate the Safety, Tolerability (any side effects of the drug) and Pharmacodynamic (biochemical and physiological effects of drugs). The effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease.	A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease - AiM-PD	Parkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: AMBROSAN 60mg Tablets Product Name: Ambroxol INN or Proposed INN: Ambroxol hydrochloride	Joint Research Office	NULL	Not Recruiting			Female: yes Male: yes	20	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
432	EUCTR2016-002391-27-GB (EUCTR)	07/10/2016	04/08/2016	Opicapone in clinical practice (OPTIPARK)	This action will amend the information submitted in this data field for all relevant applications. Please refer to the guidance under the Amendment tab and consider whether further notification to review bodies is required. - Opicapone in clinical practice (OPTIPARK)_V1	Parkinson's disease (PD) patients with wearing-off motor fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ongentys Product Name: Ongentys	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Germany;United Kingdom
433	EUCTR2016-002391-27-DE (EUCTR)	05/10/2016	05/08/2016	OPTIPARK	Efficacy and safety of opicapone in clinical practice in Parkinson’s Disease patients with wearing-off motor fluctuations	Parkinson's disease (PD) patients with wearing-off motor fluctuations;Therapeutic area: Not possible to specify	Trade Name: Ongentys Product Name: Ongentys	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Germany;United Kingdom
434	NCT02818777 (ClinicalTrials.gov)	October 2016	6/5/2016	A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease	A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease	Parkinson's Disease	Drug: cannabidiol	University of Colorado, Denver	Colorado Department of Public Health and Environment;GW Research Ltd	Completed	40 Years	80 Years	All	13	Phase 2	United States
435	NCT02803749 (ClinicalTrials.gov)	October 2016	14/6/2016	Buspirone in Parkinson's Disease	The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson's Disease	Parkinson Disease;Anxiety	Drug: Buspirone;Drug: Placebo	University of Rochester	Michael J. Fox Foundation for Parkinson's Research	Completed	18 Years	N/A	All	21	Phase 2	United States
436	NCT02538315 (ClinicalTrials.gov)	October 2016	25/8/2015	Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients	Using 3,4-dihydroxy-6-[18F]-Fluoro-l-phenylalanine ( [18F]FDOPA) PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients	Parkinson`s Disease	Drug: [18F]FDOPA PET/CT	University of Saskatchewan	University of Manitoba	Recruiting	18 Years	N/A	All	30	N/A	Canada
437	EUCTR2015-005078-39-DE (EUCTR)	21/09/2016	02/03/2016	-	A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's disease	Subjects with advanced Parkinson's disease MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Not Recruiting			Female: yes Male: yes	47	Phase 2	United States;Austria;Israel;Germany;Italy
438	EUCTR2016-001403-23-IT (EUCTR)	13/09/2016	06/09/2021	12-Week study comparing Levodopa-Carbidopa Intestinal Gel / Levodopa Carbidopa Enteral Suspension to Optimized Medical Treatment on dyskinesia in subjects with advanced Parkinson's disease.	An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with Advanced Parkinson's Disease - DYSCOVER (DYSkinesia COmparativeinterventional trial on Duodopa VERsus oral medication) - DYSCOVER Study	Dyskinesia in advanced Parkinson's disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa Product Name: na Product Code: [na] INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Other descriptive name: CARBIDOPA MONOHYDRATE	ABBVIE DEUTSCHLAND GMBH & CO. KG	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 3	United States;Hungary;Slovakia;European Union;Greece;Finland;Spain;Italy
439	EUCTR2015-003513-24-DE (EUCTR)	08/09/2016	15/04/2016	OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004	MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill™ Carbidopa/Levodopa 50/500 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA	Intec Pharma, Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	266	Phase 3	United States;Hungary;Slovakia;Poland;Spain;Ukraine;Israel;Bulgaria;Germany;Italy;United Kingdom
440	NCT02601586 (ClinicalTrials.gov)	September 2016	17/8/2015	Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease	Evaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA Trial	Parkinson Disease	Drug: PR Oxycodone;Drug: Levodopa;Drug: Oxycodone Placebo;Drug: Levodopa placebo	University Hospital, Toulouse	NULL	Completed	40 Years	75 Years	All	67	Phase 2/Phase 3	France
441	NCT02365870 (ClinicalTrials.gov)	August 2016	11/2/2015	Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment	Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment	Anxiety Disorders;Parkinson Disease	Drug: rotigotine transdermal patch;Drug: placebo	Johns Hopkins University	National Institute on Aging (NIA)	Terminated	21 Years	89 Years	All	4	Phase 4	United States
442	NCT02782481 (ClinicalTrials.gov)	August 2016	22/5/2016	A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations	A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations	Parkinson's Disease	Drug: ND0612;Drug: Placebo	NeuroDerm Ltd.	NULL	Withdrawn	30 Years	80 Years	All	0	Phase 3	Israel
443	NCT02452723 (ClinicalTrials.gov)	July 2016	18/5/2015	A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's Disease	A Single Arm, Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease	Parkinson Disease	Biological: ISC-hpNSC	Cyto Therapeutics Pty Limited	NULL	Active, not recruiting	30 Years	70 Years	All	12	Phase 1	Australia
444	NCT02382198 (ClinicalTrials.gov)	July 2016	21/1/2015	Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease	A Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's Disease	Sialorrhea;Parkinson's Disease	Drug: Glycopyrrolate;Drug: Placebo	Ottawa Hospital Research Institute	NULL	Unknown status	30 Years	N/A	All	28	Phase 2	Canada
445	NCT02789592 (ClinicalTrials.gov)	July 2016	31/5/2016	Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease	A Randomized Double-Blind, Double-Dummy, Crossover Study to Evaluate the Efficacy and Safety of Prolonged-Release Melatonin and Clonazepam in Patients With Rapid Eye Movement (REM) Sleep Behavior Disorder in Parkinson Disease	REM Sleep Behavior Disorder;Parkinson Disease	Drug: Melatonin PR;Drug: Clonazepam;Drug: Melatonin PR placebo;Drug: Clonazepam placebo	Seoul National University Hospital	Kuhnil Pharmaceutical Co., Ltd.	Not yet recruiting	30 Years	N/A	Both	30	Phase 2	Korea, Republic of
446	NCT02615873 (ClinicalTrials.gov)	July 2016	23/11/2015	A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004	An Open-Label,Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004	Parkinson's Disease	Drug: Accordion Pill™ Carbidopa/Levodopa	Intec Pharma Ltd.	NULL	Unknown status	30 Years	100 Years	All	460	Phase 3	United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom
447	EUCTR2015-003513-24-BG (EUCTR)	27/06/2016	26/04/2016	OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004	MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill™ Carbidopa/Levodopa 50/500 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA	Intec Pharma, Ltd.	NULL	Not Recruiting			Female: yes Male: yes	266	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Hungary;Slovakia;Poland;Spain;Ukraine;Israel;Bulgaria;Germany;Italy;United Kingdom
448	EUCTR2015-003513-24-IT (EUCTR)	23/06/2016	05/11/2020	OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004 - OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004	Parkinson's Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Accordion Pill ¿ Carbidopa/Levodopa 50/400 mg Product Code: [NA] INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: Accordion Pill ¿ Carbidopa/Levodopa 50/500 mg Product Code: [NA] INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA	INTEC PHARMA LTD	NULL	Not Recruiting			Female: yes Male: yes	266	Phase 3	United States;Hungary;Slovakia;Spain;Poland;Ukraine;Israel;Bulgaria;Germany;United Kingdom;Italy
449	EUCTR2015-003512-20-PL (EUCTR)	22/06/2016	01/04/2016	Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson’s Disease	A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson’s Disease Patients	Parkinson's Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SINEMET 25-100 Product Name: Immediate Release carbidopa/levodopa 25/100 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill™ Carbidopa/Levodopa 50/500 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA	Intec Pharma, Ltd.	NULL	Not Recruiting			Female: yes Male: yes	420	Phase 3	United States;Hungary;Slovakia;Spain;Poland;Ukraine;Israel;Bulgaria;Germany;Italy;United Kingdom
450	EUCTR2015-004912-39-DE (EUCTR)	14/06/2016	11/02/2016	A 15-WEEK CLINICAL STUDY TO DETERMINE THEEFFECTIVENESS, SAFETY AND TOLERABILITY OF PF-06649751 IN PATIENTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON’S DISEASE	A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THEEFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON’S DISEASE	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PF-06649751 Product Code: PF-06649751 INN or Proposed INN: PF-06649751 Other descriptive name: PF-06649751 Product Name: PF-06649751 Product Code: PF-06649751 INN or Proposed INN: PF-06649751 Other descriptive name: PF-06649751	Pfizer, Inc.	NULL	Not Recruiting			Female: yes Male: yes	198	Phase 2	France;United States;Spain;Germany;Japan;United Kingdom
451	EUCTR2015-005078-39-IT (EUCTR)	08/06/2016	19/01/2021	NA	A multicenter, parallel-group, rater-blinded, randomized clinical studyinvestigating the efficacy, safety, tolerability and pharmacokinetics of2 dosing regimens of ND0612H, a solution of levodopa/carbidopadelivered via a pump system as a continuous subcutaneous infusion insubjects with advanced Parkinson's disease - NA	advanced Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: soluzione di levodopa/carbidopa Product Code: ND0612 INN or Proposed INN: LEVODOPA Other descriptive name: NA INN or Proposed INN: CARBIDOPA Other descriptive name: NA	NEURODERM LTD.	NULL	Not Recruiting			Female: yes Male: yes	47	Phase 2	United States;Austria;Israel;Germany;Italy
452	EUCTR2015-003512-20-IT (EUCTR)	08/06/2016	05/11/2020	Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson¿s Disease	A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill¿ Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson¿s Disease Patients - Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson¿s Disease	Parkinson's Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 MedDRA version: 20.0;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SINEMET 25-100 Product Name: Immediate Release carbidopa/levodopa 25/100 mg Product Code: [na] INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: Accordion Pill ¿ Carbidopa/Levodopa 50/400 mg Product Code: [na] INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: Accordion Pill ¿ Carbidopa/Levodopa 50/500 mg Product Code: [na] INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA	INTEC PHARMA LTD	NULL	Not Recruiting			Female: yes Male: yes	420	Phase 3	United States;Hungary;Slovakia;Spain;Poland;Ukraine;Russian Federation;Israel;Bulgaria;Germany;United Kingdom;Italy
453	JPRN-UMIN000022533	2016/06/01	01/06/2016	A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease	A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease - The DAT-SPECT study for the benefit of Selegilline or Zonisamide in Parkinson's Disease(DATSZ-PD study)	Parkinson's disease	L-Dopa/DCI only The drug is administered per oral at 150 to 300 mg/day. The treatment is started within 14days after registration and continued until day 365. L-Dopa/DCI + selegiline L-Dopa/DCI is administered per oral at 150 to 300 mg/day and selegiline is administered at 5mg/day. The treatment is started within 14days after registration and continued until day 365. L-Dopa/DCI + zonisamide L-Dopa/DCI is administered per oral at 150 to 300 mg/day and zonisamide is administered at 25mg/day. The treatment is started within 14days after registration and continued until day 365.	Osaka Redcross HospitalWakayama Prefectural Medical College	NULL	Recruiting	55years-old	80years-old	Male and Female	180	Phase 2	Japan
454	NCT02642393 (ClinicalTrials.gov)	June 2016	19/12/2015	Study of Urate Elevation in Parkinson's Disease, Phase 3	A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's Disease	Parkinson's Disease	Drug: Inosine;Drug: Placebo	Michael Alan Schwarzschild	The Parkinson Study Group;Michael J. Fox Foundation for Parkinson's Research;University of Rochester;National Institute of Neurological Disorders and Stroke (NINDS)	Completed	30 Years	N/A	All	298	Phase 3	United States;Puerto Rico
455	NCT02807675 (ClinicalTrials.gov)	June 2016	17/6/2016	A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)	A Phase 1 Study of the Safety and Tolerability of a Single Dose Administration of CVT- 301 (Levodopa Inhalation Powder) When Administered for Early Morning OFF Symptoms in Patients With Parkinson's Disease	Parkinson's Disease	Drug: CVT-301, LIP;Other: Placebo	Acorda Therapeutics	NULL	Completed	30 Years	85 Years	All	36	Phase 1	United States
456	NCT02785978 (ClinicalTrials.gov)	June 2016	11/5/2016	Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers	Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers	Parkinson Disease;Healthy Volunteers	Drug: Levodopa acute challenge;Other: Controlled environment tests (series of tasks of everyday life);Other: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS;Device: ActiMyo recording;Other: Diary completion	Institut de Myologie, France	NULL	Completed	18 Years	N/A	All	30	N/A	France
457	NCT02812394 (ClinicalTrials.gov)	June 2016	22/6/2016	A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets	A Phase 1 Single Dose Pharmacokinetic Bridging Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets	Parkinson Disease	Drug: CVT-301 (Dose Level 1);Drug: CVT-301 (Dose Level 2);Drug: Sinemet®	Acorda Therapeutics	NULL	Completed	25 Years	65 Years	Both	24	Phase 1	United States
458	EUCTR2016-000679-25-ES (EUCTR)	31/05/2016	18/03/2016	Clinical study for the assessment of security of candesartan in Parkinson?s disease population and its potential benefit in cognitive impairment associated to Parkinson?s disease.	A prospective, randomized, double-blind and placebo-controlled, parallel group, phase II study to compare the efficacy and safety of candesartan versus placebo on cognitive impairment associated with Parkinson?s disease. Exploratory study.	Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Parapres	INSTITUT DE RECERCA HSCSP	NULL	Not Recruiting			Female: yes Male: yes	56	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Spain
459	EUCTR2015-005078-39-AT (EUCTR)	30/05/2016	09/03/2016	-	A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's disease	Subjects with advanced Parkinson's disease MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: levodopa/carbidopa solution Product Code: ND0612 INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA	NeuroDerm Ltd.	NULL	Not Recruiting			Female: yes Male: yes	47	Phase 2	United States;Austria;Israel;Germany;Italy
460	JPRN-UMIN000009062	2016/05/30	09/10/2012	An open-label, single-centered, non-randomized trial of inosine to assess its safety for patients with Parkinson's disease	An open-label, single-centered, non-randomized trial of inosine to assess its safety for patients with Parkinson's disease - An evaluation of the safety of inosine for patients with Parkinson's disease	Parkinson's disease	Take oral inosine 500-3000mg/day to achieve a serum UA level between 6.0-8.0 mg/dL	Dept. of Clinical pharmacology and Neurology	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	20	Phase 1	Japan
461	EUCTR2015-003513-24-HU (EUCTR)	24/05/2016	02/03/2016	OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004	MedDRA version: 19.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill™ Carbidopa/Levodopa 50/500 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA	Intec Pharma, Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	460	Phase 3	United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom
462	EUCTR2015-003512-20-ES (EUCTR)	18/05/2016	18/03/2016	Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson?s Disease	A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill? Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson?s Disease Patients	Parkinson's Disease MedDRA version: 18.1;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SINEMET 25-100 Product Name: Immediate Release carbidopa/levodopa 25/100 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Trade Name: SINEMET 10-100 Product Name: Immediate Release carbidopa/levodopa 10/100 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill? Carbidopa/Levodopa 50/400 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill? Carbidopa/Levodopa 50/500 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Immediate Release carbidopa/levodopa 25/100 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA	Intec Pharma, Ltd.	NULL	Not Recruiting			Female: yes Male: yes	460	Phase 3	United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom
463	EUCTR2015-003513-24-ES (EUCTR)	18/05/2016	18/03/2016	OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004	Parkinson's Disease MedDRA version: 18.1;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Accordion Pill? Carbidopa/Levodopa 50/400 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill? Carbidopa/Levodopa 50/500 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA	Intec Pharma, Ltd.	NULL	Not Recruiting			Female: yes Male: yes	460	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom
464	EUCTR2016-000637-43-GB (EUCTR)	12/05/2016	04/03/2016	Safety, tolerability and efficacy study to examine APL-130277 in patients with Parkinson’s Disease.	An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF” Episodes).	Levodopa Responsive Patients with Parkinson’s Disease complicated by Motor Fluctuations (OFF” Episodes) MedDRA version: 22.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE	Sunovion Pharmaceuticals Inc.	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;France;Canada;Spain;Austria;Germany;Italy;United Kingdom
465	EUCTR2016-000636-18-GB (EUCTR)	12/05/2016	04/03/2016	Phase 3, placebo controlled study to examine the efficacy, safety and tolerability of APL-130277 in patients with Parkinson's disease.	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF” Episodes).	Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF” Episodes) MedDRA version: 19.0;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE Product Name: Apomorphine hydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: APOMORPHINE HYDROCHLORIDE	Sunuvion Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	126	Phase 3	Canada;United States;United Kingdom
466	JPRN-UMIN000022023	2016/05/10	10/05/2016	A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora-	A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora- - A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora-	Parkinson diseaseChronic constipation	Study drug group: A 12-week administration of lubiprostone 24 microgrum (adjustable) twice daily after switching from magnesium oxide Control group: Continuous administration of magnesium oxide at the same dosage regimen as before the enrollmen	Dokkyo Medical University	NULL	Complete: follow-up complete	20years-old	90years-old	Male and Female	64	Not selected	Japan
467	EUCTR2015-003512-20-HU (EUCTR)	09/05/2016	02/03/2016	Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson’s Disease	A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson’s Disease Patients	Parkinson's Disease MedDRA version: 19.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SINEMET 25-100 Product Name: Immediate Release carbidopa/levodopa 25/100 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Trade Name: SINEMET 10-100 Product Name: Immediate Release carbidopa/levodopa 10/100 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill™ Carbidopa/Levodopa 50/500 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Trade Name: SINEMET 25-100 Product Name: Immediate Release carbidopa/levodopa 25/100 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA	Intec Pharma, Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	460	Phase 3	United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom
468	EUCTR2015-003887-34-PL (EUCTR)	06/05/2016	26/02/2016	A Phase 3, Long-term, Open-label Study of Istradefylline inSubjects with Moderate to Severe Parkinson’s Disease	A Phase 3, Long-term, Open-label Study of Istradefylline inSubjects with Moderate to Severe Parkinson’s Disease	Moderate to severe Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE	Kyowa Kirin Pharmaceutical Development, Inc.	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 3	Serbia;United States;Czech Republic;Canada;Poland;Israel;Germany
469	NCT02784145 (ClinicalTrials.gov)	May 2016	17/5/2016	Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease	Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease	Parkinson Disease	Dietary Supplement: Resistant starch;Other: Recommendation with regard to nutrition	Saarland University	NULL	Completed	18 Years	N/A	All	95	N/A	Germany
470	NCT02728947 (ClinicalTrials.gov)	May 2016	31/3/2016	Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease	A Single Group and Open-label Study to Evaluate Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease	Parkinson's Disease	Drug: ROTIGOTINE	Luye Pharma Group Ltd.	NULL	Completed	18 Years	99 Years	Both	28	Phase 1	United States
471	NCT02705755 (ClinicalTrials.gov)	May 2016	7/3/2016	TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)	A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension	Neurogenic Orthostatic Hypotension;Multiple System Atrophy (MSA) With Orthostatic Hypotension;Pure Autonomic Failure;Parkinson Disease;Hypotension, Orthostatic;Orthostatic Hypotension;Pure Autonomic Failure With Orthostatic Hypotension;Parkinson Disease With Orthostatic Hypotension	Drug: TD-9855;Drug: Placebo	Theravance Biopharma	NULL	Completed	40 Years	N/A	All	34	Phase 2	United States
472	EUCTR2015-003512-20-GB (EUCTR)	28/04/2016	03/03/2016	Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson’s Disease	A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson’s Disease Patients	Parkinson's Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SINEMET 25-100 Product Name: Immediate Release carbidopa/levodopa 25/100 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill™ Carbidopa/Levodopa 50/500 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA	Intec Pharma, Ltd.	NULL	Not Recruiting			Female: yes Male: yes	420	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom
473	EUCTR2015-003513-24-GB (EUCTR)	28/04/2016	04/03/2016	OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects who Completed Study IN 11 004	MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill™ Carbidopa/Levodopa 50/500 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA	Intec Pharma, Ltd.	NULL	Not Recruiting			Female: yes Male: yes	266	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom
474	EUCTR2015-004507-23-DE (EUCTR)	25/04/2016	13/01/2016	Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.	Efficacy and safety of ODM-104 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson’s disease and end-of-dose wearing-off. - COMPOC	Parkinson’s disease (PD) patients with end-of-dose wearing-off (motor fluctuations);Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]	Product Name: Levodopa 75 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Levodopa 100 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Levodopa 125 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Levodopa 150 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Carbidopa 65 mg capsule INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA Product Name: ODM-104 INN or Proposed INN: na Other descriptive name: ODM-104	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	80	Phase 2	Hungary;Finland;Latvia;Germany
475	EUCTR2015-003512-20-SK (EUCTR)	22/04/2016	04/03/2016	Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson’s Disease	A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson’s Disease Patients	Parkinson's Disease MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SINEMET 25-100 Product Name: Immediate Release carbidopa/levodopa 25/100 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Trade Name: SINEMET 10-100 Product Name: Immediate Release carbidopa/levodopa 10/100 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA	Intec Pharma, Ltd.	NULL	Not Recruiting			Female: yes Male: yes	420	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Hungary;Slovakia;Poland;Spain;Ukraine;Israel;Bulgaria;Germany;Italy;United Kingdom
476	EUCTR2015-003887-34-DE (EUCTR)	12/04/2016	23/12/2015	A Phase 3, Long-term, Open-label Study of Istradefylline inSubjects with Moderate to Severe Parkinson’s Disease	A Phase 3, Long-term, Open-label Study of Istradefylline inSubjects with Moderate to Severe Parkinson’s Disease	Moderate to severe Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE	Kyowa Kirin Pharmaceutical Development, Inc.	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 3	Serbia;United States;Czech Republic;Canada;Poland;Israel;Germany
477	EUCTR2014-005630-60-AT (EUCTR)	12/04/2016	04/12/2015	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine theEfficacy and Safety of Tozadenant as Adjunctive Therapy inLevodopa-Treated Patients with Parkinson’s DiseaseExperiencing End-of-Dose Wearing-Off” (TOZ-PD)	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine theEfficacy and Safety of Tozadenant as Adjunctive Therapy inLevodopa-Treated Patients with Parkinson’s DiseaseExperiencing End-of-Dose Wearing-Off” (TOZ-PD) - TOZ-PD	Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tozadenant Product Code: SYN115 INN or Proposed INN: Tozadenant Other descriptive name: TOZADENANT	Biotie Therapies Inc.(a wholly owned subsidiary of Acorda Therapeutics Inc.)	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Czech Republic;European Union;Canada;Spain;Austria;Germany
478	NCT02764125 (ClinicalTrials.gov)	April 8, 2016	13/1/2016	Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)	Efficacy and Safety of ODM-104 Compared to a Standard Combination (Stalevo®); a Randomized Double-blind, Crossover Proof-of-concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off	Parkinson's Disease	Drug: Stalevo;Drug: levodopa MR	Orion Corporation, Orion Pharma	NULL	Completed	30 Years	N/A	All	84	Phase 2	Finland;Germany;Hungary;Latvia
479	NCT03034538 (ClinicalTrials.gov)	April 8, 2016	25/1/2017	An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease	An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease	Parkinson Disease;Parkinsonism;Dyskinesias	Drug: Zonegran	The Cooper Health System	NULL	Suspended	18 Years	N/A	All	20	Phase 4	United States
480	NCT02719496 (ClinicalTrials.gov)	April 2016	15/3/2016	Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease	Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease	Gastrointestinal Disorders in Parkinson's Disease	Drug: IBEROGAST	Nantes University Hospital	NULL	Completed	30 Years	80 Years	All	45	Phase 2	France
481	EUCTR2015-003887-34-IT (EUCTR)	25/03/2016	21/01/2021	A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects with Moderate to Severe Parkinson¿s Disease	A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects with Moderate to Severe Parkinson¿s Disease - A Phase 3, Long-term, Open-label Study of Istradefylline inSubjects with Moderate to Severe Parkinso	Moderate to severe Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE	KYOWA HAKKO KIRIN PHARMA, INC.	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 3	United States;Serbia;Czech Republic;Canada;Poland;Israel;Germany;Italy
482	JPRN-jRCTs061180060	22/03/2016	18/03/2019	Randomized clinical trial to assess the disease modifying effect of oral inosine for patients with Parkinson's disease	Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease - Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease	Parkinson's disease;D010300	Inosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years or placebo (500mg/CP)	Nagai Masahiro	NULL	Complete	>= 20age old	Not applicable	Both	100	Phase 2	Japan
483	EUCTR2015-004507-23-LV (EUCTR)	15/03/2016	13/01/2016	Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.	Efficacy and safety of ODM-104 compared to a standard combination (Stalevo); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson's disease and end-of-dose wearing-off. - COMPOC	Parkinson's disease (PD) patients with end-of-dose wearing-off (motor fluctuations);Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]	Product Name: Levodopa 75 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Levodopa 100 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Levodopa 125 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Levodopa 150 mg A CAP INN or Proposed INN: levodopa Other descriptive name: LEVODOPA Product Name: Carbidopa 65 mg capsule INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA Product Name: ODM-104 INN or Proposed INN: na Other descriptive name: ODM-104	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	Hungary;Finland;Germany;Latvia
484	EUCTR2015-004129-15-ES (EUCTR)	07/03/2016	24/02/2016	Subjects participating in a Parkinson Disease cohort are offered to undergo a PET imaging scan requiring an intravenous diagnostic drug (florbetaben) with the aim of identifying markers of disease progression	Evaluation of [18F] florbetaben in subjects participating in the Parkinson?s Progression Markers Initiative (PPMI) Protocol	Parkinson's Disease MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neuraceq Product Name: 18F florbetaben INN or Proposed INN: FLORBETABEN (18F)	Institute for Neurodegenerative Disorders	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Spain
485	NCT02687542 (ClinicalTrials.gov)	March 3, 2016	29/1/2016	Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations	A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE	Parkinson Disease	Drug: Placebo;Drug: PF-06649751 low dose (1 mg QD);Drug: PF-06649751 middle dose 1 (3 mg QD);Drug: PF-06649751 middle dose 2 (7 mg QD);Drug: PF-06649751 high dose (15 mg QD)	Pfizer	NULL	Terminated	40 Years	85 Years	All	108	Phase 2	United States;Canada;France;Germany;Japan;Spain
486	EUCTR2015-003887-34-CZ (EUCTR)	02/03/2016	30/12/2015	A Phase 3, Long-term, Open-label Study of Istradefylline inSubjects with Moderate to Severe Parkinson’s Disease	A Phase 3, Long-term, Open-label Study of Istradefylline inSubjects with Moderate to Severe Parkinson’s Disease	Moderate to severe Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE	Kyowa Kirin Pharmaceutical Development, Inc.	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 3	Serbia;United States;Czech Republic;Canada;Poland;Israel;Germany
487	NCT02605434 (ClinicalTrials.gov)	March 2016	5/11/2015	A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients	Phase 3 Multicenter Randomized Double-Blind, Double-dummy, Active-Controlled Study Comparing Efficacy/Safety of Gastric-retentive, Controlled-release Accordion Pill Carbidopa/Levodopa to Immediate Release in Fluctuating Parkinson's Patients	Parkinson's Disease	Drug: Accordion Pill™ Carbidopa/Levodopa;Drug: Sinemet®;Drug: Placebo -AP-CD/LD;Drug: Placebo- Sinemet	Intec Pharma Ltd.	NULL	Unknown status	30 Years	N/A	All	420	Phase 3	United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;Hungary
488	NCT02668497 (ClinicalTrials.gov)	March 2016	26/1/2016	Kinematic-based BoNT-A Bilateral Upper Limb PD Therapy	Kinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A Therapy	Parkinson's Disease	Drug: Botulinum Toxin Type A	Western University, Canada	NULL	Active, not recruiting	18 Years	80 Years	All	50	Phase 2	Canada
489	NCT02618941 (ClinicalTrials.gov)	February 2, 2016	25/11/2015	Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)	Phase IB Follow-up, Controlled, Parallel Group, Single-center Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological and Clinical Activity in Patients Who Have Participated in the AFF008 Program	Parkinson's Disease	Biological: AFFITOPE® PD01A	Affiris AG	NULL	Completed	40 Years	68 Years	All	26	Phase 1	Austria
490	JPRN-UMIN000020527	2016/02/01	01/02/2016	Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease	Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease - Randomized clinical trial to assess the disease modifying effect of oral inosine for patients with Parkinson's disease	Parkinson's disease	Inosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years Lactose as a placebo for 2 years	Ehime University Graduate School of Medicine	NULL	Recruiting	20years-old	Not applicable	Male and Female	100	Phase 2	Japan
491	JPRN-UMIN000020288	2016/02/01	28/12/2015	Intervention Study of Istradefylline for the Treatment of Gait Disorders in Patients with Parkinson's Disease.	Intervention Study of Istradefylline for the Treatment of Gait Disorders in Patients with Parkinson's Disease. - Intervention Study of Istradefylline for the Treatment of Gait Disorders in Patients with Parkinson's Disease.	Parkinson's disease	In this research, the duration of evaluation will be 12 weeks. Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by istradefylline.	Juntendo University Shizuoka Hospital	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	30	Not selected	Japan
492	NCT02641054 (ClinicalTrials.gov)	February 2016	7/12/2015	Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease	Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge Test	Idiopathic Parkinson Disease	Drug: CVXL-0107;Drug: Placebo;Drug: Levodopa	CleveXel Pharma	NULL	Completed	40 Years	75 Years	All	21	Phase 2	France
493	JPRN-JapicCTI-153112	22/1/2016	25/12/2015	ONO-2370 Phase 2 study(ONO-2370-02)	ONO-2370 a Phase 2 Double-Blind, Randomised, Placebo-Controlled, Parallel-Group study, and an Open-Label, Uncontrolled, Multicenter, Long-term, Extension study(ONO-2370-02)	Parkinson's disease	Intervention name : ONO-2370 INN of the intervention : Opicapone Dosage And administration of the intervention : ONO-2370 once-daily Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Once-daily placebo equivalent to active control	ONO PHARMACEUTICAL CO.,LTD.	NULL	complete	30	83	BOTH	399	Phase 2	Japan
494	NCT02639221 (ClinicalTrials.gov)	January 2016	17/12/2015	A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects	PXT002331 A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects	Parkinson's Disease	Drug: PXT002331	Prexton Therapeutics	NULL	Completed	18 Years	60 Years	Both	64	Phase 1	United Kingdom
495	NCT02579473 (ClinicalTrials.gov)	January 2016	13/10/2015	A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214	A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose Titration	Parkinson's Disease	Drug: SER-214	Serina Therapeutics	NULL	Active, not recruiting	40 Years	80 Years	All	20	Phase 1	United States
496	NCT02649608 (ClinicalTrials.gov)	January 2016	6/1/2016	An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients	Interventional, Open-label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral Doses of Lu AE04621 to Patients With Parkinson's Disease	Parkinson Disease	Drug: 0.2 mg Lu AE04621;Drug: 0.4 mg Lu AE04621;Drug: 0.6 mg Lu AE04621;Drug: 0.8 mg Lu AE04621;Drug: 1.0 mg Lu AE04621;Drug: 1.2 mg Lu AE04621;Drug: 0.04 mg Lu AE04621;Drug: 0.08 mg Lu AE04621	H. Lundbeck A/S	NULL	Completed	45 Years	75 Years	All	15	Phase 1	United States
497	EUCTR2014-002600-24-AT (EUCTR)	30/12/2015	25/09/2015	Safinamide versus placebo in patients with Parkinson’s disease for improvement of motor complications	A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS - EVEREST	Idiopathic Parkinson's Disease MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xadago Product Name: safinamide Other descriptive name: SAFINAMIDE Trade Name: Xadago Product Name: safinamide Other descriptive name: SAFINAMIDE	Zambon S.P.A.	NULL	Not Recruiting			Female: yes Male: yes	556	Phase 3	France;Spain;Austria;Russian Federation;Germany;Italy;United Kingdom;Switzerland;Sweden
498	EUCTR2014-005630-60-ES (EUCTR)	11/12/2015	05/10/2015	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine theEfficacy and Safety of Tozadenant as Adjunctive Therapy inLevodopa-Treated Patients with Parkinson´s DiseaseExperiencing End-of-Dose Wearing-Off (TOZ-PD)	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine theEfficacy and Safety of Tozadenant as Adjunctive Therapy inLevodopa-Treated Patients with Parkinson´s DiseaseExperiencing End-of-Dose Wearing-Off (TOZ-PD) - TOZ-PD	Parkinson´s Disease MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tozadenant Product Code: SYN115 INN or Proposed INN: Tozadenant Other descriptive name: TOZADENANT	Biotie Therapies Inc.	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Czech Republic;European Union;Canada;Spain;Austria;Germany
499	EUCTR2014-002600-24-IT (EUCTR)	11/12/2015	16/02/2018	Safinamide versus placebo in patients with Parkinson's disease for improvement of motor complications	A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS - EVEREST	Idiopathic Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xadago Product Name: Safinamide Product Code: na INN or Proposed INN: SAFINAMIDE METANSOLFONATO Other descriptive name: SAFINAMIDE METANSOLFONATO Trade Name: Xadago INN or Proposed INN: SAFINAMIDE METANSOLFONATO Other descriptive name: SAFINAMIDE METANSOLFONATO	ZAMBON SPA	NULL	Not Recruiting			Female: yes Male: yes	556	Phase 3	France;Spain;Austria;Russian Federation;Germany;United Kingdom;Switzerland;Italy;Sweden
500	EUCTR2014-002600-24-SE (EUCTR)	03/12/2015	30/07/2015	Safinamide versus placebo in patients with Parkinson’s disease for improvement of motor complications	A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS - EVEREST	Idiopathic Parkinson's Disease MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xadago Product Name: safinamide INN or Proposed INN: SAFINAMIDE Other descriptive name: SAFINAMIDE Trade Name: Xadago Product Name: safinamide INN or Proposed INN: SAFINAMIDE Other descriptive name: SAFINAMIDE	Zambon S.P.A.	NULL	Not Recruiting			Female: yes Male: yes	556	Phase 3	France;Spain;Austria;Russian Federation;Germany;Italy;United Kingdom;Switzerland;Sweden
501	NCT02610231 (ClinicalTrials.gov)	December 2015	13/11/2015	Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease	A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease	Idiopathic Parkinson's Disease	Drug: Istradefylline 20 mg or 40 mg	Kyowa Hakko Kirin Pharma, Inc.	Kyowa Kirin Co., Ltd.	Completed	30 Years	N/A	All	239	Phase 3	United States;Canada;Czechia;Germany;Israel;Italy;Poland;Serbia;Czech Republic
502	EUCTR2014-002600-24-ES (EUCTR)	19/11/2015	05/10/2015	Safinamide versus placebo in patients with Parkinson?s disease for improvement of motor complications	A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSON?S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS - EVEREST	Idiopathic Parkinson's Disease MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xadago Product Name: safinamide INN or Proposed INN: safinamide Other descriptive name: SAFINAMIDE Trade Name: Xadago Product Name: safinamide INN or Proposed INN: safinamide Other descriptive name: SAFINAMIDE	Zambon S.P.A.	NULL	Not Recruiting			Female: yes Male: yes	556	Phase 3	France;Spain;Austria;Russian Federation;Germany;Italy;United Kingdom;Switzerland;Sweden
503	NCT02565628 (ClinicalTrials.gov)	November 16, 2015	28/9/2015	PF-06669571 In Subjects With Idiopathic Parkinson's Disease	A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease.	Idiopathic Parkinson's Disease	Drug: PF-06669571;Drug: Placebo	Pfizer	NULL	Completed	N/A	N/A	All	20	Phase 1	United States
504	EUCTR2015-000148-40-GB (EUCTR)	09/11/2015	16/09/2015	A trial comparing simvastatin to placebo as a neuronal protective treatment for Parkinson's disease.	Simvastatin as a neuroprotective treatment for Parkinson's disease: a double-blind, randomised, placebo controlled futility study in patients of moderate severity. - Simvastatin as a neuroprotective treatment for moderate PD (PD STAT)	Parkinson's disease MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 18.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Simvastatin INN or Proposed INN: Simvastatin	Plymouth Hospitals NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	198	Phase 3	United Kingdom
505	JPRN-UMIN000019654	2015/11/06	06/11/2015	The effect of rich-hydrogen water drinking to gut peptide	The effect of rich-hydrogen water drinking to gut peptide - The effect of rich-hydrogen water drinking to gut peptide	Parkinson's disease, healthy control	hydrogen water natural water	Nagoya graduate school of medicine university	NULL	Pending	20years-old	80years-old	Male and Female	40	Not applicable	Japan
506	JPRN-jRCTs041180070	04/11/2015	07/03/2019	Trerief Impact in PD PET Study	Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - TIPPS	Parkinson's disease Parkinson's disease;D010300	[1] Zonisamide treatment group Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration. Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms. [2] Zonisamide non-treatment group Only levodopa/DCI with fixed dosage and administration. Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.	Ouchi Yasuomi	NULL	Not Recruiting	Not applicable	< 80age old	Both	20	N/A	Japan
507	EUCTR2014-002600-24-GB (EUCTR)	03/11/2015	28/07/2015	Safinamide versus placebo in patients with Parkinson’s disease for improvement of motor complications	A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS - EVEREST	Idiopathic Parkinson's Disease MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xadago Product Name: safinamide Other descriptive name: SAFINAMIDE Trade Name: Xadago Product Name: safinamide Other descriptive name: SAFINAMIDE	Zambon S.P.A.	NULL	Not Recruiting			Female: yes Male: yes	556	Phase 3	France;Spain;Austria;Russian Federation;Germany;Switzerland;Italy;United Kingdom;Sweden
508	NCT04110678 (ClinicalTrials.gov)	November 1, 2015	18/9/2019	Tolerance to NeuroEPO in Parkinson Disease	Nasal Administration of the NeuroEPO in Parkinson Disease: Short-term Tolerance Physician Lead Trial	Parkinson Disease	Drug: NeuroEPO	International Center for Neurological Restoration, Cuba	Center of Molecular Immunology, Cuba;University of Electronic Science and Technology of China	Completed	40 Years	70 Years	All	26	Phase 1/Phase 2	Cuba
509	NCT02758730 (ClinicalTrials.gov)	November 2015	26/4/2016	Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients	A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Single-center Phase I Pilot Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A, a New Vaccine Against Alpha-synuclein, in Patients With PD-GBA	Parkinson's Disease	Biological: AFFITOPE® PD01A + Adjuvant;Biological: Adjuvant without active component	Affiris AG	University Hospital Tuebingen	Withdrawn	40 Years	80 Years	Both	0	Phase 1	Germany
510	NCT02577523 (ClinicalTrials.gov)	November 2015	6/10/2015	A Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of ND0612H, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease	A Multicenter, Parallel-group, Rater-blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease	Parkinson's Disease	Drug: ND0612 (Levodopa/Carbidopa solution)	NeuroDerm Ltd.	NULL	Completed	30 Years	80 Years	All	38	Phase 2	United States;Austria;Israel;Italy
511	NCT02271503 (ClinicalTrials.gov)	November 2015	13/10/2014	A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease	A Study to Assess the Pharmacokinetics and Pharmacodynamics of a Single Dose of IPX203 in Patients With Advanced Parkinson's Disease	Parkinson's Disease	Drug: CD-LD IR;Drug: IPX203 180 mg;Drug: IPX203 270 mg;Drug: Rytary 195 mg;Drug: Rytary 145 mg	Impax Laboratories, LLC	NULL	Completed	40 Years	N/A	All	26	Phase 2	United States
512	EUCTR2014-005630-60-DE (EUCTR)	29/10/2015	07/07/2015	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine theEfficacy and Safety of Tozadenant as Adjunctive Therapy inLevodopa-Treated Patients with Parkinson’s DiseaseExperiencing End-of-Dose Wearing-Off” (TOZ-PD)	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine theEfficacy and Safety of Tozadenant as Adjunctive Therapy inLevodopa-Treated Patients with Parkinson’s DiseaseExperiencing End-of-Dose Wearing-Off” (TOZ-PD) - TOZ-PD	Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tozadenant Product Code: SYN115 INN or Proposed INN: Tozadenant Other descriptive name: TOZADENANT	Biotie Therapies Inc.(a wholly owned subsidiary of Acorda Therapeutics Inc.)	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Czech Republic;European Union;Canada;Spain;Austria;Germany
513	NCT02549092 (ClinicalTrials.gov)	October 26, 2015	11/9/2015	A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)	An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study	Advanced Parkinson's Disease	Drug: Optimized Medical Treatment;Drug: Levodopa-Carbidopa Intestinal Gel;Device: Nasojejunal (NJ) tube;Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube	AbbVie	NULL	Completed	30 Years	N/A	All	89	Phase 3	United States;Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden
514	JPRN-UMIN000019524	2015/10/01	28/10/2015	Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images	Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - Trerief Impact in PD PET Study (TIPPS)	Parkinson's Disease	Zonisamide treatment group: Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration. Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms. Zonisamide non-treatment group: Only Levodopa/DCI with fixed dosage and administration. Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.	Hamamatsu University School of Medicine	NULL	Complete: follow-up complete	Not applicable	80years-old	Male and Female	20	Not applicable	Japan
515	NCT02562768 (ClinicalTrials.gov)	September 30, 2015	28/9/2015	A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease	Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3154207 in Healthy Subjects and Subjects With Parkinson's Disease	Parkinson's Disease	Drug: LY3154207;Drug: Placebo	Eli Lilly and Company	NULL	Completed	20 Years	N/A	All	80	Phase 1	United States
516	EUCTR2014-005630-60-CZ (EUCTR)	23/09/2015	10/07/2015	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine theEfficacy and Safety of Tozadenant as Adjunctive Therapy inLevodopa-Treated Patients with Parkinson’s DiseaseExperiencing End-of-Dose Wearing-Off” (TOZ-PD)	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine theEfficacy and Safety of Tozadenant as Adjunctive Therapy inLevodopa-Treated Patients with Parkinson’s DiseaseExperiencing End-of-Dose Wearing-Off” (TOZ-PD) - TOZ-PD	Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tozadenant Product Code: SYN115 INN or Proposed INN: Tozadenant Other descriptive name: TOZADENANT	Biotie Therapies Inc. (a wholly owned subsidiary of Acorda Therapeutics Inc.)	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Czech Republic;European Union;Canada;Spain;Austria;Germany
517	EUCTR2014-005630-60-IT (EUCTR)	23/09/2015	17/01/2022	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's DiseaseExperiencing End-of-Dose Wearing-Off (TOZ-PD)	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's DiseaseExperiencing End-of-Dose Wearing-Off (TOZ-PD) - TOZ-PD	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tozadenant Product Code: SYN115 Other descriptive name: TOZADENANT	BIOTIE THERAPIES INC.	NULL	Not Recruiting			Female: yes Male: yes	450	Phase 3	United States;Czech Republic;Canada;Spain;Austria;Germany;Italy
518	EUCTR2014-004865-26-IT (EUCTR)	21/09/2015	29/05/2015	26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease	An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkinson's Disease – INSIGHTS Study - INSIGHTS Study	Non-motor symptoms in advanced Parkinson's disease MedDRA version: 18.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA MONOHYDRATE	AbbVie Deutschland GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	88		European Union;Canada;Spain;Australia;Germany;Italy;Sweden
519	NCT02542696 (ClinicalTrials.gov)	August 31, 2015	3/9/2015	Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease	An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)	Parkinson Disease	Drug: APL-130277	Sunovion	NULL	Completed	18 Years	N/A	All	427	Phase 3	United States;Austria;Canada;France;Germany;Italy;Spain;United Kingdom
520	EUCTR2014-004865-26-DE (EUCTR)	27/08/2015	22/05/2015	26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease	An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkinson's Disease – INSIGHTS Study - INSIGHTS Study	Non-motor symptoms in advanced Parkinson's disease MedDRA version: 19.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA MONOHYDRATE	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	88	Phase 3	European Union;Canada;Spain;Australia;Germany;Italy;Sweden
521	EUCTR2015-000373-13-DE (EUCTR)	18/08/2015	18/05/2015	A study to examine the effectiveness and safety of a new drug for involuntary muscle movements in patients with Parkinson’s disease	Phase 2, multicenter, randomized, double-blind, placebo-controlled, four-period cross-over, dose-range finding study to evaluate the safety, tolerability and efficacy of Eltoprazine in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease.	Parkinson’s disease levodopa induced dyskinesia (PD-LID) MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Eltoprazine Hydrochloride INN or Proposed INN: ELTOPRAZINE Product Name: Eltoprazine Hydrochloride INN or Proposed INN: ELTOPRAZINE Product Name: Eltoprazine Hydrochloride INN or Proposed INN: ELTOPRAZINE	Amarantus BioScience Holdings, Inc.	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	France;United States;Germany;Sweden
522	EUCTR2014-004865-26-SE (EUCTR)	05/08/2015	25/05/2015	26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease	An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkinson's Disease – INSIGHTS Study - INSIGHTS Study	Non-motor symptoms in advanced Parkinson's disease MedDRA version: 19.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA MONOHYDRATE	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	88	Phase 3	United States;European Union;Greece;Canada;Spain;Australia;Germany;Italy;Sweden
523	NCT02337751 (ClinicalTrials.gov)	July 10, 2015	9/1/2015	A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants	A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa	Parkinson's Disease	Drug: TVP-1012 1mg	Takeda	NULL	Completed	30 Years	79 Years	All	198	Phase 3	Japan
524	NCT02459886 (ClinicalTrials.gov)	July 1, 2015	29/5/2015	Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease	A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects With Early Parkinson's Disease	Parkinson's Disease;Healthy	Drug: BIIB054;Drug: Placebo	Biogen	NULL	Completed	40 Years	80 Years	All	66	Phase 1	United States
525	NCT02453386 (ClinicalTrials.gov)	July 2015	21/5/2015	Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off (TOZ-PD)	Idiopathic Parkinson's Disease	Drug: tozadenant;Drug: placebo	Biotie Therapies Inc.	NULL	Terminated	30 Years	80 Years	All	449	Phase 3	United States;Austria;Canada;Czechia;Germany;Italy;Spain;Czech Republic
526	EUCTR2014-003738-24-AT (EUCTR)	26/06/2015	01/04/2015	A clinical trial to see if ADS-5102 is safe and effective in people with drug induced abnormal movements in Parkinson's disease	ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients with Levodopa-Induced Dyskinesia - EASE LID 3 STUDY	Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease MedDRA version: 17.1;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Amantadine HCl Extended Release Capsule Product Code: ADS-5102 INN or Proposed INN: Amantadine hydrochloride (HCl) Other descriptive name: AMANTADINE HYDROCHLORIDE	Adamas Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	72	Phase 3	Germany;Spain;Austria;United States
527	EUCTR2014-000657-36-NL (EUCTR)	22/06/2015	03/06/2015	Trial to investigate the efficacy of treatments in apomorphine-induced skin reactions	Open-label crossover trial to investigate the efficacy of treatments in apomorphine-induced skin reactions - Treatment of apomorphine-induced skin reactions: a pilot study	Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Hydrocortisone cream 10mg/g FNA Fagron Product Name: Hydrocortisone cream Trade Name: Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial' Product Name: Solu-Cortef Trade Name: APO-go Product Name: Apomorphine	University Medical Center Groningen	NULL	Not Recruiting			Female: yes Male: yes	20	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Netherlands
528	EUCTR2014-003739-20-AT (EUCTR)	19/06/2015	01/04/2015	A clinical trial to see if ADS-5102 is safe in people with drug induced abnormal movements in Parkinson's disease	Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia	Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease MedDRA version: 18.1;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Amantadine HCl Extended Release Capsule Product Code: ADS-5102 INN or Proposed INN: Amantadine hydrochloride (HCl) Other descriptive name: AMANTADINE HYDROCHLORIDE	Adamas Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	250	Phase 3	United States;Spain;Austria;Germany
529	EUCTR2014-004865-26-ES (EUCTR)	19/06/2015	15/06/2015	26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease	An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkinson's Disease ? INSIGHTS Study - INSIGHTS Study	Non-motor symptoms in advanced Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa INN or Proposed INN: Levodopa Other descriptive name: LEVODOPA INN or Proposed INN: Carbidopa Other descriptive name: CARBIDOPA MONOHYDRATE	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	88	Phase 3	Greece;Canada;Sweden;European Union;Italy;Australia;Germany;Spain
530	NCT02469090 (ClinicalTrials.gov)	June 18, 2015	9/6/2015	Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)	Parkinson Disease, Off Episodes	Drug: APL-130277;Drug: Placebo	Sunovion	NULL	Completed	18 Years	N/A	All	141	Phase 3	United States;Canada;United Kingdom
531	NCT02230930 (ClinicalTrials.gov)	June 2015	29/8/2014	Treatment of Apomorphine-induced Skin Reactions: a Pilot Study	Open-label Crossover Trial to Investigate the Efficacy of Treatments in Apomorphine-induced Skin Reactions	Parkinson's Disease;Apomorphine-induced Skin Reactions	Drug: Apomorphine 0.25% (2.5mg/ml);Device: Massage with a spiky ball;Drug: Hydrocortisone cream 1%;Drug: Subcutaneous hydrocortisone 10mg	University Medical Center Groningen	NULL	Recruiting	30 Years	N/A	All	20	Phase 2	Netherlands
532	EUCTR2014-005422-35-GB (EUCTR)	28/05/2015	02/04/2015	The role of Buspirone in attenuating involuntary movements (Dyskinesias) in patients with Parkinson's disease.	THE ROLE OF BUSPIRONE IN ATTENUATING LEVODOPA-INDUCED DYSKINESIAS IN PATIENTS WITH PARKINSON'S DISEASE: A CLINICAL AND POSITRON EMISSION TOMOGRAPHY STUDY WITH 11C-PHNO. - The role of buspirone in LIDs in patients with Parkinson’s disease.	Levodopa induced dyskinesias within Parkinson's disease. MedDRA version: 17.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Buspirone Hydrochloride Product Name: Buspirone Hydrochloride INN or Proposed INN: Buspirone Hydrochloride	Imperial College London-Imperial College Healthcare NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	24	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom
533	JPRN-jRCTs061180028	11/05/2015	26/02/2019	Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine	A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine	Parkinson's disease;D010300	The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule.	Ando Rina	NULL	Complete	20 years old	None	Both	50	Phase 2	Japan
534	EUCTR2014-003799-22-AT (EUCTR)	08/05/2015	12/01/2015	A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease	A Phase 3, Randomized Study Investigating the Safety ofCVT-301 (Levodopa Inhalation Powder) in Parkinson’s DiseasePatients With Motor Response Fluctuations (OFF Phenomena)Compared to an Observational Cohort Control	Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) MedDRA version: 19.0;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA	Civitas Therapeutics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	408	Phase 3	Serbia;United States;Spain;Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Romania;Germany
535	EUCTR2010-024424-26-SK (EUCTR)	05/05/2015	28/04/2015	Clinical study for the evaluation of the safety and efficacy of masitinib in patients suffering from parkinson's disease	A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo on cognitive impairment associated with Parkinson's disease	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: masitinib Product Code: AB1010 INN or Proposed INN: masitinib mesylate Product Name: masitinib Product Code: AB1010 INN or Proposed INN: masitinib mesylate	AB Science	NULL	Not Recruiting			Female: yes Male: yes	45	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	France;United States;Hungary;Czech Republic;Slovakia;Spain;Romania;Bulgaria;South Africa;Germany
536	NCT02439203 (ClinicalTrials.gov)	May 2015	30/4/2015	Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia	A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010	Parkinson's Disease;Levodopa Induced Dyskinesia (LID)	Drug: JM-010;Drug: Placebo	Bukwang Pharmaceutical	Contera Pharma ApS	Completed	18 Years	N/A	Both	30	Phase 2	South Africa
537	NCT02439125 (ClinicalTrials.gov)	May 2015	13/4/2015	A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients	Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease	Parkinson's Disease;Dyskinesia	Drug: Eltoprazine HCl;Drug: Placebo	Amarantus BioScience Holdings, Inc.	NULL	Active, not recruiting	30 Years	85 Years	Both	60	Phase 2	United States
538	NCT02604914 (ClinicalTrials.gov)	May 2015	3/11/2015	A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects	1) To Identify the Concentration of CD That Provides Optimal Bioavailability of a Concomitant Fixed Concentration of LD Infused SC Continuously; 2) To Compare the Bioavailability of the Optimal LD/CD Solution to That of LD/CD Intestinal Gel	Parkinson's Disease	Drug: ND0612;Drug: LCIG	NeuroDerm Ltd.	Quotient Clinical	Completed	30 Years	65 Years	All	36	Phase 1	United Kingdom
539	NCT02448914 (ClinicalTrials.gov)	May 2015	12/5/2015	A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients	A Single Centre, Two-period, Open Label, Randomised, Cross-over Study to Assess Plasma Levodopa, Carbidopa and Entacapone Concentrations After Continuous Infusion of TRIGEL or Duodopa in Patients With Advanced Parkinson´s Disease	Parkinson's Disease	Drug: TRIGEL;Drug: Duodopa	LobSor Pharmaceuticals AB	TFS Trial Form Support	Completed	30 Years	N/A	All	11	Phase 1	Sweden
540	EUCTR2014-003738-24-DE (EUCTR)	23/04/2015	21/01/2015	A clinical trial to see if ADS-5102 is safe and effective in people with drug induced abnormal movements in Parkinson's disease	ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients with Levodopa-Induced Dyskinesia - EASE LID 3 STUDY	Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease MedDRA version: 18.0;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Amantadine HCl Extended Release Capsule Product Code: ADS-5102 INN or Proposed INN: Amantadine hydrochloride (HCl) Other descriptive name: AMANTADINE HYDROCHLORIDE	Adamas Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	72	Phase 3	United States;Spain;Austria;Germany
541	EUCTR2014-003739-20-DE (EUCTR)	23/04/2015	21/01/2015	A clinical trial to see if ADS-5102 is safe in people with drug induced abnormal movements in Parkinson's disease	Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia	Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease MedDRA version: 18.1;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Amantadine HCl Extended Release Capsule Product Code: ADS-5102 INN or Proposed INN: Amantadine hydrochloride (HCl) Other descriptive name: AMANTADINE HYDROCHLORIDE	Adamas Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	250	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	France;United States;Spain;Austria;Germany
542	EUCTR2014-003799-22-DE (EUCTR)	22/04/2015	04/12/2014	A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease	A Phase 3, Randomized Study Investigating the Safety ofCVT-301 (Levodopa Inhalation Powder) in Parkinson’s DiseasePatients With Motor Response Fluctuations (OFF Phenomena)Compared to an Observational Cohort Control	Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) MedDRA version: 19.0;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA	Civitas Therapeutics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	408	Phase 3	Serbia;United States;Spain;Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Romania;Germany
543	EUCTR2014-003739-20-FR (EUCTR)	10/04/2015	19/06/2015	A clinical trial to see if ADS-5102 is safe in people with drug induced abnormal movements in Parkinson's disease	Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia	Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease MedDRA version: 18.0;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Amantadine HCl Extended Release Capsule Product Code: ADS-5102 INN or Proposed INN: Amantadine hydrochloride (HCl) Other descriptive name: AMANTADINE HYDROCHLORIDE	Adamas Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	200	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;France;Spain;Austria;Germany
544	NCT02486432 (ClinicalTrials.gov)	April 2015	22/6/2015	A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)	A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Doses Administered Using a Divided Dose Approach	Parkinson's Disease	Drug: Levodopa/Carbidopa (Sinemet)	NeuroDerm Ltd.	Quotient Clinical	Completed	40 Years	65 Years	Both	6	Phase 1	NULL
545	NCT02390089 (ClinicalTrials.gov)	April 2015	19/2/2015	Cough According to Stimulus Type in PD	Airway Protection Deficits According to Stimulus Type in Parkinson's Disease	Parkinson's Disease	Drug: Capsaicin vapor;Other: fog;Radiation: Videofluoroscopic swallow evaluation;Device: Nebulizer	University of Florida	National Institute on Deafness and Other Communication Disorders (NIDCD)	Completed	50 Years	80 Years	All	158	Phase 1	United States
546	EUCTR2014-003739-20-ES (EUCTR)	24/03/2015	16/02/2015	A clinical trial to see if ADS-5102 is safe in people with drug induced abnormal movements in Parkinson's disease	Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia	Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease MedDRA version: 18.0;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Amantadine HCl Extended Release Capsule Product Code: ADS-5102 INN or Proposed INN: Amantadine hydrochloride (HCl) Other descriptive name: AMANTADINE HYDROCHLORIDE	Adamas Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	200	Phase 3	United States;Spain;Austria;Germany
547	EUCTR2014-003738-24-ES (EUCTR)	24/03/2015	16/02/2015	A clinical trial to see if ADS-5102 is safe and effective in people with drug induced abnormal movements in Parkinson's disease	ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients with Levodopa-Induced Dyskinesia - EASE LID 3 STUDY	Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease MedDRA version: 18.0;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Amantadine HCl Extended Release Capsule Product Code: ADS-5102 INN or Proposed INN: Amantadine hydrochloride (HCl) Other descriptive name: AMANTADINE HYDROCHLORIDE	Adamas Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	72	Phase 3	United States;Spain;Austria;Germany
548	EUCTR2014-003799-22-BE (EUCTR)	16/03/2015	16/12/2014	A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease	A Phase 3, Randomized Study Investigating the Safety ofCVT-301 (Levodopa Inhalation Powder) in Parkinson’s DiseasePatients With Motor Response Fluctuations (OFF Phenomena)Compared to an Observational Cohort Control	Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) MedDRA version: 18.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA	Civitas Therapeutics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	365	Phase 3	Serbia;United States;Spain;Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Romania;Germany
549	NCT02393027 (ClinicalTrials.gov)	March 2015	6/3/2015	Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999	Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999	Idiopathic Parkinson Disease	Drug: [18F] LBT-999 PET	University Hospital, Tours	NULL	Terminated	45 Years	75 Years	All	16	Early Phase 1	France
550	NCT02373072 (ClinicalTrials.gov)	March 2015	20/2/2015	A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease	A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease	Idiopathic Parkinson Disease	Drug: PF-06649751;Drug: Trimethobenzamide Hydrochloride;Drug: Placebo	Pfizer	NULL	Completed	N/A	N/A	All	18	Phase 1	United States;Belgium
551	NCT02066571 (ClinicalTrials.gov)	March 2015	18/2/2014	Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease	A Phase II, Double-Blind, Placebo-Controlled, Crossover Study to Assess Clinical Benefit and Safety of Droxidopa in the Treatment of Parkinson's Disease	Parkinson's Disease;Freezing of Gait;Cognitive Ability, General	Drug: Droxidopa;Drug: sugar pill	Henry Ford Health System	NULL	Enrolling by invitation	30 Years	N/A	Both	20	Phase 2	United States
552	NCT02352363 (ClinicalTrials.gov)	March 2015	26/1/2015	Randomized Safety Study of CVT-301 Compared to an Observational Control Group	A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease (PD) Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control	Idiopathic Parkinson's Disease	Drug: CVT-301;Other: Observational cohort	Acorda Therapeutics	NULL	Completed	30 Years	85 Years	All	408	Phase 3	United States;Austria;Belgium;Czechia;France;Germany;Hungary;Israel;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;Czech Republic;Italy
553	EUCTR2014-003799-22-CZ (EUCTR)	26/02/2015	26/11/2014	A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease	A Phase 3, Randomized Study Investigating the Safety ofCVT-301 (Levodopa Inhalation Powder) in Parkinson’s DiseasePatients With Motor Response Fluctuations (OFF Phenomena)Compared to an Observational Cohort Control	Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) MedDRA version: 19.0;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA	Civitas Therapeutics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	408	Phase 3	Serbia;United States;Spain;Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Romania;Germany
554	EUCTR2014-003799-22-HU (EUCTR)	11/02/2015	20/11/2014	A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease	A Phase 3, Randomized Study Investigating the Safety ofCVT-301 (Levodopa Inhalation Powder) in Parkinson’s DiseasePatients With Motor Response Fluctuations (OFF Phenomena)Compared to an Observational Cohort Control	Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) MedDRA version: 17.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA	Civitas Therapeutics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	365	Phase 3	Serbia;Spain;Austria;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Belgium;Poland;Romania;Germany
555	NCT02337725 (ClinicalTrials.gov)	February 7, 2015	9/1/2015	A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa	Parkinson's Disease	Drug: TVP-1012;Drug: Placebo	Takeda	NULL	Completed	30 Years	80 Years	All	244	Phase 3	Japan
556	NCT02337764 (ClinicalTrials.gov)	February 3, 2015	9/1/2015	A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants	A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients	Parkinson's Disease	Drug: TVP-1012 1mg	Takeda	NULL	Completed	30 Years	79 Years	All	222	Phase 3	Japan
557	JPRN-JapicCTI-152762	03/2/2015	06/01/2015	A long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Patients	A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients	Parkinson's disease	Intervention name : TVP-1012 (1 mg/day) with levodopa INN of the intervention : - Dosage And administration of the intervention : TVP-1012 (1 mg/day) once daily, before or after breakfast. A levodopa combination drug will be concomitantly administered in principle without change in the dose regimen throughout the study period from the start of the screening period. Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -	Takeda Pharmaceutical Company Limited	NULL	complete	30	79	BOTH	222	Phase 3	Japan
558	EUCTR2014-003799-22-ES (EUCTR)	02/02/2015	16/12/2014	A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson?s disease	A Phase 3, Randomized Study Investigating the Safety ofCVT-301 (Levodopa Inhalation Powder) in Parkinson?s DiseasePatients With Motor Response Fluctuations (OFF Phenomena)Compared to an Observational Cohort Control	Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) MedDRA version: 17.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA	Civitas Therapeutics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	365	Phase 3	Serbia;Spain;Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Romania;Germany
559	NCT02339064 (ClinicalTrials.gov)	February 2015	31/3/2014	Infusion of Apomorphine: Long-term Safety Study	A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy	Idiopathic Parkinson's Disease	Drug: apomorphine infusion	US WorldMeds LLC	NULL	Active, not recruiting	30 Years	N/A	All	99	Phase 3	United States
560	NCT02337738 (ClinicalTrials.gov)	January 27, 2015	9/1/2015	A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off	Parkinson's Disease	Drug: TVP-1012 1mg;Drug: TVP-1012 0.5mg;Drug: Placebo	Takeda	NULL	Completed	30 Years	79 Years	All	404	Phase 2/Phase 3	Japan
561	EUCTR2014-003799-22-GB (EUCTR)	15/01/2015	21/11/2014	A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s disease	A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control	Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) MedDRA version: 18.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA Product Name: CVT-301 Product Code: CVT-301 INN or Proposed INN: LEVODOPA Other descriptive name: LEVODOPA	Civitas Therapeutics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	365	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Serbia;United States;Spain;Austria;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Romania;Germany
562	NCT02406105 (ClinicalTrials.gov)	January 2015	22/2/2015	An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson Disease	An Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in Poland	Parkinson Disease	Radiation: Radiosurgical thalamotomy;Drug: CyberKnife	Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology	NULL	Recruiting	18 Years	N/A	Both	27	Phase 2	Poland
563	NCT02347059 (ClinicalTrials.gov)	January 2015	20/1/2015	L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease	A Randomized, Single-blind Trial on the Efficacy and Safety of L-dopa Monotherapy Versus Dopamine Agonists Monotherapy After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease	Parkinson's Disease	Drug: L-dopa;Drug: Dopamine Agonists (pramipexole, ropirinole)	University of Toronto	Michael J. Fox Foundation for Parkinson's Research	Recruiting	N/A	N/A	Both	40	Phase 2	Canada
564	NCT02258152 (ClinicalTrials.gov)	December 22, 2014	3/10/2014	SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)	SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)	Parkinson's Disease Dementia (PDD)	Drug: SYN120;Drug: Placebo	Biotie Therapies Inc.	Michael J. Fox Foundation for Parkinson's Research;Massachusetts General Hospital;Acorda Therapeutics	Completed	50 Years	N/A	All	82	Phase 2	United States
565	EUCTR2014-004501-32-NL (EUCTR)	11/12/2014	03/12/2014	Treatment in Advanced Parkinson's disease: a cost-effectiveness analysis of two different treatments	Infusion VErsus STimulation, a cost-effectiveness analysis of the treatment in advanced Parkinson's diseasecomparing Continuous Intrajejunal Levodopa Infusion to the traditional standard treetment Deep BrainStimulation; - INVEST (INfusion VErsus STimulation)	Patients with advanced PD who's motor symptoms — severe responsefluctuations, dyskinesias, painful dystonia and / or bradykinesia —cannot be controlled despite optimal oral pharmacological therapy.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa, levodopa 20 mg/ml + carbidopa 5 mg/ml, intestinal gel	Academic Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands
566	NCT02267434 (ClinicalTrials.gov)	December 2014	4/9/2014	Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease	A Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE® PD03A Formulated With Adjuvant to Patients With Early Parkinson's Disease	Parkinson Disease;Neurodegenerative Diseases	Biological: Low dose AFFITOPE® PD03A + Adjuvant;Biological: High dose AFFITOPE® PD03A + Adjuvant;Biological: Adjuvant without active component	Affiris AG	PROSENEX AmbulatoriumbetriebsGMBH;Medical University Innsbruck;Forschungszentrum Juelich	Completed	45 Years	70 Years	Both	36	Phase 1	Austria
567	EUCTR2014-001132-10-FR (EUCTR)	18/11/2014	18/06/2015	A 26 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson’s Disease Patients with Abnormal Involuntary Movements caused by Levodopa	A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson’s Disease Subjects with Levodopa-Induced Dyskinesias	Parkinson’s Disease Subjects with Levodopa-Induced Dyskinesias MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Amantadine HCl Extended Release INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE Product Name: Amantadine HCl Extended Release INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE Product Name: Amantadine HCl Extended Release INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE	Osmotica Pharmaceutical Corp.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	162		United States;France;Canada;Spain;Germany
568	ChiCTR-DDD-17010794	2014-11-08	2017-03-05	The study on early diagnosis of Parkinson 's disease by transcranial ultrasonography	the study on early diagnosis of Parkinson 's disease by transcranial ultrasonography	Parkinson's Disease	Gold Standard:Diagnosis of Parkinson disease needs to meet 3 or more: unilateral onset;resting tremor;progressive course; long term asymmetry, the most obvious symptoms is the onset side; a good response to levodopa (70% ~ 100%); levodopa induced chorea; a reaction of levodopa lasts 5 years or more; clinical course last;Index test:Laboratory apparatus As shown in Figure 1, The ultrasound equipment, Philips IE33-BOMJH1 color Doppler ultrasonography, Model IE-ELite, with 2-4MHz phased array probe (S5-1 probe) was used for TCS to examine SN in our study. Transcranial ultrasound study Ultrasonography through temporal window, alon;	Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital	NULL	Completed	36	84	Both	Target condition:135;Difficult condition:0		China
569	EUCTR2014-001131-36-ES (EUCTR)	23/10/2014	03/09/2014	A 16 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by Levodopa	A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias	Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias MedDRA version: 17.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Amantadine HCl Extended Release INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE Product Name: Amantadine HCl Extended Release INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE Product Name: Amantadine HCl Extended Release INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE	Osmotica Pharmaceutical Corp.	NULL	Not Recruiting			Female: yes Male: yes	162	Phase 3	France;United States;Canada;Spain;Germany
570	EUCTR2014-001132-10-ES (EUCTR)	23/10/2014	02/09/2014	A 26 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by Levodopa	A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias	Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias MedDRA version: 17.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Amantadine HCl Extended Release INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE Product Name: Amantadine HCl Extended Release INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE Product Name: Amantadine HCl Extended Release INN or Proposed INN: Amantadine hydrochloride Other descriptive name: AMANTADINE HYDROCHLORIDE	Osmotica Pharmaceutical Corp.	NULL	Not Recruiting			Female: yes Male: yes	162	Phase 3	France;United States;Canada;Spain;Germany
571	EUCTR2014-002295-87-IT (EUCTR)	13/10/2014	29/09/2014	A Phase IIa study to assess the safety, tolerability, plasma pharmacokinetics and efficacy of intermittent oral administration of standard levodopa/carbidopa vs. semi-continuous intra-oral administration of levodopa/carbidopa in patients with advanced Parkinson’s disease who suffer motor fluctuations.	A Phase IIa study to assess the safety, tolerability, plasma pharmacokinetics and efficacy of intermittent oral administration of standard levodopa/carbidopa vs. semi-continuous intra-oral administration of levodopa/carbidopa in patients with advanced Parkinson’s disease who suffer motor fluctuations.	Parkinson's disease patients who suffer motor fluctuations willparticipate in the study MedDRA version: 17.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SINEMET 100 mg + 25 mg compresse Product Name: SINEMET 100 mg + 25 mg compresse Product Code: NA	SynAgile Corporation	NULL	Not Recruiting			Female: yes Male: yes	18	Phase 2	Italy
572	NCT02224664 (ClinicalTrials.gov)	October 2014	15/8/2014	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease	A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations	Parkinson`s Disease	Drug: PF-06649751	Pfizer	NULL	Completed	30 Years	80 Years	All	50	Phase 1	United States;Belgium
573	JPRN-UMIN000016893	2014/09/22	01/04/2015	A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression.	A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression. - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine.	PD patients	The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule. The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule.	Ehime University HospitalDept. of Clinical pharmacology and Neurology	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	50	Phase 2	Japan
574	NCT02236260 (ClinicalTrials.gov)	September 3, 2014	29/8/2014	Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation	Evaluation of the Benefit Provided by the Addition of Acupunctural Analgesia With Electrostimulation to Conventional Local Anesthesia Compared to Conventional Local Anesthesia Alone in Surgery of Deep Brain Stimulation for Movement Disorders.	Parkinson's Disease	Procedure: Electroacupuncture;Drug: Local Anesthesia (lidocaine hydrochloride)	Nantes University Hospital	NULL	Completed	18 Years	74 Years	All	20	N/A	France
575	NCT02230904 (ClinicalTrials.gov)	September 2014	29/8/2014	A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease	A Multicenter, Randomized, Double-blind, 2-way Cross-over Study to Compare the Adhesiveness of 2 Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: Rotigotine (Test product PR 2.3.1);Drug: Rotigotine (Reference product PR 2.1.1)	UCB BIOSCIENCES GmbH	Pharmaceutical Health Sciences;Bracket Global	Completed	18 Years	N/A	All	57	Phase 1	Germany
576	NCT02225548 (ClinicalTrials.gov)	September 2014	22/8/2014	Sagene 2014 - Parkinson's Disease and Erectile Dysfunction	An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.	Parkinson's Disease;Erectile Dysfunction	Drug: Selegiline;Drug: Tadalafil	University of South Florida	NULL	Recruiting	40 Years	64 Years	Male	10	Phase 4	United States
577	NCT02228590 (ClinicalTrials.gov)	August 31, 2014	26/8/2014	A Study to Examine APL-130277 in Patients With Parkinson's Disease	A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease	Parkinson's Disease	Drug: APL-130277	Sunovion	NULL	Completed	18 Years	80 Years	All	20	Phase 2	United States
578	NCT02153645 (ClinicalTrials.gov)	August 18, 2014	30/5/2014	Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.	A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias	Parkinson's Disease;Levodopa Induced Dyskinesias (LID)	Drug: 240mg Amantadine HCl ER tablets;Drug: Placebo tablets;Drug: 320mg Amantadine HCl ER tablets	Adamas Pharmaceuticals, Inc.	NULL	Terminated	30 Years	85 Years	All	87	Phase 3	United States;Canada;France;Germany;Spain
579	NCT02216188 (ClinicalTrials.gov)	August 2014	12/8/2014	Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity	Phase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological + Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008	Parkinson's Disease	Biological: AFFITOPE® PD01A;Other: Control	Affiris AG	NULL	Completed	40 Years	68 Years	Both	28	Phase 1	Austria
580	NCT02438215 (ClinicalTrials.gov)	August 2014	7/8/2014	Study of IRX4204 for Treatment of Early Parkinson's Disease	An Open-Label, Single Site Study Using [123I]ß-CIT Single Photon Emission Tomography (SPECT) to Evaluate Dopamine Transporter Binding Following Treatment With IRX4204 in Early Parkinson's Disease Subjects	Parkinson's Disease	Drug: IRX4204	Io Therapeutics	NULL	Completed	18 Years	N/A	Both	15	Phase 1	United States
581	NCT02153632 (ClinicalTrials.gov)	July 30, 2014	30/5/2014	Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID	A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias	Parkinson's Disease;Levodopa Induced Dyskinesia (LID)	Drug: amantadine HCl ER;Drug: Placebo	Adamas Pharmaceuticals, Inc.	NULL	Terminated	30 Years	85 Years	All	135	Phase 3	United States;Canada;France;Germany;Spain
582	NCT02763137 (ClinicalTrials.gov)	July 30, 2014	26/4/2016	Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients	A Phase IIa Study to Assess the Safety, Tolerability, Plasma Pharmacokinetics and Efficacy of Intermittent Oral Administration of Standard Levodopa/Carbidopa vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Patients With Advanced Parkinson's Disease Who Suffer Motor Fluctuations	Parkinson Disease	Drug: Standard LD/CD;Drug: Semi continuous intra-oral administration of LD/CD	IRCCS San Raffaele Roma	SynAgile Corporation	Completed	35 Years	75 Years	All	18	Phase 2	Italy
583	JPRN-UMIN000014709	2014/07/01	01/08/2014	Study on Parkinson's disease and related disorders with dopamine transporter ligand [C-11]PE2I	Study on Parkinson's disease and related disorders with dopamine transporter ligand [C-11]PE2I - DAT PET with [C-11]PE2I in PD and related disorders	Patients of Parkinson's disease and related disorders	The dosage in the vein of [C-11]PE2I, [C-11]raclopride, and [F-18]FDG for PET/CT imaging.	Tokyo Metropolitan Institute of Gerontology	NULL	Complete: follow-up complete	18years-old	Not applicable	Male and Female	200	Not selected	Japan
584	NCT02472210 (ClinicalTrials.gov)	July 2014	11/6/2015	The Use of Botox in Advanced Parkinson's Patients Experiencing Pain	A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study	Parkinson's Disease	Drug: Botulinum Toxin	University Health Network, Toronto	NULL	Active, not recruiting	18 Years	N/A	Both	14	Phase 4	NULL
585	ChiCTR-TRC-14004707	2014-06-09	2014-05-27	The effect of different patterns of rehabilitation training in idiopathic Parkinson's disease	The effect of different patterns of rehabilitation training in idiopathic Parkinson's disease	Parkinson's disease	Tai Chi group:Tai Chi;Balance function training group:Balance function training;	Shanghai Tongji Hospital	NULL	Completed	20	90	Both	Tai Chi group:30;Balance function training group:30;		China
586	EUCTR2013-000980-10-DK (EUCTR)	06/06/2014	09/01/2014	Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s disease	TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson’s disease patients with motor complications not well controlled on medical treatment - TOLEDO	Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment MedDRA version: 18.0;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Apo-go® Product Name: Apomorphine hydrochloride Product Code: Apo-go® INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: Apomorphine hydrochloride	Britannia Pharmaceuticals Limited	NULL	Not Recruiting			Female: yes Male: yes	102	Phase 3	France;Spain;Austria;Denmark;Netherlands;Germany
587	EUCTR2012-005539-10-DE (EUCTR)	29/04/2014	18/12/2013	Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions.	Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation	Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury. MedDRA version: 18.1;Level: PT;Classification code 10039424;Term: Salivary hypersecretion;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A	Merz Pharmaceuticals GmbH	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 3	United States;Poland;Germany
588	EUCTR2013-002254-70-PL (EUCTR)	28/04/2014	03/02/2014	Study to test the safety and effect of an investigational study drug, Istradefylline, in moderate to severe Parkinson's Disease (PD) patients who have been treated with levodopa combination therapy.	A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaulate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Severe Parkinson's Disease	Moderate to severe Parkinson's disease MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE	Kyowa Kirin Pharmaceutical Development, Inc.	NULL	Not Recruiting			Female: yes Male: yes	609	Phase 3	Serbia;United States;Czech Republic;Canada;Poland;Israel;Germany
589	NCT02741947 (ClinicalTrials.gov)	April 2014	31/3/2016	Levodopa Benserazide Generic Formulation Versus the Originator	Clinical and Pharmacokinetics Study to Evaluate the Therapeutic Equivalence and Bioequivalence of Levodopa Benserazide Generic Formulation (Teva Italia) Versus the Originator (Madopar®)	Parkinson Disease	Drug: Levodopa Benserazide Madopar;Drug: Levodopa Benserazide Teva Italia	IRCCS San Raffaele	Agenzia Italiana del Farmaco	Completed	30 Years	75 Years	Both	44	Phase 4	Italy
590	NCT02091739 (ClinicalTrials.gov)	April 2014	18/3/2014	Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions	Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Study, With an Extension Period of Dose-blinded Active Treatment, to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions	Chronic Troublesome Sialorrhea;Parkinson's Disease;Post-stroke;Traumatic Brain Injury	Drug: IncobotulinumtoxinA (100 Units);Drug: IncobotulinumtoxinA (75 Units);Drug: Placebo	Merz Pharmaceuticals GmbH	NULL	Completed	18 Years	80 Years	All	184	Phase 3	Germany;Poland;United States
591	NCT01738178 (ClinicalTrials.gov)	April 2014	28/11/2012	Caffeine as a Therapy for Parkinson's Disease	Caffeine as a Therapeutic Agent in Parkinson's Disease	Parkinson's Disease	Drug: Caffeine;Drug: Placebo	McGill University Health Center	Pontifícia Universidade Católica do Paraná;University of Calgary;University of Newfoundland and Eastern Health;University Health Network, Toronto;UBC Hospital;Movement Disorder Clinic - Deer Lodge Centre;The Ottawa Hospital	Completed	45 Years	75 Years	All	119	Phase 3	Brazil;Canada
592	NCT02082249 (ClinicalTrials.gov)	March 10, 2014	14/2/2014	An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications	An Open-Label Three-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications	Advanced Parkinson's Disease	Drug: ABT-SLV187	AbbVie	NULL	Completed	30 Years	99 Years	All	30	Phase 3	Japan;Korea, Republic of;Taiwan
593	EUCTR2013-002254-70-CZ (EUCTR)	05/03/2014	02/12/2013	Study to test the safety and effect of an investigational study drug, Istradefylline, in moderate to severe Parkinson's Disease (PD) patients who have been treated with levodopa combination therapy.	A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaulate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Severe Parkinson's DiseaseRandomizovaná, multicentrická, dvojite zaslepená, placebem kontrolovaná, 12týdenní studie fáze 3 hodnotící úcinnost perorálního istradefylinu 20 a 40 mg/den v lécbe subjektu se stredne závažnou až závažnou Parkinsonovou nemocí	Moderate to severe Parkinson's disease MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE	Kyowa Kirin Pharmaceutical Development, Inc.	NULL	Not Recruiting			Female: yes Male: yes	609	Phase 3	United States;Serbia;Czech Republic;Canada;Poland;Israel;Germany
594	NCT02006121 (ClinicalTrials.gov)	March 3, 2014	22/11/2013	Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease	Multicentre,Parallel-group,Double-blind,Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Apomorphine sc Infusion in Parkinson's Disease Patients With Motor Complications Not Well Controlled on Medical Treatment	Parkinson's Disease	Drug: Apomorphine hydrochloride;Drug: Placebo	Britannia Pharmaceuticals Ltd.	NULL	Completed	30 Years	N/A	All	107	Phase 3	Austria;Denmark;France;Germany;Netherlands;Spain;United Kingdom
595	EUCTR2013-000980-10-FR (EUCTR)	03/03/2014	22/11/2013	Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s disease	TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson’s disease patients with motor complications not well controlled on medical treatment - TOLEDO	Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment MedDRA version: 16.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Apo-go® Product Name: Apomorphine hydrochloride Product Code: Apo-go® INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: Apomorphine hydrochloride	STADA Arzneimittel AG	NULL	Not Recruiting			Female: yes Male: yes	102	Phase 3	France;Spain;Denmark;Austria;Netherlands;Germany
596	NCT02111330 (ClinicalTrials.gov)	March 2014	20/3/2014	Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers	Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers	Parkinson Disease	Drug: PBF-509;Drug: Placebo	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Palo Biofarma, S.L	Completed	18 Years	45 Years	Both	16	Phase 1	Spain
597	NCT02006290 (ClinicalTrials.gov)	March 2014	5/12/2013	Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease	A Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's Disease	Parkinson's Disease	Drug: PF-06412562;Drug: Placebo	Pfizer	NULL	Completed	30 Years	75 Years	Both	19	Phase 1	United States
598	EUCTR2013-002254-70-DE (EUCTR)	28/02/2014	19/11/2013	Study to test the safety and effect of an investigational study drug, Istradefylline, in moderate to severe Parkinson's Disease (PD) patients who have been treated with levodopa combination therapy.	A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaulate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Severe Parkinson's Disease	Moderate to severe Parkinson's disease MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE	Kyowa Kirin Pharmaceutical Development, Inc.	NULL	Not Recruiting			Female: yes Male: yes	609	Phase 3	United States;Serbia;Czech Republic;Canada;Poland;Israel;Germany
599	EUCTR2013-002254-70-IT (EUCTR)	21/02/2014	27/11/2013	A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaulate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Severe Parkinson's Disease	A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaulate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Severe Parkinson's Disease	Moderate to severe Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE Product Name: KW-6002 (istradefylline) Product Code: KW-6002 INN or Proposed INN: Istradefylline Other descriptive name: ISTRADEFYLLINE	Kyowa Hakko Kirin Pharma, Inc.	NULL	Not Recruiting			Female: yes Male: yes	609	Phase 3	United States;Serbia;Czech Republic;Canada;Poland;Israel;Germany;Italy
600	EUCTR2013-000980-10-ES (EUCTR)	12/02/2014	12/11/2013	Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson?s disease	TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson?s disease patients with motor complications not well controlled on medical treatment - TOLEDO	Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment MedDRA version: 16.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Apo-go® Product Name: Apomorphine hydrochloride Product Code: Apo-go® INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: Apomorphine hydrochloride	STADA Arzneimittel AG	NULL	Not Recruiting			Female: yes Male: yes	102	Phase 3	France;Spain;Denmark;Austria;Netherlands;Germany
601	EUCTR2013-000980-10-NL (EUCTR)	06/02/2014	27/01/2014	Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s disease	TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson’s disease patients with motor complications not well controlled on medical treatment - TOLEDO	Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment MedDRA version: 18.0;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Apo-go® Product Name: Apomorphine hydrochloride Product Code: Apo-go® INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: Apomorphine hydrochloride	Britannia Pharmaceuticals Limited	NULL	Not Recruiting			Female: yes Male: yes	102	Phase 3	France;Spain;Denmark;Austria;Germany;Netherlands
602	NCT02103894 (ClinicalTrials.gov)	February 2014	12/2/2014	Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects	Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects	Alzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;Tauopathies	Drug: [18F]T807 ([18F]MNI-777)	Molecular NeuroImaging	Institute for Neurodegenerative Disorders	Completed	18 Years	85 Years	Both	16	Phase 1	United States
603	NCT02064166 (ClinicalTrials.gov)	February 2014	13/2/2014	Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.	A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy	Parkinson Disease;Multiple System Atrophy	Drug: Intranasal Insulin	Peter Novak	NULL	Completed	18 Years	N/A	All	15	Phase 2	United States
604	EUCTR2013-002545-10-SE (EUCTR)	08/01/2014	11/11/2013	An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy.	An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy. - OSU6162Open1309	Parkinsons diseaseHuntingtons diseaseMultiple sclerosBrain traumaStrokeMyalgic encephalomyelitisNarcolepsy;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: OSU6162 similar to (-)-OSU 6162	A. Carlsson Research AB	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 2	Sweden
605	NCT02384512 (ClinicalTrials.gov)	January 2014	4/3/2015	Azilect® In Wearing-Off (AIWO)	Azilect® In Wearing-Off (AIWO) Non-interventional Study on Efficacy and Tolerability of Rasagiline (1mg/d) add-on in Ambulatory Parkinson's Disease Patients With Wearing-off Symptoms Diagnosed by Wearing-off Questionnaire (WOQ-32)	Parkinson's Disease	Drug: Azilect®	Teva Pharma GmbH	Anfomed GmbH	Completed	18 Years	N/A	Both	261	N/A	Germany
606	NCT01968460 (ClinicalTrials.gov)	December 2013	15/10/2013	Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease	A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease	Parkinson's Disease	Drug: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),;Drug: Placebo;Drug: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),	Pharma Two B Ltd.	NULL	Completed	35 Years	75 Years	All	149	Phase 2/Phase 3	United States;Israel
607	NCT01883505 (ClinicalTrials.gov)	December 2013	9/6/2013	A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612	A Phase 2a Multicentre Randomized Double Blind Placebo Controlled Study Followed by an Open Label Period, to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Continuous Subcutaneous ND0612	Parkinson's Disease	Drug: Levodopa and carbidopa;Drug: Placebo	NeuroDerm Ltd.	NULL	Completed	30 Years	N/A	Both	30	Phase 2	Israel
608	NCT04044547 (ClinicalTrials.gov)	November 22, 2013	30/7/2019	A Study of LY03003 in Patients With Early-stage Parkinson's Disease	A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections	Parkinson Disease	Drug: Rotigotine, extended-release microspheres;Drug: Placebo, extended-release microspheres	Luye Pharma Group Ltd.	Beijing Bozhiyin T&S Co., Ltd.	Completed	18 Years	75 Years	All	60	Phase 1	NULL
609	EUCTR2012-002840-26-RO (EUCTR)	12/11/2013	17/07/2014	Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease	A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood	Parkinson's disease MedDRA version: 17.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE	UCB Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	504	Phase 4	Serbia;United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Romania;Croatia;Bulgaria
610	NCT01856738 (ClinicalTrials.gov)	November 2013	14/5/2013	Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease	Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease:a Multi-center Placebo-controlled Trial.	Parkinson's Disease	Drug: Rivastigmine;Drug: Placebo (for rivastigmine)	VU University Medical Center	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);Atrium Medical Center;University Medical Center Groningen;Leiden University Medical Center;University Medical Center Nijmegen;International Parkinson Fonds Germany GmbH;ZonMw: The Netherlands Organisation for Health Research and Development	Terminated	40 Years	N/A	All	91	Phase 4	Netherlands
611	NCT01927055 (ClinicalTrials.gov)	November 2013	16/8/2013	A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy	A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy	Symptomatic Neurogenic Orthostatic Hypotension;Parkinson's Disease;Multiple Systems Atrophy;Pure Autonomic Failure;Dopamine Beta Hydroxylase Deficiency	Drug: Droxidopa;Drug: Placebo	Chelsea Therapeutics	NULL	Terminated	18 Years	N/A	All	61	Phase 3	United States
612	EUCTR2011-004438-32-DE (EUCTR)	23/10/2013	13/08/2013	The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptying	A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s disease exhibiting delayed gastric emptying - GSK962040 Parkinson's disease PoC	Investigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism. MedDRA version: 16.1;Level: PT;Classification code 10051153;Term: Diabetic gastroparesis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: GSK962040 Product Code: GSK962040 INN or Proposed INN: GSK962040 Other descriptive name: GSK962040	GlaxoSmithKline Research and Development Limited	NULL	Not Recruiting			Female: yes Male: yes	70		Australia;Germany;United Kingdom;Sweden
613	EUCTR2013-000980-10-AT (EUCTR)	18/10/2013	31/07/2013	Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s disease	TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson’s disease patients with motor complications not well controlled on medical treatment - TOLEDO	Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment MedDRA version: 18.0;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Apo-go® Product Name: Apomorphine hydrochloride Product Code: Apo-go® INN or Proposed INN: Apomorphine hydrochloride Other descriptive name: Apomorphine hydrochloride	Britannia Pharmaceuticals Limited	NULL	Not Recruiting			Female: yes Male: yes	102	Phase 3	France;Spain;Denmark;Austria;Netherlands;Germany
614	NCT01960842 (ClinicalTrials.gov)	October 2013	9/10/2013	A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications	An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medication	Advanced Parkinson's Disease	Drug: Levodopa-carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube	AbbVie	NULL	Completed	30 Years	N/A	All	31	Phase 3	Japan;Korea, Republic of;Taiwan
615	NCT01973543 (ClinicalTrials.gov)	October 2013	25/10/2013	Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease	An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to Levodopa	Parkinson's Disease	Biological: VY-AADC01	Neurocrine Biosciences	University of California, San Francisco;Veristat, Inc.;Feinstein Institute for Medical Research;Oregon Health and Science University;Voyager Therapeutics	Completed	40 Years	70 Years	All	15	Phase 1	United States
616	NCT01968031 (ClinicalTrials.gov)	October 2013	18/10/2013	A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease	A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease	Idiopathic Parkinson's Disease	Drug: Istradefylline 40 mg;Drug: Istradefylline 20 mg;Drug: Placebo	Kyowa Hakko Kirin Pharma, Inc.	Kyowa Kirin Co., Ltd.	Completed	30 Years	N/A	All	613	Phase 3	United States;Canada;Czechia;Germany;Israel;Italy;Poland;Serbia;Czech Republic
617	NCT02055274 (ClinicalTrials.gov)	October 2013	31/1/2014	Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease	A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections	Parkinson's Disease	Drug: LY03003;Drug: Neupro	Luye Pharma Group Ltd.	NULL	Completed	18 Years	N/A	Both	39	Phase 1	United States
618	EUCTR2013-001881-40-GB (EUCTR)	16/09/2013	05/08/2013	Extension study to Assess the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease (PD)	An Extension Study to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via onvection Enhanced Delivery (CED) in Subjects with Parkinson’s Disease - Intermittent Bilateral GDNF for Parkinson’s Disease	Parkinson's disease MedDRA version: 18.1;Level: LLT;Classification code 10034008;Term: Parkinson's syndrome;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Glial Cell Line-Derived Neurotrophic Factor (GDNF) INN or Proposed INN: Liatermin Other descriptive name: r-metHuGDNF	North Bristol NHS Trust (NBT)	NULL	Not Recruiting			Female: yes Male: yes	42	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
619	NCT01955616 (ClinicalTrials.gov)	September 2013	25/9/2013	A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation	A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients With Parkinson's Disease and Chronic Constipation Dissatisfied With Current Therapy	Parkinson's Disease	Drug: RM-131;Drug: Placebo	Motus Therapeutics, Inc.	Michael J. Fox Foundation for Parkinson's Research	Terminated	18 Years	80 Years	Both	18	Phase 2	United States
620	NCT01929317 (ClinicalTrials.gov)	August 28, 2013	22/8/2013	A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.	A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease.	Parkinson Disease	Drug: Ropinirole CR 2mg tablet;Drug: Ropinirole CR 8mg tablet;Drug: Ropinirole CR matching Placebo tablet	GlaxoSmithKline	NULL	Terminated	20 Years	N/A	All	81	Phase 3	Japan
621	EUCTR2013-001722-25-NL (EUCTR)	27/08/2013	12/08/2013	Rivastigmine as an early treatment for visual hallucinations in Parkinson’s disease (CHEVAL)	Cholinesterase inhibitors to slow progression of visual hallucinations in Parkinson’s disease: a multi-center placebo-controlled trial (CHEVAL) - CHEVAL	Parkinson's disease MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rivastigmine CF	VU University Medical Center	NULL	Not Recruiting			Female: yes Male: yes	168	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Netherlands
622	EUCTR2011-004438-32-SE (EUCTR)	26/08/2013	01/07/2013	The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptying	A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s disease exhibiting delayed gastric emptying - GSK962040 Parkinson's disease PoC	Investigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism. MedDRA version: 16.0;Level: PT;Classification code 10051153;Term: Diabetic gastroparesis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: GSK962040 Product Code: GSK962040 INN or Proposed INN: GSK962040 Other descriptive name: GSK962040	GlaxoSmithKline Research and Development Limited	NULL	Not Recruiting			Female: yes Male: yes	70		Australia;Germany;United Kingdom;Sweden
623	NCT01767129 (ClinicalTrials.gov)	July 2013	9/1/2013	Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients	A Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients.	Dyskinesia;Parkinson's Disease	Drug: AVP-923-45;Drug: Placebo	Avanir Pharmaceuticals	Michael J. Fox Foundation for Parkinson's Research	Completed	30 Years	80 Years	All	14	Phase 2	United States;Canada
624	EUCTR2012-001245-40-IT (EUCTR)	05/06/2013	17/05/2013	CLINICAL AND PHARMACOLOGICAL STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®)	CLINICAL AND PHARMACOKINETICS STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®)	PARKINSON'S DISEASE MedDRA version: 16.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Madopar 200+50 mg Trade Name: LEVODOPA / BENSERAZIDE 200 + 50 MG		NULL	Not Recruiting			Female: yes Male: yes			Italy
625	NCT01879748 (ClinicalTrials.gov)	June 2013	13/6/2013	A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline	A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses (0.5, 1.0, and 2.0 mg) of Rasagiline Administered to Healthy Japanese and Caucasian Subjects	Parkinson's Disease	Drug: Rasagiline;Drug: Placebo	Teva Pharmaceutical Industries	NULL	Completed	20 Years	50 Years	Both	64	Phase 1	United States
626	NCT01850381 (ClinicalTrials.gov)	June 2013	7/5/2013	Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease	GM 608 in A Phase IIA Pilot Double-blinded, Randomized, Placebo Controlled Trial in Mild to Moderate Parkinson Disease	Parkinson's Disease	Drug: GM608;Drug: Placebo Comparator	Genervon Biopharmaceuticals, LLC	Columbia University	Completed	30 Years	N/A	All	6	Phase 2	United States
627	NCT01765257 (ClinicalTrials.gov)	June 2013	8/1/2013	Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study	Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study.	Drug-naïve Patients With Parkinson's Disease;Apathy	Drug: AZILECT®;Drug: Placebo	University Hospital, Clermont-Ferrand	H. Lundbeck A/S, TEVA;CHU Purpan (Toulouse);Hôpital Haut-Levêque (Pessac);Centre Hospitalier de la Côte Basque;Centre Hospitalier Universitaire de Poitiers (Poitiers);CHU de Rennes (Rennes);University Hospital, Lille;CHU Dupuytren (Limoges);University Hospital, Caen;Hôpital Caremeau (NIMES);Centre Hospitalier Pays D'Aix;Hôpital de la Timone (MARSEILLE);University Hospital, Rouen;Centre Hospitalier Universitaire, Amiens;Centre Hospitalier Universitaire de Saint Etienne;Fondation Rothschild Paris	Not yet recruiting	30 Years	70 Years	Both	50	Phase 4	France
628	NCT01860794 (ClinicalTrials.gov)	May 2013	14/5/2013	Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease	Investigator Clinical Trial for Evaluation of Safety and Tolerability After Transplantation of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients With Parkinson's Disease	Idiopathic Parkinson Disease;Primary Parkinsonism	Drug: Mesencephalic Neuronal Precursor Cells	Bundang CHA Hospital	NULL	Recruiting	18 Years	70 Years	Female	15	Phase 1/Phase 2	Korea, Republic of
629	EUCTR2012-002840-26-BG (EUCTR)	26/04/2013	06/02/2013	Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease	A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood	Parkinson's disease MedDRA version: 16.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE	UCB Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	504	Phase 4	Serbia;United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Romania;Croatia;Bulgaria
630	EUCTR2011-002828-41-EE (EUCTR)	23/04/2013	08/02/2013	A study to test the effectiveness of varying doses of ropinirole PR while taking L-dopa in patients with late stage Parkinson's disease.	A fixed dose, dose-response study of ropinirole prolonged release (PR) as adjunctive treatment to L-dopa in patients with advanced Parkinson's disease.	Advanced Parkinson's disease. MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: REQUIP-MODUTAB, 2mg Product Name: ropinirole PR, 2mg Product Code: SK&F101468 INN or Proposed INN: ROPINIROLE Trade Name: REQUIP-MODUTAB, 4mg Product Name: ropinirole PR, 2mg Product Code: SK&F101468 INN or Proposed INN: ROPINIROLE Trade Name: REQUIP-MODUTAB, 8mg Product Name: ropinirole PR Product Code: SK&F101468 INN or Proposed INN: ROPINIROLE	GlaxoSmithKline Research & Development Limited	NULL	Not Recruiting			Female: yes Male: yes	406		United States;Taiwan;Estonia;Slovakia;Argentina;Chile;Russian Federation;Korea, Republic of
631	JPRN-UMIN000010371	2013/04/08	01/04/2013	Study of zonisamide ( TRERIEF&reg; tablet 25mg ) to tremor in patients with early Parkinson's disease.	Study of zonisamide ( TRERIEF&reg; tablet 25mg ) to tremor in patients with early Parkinson's disease. - Study of zonisamide to tremor in patients with early Parkinson's disease.	Parkinson's disease	Start 25mg of Zonisamide and carry out observation 24weeks. Evaluate start point, after 4weeks, after 8weeks, after 16weeks, and after 24weeks.	Department of Neurology, University of Yamanashi	NULL	Pending	Not applicable	Not applicable	Male and Female	10	Not selected	Japan
632	EUCTR2012-002608-42-GB (EUCTR)	07/04/2013	01/11/2012	A study to evaluate the efficacy of Rotigotine (the treatment) versus placebo in patients with pain associated with Parkinson's Disease	A Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain	Parkinson’s disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE	UCB Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	478	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	France;United States;Hungary;Mexico;Slovakia;Argentina;Poland;Ukraine;Russian Federation;Germany;United Kingdom;Korea, Republic of
633	NCT01829867 (ClinicalTrials.gov)	April 2013	9/4/2013	A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.	A Phase I, Open-label Study in Patients With Parkinson's Disease to Further Assess Safety and Tolerability of sNN0031 Administered at the Total Dose of 95 µg by Intracerebroventricular Infusion	Parkinson's Disease	Drug: sNN0031	Newron Sweden AB	NULL	Terminated	55 Years	75 Years	Both	5	Phase 1	Sweden
634	EUCTR2011-002828-41-SK (EUCTR)	27/03/2013	04/03/2013	A study to test the effectiveness of varying doses of ropinirole PR while taking L-dopa in patients with late stage Parkinson's disease.	A fixed dose, dose-response study of ropinirole prolonged release (PR) as adjunctive treatment to L-dopa in patients with advanced Parkinson's disease.	Advanced Parkinson's disease. MedDRA version: 16.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Requip Modutab, 2mg Product Name: ropinirole PR, 2mg Product Code: SK&F101468 INN or Proposed INN: ROPINIROLE Trade Name: Requip Modutab, 4mg Product Name: ropinirole PR, 2mg Product Code: SK&F101468 INN or Proposed INN: ROPINIROLE Trade Name: Requip Modutab, 8mg Product Name: ropinirole PR Product Code: SK&F101468 INN or Proposed INN: ROPINIROLE	GlaxoSmithKline Research & Development Limited	NULL	Not Recruiting			Female: yes Male: yes	406		United States;Estonia;Taiwan;Slovakia;Argentina;Chile;Russian Federation;Korea, Republic of
635	EUCTR2012-002840-26-SI (EUCTR)	26/03/2013	18/03/2013	Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease	A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE	UCB Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	504	Phase 4	United States;Serbia;Slovenia;Slovakia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Croatia;Romania;Bulgaria
636	NCT04627155 (ClinicalTrials.gov)	March 15, 2013	5/11/2020	A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003	A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Human Tolerance and Kinetics of LY03003 By Single Intramuscular Injection	Parkinson Disease	Drug: LY03003	Luye Pharma Group Ltd.	NULL	Completed	18 Years	45 Years	All	20	Phase 1	NULL
637	JPRN-UMIN000009958	2013/03/08	01/03/2013	Effects of donepezil on the prognosis of Parkinson's disease with severe olfactory dysfunction	Effects of donepezil on the prognosis of Parkinson's disease with severe olfactory dysfunction - Effects of donepezil on the prognosis of Parkinson's disease with severe olfactory dysfunction	Parkinson's disease	Donepezil hydrochloride added to standard therapy Placebo added to standard therapy	National Hospital Organization, Sendai-Nishitaga Hospital	NULL	Complete: follow-up complete	55years-old	75years-old	Male and Female	200	Not applicable	Japan
638	EUCTR2012-002840-26-AT (EUCTR)	05/03/2013	06/11/2012	Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease	A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE	UCB Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	504	Phase 4	United States;Serbia;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Croatia;Romania;Bulgaria
639	JPRN-UMIN000046104	2013/03/01	21/11/2021	Research for the development of assessment strategy and treatment for cognitive impairment of Parkinson's disease	Neuroimaging study for the assessment and treatment of cognitive impairment of the patients with Parkinson's disease - RCIP-Nagoya Study: Research for the cognitive impairment of Parkinson's disease in Nagoya	Parkinson's disease	This study followed a randomized double-blind crossover design for the patients with mild cognitive impairments in PD. Patients in the memantine group were given memantine at 5 mg/day in the first week, and the dose was increased by 5 mg/day per week, with the final dose of 20 mg/day. The patients in the placebo group were given a placebo following the same regimen. During maximum dose administration, fMRI scanning and neuropsychological tests were performed. Group comparisons between memantine and placebo were performed to explore the significant differences.	Nagoya City University	NULL	Complete: follow-up complete	60years-old	75years-old	Male and Female	12	Not applicable	Japan
640	NCT01789047 (ClinicalTrials.gov)	March 2013	7/2/2013	Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease	Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease	Idiopathic Parkinson's Disease;Drug Induced Dyskinesia	Drug: Topiramate;Drug: Placebo;Drug: Amantadine	Rush University Medical Center	Michael J. Fox Foundation for Parkinson's Research	Terminated	30 Years	90 Years	All	42	Phase 2	United States
641	NCT01736176 (ClinicalTrials.gov)	March 2013	27/11/2012	A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease	An Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects With Advanced Parkinson's Disease	Advanced Parkinson's Disease	Drug: Levodopa-Carbidopa Intestinal Gel;Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J);Drug: Levodopa-carbidopa Immediate Release (LC-IR) Tablets	AbbVie (prior sponsor, Abbott)	NULL	Completed	30 Years	N/A	All	39	Phase 3	United States
642	EUCTR2012-002840-26-IT (EUCTR)	18/02/2013	11/01/2013	Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease	A MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PHASE 4 STUDY TO EVALUATE THE EFFICACY OF ROTIGOTINE ON PARKINSON’S DISEASE-ASSOCIATED APATHY, MOTOR SYMPTOMS, AND MOOD	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro INN or Proposed INN: ROTIGOTINE	UCB BIOSCIENCES GMBH	NULL	Not Recruiting			Female: yes Male: yes	600	Phase 4	United States;Hungary;Slovenia;Spain;Ukraine;Turkey;Austria;Bulgaria;Russian Federation;Italy
643	EUCTR2012-002840-26-HU (EUCTR)	11/02/2013	13/12/2012	Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease	A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood	Parkinson's disease MedDRA version: 16.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE	UCB Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	504	Phase 4	Serbia;United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Romania;Croatia;Bulgaria
644	NCT01782222 (ClinicalTrials.gov)	February 2013	30/1/2013	Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy	A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 3-Arm, Phase 4 Study To Evaluate The Efficacy Of Rotigotine On Parkinson's Disease-Associated Apathy, Motor Symptoms, And Mood	Idiopathic Parkinson's Disease	Drug: Rotigotine;Other: Placebo	UCB BIOSCIENCES GmbH	NULL	Completed	18 Years	N/A	All	122	Phase 4	United States;Austria;Hungary;Poland;Slovakia;Slovenia;Spain
645	EUCTR2012-002840-26-ES (EUCTR)	23/01/2013	29/11/2012	Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease	A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE	UCB Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	504	Phase 4	Serbia;United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Romania;Croatia;Bulgaria
646	EUCTR2012-002608-42-HU (EUCTR)	10/01/2013	12/11/2012	A study to evaluate the efficacy of Rotigotine (the treatment) versus placebo in patients with pain associated with Parkinson's Disease	A Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain	Parkinson’s disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE	UCB Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	478		France;United States;Hungary;Mexico;Slovakia;Argentina;Poland;Ukraine;Russian Federation;Germany;United Kingdom;Korea, Republic of
647	EUCTR2012-002608-42-DE (EUCTR)	10/01/2013	26/09/2012	A study to evaluate the efficacy of Rotigotine (the treatment) versus placebo in patients with pain associated with Parkinson's Disease	A Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain	Parkinson’s disease MedDRA version: 16.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE	UCB Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	64		United States;Hungary;Slovakia;Poland;Germany;United Kingdom
648	EUCTR2012-002840-26-SK (EUCTR)	07/01/2013	09/03/2016	Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's Disease	A Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and Mood	Parkinson's disease MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE	UCB Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	504	Phase 4	Serbia;United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Croatia;Romania;Bulgaria
649	NCT01803945 (ClinicalTrials.gov)	January 2013	26/2/2013	A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease	A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease	Parkinson's Disease	Drug: AVE8112;Drug: Placebo	Michael J. Fox Foundation for Parkinson's Research	Sanofi	Terminated	35 Years	70 Years	Both	32	Phase 1	United States
650	NCT01500707 (ClinicalTrials.gov)	January 2013	22/12/2011	Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)	A Single Dose Study to Assess the Pharmacokinetics of SCH 900800 Administered as Oral Tablets in L-DOPA-treated Subjects With Parkinson's Disease	Parkinson's Disease	Drug: SCH 900800	Merck Sharp & Dohme Corp.	NULL	Withdrawn	30 Years	85 Years	Both	0	Phase 1	NULL
651	EUCTR2012-002608-42-SK (EUCTR)	17/12/2012	09/03/2016	A study to evaluate the efficacy of Rotigotine (the treatment) versus placebo in patients with pain associated with Parkinson's Disease	A Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain	Parkinson’s disease MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE Trade Name: Neupro Product Name: Rotigotine INN or Proposed INN: ROTIGOTINE	UCB Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	478		France;United States;Hungary;Mexico;Slovakia;Argentina;Poland;Ukraine;Russian Federation;Germany;United Kingdom;Korea, Republic of
652	NCT02112812 (ClinicalTrials.gov)	December 2012	10/4/2014	Effects of Helicobacter Pylori Infection Eradication in Patients With Parkinson's Disease	A Study on Clinical Response Following Eradication Therapy of Helicobacter Pylori Infection in Parkinson's Disease	Response to Levodopa;Motor Outcomes;Quality of Life Outcomes	Drug: Eradication therapy for H.pylori infection;Drug: Eradication of Helcobacter Pylori;Drug: Eradication therapy for Helicobacter pylori	National University of Malaysia	NULL	Completed	17 Years	N/A	Both	82	N/A	Malaysia
653	NCT01725802 (ClinicalTrials.gov)	December 2012	4/11/2012	A Phase I/IIa Study of Safety, Tolerability and Plasma Concentration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients	A Phase I/IIa, Single Dose, Single-centre, Randomized, Crossover, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients	Parkinson's Disease	Drug: levodopa and carbidopa solution for SC administration;Drug: Placebo	NeuroDerm Ltd.	NULL	Completed	30 Years	N/A	Both	8	Phase 1/Phase 2	Israel
654	NCT01683253 (ClinicalTrials.gov)	November 2012	7/9/2012	Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa	The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy	Impulse Control Disorder	Drug: Levodopa/Carbidopa(200mg/50mg);Drug: Dopaminergic Agonists	Sandoz	NULL	Completed	30 Years	80 Years	All	150	Phase 4	Korea, Republic of
655	NCT01723228 (ClinicalTrials.gov)	November 2012	5/11/2012	Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease	A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease	Parkinson's Disease	Drug: Rasagiline;Drug: Placebo	Teva Branded Pharmaceutical Products R&D, Inc.	NULL	Completed	45 Years	80 Years	All	170	Phase 4	United States
656	NCT01744496 (ClinicalTrials.gov)	November 2012	5/12/2012	Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain	A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain	Advanced Idiopathic Parkinson's Disease	Drug: Rotigotine;Drug: Placebo	UCB BIOSCIENCES GmbH	NULL	Completed	18 Years	N/A	All	68	Phase 4	United States;Germany;Poland;Slovakia;Hungary;Korea, Republic of
657	NCT03652363 (ClinicalTrials.gov)	October 25, 2012	21/8/2018	GDNF in ideopathicParkinsons Disease	A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal (GDNF) Infusions Administered Via Convection Enhanced Delivery (CED) in Subjects With Parkinson&Apos;s Disease	Idiopathic Parkinson Disease	Drug: glial cell line-derived neurotrophic factor	North Bristol NHS Trust	NULL	Completed	35 Years	75 Years	All	42	Phase 2	NULL
658	NCT01691924 (ClinicalTrials.gov)	October 2012	13/9/2012	Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers	Randomized, Double Blind, Placebo Controlled First In-human Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-509 in Male Healthy Volunteers	Parkinson Disease	Drug: PBF-509;Drug: Placebo	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Palo Biofarma, S.L	Completed	18 Years	45 Years	Male	56	Phase 1	Spain
659	NCT01603069 (ClinicalTrials.gov)	October 2012	14/5/2012	A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease	A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease	Parkinson's Disease	Drug: AZD3241 300 mg BID;Drug: AZD3241 600 mg BID;Drug: Placebo	AstraZeneca	NULL	Completed	30 Years	80 Years	Both	51	Phase 2	United States
660	NCT01560754 (ClinicalTrials.gov)	October 2012	9/3/2012	Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease	A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease in Germany and the USA	Parkinson's Disease	Drug: nicotine transdermal patch	James BOYD MD	Michael J. Fox Foundation for Parkinson's Research;Parkinson Study Group (PSG);International Parkinson Fonds (IPF);German Parkinson Study Group (GPS);German Parkinson Society (DPG);Philipps-University Marburg, Germany	Active, not recruiting	30 Years	N/A	Both	160	Phase 2	United States;Germany
661	NCT01723904 (ClinicalTrials.gov)	October 2012	6/11/2012	A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease	An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3B	Advanced Parkinson's Disease	Drug: Rotigotine	UCB BIOSCIENCES GmbH	Otsuka Pharmaceutical Co., Ltd.	Completed	30 Years	80 Years	All	90	Phase 3	Australia;Korea, Republic of;Malaysia;Singapore;Taiwan
662	EUCTR2011-003866-34-GB (EUCTR)	24/09/2012	01/05/2012	Assessing the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease (PD)	A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery (CED) in Subjects with Parkinson’s Disease - Intermittent Bilateral GDNF for Parkinson’s Disease	Parkinson's disease MedDRA version: 18.1;Level: LLT;Classification code 10034008;Term: Parkinson's syndrome;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Glial Cell Line-Derived Neurotrophic Factor (GDNF) INN or Proposed INN: Liatermin Other descriptive name: r-metHuGDNF	North Bristol NHS Trust (NBT)	NULL	Not Recruiting			Female: yes Male: yes	42	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
663	EUCTR2011-004378-27-AT (EUCTR)	04/09/2012	20/07/2012	Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias	L-dopa induced dyskinesias in patients with Parkinson’s disease MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: mavoglurant Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: mavoglurant Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: mavoglurant Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: mavoglurant	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	65		United States;France;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Switzerland;Italy
664	NCT01684475 (ClinicalTrials.gov)	September 2012	11/9/2012	A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE	A STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASE	Parkinson's Disease	Drug: CJH1 (CLR4001)	Alexandra Marine and General Hospital	NULL	Recruiting	40 Years	85 Years	Both	21	Phase 1/Phase 2	Canada
665	NCT01711866 (ClinicalTrials.gov)	September 2012	18/10/2012	A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease	An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4	Advanced Idiopathic Parkinson's Disease	Drug: Rotigotine	UCB BIOSCIENCES GmbH	Otsuka Pharmaceutical Co., Ltd.	Completed	30 Years	80 Years	All	87	Phase 4	United States;Korea, Republic of;Malaysia;Singapore;Taiwan
666	EUCTR2011-004803-19-FI (EUCTR)	16/08/2012	16/05/2012	PET study in PD patients	A Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients with Parkinson’s Disease	Parkinson's Disease; Microglia activation as measured by [11C]PBR28 binding to TSPO MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AZD3241 Extended release tablets 25 mg Product Code: AZD3241 Product Name: AZD3241 Extended release tablets 100 mg Product Code: AZD3241 Product Name: [11C]PBR28 Product Code: [11C]PBR28 Product Name: [18F]FE-PE2I Product Code: [18F]FE-PE2I	AstraZeneca AB	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 2	Finland;Sweden
667	NCT00947037 (ClinicalTrials.gov)	August 2012	24/7/2009	Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects	Parkinson's Disease	Drug: AP-CD/LD	Intec Pharma Ltd.	NULL	Withdrawn	30 Years	95 Years	Both	0	Phase 2	Israel
668	NCT02764892 (ClinicalTrials.gov)	August 2012	25/9/2015	A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's Disease	An Open Label Study of V81444 Using Positron Emission Tomography to Assess Occupancy of Brain Adenosine A2A Receptors & Functional & Perfusion MRI to Explore Effects on Regional Brain Activity & Perfusion in Healthy Male Volunteers	Parkinson's Disease	Drug: V81444	Vernalis (R&D) Ltd	NULL	Completed	25 Years	55 Years	Male	6	Phase 1	NULL
669	JPRN-UMIN000008477	2012/07/19	19/07/2012	Clinical study of selegiline hydrochloride ( FP OD tablet 2.5) to flexion of spine in Parkinson's disease.	Clinical study of selegiline hydrochloride ( FP OD tablet 2.5) to flexion of spine in Parkinson's disease. - Clinical study of selegiline to flexion of spine in Parkinson's disease.	Parkinson disease	Selegiline hydrochloride 5mg 8weeks, 7.5mg 8weeks and stop it, followed after 8weeks, and evaluate each points.	Department of Neurology, Juntendo Koshigaya Hospital	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	20	Not selected	Japan
670	NCT01646268 (ClinicalTrials.gov)	July 2012	18/7/2012	Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients	A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Of The Efficacy And Safety Of The Rotigotine Transdermal Patch In Chinese Subjects With Early-stage Idiopathic Parkinson's Disease	IDIOPATHIC PARKINSON'S DISEASE	Drug: Rotigotine;Drug: Placebo Patch	UCB Pharma	NULL	Completed	30 Years	N/A	All	249	Phase 3	China
671	NCT01646255 (ClinicalTrials.gov)	July 2012	18/7/2012	Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients	A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of The Efficacy And Safety of Rotigotine Transdermal Patch In Chinese Subjects With Advanced-stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled On Levodopa	Idiopathic Parkinson's Disease	Drug: Rotigotine;Drug: Placebo Patch;Drug: L-dopa	UCB Pharma	UCB Trading (Shanghai) Co. Ltd.	Completed	30 Years	N/A	All	346	Phase 3	China
672	NCT01602549 (ClinicalTrials.gov)	July 2012	17/5/2012	A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying	A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying	Gastroparesis	Drug: GSK962040 (25 mg tablet);Drug: Placebo	GlaxoSmithKline	NULL	Completed	40 Years	80 Years	All	58	Phase 2	Australia;Germany;Sweden;United Kingdom
673	NCT01491022 (ClinicalTrials.gov)	July 2012	8/12/2011	A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease	A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease	Parkinson's Disease	Drug: Ampyra first, then Placebo;Drug: placebo first, then Ampyra	University of Miami	Acorda Therapeutics	Completed	45 Years	80 Years	All	22	Phase 1/Phase 2	United States
674	EUCTR2011-003053-25-GB (EUCTR)	18/06/2012	01/05/2012	The ReSPonD Study -Rivastigmine to Stabilise gait in Parkinson’s Disease. A study looking at whether Rivastigmine, a drug that can augment mental function, can stabilise walking in people with Parkinson's disease who have fallen.	A randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in people with Parkinson’s disease who have fallen. - ReSPonD Study - Rivastigmine to Stabilise gait in Parkinson’s Disease	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Exelon ® Product Name: ENA713 Product Code: N/A INN or Proposed INN: Rivastigmine Trade Name: Exelon Product Name: ENA713 Product Code: N/A INN or Proposed INN: Rivastigmine Trade Name: Exelon Product Name: ENA713 Product Code: N/A INN or Proposed INN: Rivastigmine Trade Name: Exelon Product Name: ENA713 Product Code: N/A INN or Proposed INN: Rivastigmine	Research and Enterprise Department	NULL	Not Recruiting			Female: yes Male: yes	130	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
675	EUCTR2011-002074-23-AT (EUCTR)	05/06/2012	07/05/2012	Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease	L-dopa induced dyskinesias in patients with Parkinson's disease MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	140		United States;France;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Switzerland;Italy
676	JPRN-UMIN000008057	2012/06/01	06/06/2012	Effect of enteral formula enriched with omega-3 fatty acid to prevention of weight reduction in patients with Parkinson's Disease	Effect of enteral formula enriched with omega-3 fatty acid to prevention of weight reduction in patients with Parkinson's Disease - Effect of enteral formula enriched with omega-3 fatty acid in patients with Parkinson's Disease	Parkinson's Disease	Daily oral administration of enteral nutrition formula (Racol NF) 400ml for 12 weeks consecutively.	St. Mariannna University School of Medicine	NULL	Complete: follow-up complete	35years-old	80years-old	Male and Female	25	Not applicable	Japan
677	NCT01993680 (ClinicalTrials.gov)	June 2012	27/4/2012	Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment	A Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson's Disease	Autonomic Disturbances in Parkinson's Disease	Drug: Pyridostigmine bromide;Drug: fludrocortisone	Christian Baumann	NULL	Completed	50 Years	80 Years	All	18	Phase 2	Switzerland
678	EUCTR2011-004378-27-DE (EUCTR)	15/05/2012	24/02/2012	Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias	L-dopa induced dyskinesias in patients with Parkinson’s disease MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	65		France;United States;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Italy;Switzerland
679	EUCTR2011-004378-27-SK (EUCTR)	02/05/2012	12/04/2012	Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias	L-dopa induced dyskinesias in patients with Parkinson’s disease MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: mavoglurant Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: mavoglurant Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: mavoglurant Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: mavoglurant	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	65		France;United States;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Italy;Switzerland
680	JPRN-UMIN000007896	2012/05/01	07/05/2012	Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes	Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes - Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes	Parkinson's disease and other parkinsonian syndromes	The patients are given domperidone 30 mg/day for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day lactose powder is given to the patients and levodopa (250 mg)/carbidopa (25 mg) is given on the fifth day in a double-blind manner. On fourth and fifth day, motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug. The patients are given domperidone 30 mg/day (standard dose in Japan) for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day levodopa (250 mg)/carbidopa (25 mg) is given to the patients and lactose powder is given on the fifth day in a double-blind manner. Motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug.	Kansai Medical University	NULL	Recruiting	Not applicable	Not applicable	Male and Female	100	Not selected	Japan
681	EUCTR2011-004438-32-GB (EUCTR)	25/04/2012	18/04/2012	The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptying	A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s disease exhibiting delayed gastric emptying - GSK962040 Parkinson's disease PoC	Investigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism. MedDRA version: 20.1;Level: PT;Classification code 10051153;Term: Diabetic gastroparesis;System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: GSK962040 Product Code: GSK962040 INN or Proposed INN: GSK962040 Other descriptive name: GSK962040 Product Name: GSK962040 Product Code: GSK962040 INN or Proposed INN: GSK962040 Other descriptive name: GSK962040 Product Name: GSK962040 Product Code: GSK962040 INN or Proposed INN: GSK962040 Other descriptive name: GSK962040	GlaxoSmithKline Research and Development Limited	NULL	Not Recruiting			Female: yes Male: yes	70	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Germany;United Kingdom;Sweden
682	EUCTR2011-001092-39-IT (EUCTR)	19/04/2012	20/06/2012	efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias in Parkinson's patients with moderate to severe L-dopa induced dyskinesias	A multi-centre, randomized, double-blind, placebo-controlled, parallelgroup, multiple oral dose study to assess the efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias in Parkinson's patients with moderate to severe L-dopa induced dyskinesias	L-dopa induced dyskinesias in Parkinson's patients MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: NA Product Code: AQW051 Other descriptive name: Not established Product Name: NA Product Code: AQW051 Other descriptive name: Not established	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	72		United States;Germany;Italy
683	NCT01494532 (ClinicalTrials.gov)	April 2, 2012	1/12/2011	A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease	A Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's Disease	Parkinson Disease	Drug: ropinirole/L-dopa;Drug: placebo/L-dopa	GlaxoSmithKline	NULL	Completed	30 Years	N/A	All	352	Phase 4	United States;Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Poland
684	NCT01527695 (ClinicalTrials.gov)	April 2012	22/12/2011	PET Study in Parkinson's Disease Patients	A Phase IIA, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment With Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients With Parkinson's Disease	Parkinson's Disease	Drug: ER tablet 25 mg AZD3241;Drug: ER tablet 100 mg AZD3241;Drug: Placebo for AZD3241 25 mg;Drug: Placebo for AZD3241 100 mg	AstraZeneca	NULL	Completed	45 Years	75 Years	Both	24	Phase 2	Sweden
685	NCT01550484 (ClinicalTrials.gov)	April 2012	6/3/2012	A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders	An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis	Parkinson's Disease;Primary Parkinsonism;Lewy Body Parkinson's Disease	Drug: 18F-AV-133	Avid Radiopharmaceuticals	NULL	Completed	40 Years	N/A	All	170	Phase 2/Phase 3	United States;Australia
686	NCT01486628 (ClinicalTrials.gov)	April 2012	4/12/2011	Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers	A Phase I, Single Dose, Single-centre, Randomized, Double-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers	Parkinson's Disease	Drug: ND0612;Drug: Placebo	NeuroDerm Ltd.	NULL	Completed	18 Years	40 Years	Male	36	Phase 1	Israel
687	NCT01331122 (ClinicalTrials.gov)	April 2012	13/10/2010	Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease	A Phase II, Double-Blind, Placebo-Controlled Randomized Crossover Study to Assess the Clinical Benefit and Safety of Droxidopa in the Treatment of Freezing of Gait Symptoms in Patients With Parkinson's Disease	Gait Disorders, Neurologic	Drug: droxidopa	Chelsea Therapeutics	NULL	Withdrawn	30 Years	N/A	Both	0	Phase 1/Phase 2	United States;Canada
688	NCT01491529 (ClinicalTrials.gov)	April 2012	12/12/2011	Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease	Dyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders;Anti-Dyskinesia Agents	Drug: AFQ056;Drug: Placebo	Novartis Pharmaceuticals	NULL	Completed	30 Years	80 Years	All	154	Phase 2	United States;Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey
689	NCT01523301 (ClinicalTrials.gov)	April 2012	27/1/2012	Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients	Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients	Idiopathic Parkinson's Disease	Drug: Rotigotine;Drug: Placebo	UCB Korea Co., Ltd.	NULL	Completed	20 Years	N/A	All	380	Phase 4	Korea, Republic of
690	EUCTR2011-002074-23-ES (EUCTR)	30/03/2012	06/02/2012	Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson?s disease	L-dopa induced dyskinesias in patients with Parkinson's disease MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056	Novartis Farmacéutica, S.A.	NULL	Not Recruiting			Female: yes Male: yes	92		France;United States;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Italy;Switzerland
691	EUCTR2011-002074-23-SK (EUCTR)	28/03/2012	30/03/2012	Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease	L-dopa induced dyskinesias in patients with Parkinson's disease MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	92		United States;France;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Switzerland;Italy
692	EUCTR2011-004378-27-HU (EUCTR)	28/03/2012	15/02/2012	Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias	L-dopa induced dyskinesias in patients with Parkinson’s disease MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: mavoglurant Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: mavoglurant Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: mavoglurant Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: mavoglurant	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	65		United States;France;Hungary;Canada;Spain;Austria;Germany;Italy
693	EUCTR2011-004378-27-IT (EUCTR)	27/03/2012	02/03/2012	Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson's patients with L-dopa induced dyskinesias	L-dopa induced dyskinesias in patients with Parkinson's disease MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: NA Product Code: AFQ056 INN or Proposed INN: mavoglurant Other descriptive name: NA Product Name: NA Product Code: AFQ056 INN or Proposed INN: mavoglurant Other descriptive name: NA Product Name: NA Product Code: AFQ056 INN or Proposed INN: mavoglurant Other descriptive name: NA Product Name: NA Product Code: AFQ056 INN or Proposed INN: mavoglurant Other descriptive name: NA	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	65		United States;Hungary;Canada;Spain;Austria;Germany;Italy
694	EUCTR2011-002074-23-HU (EUCTR)	21/03/2012	06/02/2012	Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease	L-dopa induced dyskinesias in patients with Parkinson's disease MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	140		United States;France;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Switzerland;Italy
695	EUCTR2011-002074-23-DE (EUCTR)	20/03/2012	06/02/2012	Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease	L-dopa induced dyskinesias in patients with Parkinson's disease MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	140		France;United States;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Italy;Switzerland
696	EUCTR2011-002074-23-IT (EUCTR)	15/03/2012	02/03/2012	Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe Ldopa induced dyskinesias in patients with Parkinson’s disease	L-dopa induced dyskinesias in patients with Parkinson's disease MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: NA Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA Product Name: NA Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA Product Name: NA Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA Product Name: NA Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA Product Name: NA Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA Product Name: NA Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA Product Name: NA Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA Product Name: NA Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA Product Name: NA Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA Product Name: NA Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	92		United States;Hungary;Slovakia;Canada;Spain;Turkey;Austria;Germany;Switzerland;Italy
697	EUCTR2011-002901-31-DE (EUCTR)	08/03/2012	06/10/2011	not applicable	A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson’s disease associated pain - A randomised placebo controlled study of OXN PR for severe Parkinson’s disease associated pain	Subjects will have idiopathic Parkinson's disease and be suffering from severe PD associated pain. MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Targinact 5 mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg Product Code: OXN 5 mg/2.5 mg PR INN or Proposed INN: Oxycodone hydrochloride Other descriptive name: OXYCODONE HYDROCHLORIDE INN or Proposed INN: Naloxone Hydrochloride Dihydrate Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10 mg /5 mg Product Code: OXN 10 mg / 5 mg PR INN or Proposed INN: Oxycodone Hydrochloride Other descriptive name: OXYCODONE HYDROCHLORIDE INN or Proposed INN: Naloxone Hydrochloride Dihydrate Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE Trade Name: Targinact 20 mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20 mg /10 mg Product Code: OXN 20 mg / 10 mg PR INN or Proposed INN: OXYCODONE HYDROCHLORIDE Other descriptive name: OXYCODONE HYDROCHLORIDE INN or Proposed INN: NAL	Mundipharma Research GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	210		Hungary;Czech Republic;Spain;Germany;United Kingdom
698	NCT01538329 (ClinicalTrials.gov)	March 4, 2012	20/2/2012	Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease	Impact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study)	Parkinson Disease	Drug: Amantadine;Drug: placebo	University Hospital, Toulouse	NULL	Completed	35 Years	N/A	All	210	Phase 2	France
699	NCT01653132 (ClinicalTrials.gov)	March 2012	25/7/2012	Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism	Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism	Sialorrhea	Drug: Incobotulinum Toxin A;Drug: Placebo	Beth Israel Deaconess Medical Center	NULL	Completed	18 Years	90 Years	All	10	Phase 2	United States
700	NCT01491932 (ClinicalTrials.gov)	March 2012	1/12/2011	Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	Dyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders;Anti-Dyskinesia Agents	Drug: AFQ056	Novartis Pharmaceuticals	NULL	Completed	N/A	N/A	All	129	Phase 2	United States;Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey
701	NCT01565395 (ClinicalTrials.gov)	March 2012	26/3/2012	Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)	Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)	Parkinson Disease;Amyotrophic Lateral Sclerosis	Drug: Incobotulinum Toxin A;Drug: placebo	Beth Israel Deaconess Medical Center	Merz Pharmaceuticals	Withdrawn	20 Years	80 Years	All	0	Phase 2	United States
702	NCT03061513 (ClinicalTrials.gov)	February 28, 2012	13/2/2017	Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers	Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers	Parkinson Disease	Drug: Ubiquinol;Dietary Supplement: Placebo	Weill Medical College of Cornell University	NULL	Completed	40 Years	75 Years	All	11	Phase 2	NULL
703	EUCTR2011-004803-19-SE (EUCTR)	22/02/2012	16/12/2011	PET study in PD patients	A Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients with Parkinson’s Disease	Parkinson's Disease; Microglia activation as measured by [11C]PBR28 binding to TSPO MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AZD3241 Extended release tablets 25 mg Product Code: AZD3241 Product Name: AZD3241 Extended release tablets 100 mg Product Code: AZD3241 Product Name: [11C]PBR28 Product Code: [11C]PBR28 Product Name: [18F]FE-PE2I Product Code: [18F]FE-PE2I	AstraZeneca AB	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 2	Finland;Sweden
704	EUCTR2011-005054-59-RO (EUCTR)	21/02/2012	13/06/2013	SYN115 in Parkinson’s disease	A double-blind, randomized, placebo-controlled study of the safety and efficacy of SYN115 as adjunctive therapy in levodopa-treated Parkinson’s subjects with end of dose wearing off - (none)	Parkinson’s disease MedDRA version: 16.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: SYN115 Tablets, 60 mg Product Code: SYN115 INN or Proposed INN: tozadenant Other descriptive name: tozadenant	Biotie Therapies Inc.	NULL	Not Recruiting			Female: yes Male: yes	400		United States;Canada;Argentina;Ukraine;Romania;Chile
705	NCT01568099 (ClinicalTrials.gov)	February 2012	16/3/2012	Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease	A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of Two Doses of AFFITOPE® PD01A Formulated With Adjuvant to Patients With Parkinson's Disease	Parkinson's Disease	Biological: AFFITOPE® PD01A;Other: Control	Affiris AG	NULL	Completed	40 Years	65 Years	Both	32	Phase 1	Austria
706	EUCTR2011-005201-75-FR (EUCTR)	12/01/2012	24/01/2012	N/A	N/A	MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: mantadix Product Name: amantadine	CHU de Toulouse	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	France
707	NCT01536015 (ClinicalTrials.gov)	January 2012	15/2/2012	Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction	A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction	Advanced Parkinson's Disease	Drug: Rotigotine;Drug: Placebo	UCB Pharma	NULL	Terminated	30 Years	N/A	All	25	Phase 3	United States
708	NCT01515410 (ClinicalTrials.gov)	January 2012	11/1/2012	Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations	A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patients With Advanced Parkinson's Disease With Motor Fluctuations	Parkinson's Disease;Motor Fluctuations	Drug: DM-1992;Drug: Sinemet IR	Depomed	NULL	Completed	30 Years	N/A	All	34	Phase 2	United States
709	EUCTR2011-002901-31-HU (EUCTR)	21/12/2011	13/10/2011	not applicable	A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson’s disease associated pain - A randomised placebo controlled study of OXN PR for severe Parkinson’s disease associated pain	Subjects will have idiopathic Parkinson's disease and be suffering from severe PD associated pain. MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Targinact 5 mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg Product Code: OXN 5 mg/2.5 mg PR INN or Proposed INN: Oxycodone hydrochloride Other descriptive name: OXYCODONE HYDROCHLORIDE INN or Proposed INN: Naloxone Hydrochloride Dihydrate Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10 mg /5 mg Product Code: OXN 10 mg / 5 mg PR INN or Proposed INN: Oxycodone Hydrochloride Other descriptive name: OXYCODONE HYDROCHLORIDE INN or Proposed INN: Naloxone Hydrochloride Dihydrate Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE Trade Name: Targinact 20 mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20 mg /10 mg Product Code: OXN 20 mg / 10 mg PR INN or Proposed INN: OXYCODONE HYDROCHLORIDE Other descriptive name: OXYCODONE HYDROCHLORIDE INN or Proposed INN: NAL	Mundipharma Research GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	210		Czech Republic;Hungary;Spain;Germany;United Kingdom
710	EUCTR2009-017412-32-IT (EUCTR)	13/12/2011	27/04/2010	RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE - ND	RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE - ND	Parkinson disease MedDRA version: 9.1;Level: LLT;Classification code 10013363	Trade Name: BOTOX INN or Proposed INN: Botulinum toxin Trade Name: NEUROBLOC INN or Proposed INN: Botulinum toxin	AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI	NULL	Not Recruiting			Female: yes Male: yes			Italy
711	EUCTR2011-002901-31-CZ (EUCTR)	12/12/2011	10/10/2011	not applicable	A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson’s disease associated pain - A randomised placebo controlled study of OXN PR for severe Parkinson’s disease associated pain	Subjects will have idiopathic Parkinson's disease and be suffering from severe PD associated pain. MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Targinact 5 mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg Product Code: OXN 5 mg/2.5 mg PR INN or Proposed INN: Oxycodone hydrochloride Other descriptive name: OXYCODONE HYDROCHLORIDE INN or Proposed INN: Naloxone Hydrochloride Dihydrate Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10 mg /5 mg Product Code: OXN 10 mg / 5 mg PR INN or Proposed INN: Oxycodone Hydrochloride Other descriptive name: OXYCODONE HYDROCHLORIDE INN or Proposed INN: Naloxone Hydrochloride Dihydrate Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE Trade Name: Targinact 20 mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20 mg /10 mg Product Code: OXN 20 mg / 10 mg PR INN or Proposed INN: OXYCODONE HYDROCHLORIDE Other descriptive name: OXYCODONE HYDROCHLORIDE INN or Proposed INN: NAL	Mundipharma Research GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	210		Hungary;Czech Republic;Spain;Germany;United Kingdom
712	NCT01521117 (ClinicalTrials.gov)	December 2011	12/1/2012	The Effect of Donepezil on Gait and Balance in Parkinson's Disease	A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's Disease	Parkinson's Disease	Drug: Donepezil	Oregon Health and Science University	NULL	Recruiting	N/A	N/A	Both	12	Phase 4	United States
713	EUCTR2011-002901-31-ES (EUCTR)	30/11/2011	05/10/2011	not applicable	A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain - A randomised placebo controlled study of OXN PR for severe Parkinson?s disease associated pain	Subjects will have idiopathic Parkinson's disease and be suffering from severe PD associated pain. MedDRA version: 14.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Targinact 5 mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg Product Code: OXN 5 mg/2.5 mg PR INN or Proposed INN: Oxycodone hydrochloride Other descriptive name: OXYCODONE HYDROCHLORIDE INN or Proposed INN: Naloxone Hydrochloride Dihydrate Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10 mg /5 mg Product Code: OXN 10 mg / 5 mg PR INN or Proposed INN: Oxycodone Hydrochloride Other descriptive name: OXYCODONE HYDROCHLORIDE INN or Proposed INN: Naloxone Hydrochloride Dihydrate Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE Trade Name: Targinact 20 mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20 mg /10 mg Product Code: OXN 20 mg / 10 mg PR INN or Proposed INN: OXYCODO	Mundipharma Research GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	210	Phase 3	Hungary;Czech Republic;Spain;Germany;United Kingdom
714	EUCTR2011-002901-31-GB (EUCTR)	25/11/2011	21/09/2011	A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain	A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain - Efficacy of OXN PR in severe Parkinson's disease associated pain	Subjects will have idiopathic Parkinson's disease and be suffering from severe PD associated pain. MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Targinact 5 mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg Product Code: OXN 5 mg/2.5 mg PR INN or Proposed INN: Oxycodone hydrochloride Other descriptive name: Oxycodone hydrochloride INN or Proposed INN: Naloxone Hydrochloride Dihydrate Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10 mg /5 mg Product Code: OXN 10 mg / 5 mg PR INN or Proposed INN: Oxycodone Hydrochloride Other descriptive name: OXYCODONE HYDROCHLORIDE INN or Proposed INN: Naloxone Hydrochloride Dihydrate Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE Trade Name: Targinact 20 mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20 mg /10 mg Product Code: OXN 20 mg / 10 mg PR INN or Proposed INN: OXYCODONE HYDROCHLORIDE Other descriptive name: OXYCODONE HYDROCHLORIDE INN or Proposed INN: NAL	Mundipharma Research GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	210	Phase 3	Hungary;Czech Republic;Spain;Germany;United Kingdom
715	EUCTR2009-015162-57-NL (EUCTR)	21/11/2011	11/05/2011	An Active-Controlled Extension Study to P04938 and P07037 (P06153)	A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE	Merck Sharp & Dohme corp.	NULL	Not Recruiting			Female: yes Male: yes	750	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Serbia;Portugal;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Latvia;Netherlands;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden
716	EUCTR2011-002073-30-IT (EUCTR)	14/11/2011	06/03/2012	Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	12-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson's disease	L-dopa induced dyskinesias in patients with Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10043118;Term: Tardive dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA Product Name: AFQ056 Product Code: AFQ056 INN or Proposed INN: NA Other descriptive name: NA	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	63		United States;European Union;Canada;Spain;Germany;Switzerland;Italy
717	EUCTR2009-015162-57-PT (EUCTR)	04/11/2011	12/08/2011	An Active-Controlled Extension Study to P04938 and P07037 (P06153)	A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)	Parkinson's disease MedDRA version: 15.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	United States;Serbia;Portugal;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden
718	NCT01736891 (ClinicalTrials.gov)	November 2011	27/11/2012	Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations	Evaluation for the Efficacy,Tolerability,and Safety of Rasagiline in Levodopa-treated PD Patients With Motor Fluctuations: A Multicenter, Double Blind, Randomized, Placebo-Controlled Group Study (China)	Parkinson´s Disease	Drug: Rasagiline;Drug: Placebo	Chongqing Fortune Pharmaceutical Co., Ltd.	Beijing Bionovo Medicine Development Co., Ltd.	Completed	30 Years	75 Years	Both	268	Phase 3	China
719	NCT01385592 (ClinicalTrials.gov)	November 2011	28/6/2011	Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	12-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease	Dyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders	Drug: AFQ056;Drug: Placebo	Novartis Pharmaceuticals	NULL	Completed	30 Years	80 Years	Both	78	Phase 2	United States;Canada;France;Germany;Hungary;Italy;Spain
720	NCT01457807 (ClinicalTrials.gov)	November 2011	10/10/2011	To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers	A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Different Extended Release Formulations of Tablets of AZD3241 (300 mg) After Administration of Multiple Doses in Healthy Male and Female Volunteers	Parkinson's Disease	Drug: AZD3241 ER formulation 1;Drug: Placebo;Drug: AZD3241 Alternative titration scheme with formulation 1 or 2	AstraZeneca	NULL	Completed	30 Years	65 Years	Both	24	Phase 1	United Kingdom
721	EUCTR2009-015162-57-PL (EUCTR)	25/10/2011	30/08/2011	An Active-Controlled Extension Study to P04938 and P07037 (P06153)	A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)	Parkinson's disease MedDRA version: 15.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	United States;Serbia;Portugal;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden
722	EUCTR2011-000056-42-GB (EUCTR)	07/10/2011	11/08/2011	Sleep efficiency assessed by Polysomnography (PSG sleep lab testing) in advanced Parkinson's disease	A MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECTS OF ROTIGOTINE ON SLEEP EFFICIENCY IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE - sleep efficiency assessed by polysomnography in advanced Parkinson's Disease	Advanced Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro 4mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 6mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 8mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE	UCB Celltech, UK - Registered Branch of UCB Pharma SA	NULL	Not Recruiting			Female: yes Male: yes			United Kingdom
723	JPRN-UMIN000006521	2011/10/01	11/10/2011	Switch trial from Pramipexole IR (Bi-sifrol) to Pramipexole ER (Mirapex LA) in patients with Parkinson's disease	Switch trial from Pramipexole IR (Bi-sifrol) to Pramipexole ER (Mirapex LA) in patients with Parkinson's disease - Switch trial from IR to ER of Pramipexole	Parkinson's disease	Rapid switch of Pramipexole ER (once in a day) which is same dose as IR. The period of administration is 8 weeks.	Department of Neurology, Juntendo University	NULL	Recruiting	20years-old	Not applicable	Male and Female	30	Not selected	Japan
724	NCT02427646 (ClinicalTrials.gov)	October 2011	22/4/2015	Kinematic-guided BoNT-A Treatment for ET and PD Tremor	Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease	Tremor	Drug: BoNT-A	Western University, Canada	NULL	Active, not recruiting	18 Years	80 Years	All	54	Phase 2	NULL
725	NCT01479127 (ClinicalTrials.gov)	October 2011	26/9/2011	Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease	An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease	Advanced Parkinson's Disease	Drug: ABT-SLV187;Drug: Oral Levodopa/Carbidopa;Device: Infusion Pump: CADD-Legacy® 1400 Pump;Device: NJ-Tube: Silicon ED Tube;Device: Adaptor: Hakko Adaptor	AbbVie (prior sponsor, Abbott)	Abbott Japan Co.,Ltd	Completed	30 Years	99 Years	All	8	Phase 2	Japan
726	NCT01446614 (ClinicalTrials.gov)	October 2011	4/10/2011	Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease	Phase?/?Trial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Parkinson's Disease.	Parkinson's Disease	Biological: bone marrow derived mesenchymal stem cells	Guangzhou General Hospital of Guangzhou Military Command	NULL	Recruiting	30 Years	65 Years	Both	20	Phase 1/Phase 2	China
727	EUCTR2010-018534-44-CZ (EUCTR)	23/09/2011	04/07/2011	Investigation of Cogane (PYM50028) in early stage Parkinson's disease	A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane™ (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson’s disease when administered once daily for 28 weeks - CONFIDENT-PD	Early-Stage Parkinson’s Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PYM50028 Product Code: PYM50028 INN or Proposed INN: SMILAGENIN Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol Product Name: PYM50028 Product Code: PYM50028 INN or Proposed INN: SMILAGENIN Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol Product Name: PYM50028 Product Code: PYM50028 INN or Proposed INN: SMILAGENIN Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol	Phytopharm plc	NULL	Not Recruiting			Female: yes Male: yes	408	Phase 2	United States;Serbia;France;Hungary;Czech Republic;Canada;Poland;Romania;Germany;United Kingdom
728	EUCTR2009-015162-57-IT (EUCTR)	22/09/2011	27/04/2011	A Phase 3, 40-week. Active-controlled, Double-blind, Double-Dummy Extension Study of Preladenant in Subjects with moderate to severe Parkinson`s Disease. - ND	A Phase 3, 40-week. Active-controlled, Double-blind, Double-Dummy Extension Study of Preladenant in Subjects with moderate to severe Parkinson`s Disease. - ND	Parkinson`s disease MedDRA version: 13.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders	Product Name: Preladenant Product Code: SCH420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH420814 INN or Proposed INN: Preladenant Trade Name: Azilect INN or Proposed INN: Rasagiline	Schering-Plough Research Institute, division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	Portugal;Czech Republic;Finland;Poland;Spain;Lithuania;Bulgaria;Netherlands;Latvia;United Kingdom;Italy;Sweden
729	EUCTR2011-000612-26-IT (EUCTR)	19/09/2011	05/03/2012	Open-label study on the use of Finasteride in prolonged treatment (4 years) of tics in Tourette's disease and Parkinson's disease in the pounding - FINTOURPARK	Open-label study on the use of Finasteride in prolonged treatment (4 years) of tics in Tourette's disease and Parkinson's disease in the pounding - FINTOURPARK	Syndrome Gilles de la Tourette's disease Parkinosn Pounding MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: PROSCAR*30CPR RIV 5MG INN or Proposed INN: Finasteride	AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
730	NCT01474421 (ClinicalTrials.gov)	September 15, 2011	5/10/2011	Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease	A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias	Dyskinesias;Drug-induced	Drug: AQW051;Drug: Placebo	Novartis Pharmaceuticals	NULL	Completed	30 Years	85 Years	All	71	Phase 2	United States;France;Germany;Italy
731	NCT01515774 (ClinicalTrials.gov)	September 2011	10/1/2012	Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)	An Open-label, Randomized, Multi-center, Crossover Study to Observe the Effect of Once-daily Mirapex ER® and Twice-daily Mirapex ER® in Patients With Parkinson Disease	Parkinson's Disease	Drug: Mirapex ER	Seoul National University Hospital	NULL	Recruiting	30 Years	80 Years	Both	200	Phase 4	Korea, Republic of
732	NCT01178047 (ClinicalTrials.gov)	September 2011	6/8/2010	Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease	A Multicenter, Randomized, Double-blind Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease (PD)	Parkinson's Disease	Drug: Rasagiline	University of Zurich	H. Lundbeck A/S	Terminated	40 Years	N/A	Both	1	Phase 4	Switzerland
733	EUCTR2010-018534-44-HU (EUCTR)	30/08/2011	08/07/2011	Investigation of Cogane (PYM50028) in early stage Parkinson's disease	A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane™ (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson’s disease when administered once daily for 28 weeks - CONFIDENT-PD	Early-Stage Parkinson’s Disease MedDRA version: 15.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PYM50028 Product Code: PYM50028 INN or Proposed INN: SMILAGENIN Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol Product Name: PYM50028 Product Code: PYM50028 INN or Proposed INN: SMILAGENIN Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol Product Name: PYM50028 Product Code: PYM50028 INN or Proposed INN: SMILAGENIN Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol	Phytopharm plc	NULL	Not Recruiting			Female: yes Male: yes	408	Phase 2	France;United States;Serbia;Czech Republic;Hungary;Canada;Poland;Romania;Germany;United Kingdom
734	EUCTR2010-020299-42-DE (EUCTR)	30/08/2011	26/04/2011	A study in U.S. and Germany to show if patients with an early stage of Parkinson's disease could be treated with a nicotine patch. In this study the nicotine patch is being compared to a placebo patch. The placebo patch is identical in appearance to the nicotine patch but does not contain any active ingredients.	A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD) - NIC-PD	Early PD subjects within 18 months of diagnosis and not expected to require dopamine agonist or levodopa therapy for 1 year, with Hoehn and Yahr stage <2, with stable (>2 months) MAO-B inhibitor therapy allowed MedDRA version: 16.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Nicotinell 17,5 mg/24-Stunden-Pflaster Product Name: Nicotinell Other descriptive name: NICOTINE Trade Name: Nicotinell 35 mg/24-Stunden-Pflaster Product Name: Nicotinell Other descriptive name: NICOTINE	Philipps-University Marburg	NULL	Not Recruiting			Female: yes Male: yes	160	Phase 2	United States;Germany
735	EUCTR2009-015162-57-GB (EUCTR)	16/08/2011	26/01/2011	An Active-Controlled Extension Study to P04938 and P07037 (P06153)	A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	NULL	Not Recruiting			Female: yes Male: yes	750	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Serbia;Portugal;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden
736	EUCTR2010-021394-37-BG (EUCTR)	04/08/2011	02/06/2011	Placebo-controlled study in patients with Parkinson’s disease to evaluate the effect of rotigotine on nonmotor symptoms	MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro 2mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 4mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 6mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 8mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE	UCB Pharma SA	NULL	Not Recruiting			Female: yes Male: yes	345	Phase 4	Czech Republic;Hungary;Spain;Belgium;Austria;Bulgaria;Germany;Italy;Switzerland
737	EUCTR2009-015162-57-BG (EUCTR)	04/08/2011	09/06/2011	An Active-Controlled Extension Study to P04938 and P07037 (P06153)	A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	NULL	Not Recruiting			Female: yes Male: yes	750	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Serbia;Portugal;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden
738	EUCTR2010-021860-13-BG (EUCTR)	04/08/2011	02/06/2011	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I	Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations. MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Trade Name: Comtan® Product Name: Over-encapsulated Entacapone Tablets Product Code: Over-encapsulated Entacapone Tablets INN or Proposed INN: ENTACAPONE Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550		Portugal;Serbia;Slovakia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Montenegro;Italy;France;Hungary;Czech Republic;Poland;Romania;Croatia;Bulgaria;Netherlands;Latvia;Germany;Bosnia and Herzegovina
739	NCT01759888 (ClinicalTrials.gov)	August 2011	1/1/2013	Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism	From Mouse Models to Patients: Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism	Parkinson's Disease	Drug: 18F-DTBZ	Chang Gung Memorial Hospital	National Science Council, Taiwan	Completed	20 Years	80 Years	Both	49	Phase 2	Taiwan
740	NCT01411137 (ClinicalTrials.gov)	August 2011	4/8/2011	Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study	An Open Label Conversion Study of Carbidopa-Levodopa (CD-LD) Extended-Release Taken Alone or in Combination With CD-LD Immediate Release to IPX066 Followed by an Open-Label Extension Safety Study of IPX066 in Advanced PD	Parkinson's Disease	Drug: IPX066	Impax Laboratories, LLC	Michael J. Fox Foundation for Parkinson's Research	Completed	30 Years	N/A	All	43	Phase 3	United States
741	NCT01634568 (ClinicalTrials.gov)	August 2011	20/6/2012	A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy Men	A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of V81444 in Healthy Male Volunteers	Parkinson's Disease	Drug: V81444	Vernalis (R&D) Ltd	NULL	Completed	18 Years	45 Years	Male	49	Phase 1	United Kingdom
742	NCT01370811 (ClinicalTrials.gov)	August 2011	8/6/2011	A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease	A Phase II, Double-blind, Randomized, Placebo-controlled 4-way Crossover Study to Evaluate the Relative Efficacy and Safety of OC Oral Solution (Oxybutynin and Clonidine) for Sialorrhoea in Patients With Parkinson's Disease	Sialorrhoea	Drug: OC oral solution treatment A;Drug: OC oral solution treatment B;Drug: OC oral solution treatment C;Drug: OC oral solution treatment D	Orient Pharma Co., Ltd.	NULL	Completed	40 Years	80 Years	Both	24	Phase 2	United States
743	EUCTR2010-021860-13-IT (EUCTR)	25/07/2011	29/03/2012	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON`S DISEASE PATIENTS WITH `WEARING-OFF` PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON`S DISEASE PATIENTS WITH `WEARING-OFF`PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I	Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson`s Disease (PD) and end-of-dose motor fluctuations MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: NA Other descriptive name: NA Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: NA Other descriptive name: NA Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: NA Other descriptive name: NA Trade Name: Comtan® INN or Proposed INN: NA	BIAL - PORTELA & Cª, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550		Portugal;Slovakia;Spain;Lithuania;Austria;Russian Federation;Italy;Hungary;Czech Republic;Romania;Croatia;Bulgaria;Latvia;Germany;Bosnia and Herzegovina
744	EUCTR2009-015162-57-LT (EUCTR)	25/07/2011	21/04/2011	An Active-Controlled Extension Study to P04938 and P07037 (P06153)	A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Serbia;Portugal;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Netherlands;Latvia;Finland;Turkey;Lithuania;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden
745	EUCTR2009-015162-57-LV (EUCTR)	19/07/2011	11/05/2011	An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM1)	A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)	Parkinson's disease MedDRA version: 13.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Serbia;Portugal;United States;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden
746	EUCTR2010-023756-82-DE (EUCTR)	13/07/2011	28/04/2011	Study to test influence of parkinson drug of insomnia in parkinson patients	Rasagiline treatment for Sleep disorders in Parkinson´s disease - RaSPar	sleep disturbances/sleep disorders in patients with Parkinson´s disease MedDRA version: 13.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Azilect Other descriptive name: RASAGILINE MESILATE	Dresden University of Technology	NULL	Not Recruiting			Female: yes Male: yes			Germany
747	EUCTR2009-015162-57-SE (EUCTR)	12/07/2011	31/05/2011	An Active-Controlled Extension Study to P04938 and P07037 (P06153)	A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	United States;Serbia;Portugal;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden
748	EUCTR2010-020112-11-LT (EUCTR)	29/06/2011	06/04/2011	Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)	A Phase 3, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease. (Phase 3; Protocol No. P07037) - P07037	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	585	Phase 3	United States;Serbia;Mexico;Argentina;Ukraine;Croatia;Lithuania;Chile;South Africa;Russian Federation;Latvia;Colombia
749	EUCTR2011-001092-39-DE (EUCTR)	29/06/2011	17/05/2011	efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias in Parkinson’s patients with moderate to severe L-dopa induced dyskinesias	A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesiasin Parkinson’s patients with moderate to severe L-dopa induced dyskinesias	L-dopa induced dyskinesias in Parkinson’s patients with moderate to severe L-dopa induced dyskinesias MedDRA version: 14.1;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AQW051 Product Code: AQW051 Product Name: AQW051 Product Code: AQW051	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	72		France;United States;Germany;Italy
750	EUCTR2010-021860-13-CZ (EUCTR)	24/06/2011	09/11/2010	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I	Adjunct to levodopa L-DOPA/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations. MedDRA version: 17.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Trade Name: Comtan® Product Name: Over-encapsulated Entacapone Tablets Product Code: Over-encapsulated Entacapone Tablets INN or Proposed INN: ENTACAPONE Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550		Serbia;Portugal;Slovakia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Montenegro;Italy;France;Czech Republic;Hungary;Poland;Romania;Croatia;Bulgaria;Netherlands;Germany;Latvia;Bosnia and Herzegovina
751	EUCTR2010-022200-46-LV (EUCTR)	21/06/2011	01/04/2011	Efficacy and safety of ODM-101 compared to a standard combination(Stalevo®) in patients with Pakinson's disease.	Efficacy and safety of ODM-101 compared to a standard combination(Stalevo®); a randomised, double-blind, crossover, proof of conceptstudy in patients with Parkinson's disease and end-of-dose motorfluctuations. - PARPOC	Parkinson's disease MedDRA version: 14.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ODM-101 Product Code: 75 INN or Proposed INN: LEVODOPA Other descriptive name: na INN or Proposed INN: CARBIDOPA Other descriptive name: na INN or Proposed INN: ENTACAPONE Other descriptive name: na Product Name: ODM-101 Product Code: 100 INN or Proposed INN: LEVODOPA Other descriptive name: na INN or Proposed INN: CARBIDOPA Other descriptive name: na INN or Proposed INN: ENTACAPONE Other descriptive name: na Product Name: ODM-101 Product Code: 125 INN or Proposed INN: LEVODOPA Other descriptive name: na INN or Proposed INN: CARBIDOPA Other descriptive name: na	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	100		Finland;Lithuania;Germany;Latvia
752	EUCTR2010-020112-11-LV (EUCTR)	21/06/2011	08/04/2011	Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)	A Phase 3, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease. (Phase 3; Protocol No. P07037) - P07037	Parkinson's disease MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	585	Phase 3	United States;Serbia;Mexico;Argentina;Ukraine;Lithuania;Croatia;South Africa;Russian Federation;Chile;Colombia;Latvia
753	EUCTR2009-015162-57-CZ (EUCTR)	17/06/2011	15/04/2011	An Active-Controlled Extension Study to P04938 and P07037 (P06153)	A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Serbia;Portugal;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden
754	EUCTR2009-015161-31-PL (EUCTR)	08/06/2011	23/02/2011	A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)	A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P04938)	Parkinson's disease MedDRA version: 15.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE Trade Name: Azilect Product Name: Azilect Product Code: N04BD02 INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden
755	NCT01652534 (ClinicalTrials.gov)	June 2011	15/8/2011	Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease	Efficacy of Amantadine for Gait Dysfunction and Gait Freezing in Patients With Parkinson's Disease	Parkinson's Disease	Drug: Amantadine;Drug: Placebo	Northwestern University	NULL	Terminated	18 Years	85 Years	All	3	Phase 3	United States
756	EUCTR2010-022517-25-DE (EUCTR)	30/05/2011	14/02/2011	Safety, tolerability and efficacy of ADX48621 in patients with Parkinson's disease	Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease	Levodopa induced dyskinesia in Parkinson's disease patients MedDRA version: 13.1;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ADX48621 Product Code: ADX48621 INN or Proposed INN: Dipraglurant	Addex Pharma SA	NULL	Not Recruiting			Female: yes Male: yes	90	Phase 2	United States;France;Austria;Germany
757	EUCTR2008-005492-94-BG (EUCTR)	25/05/2011	23/03/2011	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Newron Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	1285		United States;Portugal;Taiwan;Estonia;Slovakia;Thailand;Spain;Chile;Colombia;Switzerland;Italy;India;France;Malaysia;Peru;South Africa;Netherlands;Korea, Republic of;Finland;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Brazil;Belgium;Poland;Romania;Croatia;Bulgaria;Germany;New Zealand
758	EUCTR2010-021394-37-AT (EUCTR)	19/05/2011	05/01/2011	Placebo-controlled study in patients with Parkinson’s disease to evaluate the effect of rotigotine on nonmotor symptoms	MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro 2mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 4mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 6mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 8mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE	UCB Pharma SA	NULL	Not Recruiting			Female: yes Male: yes	345	Phase 4	Czech Republic;Hungary;Spain;Belgium;Austria;Germany;Italy;Switzerland
759	EUCTR2010-022200-46-FI (EUCTR)	13/05/2011	23/03/2011	Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®) in patients with Parkinson’s disease.	Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover, proof of concept study in patients with Parkinson’s disease and end-of-dose motor fluctuations. - PARPOC	Parkinson's disease MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ODM-101 Product Code: 75 INN or Proposed INN: LEVODOPA Other descriptive name: na INN or Proposed INN: CARBIDOPA Other descriptive name: na INN or Proposed INN: ENTACAPONE Other descriptive name: na Product Name: ODM-101 Product Code: 100 INN or Proposed INN: LEVODOPA Other descriptive name: na INN or Proposed INN: CARBIDOPA Other descriptive name: na INN or Proposed INN: ENTACAPONE Other descriptive name: na Product Name: ODM-101 Product Code: 125 INN or Proposed INN: LEVODOPA Other descriptive name: na INN or Proposed INN: CARBIDOPA Other descriptive name: na	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	100		Finland;Germany;Latvia;Lithuania
760	EUCTR2010-022200-46-LT (EUCTR)	09/05/2011	05/04/2011	Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®) in patients with Parkinson’s disease.	Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover, proof of concept study in patients with Parkinson’s disease and end-of-dose motor fluctuations. - PARPOC	Parkinson's disease MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ODM-101 Product Code: 75 INN or Proposed INN: LEVODOPA Other descriptive name: na INN or Proposed INN: CARBIDOPA Other descriptive name: na INN or Proposed INN: ENTACAPONE Other descriptive name: na Product Name: ODM-101 Product Code: 100 INN or Proposed INN: LEVODOPA Other descriptive name: na INN or Proposed INN: CARBIDOPA Other descriptive name: na INN or Proposed INN: ENTACAPONE Other descriptive name: na Product Name: ODM-101 Product Code: 125 INN or Proposed INN: LEVODOPA Other descriptive name: na INN or Proposed INN: CARBIDOPA Other descriptive name: na	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	100		Finland;Lithuania;Germany;Latvia
761	EUCTR2007-002964-90-BE (EUCTR)	05/05/2011	04/09/2007	A trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in patients with Parkinson’s Disease with motor fluctuations, treated with levodopa and who may be receiving a dopamine agonist, an anticholinergic and/or amantadine.	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Newron Pharmaceuticals SpA	NULL	Not Recruiting			Female: yes Male: yes	605	Phase 3	United States;Estonia;Taiwan;Slovakia;Finland;Spain;Thailand;Austria;Israel;United Kingdom;Switzerland;India;France;Czech Republic;Hungary;Canada;Belgium;Malaysia;Australia;Germany;Netherlands;New Zealand;Korea, Republic of
762	EUCTR2010-021394-37-SK (EUCTR)	02/05/2011	16/12/2010	Placebo-controlled study in patients with Parkinson’s disease to evaluate the effect of rotigotine on nonmotor symptoms	MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro 2mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 4mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 6mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 8mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE	UCB Pharma SA	NULL	Not Recruiting			Female: yes Male: yes	345	Phase 4	Czech Republic;Hungary;Slovakia;Spain;Belgium;Austria;Bulgaria;Germany;Italy;Switzerland
763	NCT01856439 (ClinicalTrials.gov)	May 2011	14/5/2013	Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease	A Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease.	Parkinson's Disease	Drug: ProSavin	Axovant Sciences Ltd.	Oxford BioMedica	Terminated	N/A	N/A	All	15	Phase 1/Phase 2	France;United Kingdom
764	NCT01504178 (ClinicalTrials.gov)	May 2011	30/12/2011	Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease	Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease	Parkinson's Disease	Drug: duloxetine;Drug: placebo of duloxetine;Drug: injection of apomorphine;Drug: injection of placebo of apomorphine;Drug: L-Dopa;Drug: injection of placebo of L-Dopa	University Hospital, Toulouse	French Parkinson Association	Completed	30 Years	70 Years	All	28	Phase 3	France
765	NCT01520987 (ClinicalTrials.gov)	May 2011	26/1/2012	Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects	Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Compare the Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects	Parkinson Disease	Drug: BIA 9-1067;Drug: Placebo	Bial - Portela C S.A.	NULL	Completed	18 Years	65 Years	All	105	Phase 1	United States
766	NCT01766258 (ClinicalTrials.gov)	May 2011	22/11/2012	Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations	Efficacy and Safety of ODM-101 Compared to a Standard Combination (Stalevo®); a Randomised, Double-blind, Crossover, Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations	Parkinson's Disease	Drug: ODM-101 65mg Carbidopa;Drug: ODM-101 105mg Carbidopa;Drug: Stalevo	Orion Corporation, Orion Pharma	NULL	Completed	30 Years	N/A	Both	117	Phase 2	NULL
767	EUCTR2010-022517-25-AT (EUCTR)	15/04/2011	17/02/2011	Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease	Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease	Levodopa induced dyskinesia in Parkinson's disease patients MedDRA version: 14.0;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ADX48621 Product Code: ADX48621 INN or Proposed INN: Dipraglurant	Addex Pharma SA	NULL	Not Recruiting			Female: yes Male: yes	90	Phase 2	United States;France;Austria;Germany
768	EUCTR2008-005492-94-PT (EUCTR)	14/04/2011	19/01/2011	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Idiopathic Parkinson's Disease MedDRA version: 15.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Newron Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	1285		United States;Portugal;Taiwan;Estonia;Slovakia;Thailand;Spain;Chile;Colombia;Switzerland;Italy;India;France;Malaysia;Peru;South Africa;Netherlands;Korea, Republic of;Finland;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Brazil;Belgium;Poland;Romania;Croatia;Bulgaria;Germany;New Zealand
769	EUCTR2009-015161-31-DE (EUCTR)	04/04/2011	24/08/2010	A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)	A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P04938)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE Trade Name: Azilect Product Name: Azilect Product Code: N04BD02 INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	Portugal;United States;Finland;Spain;Turkey;Austria;Israel;Russian Federation;Italy;United Kingdom;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Netherlands;Germany;Sweden
770	NCT01937078 (ClinicalTrials.gov)	April 2011	26/7/2012	Famotidine for Levodopa-induced Dyskinesia in PD	An 'N-of-1' Study of the Histamine H@ Antagonist, Famotidine in Levodopa-induced Dyskinesia in Parkinson's Disease	Dyskinesia	Drug: Famotidine	University Health Network, Toronto	NULL	Completed	18 Years	80 Years	Both	7	Phase 2	Canada
771	NCT01338896 (ClinicalTrials.gov)	April 2011	18/4/2011	Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations	A Multicenter, Randomized, Double-blind, Two-way Cross-over Study to Compare the Adhesiveness of Two Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: Rotigotine transdermal patch	UCB Pharma	NULL	Completed	18 Years	N/A	Both	56	Phase 1	Austria;Germany;United Kingdom
772	NCT01313819 (ClinicalTrials.gov)	April 2011	10/3/2011	The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy	A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy	Parkinson`s Disease;Freezing of Gait	Drug: PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj	Seoul National University Hospital	NULL	Recruiting	30 Years	80 Years	Both	20	Phase 4	Korea, Republic of
773	NCT01336088 (ClinicalTrials.gov)	April 2011	4/4/2011	ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease	Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ADX48621 in the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease	Parkinson's Disease	Drug: ADX48621;Drug: Placebo	Addex Pharma S.A.	NULL	Completed	30 Years	75 Years	Both	83	Phase 2	United States;Austria;France;Germany
774	NCT01323855 (ClinicalTrials.gov)	March 28, 2011	24/3/2011	A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)	A Study to Assess Pharmacokinetics of Preladenant in Subjects With Chronic Renal Impairment	Parkinson Disease	Drug: Preladenant	Merck Sharp & Dohme Corp.	NULL	Completed	18 Years	75 Years	All	46	Phase 1	Germany
775	EUCTR2009-015162-57-AT (EUCTR)	17/03/2011	03/02/2011	An Active-Controlled Extension Study to P04938 and P07037 (P06153)	A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	United States;Serbia;Portugal;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden
776	EUCTR2008-005492-94-CZ (EUCTR)	14/03/2011	03/01/2011	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Newron Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	1285		Portugal;United States;Taiwan;Estonia;Slovakia;Thailand;Spain;Chile;Colombia;Italy;Switzerland;India;France;Malaysia;Peru;South Africa;Netherlands;Korea, Republic of;Finland;Austria;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Germany;New Zealand
777	EUCTR2010-018534-44-DE (EUCTR)	11/03/2011	10/08/2010	Investigation of Cogane (PYM50028) in early stage Parkinson's disease	A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane™ (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson’s disease when administered once daily for 28 weeks - CONFIDENT-PD	Early-Stage Parkinson’s Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PYM50028 Product Code: PYM50028 INN or Proposed INN: SMILAGENIN Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol Product Name: PYM50028 Product Code: PYM50028 INN or Proposed INN: SMILAGENIN Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol Product Name: PYM50028 Product Code: PYM50028 INN or Proposed INN: SMILAGENIN Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol	Phytopharm plc	NULL	Not Recruiting			Female: yes Male: yes	408	Phase 2	United States;Serbia;France;Hungary;Czech Republic;Canada;Poland;Romania;Germany;United Kingdom
778	EUCTR2010-021860-13-DE (EUCTR)	09/03/2011	18/10/2010	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I	Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations. MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Opicapone Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Trade Name: Comtan® Product Name: Over-encapsulated Entacapone Tablets Product Code: Over-encapsulated Entacapone Tablets INN or Proposed INN: ENTACAPONE Product Name: Opicapone Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Product Name: Opicapone Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550		Serbia;Portugal;Slovakia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Montenegro;Italy;France;Czech Republic;Hungary;Poland;Romania;Croatia;Bulgaria;Netherlands;Germany;Latvia;Bosnia and Herzegovina
779	EUCTR2010-021394-37-CZ (EUCTR)	09/03/2011	14/12/2010	Placebo-controlled study in patients with Parkinson’s disease to evaluate the effect of rotigotine on nonmotor symptoms	MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro 2mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 4mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 6mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 8mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE	UCB Pharma SA	NULL	Not Recruiting			Female: yes Male: yes	345	Phase 4	Hungary;Czech Republic;Spain;Belgium;Austria;Germany;Italy;Switzerland
780	EUCTR2010-021394-37-DE (EUCTR)	08/03/2011	03/12/2010	Placebo-controlled study in patients with Parkinson's disease to evaluate the effect of rotigotine on nonmotor symptoms	MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro 2mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 4mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 6mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 8mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE	UCB Pharma SA	NULL	Not Recruiting			Female: yes Male: yes	345	Phase 4	Czech Republic;Hungary;Spain;Belgium;Austria;Bulgaria;Germany;Italy;Switzerland
781	EUCTR2009-015161-31-GB (EUCTR)	07/03/2011	01/07/2010	A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)	A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P04938)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE Trade Name: Azilect Product Name: Azilect Product Code: N04BD02 INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	NULL	Not Recruiting			Female: yes Male: yes	750	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Portugal;United States;Finland;Spain;Turkey;Austria;Israel;Russian Federation;Italy;United Kingdom;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Netherlands;Germany;Sweden
782	EUCTR2008-005492-94-FI (EUCTR)	04/03/2011	13/01/2011	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Newron Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	1285		United States;Portugal;Taiwan;Estonia;Slovakia;Thailand;Spain;Chile;Colombia;Switzerland;Italy;India;France;Malaysia;Peru;South Africa;Netherlands;Korea, Republic of;Finland;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Brazil;Belgium;Poland;Romania;Croatia;Bulgaria;Germany;New Zealand
783	EUCTR2009-015162-57-FI (EUCTR)	02/03/2011	20/01/2011	An Active-Controlled Extension Study to P04938 and P07037 (P06153)	A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESILATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Serbia;Portugal;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Peru;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;Sweden
784	NCT01264861 (ClinicalTrials.gov)	March 2011	20/12/2010	A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging	Open-Label Escalating Dose Study Using [123|]ß-CIT SPECT Single Photon Emission Computerized Tomography (SPECT) to Evaluate Dopamine and Serotonin Transporter Occupancy by Safinamide in Parkinson Disease Patients	Parkinson Disease	Drug: Safinamide	Newron	NULL	Terminated	40 Years	80 Years	All	5	Phase 2	United States
785	NCT01283594 (ClinicalTrials.gov)	March 2011	24/1/2011	Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off	A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off	Parkinson's Disease	Drug: Tozadenant (SYN115) 60 mg BID;Drug: Placebo;Drug: Levodopa (L-dopa);Drug: Tozadenant (SYN115) 120 mg BID;Drug: Tozadenant (SYN115) 180 mg BID;Drug: Tozadenant (SYN115) 240 mg BID	Biotie Therapies Inc.	NULL	Completed	30 Years	80 Years	All	420	Phase 2/Phase 3	United States;Argentina;Canada;Chile;Romania;Ukraine
786	NCT02169427 (ClinicalTrials.gov)	March 2011	24/1/2012	An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites	An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites Following a Single Dose Oral Administration	Parkinson's Disease (PD)	Drug: OPC	Bial - Portela C S.A.	NULL	Completed	18 Years	55 Years	Male	6	Phase 1	Netherlands
787	NCT01294800 (ClinicalTrials.gov)	February 25, 2011	10/2/2011	A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)	A Phase 2, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Preladenant in Japanese Subjects With Moderate to Severe Parkinson's Disease. (Phase 2; Protocol No. P06402)	Parkinson's Disease	Drug: Preladenant;Drug: Placebo tablet to match Preladenant	Merck Sharp & Dohme Corp.	NULL	Completed	30 Years	85 Years	All	450	Phase 2	Japan
788	EUCTR2008-001329-33-GB (EUCTR)	24/02/2011	15/03/2010	Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease	Open-Label Continuation Treatment Study With Levodopa – Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies.	Treatment with Levodopa – Carbidopa Intestinal Gel in subjects with advanced Parkinson's disease and severe motor-fluctuations who have exhibited a persistent and positive effect to treatment in previous studies MedDRA version: 16.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel INN or Proposed INN: levodopa Other descriptive name: Ph. Eur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid INN or Proposed INN: carbidopa monohydrate Other descriptive name: Ph. Eur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid	AbbVie Inc	NULL	Not Recruiting			Female: yes Male: yes	275	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Portugal;Czech Republic;Thailand;Poland;Australia;Israel;Russian Federation;Italy;New Zealand;United Kingdom
789	EUCTR2009-015161-31-BG (EUCTR)	17/02/2011	02/02/2011	A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)	A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P04938)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE Trade Name: Azilect Product Name: Azilect Product Code: N04BD02 INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	Portugal;United States;Finland;Spain;Turkey;Austria;Israel;Russian Federation;Italy;United Kingdom;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Netherlands;Germany;Sweden
790	EUCTR2010-021860-13-SK (EUCTR)	17/02/2011	09/12/2010	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I	Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations. MedDRA version: 17.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Trade Name: Comtan® Product Name: Over-encapsulated Entacapone Tablets Product Code: Over-encapsulated Entacapone Tablets INN or Proposed INN: ENTACAPONE Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550		Serbia;Portugal;Slovakia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Montenegro;Italy;France;Czech Republic;Hungary;Poland;Romania;Croatia;Bulgaria;Netherlands;Germany;Latvia;Bosnia and Herzegovina
791	EUCTR2010-021394-37-ES (EUCTR)	17/02/2011	22/12/2010	Estudio multicéntrico, doble ciego, controlado con placebo, de grupos paralelos, fase IV para evaluar el efecto de rotigotina sobre los síntomas no motores en pacientes con enfermedad de Parkinson idiopática(Multicenter, double-blind, placebo controlled, parallel-group, phase IV study to assess the effect of rotigotine on non-motor symptoms in patients with idiopathic parkinsons disease) - SP0976	Estudio multicéntrico, doble ciego, controlado con placebo, de grupos paralelos, fase IV para evaluar el efecto de rotigotina sobre los síntomas no motores en pacientes con enfermedad de Parkinson idiopática(Multicenter, double-blind, placebo controlled, parallel-group, phase IV study to assess the effect of rotigotine on non-motor symptoms in patients with idiopathic parkinsons disease) - SP0976	Enfermedad de Parkinson MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: NEUPRO 2 mg/24 h parche transdérmico INN or Proposed INN: ROTIGOTINA Other descriptive name: ROTIGOTINE Trade Name: NEUPRO 4 mg/24 h parche transdérmico INN or Proposed INN: ROTIGOTINA Other descriptive name: ROTIGOTINE Trade Name: NEUPRO 6 mg/24 h parche transdérmico INN or Proposed INN: ROTIGOTINA Other descriptive name: ROTIGOTINE Trade Name: NEUPRO 8 mg/24 h parche transdérmico INN or Proposed INN: ROTIGOTINA Other descriptive name: ROTIGOTINE	UCB Pharma SA	NULL	Not Recruiting			Female: yes Male: yes	345	Phase 4	Czech Republic;Hungary;Slovakia;Belgium;Spain;Austria;Bulgaria;Germany;Italy
792	EUCTR2010-021394-37-HU (EUCTR)	14/02/2011	13/12/2010	Multicenter, double-blind, placebo controlled, parallel-group, phase IV study to assess the effect of rotigotine on non-motor symptoms in patients with idiopathic parkinson’s disease	MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro 2mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 4mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 6mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 8mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE	UCB Pharma SA	NULL	Not Recruiting			Female: yes Male: yes	345	Phase 4	Czech Republic;Hungary;Spain;Belgium;Austria;Germany;Italy;Switzerland
793	EUCTR2009-017174-20-AT (EUCTR)	09/02/2011	07/12/2010	A trial to determine if safinamide can attenuate levodopa induced dyskinesia in Parkinson’s disease.	A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering from levodopa induced dyskinesias. - LID study	Idiopathic Parkinson's disease MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015E, EMD 1195686, MSC2191632B INN or Proposed INN: safinamide Other descriptive name: (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	24		Germany;Canada;France;Austria;South Africa
794	NCT01296464 (ClinicalTrials.gov)	February 2011	14/2/2011	Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens	Duration of Motor Response After Administration of Experimental Levodopa/Carbidopa/Entacapone Treatment Regimens Compared to Standard Treatment (Stalevo®);a Randomised,Double-blind,Crossover,Multicentre,Single Dose Study in Patients With Parkinson?s Disease and Wearing-off Symptoms	Parkinson's Disease	Drug: Carbidopa	Orion Corporation, Orion Pharma	NULL	Completed	30 Years	N/A	Both	27	Phase 2	Finland;Sweden
795	NCT01300819 (ClinicalTrials.gov)	February 2011	18/2/2011	Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms	Multicenter, Double-blind, Placebo-controlled, Parallel-group, Phase IV Study to Assess the Effect of Rotigotine on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease	Idiopathic Parkinson's Disease	Other: Placebo;Drug: Rotigotine	UCB Pharma	NULL	Completed	18 Years	N/A	All	349	Phase 4	Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Hungary;Italy;Romania;Slovakia;Spain;Switzerland
796	EUCTR2009-015161-31-PT (EUCTR)	28/01/2011	29/10/2010	A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)	A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P04938)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE Trade Name: Azilect Product Name: Azilect Product Code: N04BD02 INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden
797	EUCTR2010-021860-13-RO (EUCTR)	27/01/2011	25/07/2011	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I	Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations. MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Trade Name: Comtan® Product Name: Over-encapsulated Entacapone Tablets Product Code: Over-encapsulated Entacapone Tablets INN or Proposed INN: ENTACAPONE Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550	Phase 3	Serbia;Portugal;Slovakia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Montenegro;Italy;France;Czech Republic;Hungary;Poland;Romania;Croatia;Bulgaria;Netherlands;Germany;Latvia;Bosnia and Herzegovina
798	EUCTR2010-021860-13-AT (EUCTR)	27/01/2011	11/10/2010	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I	Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations. MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Trade Name: Comtan® Product Name: Over-encapsulated Entacapone Tablets Product Code: Over-encapsulated Entacapone Tablets INN or Proposed INN: ENTACAPONE Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550		Serbia;Portugal;Slovakia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Montenegro;Italy;France;Czech Republic;Hungary;Poland;Romania;Croatia;Bulgaria;Germany;Latvia;Netherlands;Bosnia and Herzegovina
799	EUCTR2010-021394-37-BE (EUCTR)	25/01/2011	14/12/2010	Placebo-controlled study in patients with Parkinson's disease to evaluate the effect of rotigotine on nonmotor symptoms	MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Neupro 2mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 4mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 6mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 8mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE	UCB Pharma SA	NULL	Not Recruiting			Female: yes Male: yes	345	Phase 4	Czech Republic;Hungary;Slovakia;Spain;Belgium;Austria;Bulgaria;Germany;Italy;Switzerland
800	EUCTR2010-021860-13-ES (EUCTR)	24/01/2011	27/10/2010	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON'S DISEASE PATIENTS WITH 'WEARING-OFF' PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY.EFICACIA Y SEGURIDAD DE BIA 9-1067 EN PACIENTES CON ENFERMEDAD DE PARKINSON IDIOPÁTICA CON FENÓMENO DE 'WEARING OFF' TRATADOS CON LEVODOPA Y UN INHIBIDOR DE DOPA DESCAROBOXILASA (IDDC): ENSAYO CLÍNICO MULTICÉNTRICO, DOBLE CIEGO, ALEATORIZADO, CONTROLADO CON PLACEBO Y ACTIVO, DE GRUPOS PARALELOS - BIPARK STUDY I	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON'S DISEASE PATIENTS WITH 'WEARING-OFF' PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY.EFICACIA Y SEGURIDAD DE BIA 9-1067 EN PACIENTES CON ENFERMEDAD DE PARKINSON IDIOPÁTICA CON FENÓMENO DE 'WEARING OFF' TRATADOS CON LEVODOPA Y UN INHIBIDOR DE DOPA DESCAROBOXILASA (IDDC): ENSAYO CLÍNICO MULTICÉNTRICO, DOBLE CIEGO, ALEATORIZADO, CONTROLADO CON PLACEBO Y ACTIVO, DE GRUPOS PARALELOS - BIPARK STUDY I	Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations.Adjunto a levodopa/inhibidor dopa descarboxilasa para pacientes con enfermedad de Parkinson y fluctuaciones motoras de fin de dosis MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Trade Name: Comtan® Product Name: Over-encapsulated Entacapone Tablets Product Code: Over-encapsulated Entacapone Tablets INN or Proposed INN: ENTACAPONE Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550		Portugal;Czech Republic;Hungary;Slovakia;Spain;Romania;Lithuania;Austria;Bulgaria;Germany;Latvia;Italy
801	EUCTR2009-015161-31-CZ (EUCTR)	17/01/2011	28/07/2010	A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)	A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P04938)	Parkinson's disease MedDRA version: 15.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE Trade Name: Azilect Product Name: Azilect Product Code: N04BD02 INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden
802	EUCTR2010-022915-21-SE (EUCTR)	12/01/2011	18/11/2010	Duration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multicentre, single dose study in patients with Parkinson’s disease and wearing-off symptoms - PARTEST	Duration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multicentre, single dose study in patients with Parkinson’s disease and wearing-off symptoms - PARTEST	Parkinson's disease MedDRA version: 12.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: carbidopa 20 mg Product Code: NA INN or Proposed INN: CARBIDOPA Other descriptive name: NA Product Name: carbidopa 27.5 mg Product Code: NA INN or Proposed INN: CARBIDOPA Other descriptive name: NA Trade Name: Stalevo 100/25/200 mg Product Name: NA Product Code: NA INN or Proposed INN: LEVODOPA Other descriptive name: NA INN or Proposed INN: CARBIDOPA Other descriptive name: NA INN or Proposed INN: ENTACAPONE Other descriptive name: NA Trade Name: Stalevo 150/37.5/200 mg Product Name: NA Product Code: NA INN or Proposed INN: LEVODOPA Other descriptive name: NA INN or Proposed INN: CARBIDOPA Other descriptive name: NA INN or Proposed INN: ENTACAPONE	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	27		Finland;Sweden
803	EUCTR2010-022915-21-FI (EUCTR)	10/01/2011	11/11/2010	Duration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multicentre, single dose study in patients with Parkinson’s disease and wearing-off symptoms - PARTEST	Duration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multicentre, single dose study in patients with Parkinson’s disease and wearing-off symptoms - PARTEST	Parkinson's disease MedDRA version: 12.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: carbidopa 20 mg Product Code: NA INN or Proposed INN: CARBIDOPA Other descriptive name: NA Product Name: carbidopa 27.5 mg Product Code: NA INN or Proposed INN: CARBIDOPA Other descriptive name: NA Trade Name: Stalevo 100/25/200 mg Product Name: NA Product Code: NA INN or Proposed INN: LEVODOPA Other descriptive name: NA INN or Proposed INN: CARBIDOPA Other descriptive name: NA INN or Proposed INN: ENTACAPONE Other descriptive name: NA Trade Name: Stalevo 150/37.5/200 mg Product Name: NA Product Code: NA INN or Proposed INN: LEVODOPA Other descriptive name: NA INN or Proposed INN: CARBIDOPA Other descriptive name: NA INN or Proposed INN: ENTACAPONE	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	27		Finland;Sweden
804	NCT01229332 (ClinicalTrials.gov)	January 2011	3/10/2010	A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients	A Phase I/II, Single-center, Randomized, Cross-over, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Administration of Subcutaneous Continuously-delivered Carbidopa Solution (ND0611) on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations	Parkinson's Disease	Drug: Saline;Drug: Carbidopa	NeuroDerm Ltd.	NULL	Completed	30 Years	N/A	Both	24	Phase 1/Phase 2	Israel
805	EUCTR2010-021860-13-LV (EUCTR)	22/12/2010	14/10/2010	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I	Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations. MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Trade Name: Comtan® Product Name: Over-encapsulated Entacapone Tablets Product Code: Over-encapsulated Entacapone Tablets INN or Proposed INN: ENTACAPONE Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550		Portugal;Czech Republic;Hungary;Slovakia;Spain;Romania;Lithuania;Austria;Bulgaria;Germany;Latvia;Italy
806	EUCTR2010-021860-13-PT (EUCTR)	22/12/2010	08/11/2010	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I	Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations. MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Trade Name: Comtan® Product Name: Over-encapsulated Entacapone Tablets Product Code: Over-encapsulated Entacapone Tablets INN or Proposed INN: ENTACAPONE Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550		Portugal;Serbia;Slovakia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Montenegro;Italy;France;Hungary;Czech Republic;Poland;Romania;Croatia;Bulgaria;Netherlands;Latvia;Germany;Bosnia and Herzegovina
807	EUCTR2008-004146-88-DE (EUCTR)	20/12/2010	15/10/2010	An extension trial to investigate the long-term efficacy and safety of safinamide, as an add-on-therapy in patients with early Parkinson´s disease treated with a stable dose of a dopamine agonist	A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Newron Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	498	Phase 3	Portugal;United States;Slovakia;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;South Africa;Bulgaria;Germany
808	EUCTR2009-015161-31-NL (EUCTR)	09/12/2010	09/08/2010	A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)	A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P04938)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE Trade Name: Azilect Product Name: Azilect Product Code: N04BD02 INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Netherlands;Germany;Sweden;United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India
809	EUCTR2009-015161-31-IT (EUCTR)	06/12/2010	28/09/2010	A Phase 3, 12-Week, Double-Blind, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease. (Phase 3; Protocol No. P04938) - ND	A Phase 3, 12-Week, Double-Blind, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease. (Phase 3; Protocol No. P04938) - ND	Parkinson`s Disease MedDRA version: 9.1;Level: PT;Classification code 10061536	Product Name: Preladenant Product Code: SCH420814 Product Name: Preladenant Product Code: SCH420814 Product Name: Preladenant Product Code: SCH420814 Trade Name: Azilect INN or Proposed INN: Rasagiline	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Portugal;Finland;Spain;Austria;Italy;United Kingdom;France;Czech Republic;Poland;Bulgaria;Netherlands;Germany;Sweden
810	EUCTR2009-015161-31-SE (EUCTR)	02/12/2010	06/10/2010	A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)	A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P04938)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE Trade Name: Azilect Product Name: Azilect Product Code: N04BD02 INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden
811	EUCTR2010-020109-34-ES (EUCTR)	29/11/2010	23/09/2010	Estudio Fase II, doble ciego, aleatorizado, controlado con placebo, de grupos paralelos, para explorar los posibles efectos beneficiosos de safinamida en la cognición, en pacientes no dementes con enfermedad de Parkinson (EP) idiopática y deterioro cognitivo.A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson's disease (PD) and cognitive impairment.	Estudio Fase II, doble ciego, aleatorizado, controlado con placebo, de grupos paralelos, para explorar los posibles efectos beneficiosos de safinamida en la cognición, en pacientes no dementes con enfermedad de Parkinson (EP) idiopática y deterioro cognitivo.A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson's disease (PD) and cognitive impairment.	Cognition in non-demented patients with idiopathic Parkinson's disease Cognición en sujetos no dementes con Enfermedad de Parkinson idiopática MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamida Product Code: NW-1015 Other descriptive name: Safinamida	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 2	Spain;Italy
812	EUCTR2010-020109-34-IT (EUCTR)	24/11/2010	27/12/2010	A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson’s disease (PD) and cognitive impairment. - ND	A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson’s disease (PD) and cognitive impairment. - ND	Cognition in non-demented patients with idiopathic Parkinson’s disease MedDRA version: 9.1;Level: PT;Classification code 10061536	Product Name: SAFINAMIDE Product Code: NW-1015	MERCK SERONO SA	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 2	Spain;Italy
813	NCT01227265 (ClinicalTrials.gov)	November 19, 2010	22/10/2010	Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)	A Phase 3, 12 Week, Double-blind, Placebo-controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease.	Parkinson Disease;Idiopathic Parkinson Disease;Idiopathic Parkinson's Disease	Drug: Preladenant;Drug: Placebo	Merck Sharp & Dohme Corp.	NULL	Completed	30 Years	85 Years	All	476	Phase 3	Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States
814	NCT01215227 (ClinicalTrials.gov)	November 18, 2010	4/10/2010	An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)	A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)	Parkinson Disease;Idiopathic Parkinson Disease	Drug: Preladenant;Drug: Rasagiline;Drug: Placebo to preladenant;Drug: Placebo to rasagiline	Merck Sharp & Dohme Corp.	NULL	Terminated	30 Years	85 Years	All	839	Phase 3	Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States
815	EUCTR2010-021860-13-HU (EUCTR)	11/11/2010	27/09/2010	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY I	Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations. MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Trade Name: Comtan® Product Name: Over-encapsulated Entacapone Tablets Product Code: Over-encapsulated Entacapone Tablets INN or Proposed INN: ENTACAPONE Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067 Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive name: BIA 9-1067	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550		Portugal;Czech Republic;Hungary;Slovakia;Spain;Romania;Lithuania;Austria;Bulgaria;Germany;Latvia;Italy
816	EUCTR2007-001109-26-GB (EUCTR)	04/11/2010	05/08/2010	A phase I/II study of the safety, efficacy and dose evaluation of ProSavin®, administered using stereotactic injection to the striatum of patients with bilateral, idiopathic Parkinson’s disease	A phase I/II study of the safety, efficacy and dose evaluation of ProSavin®, administered using stereotactic injection to the striatum of patients with bilateral, idiopathic Parkinson’s disease	Patients with bilateral, idiopathic Parkinson's Disease	Product Name: ProSavin INN or Proposed INN: ProSavin	Oxford BioMedica (UK) Ltd	NULL	Not Recruiting			Female: yes Male: yes	27	Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
817	EUCTR2009-015161-31-AT (EUCTR)	03/11/2010	17/08/2010	A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)	A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P04938)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE Trade Name: Azilect Product Name: Azilect Product Code: N04BD02 INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden
818	NCT01060878 (ClinicalTrials.gov)	November 2010	1/2/2010	Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)	Phase II, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of PYM50028 in Subjects With Early-stage Parkinson's Disease Administered Once Daily for 28 Weeks	Parkinson's Disease	Drug: PYM50028;Drug: Placebo	Phytopharm	NULL	Completed	35 Years	75 Years	Both	425	Phase 2	United States;Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom
819	EUCTR2010-018534-44-GB (EUCTR)	22/10/2010	09/08/2010	Investigation of Cogane (PYM50028) in early stage Parkinson's disease	A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane™ (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson’s disease when administered once daily for 28 weeks - CONFIDENT-PD	Early-Stage Parkinson’s Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PYM50028 Product Code: PYM50028 INN or Proposed INN: SMILAGENIN Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol Product Name: PYM50028 Product Code: PYM50028 INN or Proposed INN: SMILAGENIN Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol Product Name: PYM50028 Product Code: PYM50028 INN or Proposed INN: SMILAGENIN Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol	Phytopharm plc	NULL	Not Recruiting			Female: yes Male: yes	408	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	France;United States;Serbia;Hungary;Czech Republic;Canada;Poland;Romania;Germany;United Kingdom
820	EUCTR2009-015161-31-FR (EUCTR)	19/10/2010	29/07/2010	A Phase 3, 12-Week, Double-Blind, Placebo-and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson's Disease	A Phase 3, 12-Week, Double-Blind, Placebo-and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson's Disease	Parkinson's disease MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesilate Other descriptive name: RASAGILINE MESILATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Portugal;Finland;Spain;Austria;United Kingdom;Italy;France;Czech Republic;Poland;Bulgaria;Netherlands;Germany;Sweden
821	EUCTR2009-015928-28-SE (EUCTR)	07/10/2010	13/08/2010	A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease. - ELTODYS09	A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease. - ELTODYS09	Dyskinesias related to levodopa treatment in Parkinson´s disease	Product Name: Eltoprazine HCl Product Code: Eltoprazine HCl	PsychoGenics Inc	NULL	Not Recruiting			Female: yes Male: yes	24		Sweden
822	EUCTR2007-002964-90-CZ (EUCTR)	06/10/2010	27/08/2010	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	605	Phase 3	Hungary;Finland;United Kingdom;Germany;Czech Republic;Netherlands;Belgium;Estonia;France;Spain;Austria
823	EUCTR2010-019418-25-DE (EUCTR)	01/10/2010	19/07/2010	Open label, safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias	An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias	Moderate to severe levodopa induced dyskinesia in patients with Parkinson's disease MedDRA version: 16.0;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AFQ056 Product Code: AFQ065 Product Name: AFQ056 Product Code: AFQ065	Novartis Pharma Sevices AG	NULL	Not Recruiting			Female: yes Male: yes	244		France;Canada;Finland;Australia;Germany;Italy;Japan
824	NCT01173731 (ClinicalTrials.gov)	October 2010	28/7/2010	Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	Parkinson Disease;Dyskinesia, Drug-Induced;Levodopa	Drug: AFQ056	Novartis Pharmaceuticals	NULL	Completed	N/A	N/A	All	66	Phase 2	United States;Australia;Canada;France;Germany;Italy;Finland;Spain
825	EUCTR2010-019418-25-FR (EUCTR)	29/09/2010	15/07/2010	An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias	An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias	Moderate to severe levodopa induced dyskinesia in patients with Parkinson's disease MedDRA version: 12.1;Level: LLT;Classification code 10013916;Term: Dyskinesia	Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	244		France;Finland;Germany;Italy
826	EUCTR2009-017238-39-DE (EUCTR)	16/09/2010	28/07/2010	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson’s Disease	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson’s Disease	Idiopathic Parkinson’s Disease (paralysis agitans) MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders	Product Name: IPX066 Product Code: IPX066-95 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-145 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-195 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-245 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA	Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)	NULL	Not Recruiting			Female: yes Male: yes	96	Phase 3	France;Belgium;Germany;Italy
827	EUCTR2009-017238-39-FR (EUCTR)	15/09/2010	09/07/2010	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease	Idiopathic Parkinson’s Disease (paralysis agitans) MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: IPX066 Product Code: IPX066-95 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-145 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-195 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-245 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA	Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)	NULL	Not Recruiting			Female: yes Male: yes	56	Phase 3	France;Belgium;Germany;Italy
828	EUCTR2010-019418-25-FI (EUCTR)	08/09/2010	21/07/2010	An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias	An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias	Moderate to severe levodopa induced dyskinesia in patients with Parkinson's disease MedDRA version: 12.1;Level: LLT;Classification code 10013916;Term: Dyskinesia	Product Name: AFQ056 Product Code: AFQ065 Product Name: AFQ056 Product Code: AFQ065 Product Name: AFQ056 Product Code: AFQ065	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	244		France;Finland;Germany;Italy
829	NCT01211587 (ClinicalTrials.gov)	September 2010	28/9/2010	A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease	A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment	Parkinson's Disease With Cognitive Impairments	Drug: safinamide;Drug: placebo	Newron	NULL	Completed	45 Years	80 Years	Both	103	Phase 2	United States;Spain
830	EUCTR2009-017238-39-BE (EUCTR)	27/08/2010	14/07/2010	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease	Idiopathic Parkinson’s Disease (paralysis agitans) MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: IPX066 Product Code: IPX066-95 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-145 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-195 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-245 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Trade Name: Nacom 100 INN or Proposed INN: CARBIDOPA	Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)	NULL	Not Recruiting			Female: yes Male: yes	56	Phase 3	France;Belgium;Germany;Italy
831	EUCTR2009-017253-35-GB (EUCTR)	20/08/2010	06/08/2010	Long-term study of patients who received ProSavin in the PS1/001/07 clinical trial.	A multicentre, open-label extension study to determine the long term safety, tolerability and efficacy of ProSavin® in patients with bilateral, idiopathic Parkinson’s disease	Patients with bilateral, idiopathic Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ProSavin INN or Proposed INN: ProSavin	Oxford BioMedica (UK) Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	27		United Kingdom
832	EUCTR2009-015161-31-FI (EUCTR)	17/08/2010	23/06/2010	A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)	A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P04938)	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Preladenant Product Code: SCH 420814 INN or Proposed INN: Preladenant Trade Name: Azilect Product Name: Azilect INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE Trade Name: Azilect Product Name: Azilect Product Code: N04BD02 INN or Proposed INN: Rasagiline mesylate Other descriptive name: RASAGILINE MESYLATE	Schering-Plough Research Institute, a division of Schering Corporation	NULL	Not Recruiting			Female: yes Male: yes	750	Phase 3	United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden
833	EUCTR2010-020769-25-FR (EUCTR)	10/08/2010	09/07/2010	Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médical	Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médical	Parkinson's disease MedDRA version: 12.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated	Trade Name: DUODOPA INN or Proposed INN: LEVODOPA/CARBIDOPA INN or Proposed INN: LEVODOPA/BENZERASIDE INN or Proposed INN: PERGOLIDE INN or Proposed INN: LISURIDE INN or Proposed INN: BROMOCRIPTINE INN or Proposed INN: ROPINIROLE INN or Proposed INN: PRAMIPEXOLE INN or Proposed INN: IPRONIAZID Other descriptive name: MOCLOBEMIDE INN or Proposed INN: AMANTADINE INN or Proposed INN: CLOZAPINE INN or Proposed INN: SELEGILINE INN or Proposed INN: RASAGILINE INN or Proposed INN: ENTACAPONE INN or Proposed INN: TOLCAPONE	CHU de Poitiers	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France
834	NCT01191944 (ClinicalTrials.gov)	August 2010	30/8/2010	Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients	A Double-blind, Double-dummy, Randomised, Parallel-group Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release Versus Pramipexole Immediate Release Administered Orally for 18 Weeks in Chinese Parkinson's Disease (PD) Patients Who Can be Concomitantly Treated With Levodopa	Parkinson Disease	Drug: pramipexole immediate release tablet;Drug: pramipexole extended release tablet	Boehringer Ingelheim	NULL	Completed	30 Years	N/A	All	475	Phase 3	China
835	NCT01824056 (ClinicalTrials.gov)	August 2010	12/3/2013	The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography	The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography With Vesicular Monoamine Transporter Ligand (18F-DTBZ)	Parkinson's Disease	Drug: 18F-FDG	Chang Gung Memorial Hospital	National Science Council, Taiwan	Completed	20 Years	80 Years	Both	120	Phase 2	Taiwan
836	NCT01155466 (ClinicalTrials.gov)	July 14, 2010	30/6/2010	A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)	A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3;Protocol No. P04938)	Parkinson Disease	Drug: Preladenant 2 mg tablet;Drug: Preladenant 5 mg tablet;Drug: Preladenant 10 mg tablet;Drug: Placebo to Preladenant Tablet;Drug: Rasagiline 1 mg capsule;Drug: Placebo to Rasagiline capsule	Merck Sharp & Dohme Corp.	NULL	Completed	30 Years	85 Years	All	778	Phase 3	Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
837	EUCTR2010-018650-12-FR (EUCTR)	13/07/2010	06/05/2010	Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien - DOULOX	Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien - DOULOX	maladie de Parkinson MedDRA version: 12.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Trade Name: CYMBALTA Product Name: duloxetine Trade Name: APOKINON Product Name: apomorphine Trade Name: MODOPAR Product Name: levodopa Trade Name: MOTILIUM Product Name: dompéridone	CHU de Toulouse	NULL	Not Recruiting			Female: yes Male: yes		Phase 3	France
838	NCT01174004 (ClinicalTrials.gov)	July 2010	30/7/2010	A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis	A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease	Parkinson's Disease Psychosis	Drug: pimavanserin tartrate;Drug: placebo	ACADIA Pharmaceuticals Inc.	NULL	Completed	40 Years	N/A	All	199	Phase 3	United States;Canada
839	NCT01149811 (ClinicalTrials.gov)	July 2010	10/6/2010	A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease	A Randomized, Double-Blind, Crossover Study Comparing the Safety and Tolerability of Two Dose Regimens of Oromucosal Fipamezole ODT in Adult Patients With Parkinson's Disease Who Are Receiving Levodopa	Parkinson's Disease	Drug: Fipamezole ODT;Drug: Fipamezole ODT Cohort 2	Valeant Pharmaceuticals International, Inc.	NULL	Completed	30 Years	75 Years	Both	27		United States
840	NCT01435915 (ClinicalTrials.gov)	June 28, 2010	1/9/2011	Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects	A Single Dose and Repeat Dose Study to Investigate the Pharmacokinetics of Ropinirole After Single and Multiple Doses of a PR-formulation in Chinese Healthy Male and Female Subjects	Parkinson Disease	Drug: Ropinirole	GlaxoSmithKline	NULL	Completed	18 Years	45 Years	All	24	Phase 1	China
841	EUCTR2009-017238-39-IT (EUCTR)	21/06/2010	13/07/2010	A Study to Compare IPX066 and Carbidopa / Levodopa / Entacapone (CLE) in Advanced Parkinson’s Disease - ND	A Study to Compare IPX066 and Carbidopa / Levodopa / Entacapone (CLE) in Advanced Parkinson’s Disease - ND	Idiopathic Parkinson’s Disease (paralysis agitans) MedDRA version: 9.1;Level: LLT;Classification code 10061536	Product Name: IPX066 Product Code: IPX066-95 INN or Proposed INN: CARBIDOPA LEVODOPA Product Name: IPX066 Product Code: IPX066-145 INN or Proposed INN: CARBIDOPA LEVODOPA Product Name: IPX066 Product Code: IPX066-195 INN or Proposed INN: CARBIDOPA LEVODOPA Product Name: IPX066 Product Code: IPX066-245 INN or Proposed INN: CARBIDOPA LEVODOPA Trade Name: NACOM 100 INN or Proposed INN: Levodopa and decarboxylase inhibitor Trade Name: COMTAN INN or Proposed INN: Entacapone	IMPAX LABORATORIES, INC.	NULL	Not Recruiting			Female: yes Male: yes	56		Germany;France;Italy
842	EUCTR2009-013886-24-SE (EUCTR)	08/06/2010	21/12/2009	Efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease	A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease - HARPS-2	Excessive daytime sleepiness in Parkinson’s Disease MedDRA version: 14.1;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1;Level: LLT;Classification code 10015595;Term: Excessive daytime sleepiness;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Pitolisant Product Code: BF2.649 INN or Proposed INN: Pitolisant Product Name: Pitolisant Product Code: BF2.649 INN or Proposed INN: Pitolisant Product Name: Pitolisant Product Code: BF2.649 INN or Proposed INN: Pitolisant	BIOPROJET	NULL	Not Recruiting			Female: yes Male: yes	246		Czech Republic;Germany;Sweden
843	NCT01141023 (ClinicalTrials.gov)	June 2010	8/6/2010	Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression	The Parkinson's Progression Markers Initiative (PPMI)	Parkinson Disease	Drug: DaTscan	Ken Marek, MD	Institute for Neurodegenerative Disorders	Active, not recruiting	30 Years	N/A	All	1100	Phase 2	United States;Australia;Austria;France;Germany;Greece;Israel;Italy;Norway;Spain;United Kingdom
844	NCT01140841 (ClinicalTrials.gov)	June 2010	8/6/2010	A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa	A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose-Escalation Study of Safety and Tolerability of Oromucosal Fipamezole ODT in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa	Parkinson's Disease	Drug: Fipamezole ODT;Drug: Placebo	Valeant Pharmaceuticals International, Inc.	NULL	Completed	30 Years	75 Years	Both	40		United States
845	NCT01176240 (ClinicalTrials.gov)	June 2010	30/7/2010	A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease	A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease	Orthostatic Hypotension;Parkinson's Disease	Drug: Droxidopa;Other: Placebo	Chelsea Therapeutics	NULL	Completed	18 Years	N/A	All	225	Phase 3	United States
846	EUCTR2009-016143-19-AT (EUCTR)	26/05/2010	12/05/2010	Validierung von Dyskinesie-Rating-Skalen anhand des therapeutischen Effektes von Amantadin - eine placebokontrollierte Studie	Validierung von Dyskinesie-Rating-Skalen anhand des therapeutischen Effektes von Amantadin - eine placebokontrollierte Studie	Parkinson's disease	Trade Name: Amantadin-ratiopharm 100mg Other descriptive name: AMANTADINE HYDROCHLORIDE	CHU de Toulouse	NULL	Not Recruiting			Female: yes Male: yes	66		France;Austria
847	EUCTR2010-019396-29-IT (EUCTR)	18/05/2010	05/03/2012	Levodopa and Pramipexole dministration modalities in patients affected by parkinson desease.	Levodopa Administration Modalities and Pramipexole in Parkinson's Disease (LAMP-PD study) A multicenter, randomized, four parallel groups, active-controlled, open-label study to evaluate the risk of dyskinesia in early PD. - LAMP-PD	Patients with idiopathic Parkinson's Disease.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	INN or Proposed INN: Levodopa and decarboxylase inhibitor Trade Name: COMTAN INN or Proposed INN: Entacapone INN or Proposed INN: Levodopa and decarboxylase inhibitor Trade Name: STALEVO*100CPR 50/12,5/200MG INN or Proposed INN: Levodopa, decarboxylase inhibitor and COMT inhibitor Trade Name: STALEVO*100CPR 100/25/200MG INN or Proposed INN: Levodopa, decarboxylase inhibitor and COMT inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor	AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
848	NCT01532115 (ClinicalTrials.gov)	May 2010	23/1/2012	Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women	A Randomized, Double-blind, Placebo-controlled and Open-label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women	Parkinson Disease	Drug: BIA 9-1067;Drug: Placebo;Drug: moxifloxacin	Bial - Portela C S.A.	NULL	Completed	18 Years	55 Years	Both	64	Phase 1	France
849	NCT01130493 (ClinicalTrials.gov)	May 2010	24/5/2010	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease	Parkinson's Disease	Drug: IPX066;Drug: CLE	Impax Laboratories, LLC	NULL	Completed	30 Years	N/A	All	110	Phase 3	United States;France;Germany;Italy
850	NCT01113320 (ClinicalTrials.gov)	April 2010	8/4/2010	Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects	A Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose Escalation Trial to Explore the Potential Antidyskinetic Properties of Safinamide in Patients With Parkinson's Disease Suffering From Levodopa Induced Dyskinesias	Parkinson's Disease	Drug: Placebo;Drug: Safinamide	Newron	NULL	Completed	30 Years	N/A	Both	26	Phase 2	Austria;Canada;France;Germany;South Africa
851	NCT00988117 (ClinicalTrials.gov)	April 2010	29/9/2009	The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems	The Effects of the Rivastigmine Patch on Attention and Behavior in Parkinson's Disease With Dementia (PDD)	Parkinsons Disease With Dementia;Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems	Drug: Rivastigmine Patch 9.5 cm2	University of California, San Francisco	Novartis	Completed	55 Years	N/A	All	15	Phase 4	United States
852	NCT01103011 (ClinicalTrials.gov)	April 2010	12/4/2010	Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611	A Phase I, Single Center, Blinded, Controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Repeated Administration of Oral Levodopa/Carbidopa and Continuously Delivered ND0611	Parkinson's Disease	Drug: ND0611	NeuroDerm Ltd.	NULL	Completed	18 Years	50 Years	Male	8	Phase 1	Israel
853	EUCTR2009-017174-20-DE (EUCTR)	15/03/2010	07/01/2010	A trial to determine if safinamide can attenuate levodopa induced dyskinesia in Parkinson’s disease.	A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering from levodopa induced dyskinesias. - LID study	Idiopathic Parkinson's disease MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015E, EMD 1195686, MSC2191632B INN or Proposed INN: safinamide Other descriptive name: (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	24		France;Canada;Austria;South Africa;Germany
854	EUCTR2009-013886-24-DE (EUCTR)	03/03/2010	29/10/2009	A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease - HARPS-2	A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease - HARPS-2	Excessive daytime sleepiness in Parkinson’s Disease MedDRA version: 12.0;Level: LLT;Classification code 10015595;Term: Excessive daytime sleepiness MedDRA version: 12.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism	Product Name: Pitolisant Product Code: BF2.649 INN or Proposed INN: Pitolisant Product Name: Pitolisant Product Code: BF2.649 INN or Proposed INN: Pitolisant Product Name: Pitolisant Product Code: BF2.649 INN or Proposed INN: Pitolisant	BIOPROJET	NULL	Not Recruiting			Female: yes Male: yes	246		Czech Republic;Germany;Sweden
855	NCT01092065 (ClinicalTrials.gov)	March 2010	22/3/2010	Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia	A 6-week, Double-blind, Placebo-controlled, Randomized, Multicenter Study to Explore the Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With OFF Time and Moderate-severe L-dopa Induced Dyskinesia	Parkinson's Disease	Drug: AFQ056 with L-dopa;Drug: Placebo	Novartis	NULL	Completed	30 Years	80 Years	All	23	Phase 2	United States
856	NCT01066442 (ClinicalTrials.gov)	March 2010	9/2/2010	Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease	A Randomised, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38 Week Open Label Extension Phase	Parkinson's Disease	Drug: BF2.649 (Pitolisant)	Bioprojet	NULL	Completed	30 Years	80 Years	Both	273	Phase 3	Germany
857	NCT01055379 (ClinicalTrials.gov)	March 2010	22/1/2010	Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn	A Randomised, Double-blind, Placebo-controlled Study to Evaluate if Rasagiline Can Improve Depressive Symptoms and Cognitive Function in Non-demented, Idiopathic Parkinson's Disease Patients: ACCORDO Study	Depressive Symptoms;Parkinson's Disease	Drug: Rasagiline;Drug: Placebo	Lundbeck Italia S.p.A.	Teva Pharmaceutical Industries	Completed	40 Years	80 Years	All	121	Phase 4	Italy
858	NCT01503944 (ClinicalTrials.gov)	March 2010	14/7/2010	A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)	Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers	Dementia With Lewy Bodies;Alzheimer's Disease;Parkinson's Disease	Drug: 18F-AV-133;Drug: 18F-AV-45	Avid Radiopharmaceuticals	NULL	Completed	50 Years	N/A	Both	30	Phase 1/Phase 2	United States
859	EUCTR2009-017174-20-FR (EUCTR)	24/02/2010	18/01/2010	A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering from levodopa induced dyskinesias.	A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering from levodopa induced dyskinesias.	Idiopathic Parkinson's disease MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	36	Phase 2	France;Austria;Germany
860	EUCTR2007-002963-28-DE (EUCTR)	17/02/2010	22/12/2009	A trial to determine the efficacy and safety of a low (50mg/day) and high dose (100mg / day) of safinamide, as add-on therapy, in patients with early Parkinson´s Disease treated with a sigle dopamin antagonist	A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist. - Safinamide in early IPD, as add-on to dopamine agonist	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Newron Pharmaceuticals SpA	NULL	Not Recruiting			Female: yes Male: yes	839	Phase 3	Portugal;United States;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;Bulgaria;South Africa;Germany
861	EUCTR2009-014688-37-PL (EUCTR)	09/02/2010	20/01/2010	A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson’s Disease - N/A	A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson’s Disease - N/A	Advanced Parkinson’s Disease subjects with motor fluctuations MedDRA version: 13.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders	Product Name: IPX066 Product Code: IPX066-95 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Trade Name: SINEMET®-Plus Tablets Product Name: IR CD-LD INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-145 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-195 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-245 INN or Proposed INN: CARBIDOPA	Impax Laboratories, Inc.	NULL	Not Recruiting			Female: yes Male: yes	350		Germany;France;Spain;Poland
862	EUCTR2009-016360-37-SE (EUCTR)	06/02/2010	04/12/2009	TREATMENT OF DYSKINESIAS IN PARKINSON’S DISEASE WITH OSU6162 – A PILOT STUDY	TREATMENT OF DYSKINESIAS IN PARKINSON’S DISEASE WITH OSU6162 – A PILOT STUDY	Parkinsons disease is complicated by dyskinesias and dystonia. Due stabilizing properties, we believe (-)-OSU6162 may alleviate dyskinesias, without causing parkinsonism. Aim: To evaluate in a double-blind cross over pilot study whether OSU6162 attenuates dyskinesias without worsening parkinsonism in PD patients with motor complications using clinical examination and patient diaries.	Product Name: not available Product Code: OSU 6162 similar to (-)-OSU 6162 INN or Proposed INN: not available	Björn Holmberg	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 1;Phase 2	Sweden
863	EUCTR2008-005492-94-BE (EUCTR)	25/01/2010	12/08/2009	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	1285	Phase 3	Portugal;Estonia;Slovakia;Finland;Spain;Austria;Italy;United Kingdom;France;Hungary;Czech Republic;Belgium;Bulgaria;Germany;Netherlands
864	EUCTR2008-001329-33-CZ (EUCTR)	18/01/2010	03/12/2009	Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease	Open-Label Continuation Treatment Study With Levodopa – Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies.	Treatment with Levodopa – Carbidopa Intestinal Gel in subjects with advanced Parkinson's disease and severe motor-fluctuations who have exhibited a persistent and positive effect to treatment in previous studies MedDRA version: 16.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel INN or Proposed INN: levodopa Other descriptive name: Ph. Eur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid INN or Proposed INN: carbidopa monohydrate Other descriptive name: Ph. Eur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid	AbbVie Inc	NULL	Not Recruiting			Female: yes Male: yes	275	Phase 3	Portugal;Czech Republic;Poland;Thailand;Australia;Russian Federation;Israel;United Kingdom;New Zealand;Italy
865	EUCTR2009-017416-33-DE (EUCTR)	18/01/2010	21/12/2009	Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol.	Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol.	Male and female patients with Parkinson´s disease meeting UKPDS criteria MedDRA version: 12.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Trade Name: Tasmar Product Name: Tolcapon Product Code: TO INN or Proposed INN: TOLCAPONE Trade Name: Comtess Product Name: Entacapon Product Code: EN INN or Proposed INN: ENTACAPONE Trade Name: Isicom Product Name: Levodopa/Carbidopa Product Code: LD/CD INN or Proposed INN: LEVODOPA Other descriptive name: CARBIDOPA MONOHYDRATE Trade Name: Tasmar Product Name: Tolcapon Product Code: TO INN or Proposed INN: TOLCAPONE Trade Name: Comtess Product Name: Entacapon Product Code: EN INN or Proposed INN: ENTACAPONE Trade Name: Isicom Product Name: Levodopa/Carbidopa Product Code: LD/CD INN or Proposed INN: LEVODOPA Other descriptive name: CARBIDOPA MONOHYDRATE	Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University	NULL	Not Recruiting			Female: yes Male: yes			Germany
866	EUCTR2008-005492-94-NL (EUCTR)	18/01/2010	25/09/2009	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Idiopathic Parkinson's Disease MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	1285	Phase 3	Portugal;Estonia;Slovakia;Finland;Spain;Austria;Italy;United Kingdom;France;Hungary;Czech Republic;Belgium;Bulgaria;Netherlands;Germany
867	NCT01007864 (ClinicalTrials.gov)	January 2010	3/11/2009	Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists	Influence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine Agonists	Idiopathic Parkinson's Disease	Drug: piribedil;Drug: pramipexole or ropinirole	Desitin Arzneimittel GmbH	FGK Clinical Research GmbH	Completed	35 Years	80 Years	Both	80	Phase 3	Germany
868	EUCTR2009-014688-37-ES (EUCTR)	30/12/2009	21/10/2009	A Study To Evaluate The Safety And Efficacy Of IPX066 in Advanced Parkinsons DiseaseEstudio para evaluar la seguridad y eficacia de IPX066 en la enfermedad de Parkinson avanzada.	A Study To Evaluate The Safety And Efficacy Of IPX066 in Advanced Parkinsons DiseaseEstudio para evaluar la seguridad y eficacia de IPX066 en la enfermedad de Parkinson avanzada.	Advanced Parkinsons Disease subjects with motor fluctuationsEnfermedad de Parkinson avanzada en sujetos con fluctuaciones motoras MedDRA version: 12.0;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: IPX066 Product Code: IPX066-95 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Trade Name: Sinemet-Plus Tablets Product Name: IR CD-LD INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-145 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-195 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-245 INN or Proposed INN: CARBIDOPA	Impax Laboratories, Inc.	NULL	Not Recruiting			Female: yes Male: yes	350		Germany;France;Spain;Poland
869	EUCTR2009-011541-24-NL (EUCTR)	30/12/2009	29/05/2009	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up	Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	700		Portugal;France;Hungary;Spain;Germany;Netherlands;Italy;United Kingdom
870	EUCTR2009-014688-37-DE (EUCTR)	15/12/2009	07/10/2009	A Study To Evaluate The Safety And Efficacy Of IPX066In Advanced Parkinson’s Disease	A Study To Evaluate The Safety And Efficacy Of IPX066In Advanced Parkinson’s Disease	Advanced Parkinson’s Disease subjects with motor fluctuations MedDRA version: 12.0;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: IPX066 Product Code: IPX066-95 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Trade Name: SINEMET®-Plus Tablets Product Name: IR CD-LD INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-145 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-195 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-245 INN or Proposed INN: CARBIDOPA	Impax Laboratories, Inc.	NULL	Not Recruiting			Female: yes Male: yes	350		Germany;France;Spain;Poland
871	EUCTR2008-005492-94-GB (EUCTR)	09/12/2009	01/09/2009	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	1285	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Portugal;Estonia;Slovakia;Finland;Spain;Austria;United Kingdom;Italy;France;Hungary;Czech Republic;Belgium;Bulgaria;Germany;Netherlands
872	EUCTR2009-012897-12-RO (EUCTR)	08/12/2009	30/03/2015	A double-blind, randomised, placebo-controlled study to investigate the tolerability and the effect of three multiple-dose regimens of BIA 9-1067 on the levodopa pharmacokinetics, catechol-0-methyltransferase activity and motor response in parkinson´s disease patients treated with levodopa/dopa-decarboxylaseinhibitor	A double-blind, randomised, placebo-controlled study to investigate the tolerability and the effect of three multiple-dose regimens of BIA 9-1067 on the levodopa pharmacokinetics, catechol-0-methyltransferase activity and motor response in parkinson´s disease patients treated with levodopa/dopa-decarboxylaseinhibitor	Parkinson’s Disease MedDRA version: 17.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852	Product Name: BIA 9-1067 Product Code: BIA 9-1067 Product Name: BIA 9-1067 Product Code: BIA 9-1067 Trade Name: SINEMET 25/100 INN or Proposed INN: LEVODOPA Other descriptive name: ANHYDROUS CARBIDOPA Trade Name: Restex Tabletten INN or Proposed INN: LEVODOPA INN or Proposed INN: BENSERAZIDE HYDROCHLORIDE	BIAL-Portela & Ca, SA	NULL	Not Recruiting			Female: yes Male: yes	32		Romania
873	EUCTR2009-014688-37-FR (EUCTR)	04/12/2009	09/10/2009	A Study To Evaluate The Safety And Efficacy Of IPX066In Advanced Parkinson’s Disease	A Study To Evaluate The Safety And Efficacy Of IPX066In Advanced Parkinson’s Disease	Advanced Parkinson’s Disease subjects with motor fluctuations MedDRA version: 12.0;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: IPX066 Product Code: IPX066-95 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Trade Name: SINEMET®-Plus Tablets Product Name: IR CD-LD INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-145 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA Product Name: IPX066 Product Code: IPX066-195 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODOPA	Impax Laboratories, Inc.	NULL	Not Recruiting			Female: yes Male: yes	350	Phase 3	France;Poland;Spain;Germany
874	EUCTR2009-012419-16-DE (EUCTR)	03/12/2009	20/10/2009	Influence of the Non-Ergot Dopamine agonist Piribedil on vigilance and cognitive function in patients with Parkinson's disease compared to other oral Non-Ergot Dopamine agonists - PIVICOG-PD	Influence of the Non-Ergot Dopamine agonist Piribedil on vigilance and cognitive function in patients with Parkinson's disease compared to other oral Non-Ergot Dopamine agonists - PIVICOG-PD	idiopathic Parkinson's disease MedDRA version: 12.0;Level: PT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Clarium 50 mg Retardtabletten INN or Proposed INN: piribedil	Desitin Arzneimittel GmbH	NULL	Not Recruiting			Female: yes Male: yes			Germany
875	NCT01049984 (ClinicalTrials.gov)	December 2009	13/1/2010	Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease	A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease	Parkinson's Disease	Drug: Rasagiline;Drug: Placebo	Teva Neuroscience, Inc.	H. Lundbeck A/S	Completed	30 Years	N/A	All	328	Phase 4	United States
876	NCT01036139 (ClinicalTrials.gov)	December 2009	11/12/2009	Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease	A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase	Parkinson's Disease	Drug: BF2.649 (pitolisant)	Bioprojet	NULL	Completed	30 Years	80 Years	Both	268	Phase 3	France
877	NCT00660387 (ClinicalTrials.gov)	December 2009	15/4/2008	Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects	A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations	Advanced Parkinson's Disease	Drug: Levodopa carbidopa intestinal gel (LCIG);Drug: Placebo Gel;Drug: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets;Drug: Placebo (PBO) oral capsules;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube	AbbVie (prior sponsor, Abbott)	Quintiles, Inc.	Completed	30 Years	N/A	All	35	Phase 3	United States;New Zealand
878	NCT01032486 (ClinicalTrials.gov)	December 2009	11/12/2009	Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease	An Open-Label, Multi-Center, Single Arm Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease Subjects	Parkinson's Disease	Drug: Rasagiline mesylate	Teva Pharmaceutical Industries	NULL	Completed	N/A	N/A	Both	120		Canada
879	EUCTR2009-013886-24-CZ (EUCTR)	26/11/2009	18/11/2009		A Randomized, Multicenter, 12-Week, Double-blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson Disease, followed by a 9-months Open-Label Extension Phase - HARPS-2	Excessive daytime sleepiness in Parkinson’s Disease MedDRA version: 12.0;Level: LLT;Classification code 10015595;Term: Excessive daytime sleepiness MedDRA version: 12.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism	Product Name: Pitolisant Product Code: BF2.649 INN or Proposed INN: Pitolisant Product Name: Pitolisant Product Code: BF2.649 INN or Proposed INN: Pitolisant Product Name: Pitolisant Product Code: BF2.649 INN or Proposed INN: Pitolisant	BIOPROJET	NULL	Not Recruiting			Female: yes Male: yes	246		Germany;Czech Republic;Sweden
880	EUCTR2008-005492-94-FR (EUCTR)	25/11/2009	01/10/2009	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	1285	Phase 3	Portugal;Estonia;Slovakia;Finland;Spain;Austria;Italy;United Kingdom;France;Hungary;Czech Republic;Belgium;Bulgaria;Germany;Netherlands
881	EUCTR2008-005492-94-ES (EUCTR)	23/11/2009	18/09/2009	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients.Estudio abierto para determinar la seguridad a largo plazo de la Safinamida en pacientes con enfermedad de Parkinson	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients.Estudio abierto para determinar la seguridad a largo plazo de la Safinamida en pacientes con enfermedad de Parkinson	Idiopathic Parkinson's DiseaseEnfermedad de Parkinson MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	1285	Phase 3	Portugal;Estonia;Slovakia;Finland;Spain;Austria;Italy;United Kingdom;France;Hungary;Czech Republic;Belgium;Bulgaria;Germany;Netherlands
882	EUCTR2009-013885-14-FR (EUCTR)	23/11/2009	25/09/2009	A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease followed by a 38-Week open-label extension phase	A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease followed by a 38-Week open-label extension phase	Excessive daytime sleepiness in Parkinson’s Disease MedDRA version: 12.0;Level: LLT;Classification code 10015595;Term: Excessive daytime sleepiness MedDRA version: 12.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism	Product Name: Pitolisant Product Code: BF2.649 INN or Proposed INN: Pitolisant	BIOPROJET	NULL	Not Recruiting			Female: yes Male: yes	246	Phase 3	France;Spain
883	NCT00660673 (ClinicalTrials.gov)	November 13, 2009	15/4/2008	Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD	Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies	Advanced Parkinson's Disease	Drug: Levodopa-carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump	AbbVie	IQVIA, formerly Quintiles	Completed	30 Years	99 Years	All	262	Phase 3	United States;Australia;Canada;Czechia;Israel;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;Czech Republic
884	EUCTR2009-013885-14-ES (EUCTR)	12/11/2009	23/09/2009	A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week open-label extension phase.Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de 12 semanas de duración para evaluar la eficacia y seguridad de BF2.649 en la somnolencia diurna excesiva de la enfermedad de Parkinson, seguido de una fase de extensión abierta de 38 semanas.	A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week open-label extension phase.Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de 12 semanas de duración para evaluar la eficacia y seguridad de BF2.649 en la somnolencia diurna excesiva de la enfermedad de Parkinson, seguido de una fase de extensión abierta de 38 semanas.	Excessive daytime sleepiness in Parkinson?s DiseaseSomnolencia diurna excesiva en la enfermedad de Parkinson. MedDRA version: 12.0;Level: LLT;Classification code 10015595;Term: Excessive daytime sleepiness MedDRA version: 12.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism	Product Name: Pitolisant Product Code: BF2.649 INN or Proposed INN: Pitolisant	BIOPROJET	NULL	Not Recruiting			Female: yes Male: yes	246	Phase 3	France;Spain
885	NCT01519284 (ClinicalTrials.gov)	November 2009	23/1/2012	Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic	A Double-blind, Randomised, Placebo- and Active-controlled Multiple-dose Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetics Following a Levodopa/Carbidopa 100/25 mg Single-dose in Healthy Subjects	Parkinson Disease	Drug: BIA 9-1067 5 mg;Drug: Entacapone;Drug: Placebo;Drug: levodopa/carbidopa;Drug: BIA 9-1067 15 mg;Drug: BIA 9-1067 30 mg	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	82	Phase 1	Portugal
886	NCT01023282 (ClinicalTrials.gov)	November 2009	1/12/2009	Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients	Randomised, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ACR325 in Parkinson's Disease Patients, With Evaluation of the Effect on Levodopa Induced Dyskinesias as a Secondary Measure	Parkinson's Disease;Tolerability	Drug: ACR325;Drug: Placebo	NeuroSearch A/S	NULL	Completed	30 Years	75 Years	Both	22	Phase 1	Germany
887	EUCTR2008-005492-94-HU (EUCTR)	27/10/2009	22/09/2009	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	1285		Portugal;Estonia;Spain;Austria;Italy;United Kingdom;France;Hungary;Czech Republic;Belgium;Bulgaria;Germany;Netherlands
888	EUCTR2008-004146-88-PL (EUCTR)	19/10/2009	31/08/2009	A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918	A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono SA - Geneva	NULL	Not Recruiting			Female: yes Male: yes	498	Phase 3	Portugal;Czech Republic;Finland;Spain;Poland;Bulgaria;Germany;Italy
889	EUCTR2008-005492-94-SK (EUCTR)	14/10/2009	22/10/2009	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	1285	Phase 3	Portugal;Estonia;Slovakia;Finland;Spain;Austria;Italy;United Kingdom;France;Hungary;Czech Republic;Belgium;Bulgaria;Germany;Netherlands
890	EUCTR2009-011541-24-GB (EUCTR)	09/10/2009	29/05/2009	A trial to follow-up subjects with Parkinson's disease who participated to the ADAGIO study in order to study the long-term effects of the drug rasagiline	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up	Parkinson's Disease MedDRA version: 13.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	700	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Portugal;United States;Spain;Israel;United Kingdom;Italy;France;Hungary;Canada;Argentina;Romania;Germany;Netherlands
891	EUCTR2008-005492-94-AT (EUCTR)	02/10/2009	03/09/2009	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Idiopathic Parkinson's Disease MedDRA version: 15.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Newron Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	1285		United States;Portugal;Taiwan;Estonia;Slovakia;Thailand;Spain;Chile;Colombia;Switzerland;Italy;India;France;Malaysia;Peru;South Africa;Netherlands;Korea, Republic of;Finland;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Brazil;Belgium;Poland;Romania;Croatia;Bulgaria;Germany;New Zealand
892	EUCTR2008-001329-33-PT (EUCTR)	02/10/2009	19/08/2009	Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease	Open-Label Continuation Treatment Study With Levodopa – Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies.	Treatment with Levodopa – Carbidopa Intestinal Gel in subjects with advanced Parkinson's disease and severe motor-fluctuations who have exhibited a persistent and positive effect to treatment in previous studies MedDRA version: 16.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel INN or Proposed INN: levodopa Other descriptive name: Ph. Eur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid INN or Proposed INN: carbidopa monohydrate Other descriptive name: Ph. Eur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid	AbbVie Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	275		Portugal;Czech Republic;Thailand;Poland;Australia;Israel;Russian Federation;Italy;United Kingdom;New Zealand
893	EUCTR2008-005492-94-EE (EUCTR)	01/10/2009	15/09/2009	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Newron Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	1285		United States;Portugal;Taiwan;Estonia;Slovakia;Thailand;Spain;Chile;Colombia;Switzerland;Italy;India;France;Malaysia;Peru;South Africa;Netherlands;Korea, Republic of;Finland;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Brazil;Belgium;Poland;Romania;Croatia;Bulgaria;Germany;New Zealand
894	NCT00957918 (ClinicalTrials.gov)	October 2009	11/8/2009	Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy	Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy	Parkinson's Disease	Drug: nicotine;Other: placebo comparator	Neuraltus Pharmaceuticals, Inc.	NULL	Completed	30 Years	83 Years	Both	65	Phase 1/Phase 2	United States
895	NCT01108029 (ClinicalTrials.gov)	October 2009	20/7/2009	Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease	Study of Memantine to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Monocentric Trial	Parkinson's Disease;Gait Disorders, Neurologic	Drug: memantine;Drug: placebo	University Hospital, Lille	NULL	Completed	30 Years	80 Years	Both	28	Phase 4	France
896	NCT00914095 (ClinicalTrials.gov)	October 2009	2/6/2009	Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)	Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentric Trial	Parkinson's Disease;Gait Disorders, Neurologic;Dementia	Drug: methylphenidate;Drug: placebo	University Hospital, Lille	NULL	Completed	30 Years	80 Years	Both	69	Phase 4	France
897	NCT01028586 (ClinicalTrials.gov)	October 2009	7/12/2009	MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)	A Phase III, Double-blind, Placebo-controlled Extension Trial to Investigate the Long-term Efficacy and Safety of Low (50 mg/Day) and High (100 mg/Day) Dose Safinamide, as add-on Therapy in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist	Idiopathic Parkinson's Disease	Drug: Safinamide, MAO-B inhibitor;Drug: Placebo	Newron	NULL	Terminated	30 Years	80 Years	Both	507	Phase 3	Switzerland
898	EUCTR2009-011541-24-DE (EUCTR)	22/09/2009	27/07/2009	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up	Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	700		Portugal;France;Hungary;Spain;Netherlands;Germany;Italy;United Kingdom
899	NCT01371682 (ClinicalTrials.gov)	September 18, 2009	10/6/2010	A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda	An Open Label Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets (Ropinirole XL, Marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) Manufactured at Crawley and Aranda	Parkinson Disease	Drug: Ropinirole XL	GlaxoSmithKline	NULL	Completed	18 Years	50 Years	All	50	Phase 1	Belgium
900	EUCTR2009-011541-24-PT (EUCTR)	09/09/2009	29/07/2009	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up	Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	700		France;Portugal;Hungary;Spain;Germany;Netherlands;Italy;United Kingdom
901	NCT00986414 (ClinicalTrials.gov)	September 2009	29/9/2009	Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease	13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease	Parkinson Disease;Dyskinesias	Drug: AFQ056;Drug: Placebo	Novartis	NULL	Completed	30 Years	80 Years	All	260	Phase 2	Australia;Canada;Finland;France;Germany;Italy;Japan;Spain
902	NCT00794313 (ClinicalTrials.gov)	September 2009	19/11/2008	Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease	Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease	Parkinson's Disease	Drug: Amantadine 300 mg;Drug: Topiramate;Drug: Sugar Pill	Oregon Health and Science University	NULL	Terminated	21 Years	N/A	All	3	N/A	United States
903	NCT00986245 (ClinicalTrials.gov)	September 2009	24/9/2009	Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily	An Open-label, Multi-center, Crossover Study to Compare the Effect of Once-daily Ropinirole PR and Twice-daily Ropinirole PR in Patients With Parkinson Disease	Parkinson Disease	Drug: Ropinirole Prolonged release	Seoul National University Hospital	NULL	Completed	30 Years	80 Years	All	82	Phase 4	Korea, Republic of
904	NCT00903838 (ClinicalTrials.gov)	September 2009	14/5/2009	A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.	A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.	Advanced Stage Parkinson's Disease	Drug: pardoprunox;Drug: pramipexole	Abbott Products	NULL	Terminated	30 Years	N/A	Both	37	Phase 2	Germany;Italy;Portugal
905	NCT00974974 (ClinicalTrials.gov)	September 2009	10/9/2009	A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).	A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease	Parkinson's Disease	Drug: IPX066;Drug: IR CD-LD	Impax Laboratories, LLC	NULL	Completed	30 Years	N/A	All	471	Phase 3	United States;Canada;France;Germany;Poland;Romania;Spain;Ukraine
906	NCT00909883 (ClinicalTrials.gov)	September 2009	19/5/2009	Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)	Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)	Parkinson's Disease;Foot Dystonia	Drug: Botulinum Toxin: Xeomin;Drug: Placebo	University Hospital, Clermont-Ferrand	Merz Pharma France	Recruiting	30 Years	75 Years	Both	45	Phase 3	France
907	NCT01026428 (ClinicalTrials.gov)	September 2009	1/12/2009	A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics	A Randomised, Double-blind, Placebo-controlled, Two-period, Two-sequence-crossover Interaction Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease	Idiopathic Parkinson's Disease	Drug: Safinamide + Levodopa;Other: Placebo + Levodopa	Newron	NULL	Completed	30 Years	N/A	Both	24	Phase 1/Phase 2	Italy
908	EUCTR2009-011541-24-ES (EUCTR)	27/08/2009	26/06/2009	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study. Estudio de seguimiento, multicéntrico, abierto diseñado para evaluar los efectos a largo plazo de Rasagilina en pacientes con enfermedad de Parkinson que participaron en el estudio ADAGIO - ADAGIO Follow-Up	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study. Estudio de seguimiento, multicéntrico, abierto diseñado para evaluar los efectos a largo plazo de Rasagilina en pacientes con enfermedad de Parkinson que participaron en el estudio ADAGIO - ADAGIO Follow-Up	Parkinson's Disease Enfermedad de Parkinson MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Trade Name: AZILECT 1 mg comprimidos INN or Proposed INN: RASAGILINA MESILATO Other descriptive name: RASAGILINA MESILATO	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	700	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Portugal;France;Hungary;Spain;Germany;Netherlands;Italy;United Kingdom
909	EUCTR2008-004146-88-BG (EUCTR)	13/08/2009	13/07/2009	A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918	A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918	Idiopathic Parkinson's Disease MedDRA version: 15.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 Product Name: Safinamide Product Code: NW-1015	Newron Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	498	Phase 3	United States;Portugal;Slovakia;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;South Africa;Bulgaria;Germany
910	EUCTR2008-008712-98-DE (EUCTR)	07/08/2009	13/07/2009	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease	moderate to severe levodopa induced dyskinesia in patients with Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10013916;Term: Dyskinesia	Product Name: AFQ056 Product Code: AFQ056 Other descriptive name: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Other descriptive name: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Other descriptive name: AFQ056	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	198		France;Finland;Spain;Germany;Italy
911	EUCTR2008-004146-88-PT (EUCTR)	31/07/2009	14/04/2009	A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson?s disease treated with a stable dose of a single dopamine agonist - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918	A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson?s disease treated with a stable dose of a single dopamine agonist - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono SA - Geneva	NULL	Not Recruiting			Female: yes Male: yes	498	Phase 3	Portugal;Czech Republic;Finland;Poland;Spain;Bulgaria;Germany;Italy
912	EUCTR2009-011541-24-FR (EUCTR)	17/07/2009	19/06/2009	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up	Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	700	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Portugal;France;Hungary;Spain;Germany;Netherlands;Italy;United Kingdom
913	EUCTR2009-011541-24-HU (EUCTR)	10/07/2009	05/06/2009	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up	Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	700	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Portugal;France;Hungary;Spain;Germany;Netherlands;Italy;United Kingdom
914	NCT00909545 (ClinicalTrials.gov)	July 2009	26/5/2009	Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease	A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease	Parkinson Disease	Drug: Isradipine CR 5mg;Drug: Isradipine CR 10mg;Drug: Isradipine CR 20mg;Drug: Placebo	Northwestern University	Michael J. Fox Foundation for Parkinson's Research;Northwestern University Dixon Fund;The Parkinson Study Group	Completed	30 Years	N/A	All	99	Phase 2	United States;Canada
915	NCT00936676 (ClinicalTrials.gov)	July 2009	8/7/2009	ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects	An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study	Parkinson's Disease	Drug: rasagiline mesylate	Teva Pharmaceutical Industries	Teva Neuroscience, Inc.;H. Lundbeck A/S	Completed	N/A	N/A	Both	684	N/A	United States;Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom
916	NCT00955604 (ClinicalTrials.gov)	July 2009	6/8/2009	Azilect + Antidepressant Chart Review	Investigation of the Occurrence of Serotonin Toxicity in Parkinson's Disease (PD) Patients Treated Concomitantly With Rasagiline and Antidepressants, Using Retrospective Chart Review	Serotonin Syndrome	Drug: Group R+AD Rasagiline + Antidepressant;Drug: Group R Rasagiline;Drug: Group AD Anti-PD + Antidepressant	Teva Pharmaceutical Industries	NULL	Completed	N/A	N/A	All	1500	N/A	United States
917	EUCTR2009-011541-24-IT (EUCTR)	24/06/2009	26/06/2009	An open-label, multi-center, follow-up study designed to evaluate the long-term effects of rasagiline in Parkinson?s disease subjects who participated in the ADAGIO study - ADAGIO Follow -Up	An open-label, multi-center, follow-up study designed to evaluate the long-term effects of rasagiline in Parkinson?s disease subjects who participated in the ADAGIO study - ADAGIO Follow -Up	Parkinson?s disease MedDRA version: 12.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Trade Name: AZILECT INN or Proposed INN: Rasagiline	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	700		Portugal;France;Hungary;Spain;Germany;Netherlands;United Kingdom;Italy
918	EUCTR2008-004146-88-ES (EUCTR)	16/06/2009	16/04/2009	A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson?s disease treated with a stable dose of a single dopamine agonist.Ensayo de extensión de fase III, doble ciego y controlado con placebo para investigar la eficacia y la seguridad a largo plazo de la safinamida en dosis bajas (50 mg/día) y altas (100 mg/días), como tratamiento añadido en sujetos con enfermedad de Parkinson idiopática temprana que reciben una dosis estable de un único agonista dopaminérgico - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918	A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson?s disease treated with a stable dose of a single dopamine agonist.Ensayo de extensión de fase III, doble ciego y controlado con placebo para investigar la eficacia y la seguridad a largo plazo de la safinamida en dosis bajas (50 mg/día) y altas (100 mg/días), como tratamiento añadido en sujetos con enfermedad de Parkinson idiopática temprana que reciben una dosis estable de un único agonista dopaminérgico - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918	Idiopathic Parkinson's DiseaseEnfermedad de Parkinson Idiopática MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono SA - Geneva	NULL	Not Recruiting			Female: yes Male: yes	498	Phase 3	Portugal;Czech Republic;Slovakia;Finland;Poland;Spain;Bulgaria;Germany;Italy
919	EUCTR2008-001966-10-EE (EUCTR)	16/06/2009	13/05/2009		A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinson’s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine - Safinamide in PD with motor fluctuations, as add-on to levodopa. Extension to trial 27919	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 Product Name: Safinamide Product Code: NW-1015	Merck Serono SA - Geneva	NULL	Not Recruiting			Female: yes Male: yes	416	Phase 3	Hungary;United Kingdom;Estonia;Austria
920	EUCTR2009-012529-12-FR (EUCTR)	10/06/2009	18/05/2009	A randomised, REQUIP® IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP®CR on abnormal daytime somnolence in patients with Parkinson’s Disease - REQUIP	A randomised, REQUIP® IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP®CR on abnormal daytime somnolence in patients with Parkinson’s Disease - REQUIP	parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Trade Name: REQUIP-LP Product Name: ropinirole Trade Name: REQUIP Product Name: ropinirole	CHU de Toulouse	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	10		France
921	EUCTR2008-008712-98-FR (EUCTR)	10/06/2009	28/04/2009	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease	moderate to severe levodopa induced dyskinesia in patients with Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10013916;Term: Dyskinesia	Product Name: AFQ056 Product Code: AFQ056 Other descriptive name: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Other descriptive name: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Other descriptive name: AFQ056	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	234		France;Finland;Spain;Germany;Italy
922	EUCTR2008-004146-88-CZ (EUCTR)	08/06/2009	07/04/2009	An extension trial to investigate the long-term efficacy and safety of safinamide, as add-on therapy in patients with early Parkinson’s disease treated with a stable dose of a dopamine agonist	A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 Product Name: Safinamide Product Code: NW-1015	Newron Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	498	Phase 3	United States;Portugal;Slovakia;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;South Africa;Bulgaria;Germany
923	EUCTR2009-010193-38-LV (EUCTR)	04/06/2009	24/08/2009	A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease	A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease	Idiopathic Parkinson's disease (paralysis agitans) MedDRA version: 9.1;Level: LLT;Classification code 10034010;Term: Parkinsonism	Product Name: IPX066 Product Code: IPX066-95 INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Product Name: IPX066 Product Code: IPX066-145 INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Product Name: IPX066 Product Code: IPX066-195 INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Product Name: IPX066 Product Code: IPX066-245 INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA	IMPAX Laboratories, Inc.	NULL	Not Recruiting			Female: yes Male: yes	350		Estonia;Latvia;Lithuania
924	EUCTR2009-010193-38-LT (EUCTR)	02/06/2009	26/03/2009	A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease	A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease	Idiopathic Parkinson's disease (paralysis agitans) MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: IPX066 Product Code: IPX066-95 INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Product Name: IPX066 Product Code: IPX066-145 INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Product Name: IPX066 Product Code: IPX066-195 INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Product Name: IPX066 Product Code: IPX066-245 INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA	IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.	NULL	Not Recruiting			Female: yes Male: yes	350		Estonia;Latvia;Lithuania
925	NCT00921128 (ClinicalTrials.gov)	June 2, 2009	13/6/2009	Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease	Convection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's Disease	Parkinson's Disease	Drug: Muscimol	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Withdrawn	18 Years	N/A	All	0	Phase 1	United States
926	NCT00833690 (ClinicalTrials.gov)	June 2009	27/1/2009	Safety of Urate Elevation in Parkinson's Disease	A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosine to Assess Safety and Ability to Elevate Urate in Early Parkinson's Disease	Parkinson Disease	Drug: Placebo;Drug: inosine	The Parkinson Study Group	Massachusetts General Hospital;Harvard School of Public Health;University of Rochester;Michael J. Fox Foundation for Parkinson's Research	Completed	30 Years	N/A	All	75	Phase 2	United States
927	EUCTR2008-001966-10-AT (EUCTR)	27/05/2009	08/04/2009		A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinson’s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine - Safinamide in PD with motor fluctuations, as add-on to levodopa. Extension to trial 27919	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono SA - Geneva	NULL	Not Recruiting			Female: yes Male: yes	416	Phase 3	Hungary;United Kingdom;Estonia;Austria
928	EUCTR2008-004146-88-IT (EUCTR)	26/05/2009	27/04/2009	A phase III, double-blind, placebo-controlled extension trial toinvestigate the long-term efficacy and safety of low (50 mg/day) andhigh (100 mg/day) dose safinamide, as add-on therapy in subjectswith early idiopathic Parkinson?s disease treated with a stable doseof a single dopamine agonist - MOTION Extention Study	A phase III, double-blind, placebo-controlled extension trial toinvestigate the long-term efficacy and safety of low (50 mg/day) andhigh (100 mg/day) dose safinamide, as add-on therapy in subjectswith early idiopathic Parkinson?s disease treated with a stable doseof a single dopamine agonist - MOTION Extention Study	Idiopatic Parkinson Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: Safinamide INN or Proposed INN: Safinamide Product Name: Safinamide INN or Proposed INN: Safinamide	MERCK SERONO SA	NULL	Not Recruiting			Female: yes Male: yes	498	Phase 3	Portugal;Czech Republic;Slovakia;Finland;Poland;Spain;Bulgaria;Germany;Italy
929	EUCTR2008-001966-10-SK (EUCTR)	25/05/2009	28/05/2009	A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinson’s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine - Safinamide in PD with motor fluctuations, as add-on to levodopa. Extension to trial 27919	A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinson’s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine - Safinamide in PD with motor fluctuations, as add-on to levodopa. Extension to trial 27919	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Other descriptive name: NW-1015 Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono SA - Geneva	NULL	Not Recruiting			Female: yes Male: yes	416	Phase 3	Estonia;Hungary;Slovakia;Austria;United Kingdom
930	EUCTR2008-004146-88-SK (EUCTR)	25/05/2009	28/05/2009	A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918	A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono SA - Geneva	NULL	Not Recruiting			Female: yes Male: yes	498	Phase 3	Portugal;Czech Republic;Slovakia;Finland;Poland;Spain;Bulgaria;Germany;Italy
931	EUCTR2008-004146-88-FI (EUCTR)	19/05/2009	06/04/2009	An extension trial to investigate the long-term efficacy and safety of safinamide, as add-on therapy in patients with early Parkinson’s disease treated with a stable dose of a dopamine agonist	A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 Product Name: Safinamide Product Code: NW-1015	Newron Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	498	Phase 3	United States;Portugal;Slovakia;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;South Africa;Bulgaria;Germany
932	EUCTR2008-008712-98-FI (EUCTR)	18/05/2009	08/04/2009	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease	moderate to severe levodopa induced dyskinesias in patients with Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10013916;Term: Dyskinesia	Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	198		Finland;Germany;France;Spain;Italy
933	EUCTR2008-008712-98-IT (EUCTR)	14/05/2009	05/05/2009	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson?s disease - ND	13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson?s disease - ND	moderate to severe levodopa induced dyskinesia with Parkinson`s disease MedDRA version: 9.1;Level: LLT;Classification code 10013916;Term: Dyskinesia	Product Code: AFQ056 Product Code: AFQ056 Product Code: AFQ056	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	234		Finland;Germany;France;Spain;Italy
934	EUCTR2008-001966-10-GB (EUCTR)	12/05/2009	27/04/2009		A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinson’s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine - Safinamide in PD with motor fluctuations, as add-on to levodopa. Extension to trial 27919	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono SA - Geneva	NULL	Not Recruiting			Female: yes Male: yes	416	Phase 3	Hungary;United Kingdom;Estonia;Austria
935	EUCTR2008-000400-81-DE (EUCTR)	11/05/2009	29/01/2009	A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s Disease Experiencing Motor Fluctuations and Dyskinesia	A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s Disease Experiencing Motor Fluctuations and Dyskinesia	Advanced Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Trade Name: Mirapex Product Name: pramipexole INN or Proposed INN: pramipexole Other descriptive name: pramipexole dihydrochloride monohydrate Trade Name: Mirapex Product Name: Pramipexole INN or Proposed INN: Pramipexole Other descriptive name: pramipexole dihydrochloride monohydrate	Abbott Healthcare Products B.V.	NULL	Not Recruiting			Female: yes Male: yes	50		Portugal;Germany;Italy
936	EUCTR2009-010193-38-EE (EUCTR)	07/05/2009	15/04/2009	A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease	A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease	Idiopathic Parkinson's disease (paralysis agitans) MedDRA version: 9.1;Level: LLT;Classification code 10034010;Term: Parkinsonism	Product Name: IPX066 Product Code: IPX066-95 INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Product Name: IPX066 Product Code: IPX066-145 INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Product Name: IPX066 Product Code: IPX066-195 INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Product Name: IPX066 Product Code: IPX066-245 INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA	IMPAX Laboratories, Inc.	NULL	Not Recruiting			Female: yes Male: yes	350		Estonia;Latvia;Lithuania
937	EUCTR2008-001966-10-HU (EUCTR)	04/05/2009	06/04/2009		A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinson’s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine - Safinamide in PD with motor fluctuations, as add-on to levodopa. Extension to trial 27919	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono SA - Geneva	NULL	Not Recruiting			Female: yes Male: yes	416	Phase 3	Hungary;United Kingdom;Estonia;Austria
938	EUCTR2007-002963-28-BG (EUCTR)	03/05/2009	21/05/2009	A trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with early Parkinson’s Disease treated with a single dopamine agonist.	A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist. - Safinamide in early IPD, as add-on to dopamine agonist	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Newron Pharmaceuticals SpA	NULL	Not Recruiting			Female: yes Male: yes	839	Phase 3	Portugal;United States;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;Bulgaria;South Africa;Germany
939	NCT00767546 (ClinicalTrials.gov)	May 2009	5/10/2008	Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients	Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients	Parkinson Disease;Parkinsonism;Seborrheic Dermatitis	Drug: Botulinum toxin	Rabin Medical Center	NULL	Not yet recruiting	18 Years	N/A	Both	40	Phase 1	NULL
940	NCT01515891 (ClinicalTrials.gov)	May 2009	19/1/2012	Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites	An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites Following a Single-dose Oral Administration	Parkinson Disease	Drug: BIA 9-1067	Bial - Portela C S.A.	NULL	Completed	40 Years	55 Years	Male	4	Phase 1	Switzerland
941	EUCTR2008-002769-30-IT (EUCTR)	30/04/2009	22/04/2009	A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson?s disease - A study to assess the effect of safinamide on levodopa pharmacokinetics	A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson?s disease - A study to assess the effect of safinamide on levodopa pharmacokinetics	Parkinson Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113	Product Name: Safinamide INN or Proposed INN: Safinamide INN or Proposed INN: NACOM levodopa+cardidopa	MERCK SERONO SA	NULL	Not Recruiting			Female: yes Male: yes			Italy
942	EUCTR2008-005492-94-IT (EUCTR)	30/04/2009	15/04/2009	OPEN LABEL TRIAL TO DETERMINE THE LONG TERM SAFETY OF SAFINAMIDE IN PARKINSON`S DISEASE PATIENTS - ND	OPEN LABEL TRIAL TO DETERMINE THE LONG TERM SAFETY OF SAFINAMIDE IN PARKINSON`S DISEASE PATIENTS - ND	IDIOPATHIC PARKINSON`S DISEASE MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: SAFINAMIDE Product Code: NW-1015 Product Name: SAFINAMIDE Product Code: NW-1015	MERCK SERONO SA	NULL	Not Recruiting			Female: yes Male: yes	700	Phase 3	Portugal;Estonia;Slovakia;Finland;Spain;Austria;Italy;United Kingdom;France;Hungary;Czech Republic;Belgium;Bulgaria;Germany;Netherlands
943	EUCTR2007-001095-36-SK (EUCTR)	09/04/2009	09/04/2008	The Van Gogh Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 as Adjunct Therapy to L-dopa in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - The Van Gogh Study	The Van Gogh Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 as Adjunct Therapy to L-dopa in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - The Van Gogh Study	advanced stage of idiopathic PD with dose-dependent motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	625	Phase 3	Hungary;Slovakia
944	EUCTR2008-005085-30-DE (EUCTR)	06/04/2009	04/03/2009	Reversibility of olfactory loss in patients with Idiopathic Parkinson’s disease following treatment with Rasagiline	Einfluss von Rasagilin auf das Riechvermögen von Patienten mit idiopathischem Parkinson-Syndrom(Reversibility of olfactory loss in patients with Idiopathic Parkinson’s disease following treatment with Rasagiline) - Olfaction	Idiopathic Parkinson syndrome (IPS), State according to Hoehn & Yahr: maximum III MedDRA version: 13.1;Level: LLT;Classification code 10034008;Term: Parkinson's syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Azilect INN or Proposed INN: Rasagilin	Technische Universität Dresden	NULL	Not Recruiting			Female: yes Male: yes			Germany
945	EUCTR2008-000400-81-PT (EUCTR)	03/04/2009	27/01/2009	A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s Disease Experiencing Motor Fluctuations and Dyskinesia	A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s Disease Experiencing Motor Fluctuations and Dyskinesia	Advanced Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Trade Name: Mirapex Product Name: pramipexole INN or Proposed INN: pramipexole Other descriptive name: pramipexole dihydrochloride monohydrate Trade Name: Mirapex Product Name: Pramipexole INN or Proposed INN: Pramipexole Other descriptive name: pramipexole dihydrochloride monohydrate	Solvay Pharmaceuticals BV	NULL	Not Recruiting			Female: yes Male: yes	50		Portugal;Germany;Italy
946	EUCTR2007-002964-90-AT (EUCTR)	02/04/2009	13/02/2008	A trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in patients with Parkinson’s Disease with motor fluctuations, treated with levodopa and who may be receiving a dopamine agonist, an anticholinergic and/or amantadine.	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Newron Pharmaceuticals SpA	NULL	Not Recruiting			Female: yes Male: yes	605	Phase 3	United States;Estonia;Taiwan;Finland;Spain;Thailand;Austria;Israel;United Kingdom;Switzerland;India;France;Czech Republic;Hungary;Canada;Malaysia;Belgium;Australia;Germany;Netherlands;New Zealand;Korea, Republic of
947	EUCTR2007-004235-37-AT (EUCTR)	02/04/2009	10/03/2008	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim RCV GmbH & Co KG	NULL	Not Recruiting			Female: yes Male: yes	390		Hungary;Czech Republic;United Kingdom;Spain;Italy;Poland;Austria;Sweden
948	EUCTR2007-002963-28-PL (EUCTR)	02/04/2009	27/02/2009	A trial to determine the efficacy and safety of a low (50mg/day) and high (100mg/day) dose of safinamide, as an add-on therapy, in patients with early Parkinson's Disease treated with a single dopamine agonist.	A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist. - Safinamide in early IPD, as add-on to dopamine agonist	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Newron Pharmaceuticals SpA	NULL	Not Recruiting			Female: yes Male: yes	839	Phase 3	Portugal;Czech Republic;Finland;Spain;Poland;Bulgaria;Germany;Italy
949	JPRN-UMIN000001841	2009/04/01	02/04/2009	A randomized, double blind, comparative study of vitamin D3 versus placebo in patients with Parkinson disease aged between 45 and 85 years old to improve neurological signs and quality of life	A randomized, double blind, comparative study of vitamin D3 versus placebo in patients with Parkinson disease aged between 45 and 85 years old to improve neurological signs and quality of life - RCT with vitamin D for Parkinson disease	Parkinson disease	Vitamin D3 placebo	Jikei University School of Medicine	NULL	Complete: follow-up complete	45years-old	85years-old	Male and Female	120	Not selected	Japan
950	JPRN-JapicCTI-090888	01/4/2009		A Double-Blind, 3-Arm, Parallel Group, Placebo-and Ropinirole-Controlled Study of SPM 962 in Subjects with Parkinson's Disease Treated Concomitantly with L-dopa	A Double-Blind, 3-Arm, Parallel Group, Placebo-and Ropinirole-Controlled Study of SPM 962 in Subjects with Parkinson's Disease Treated Concomitantly with L-dopa	Parkinson's Disease Treated Concomitantly with L-dopa	Intervention name : SPM 962 Dosage And administration of the intervention : SPM 962: transdermal application, 1 time per day. Initial dose:4.5mg/day, weekly increment of 4.5mg/day, maximal maintenance dose : 36.0mg/day. Placebo of ropinirole: oral application 3 times per day. Initial dose:0.75mg placebo/day, weekly increment of 0.75mg placebo/day (up to 3.0mg placebo/day), then 1.5mg placebo/day (up to 15.0mg placebo/day), maximal maintenance dose 15.0 mg placebo/day Control intervention name : Ropinirole Dosage And administration of the control intervention : placebo SPM 962: transdermal application, 1 time per day. Initial dose: 4.5mg placebo/day, weekly increment of 4.5mg placebo/day, maximal maintenance dose : 36.0mg placebo/day. Ropinirole: oral application 3 times per day. Initial dose:0.75mg/day, weekly increment of 0.75mg/day (up to 3.0mg/day), then 1.5mg/day (up to 15.0mg/day), maximal maintenance dose 15.0 mg/day. Control intervention name : Placebo Dosage And administration of the control intervention : placebo SPM 962: transermal application, 1 time per day. Initial dose: 4.5mg placebo/day, weekly increment of 4.5mg placebo/day, maximal maintenance dose : 36.0mg placebo/day. Placebo ropinirole: oral application 3 times per day. Initial dose:0.75mg placebo/day, weekly increment of 0.75mg placebo/day (up to 3.0mg placebo/day), then 1.5mg placebo/day (up to 15.0mg placebo/day), maximal maintenance dose 15.0 mg placebo/day.	Otsuka Pharmaceutical Co., Ltd.	NULL		30	79	BOTH	400	Phase 3	NULL
951	NCT00875316 (ClinicalTrials.gov)	April 2009	2/4/2009	Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease Patients	A Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane™ Over One Month	Parkinson's Disease	Drug: Cogane™ (PYM50028)	Phytopharm	NULL	Completed	40 Years	80 Years	Both	36	Phase 1	United Kingdom
952	NCT00865579 (ClinicalTrials.gov)	April 2009	10/3/2009	Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients	Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients	Parkinson's Disease	Drug: Safinamide	Newron	NULL	Terminated	30 Years	N/A	All	964	Phase 3	Romania
953	NCT00880620 (ClinicalTrials.gov)	April 2009	3/4/2009	A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease	A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease	Parkinson's Disease	Drug: Placebo;Drug: IPX066 95 mg LD;Drug: IPX066 145 mg LD;Drug: IPX066 195 mg LD;Drug: IPX066 245 mg LD	Impax Laboratories, LLC	NULL	Completed	30 Years	N/A	All	381	Phase 3	United States;Canada;Estonia;Latvia;Lithuania;Romania;Ukraine
954	NCT01568034 (ClinicalTrials.gov)	April 2009	29/3/2012	A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067	A Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067 on the Levodopa Pharmacokinetics, Motor Response, and Erythrocyte Soluble Catechol-O-methyltransferase Activity in Parkinson's Disease Patients Concomitantly Treated With Levodopa/Dopa-decarboxylase Inhibitor	Parkinson's Disease	Drug: BIA 9-1067;Drug: Placebo;Drug: Levodopa/Carbidopa;Drug: Levodopa/Benzerazide	Bial - Portela C S.A.	NULL	Completed	30 Years	75 Years	All	10	Phase 2	Portugal;Romania;Ukraine
955	EUCTR2008-000400-81-IT (EUCTR)	31/03/2009	17/04/2009	A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson?s Disease Experiencing Motor Fluctuations and Dyskinesia - ND	A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson?s Disease Experiencing Motor Fluctuations and Dyskinesia - ND	Advanced Parkinson`s Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Trade Name: Mirapex INN or Proposed INN: Pramipexole Trade Name: Mirapex INN or Proposed INN: Pramipexole Trade Name: Mirapex INN or Proposed INN: Pramipexole	SOLVAY PHARMACEUTICALS B.V.	NULL	Not Recruiting			Female: yes Male: yes	50		Portugal;Germany;Italy
956	EUCTR2007-003035-22-AT (EUCTR)	30/03/2009	26/05/2008	A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS	Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate	Acadia Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	560	Phase 2;Phase 3	Portugal;France;Belgium;Austria;Italy;United Kingdom;Sweden
957	EUCTR2007-002963-28-PT (EUCTR)	26/03/2009	07/01/2009	A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson?s Disease treated with a stable dose of a single dopamine agonist. - Safinamide in early IPD, as add-on to dopamine agonist	A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson?s Disease treated with a stable dose of a single dopamine agonist. - Safinamide in early IPD, as add-on to dopamine agonist	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono S.A-Geneva	NULL	Not Recruiting			Female: yes Male: yes	1036	Phase 3	Portugal;Czech Republic;Finland;Poland;Spain;Bulgaria;Germany;Italy
958	EUCTR2007-002964-90-FR (EUCTR)	09/03/2009	12/11/2007	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	Ideopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	1121	Phase 3	France;Czech Republic;Estonia;Hungary;Slovakia;Finland;Spain;Belgium;Austria;Germany;Netherlands;United Kingdom
959	NCT00940914 (ClinicalTrials.gov)	March 2009	16/7/2009	Dopaminergic Loss and Pain in Parkinson's Disease	Evaluation of Radioligand Uptake (FP-CIT) of Dopamine Transporters in Patients Suffering From Parkinson's Disease With or Without Pain	Parkinson's Disease;Pain	Drug: ioflupane 123I (DATSCAN®)	University Hospital, Toulouse	NULL	Completed	30 Years	70 Years	All	20	Phase 2	France
960	NCT00823836 (ClinicalTrials.gov)	March 2009	15/1/2009	Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease	Clinical Evaluation of Ropinirole PR/XR Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease	Parkinson Disease	Drug: ropinirole PR/XR;Drug: ropinirole IR	GlaxoSmithKline	NULL	Completed	20 Years	N/A	All	302	Phase 3	Japan
961	NCT00870974 (ClinicalTrials.gov)	March 2009	26/3/2009	A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions	Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions	Parkinson Disease;Huntington Disease;Autistic Spectrum Disorders;Fragile X Syndrome;Alzheimer Disease;Mild Cognitive Impairment	Drug: [18F]FPEB	Institute for Neurodegenerative Disorders	NULL	Completed	18 Years	85 Years	All	48	Phase 1	United States
962	NCT00767091 (ClinicalTrials.gov)	March 2009	1/9/2008	Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentric Trial	Parkinson's Disease;Apathy;no Dementia	Drug: rivastigmine;Drug: placebo	University Hospital, Lille	NULL	Completed	15 Years	80 Years	Both	40	Phase 3	France
963	NCT00888004 (ClinicalTrials.gov)	March 2009	23/4/2009	Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients	A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy and Tolerability of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Severe L-dopa Induced Dyskinesias	Parkinson's Disease;L-dopa Induced Dyskinesia	Drug: AFQ056;Drug: Placebo	Novartis	NULL	Completed	30 Years	85 Years	Both	28	Phase 2	Germany
964	NCT00866502 (ClinicalTrials.gov)	March 2009	18/3/2009	A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease	A Randomized, Double-blind, Placebo Controlled, Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Idiopathic Parkinson's Disease (PD) of Moderate Severity, Using an Implanted Catheter and a SynchroMed® II Pump.	Parkinson's Disease	Drug: sNN0031;Drug: Placebo	Newron Sweden AB	Medtronic;Quintiles	Completed	30 Years	75 Years	Both	12	Phase 1/Phase 2	Sweden
965	EUCTR2008-006278-13-NL (EUCTR)	04/02/2009	15/10/2008	Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations.	Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations.	patients with advanced (>5 years) Parkinson's disease and visual hallucinations. MedDRA version: 9.1;Level: LLT;Classification code 10047570;Term: Visual hallucinations MedDRA version: 9.1;Classification code 10013113;Term: Disease Parkinson's	Trade Name: Reminyl Retard Trade Name: Sinemet 125 mg	UMCG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	10		Netherlands
966	NCT00806468 (ClinicalTrials.gov)	February 2009	9/12/2008	Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease	A Double Blind, Placebo Controlled, Randomized, Monocentre Cross-over Study to Investigate the Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease	Parkinson Disease	Drug: Desmotabs	Johannes Gutenberg University Mainz	NULL	Terminated	18 Years	85 Years	Male	1	Phase 4	Germany
967	NCT01421719 (ClinicalTrials.gov)	February 2009	19/8/2011	Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease	Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy	Parkinson's Disease;Neurogenic Bladder;Urinary Incontinence;Clostridium Botulinum Toxin Adverse Reaction	Drug: Cystoscopic injection of Botox into the urinary bladder	Stanford University	Allergan	Completed	50 Years	85 Years	All	20	Phase 4	United States
968	NCT00627640 (ClinicalTrials.gov)	February 2009	13/2/2008	Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa	A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine	Idiopathic Parkinson's Disease	Drug: Safinimide 50-100 mg/day;Drug: Matching Placebo	Newron	NULL	Completed	30 Years	80 Years	Both	549	Phase 3	United States;Australia;Austria;Belgium;Canada;Estonia;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom
969	EUCTR2007-007853-30-SE (EUCTR)	28/01/2009	21/12/2007	A randomized, double-blind, placebo controlled, safety and tolerability study of intracerebroventricular administration of sNN0031 to patients with idiopathic Parkinson's disease (PD) of moderate severity, using an implanted catheter and a SynchroMed® II pump.	A randomized, double-blind, placebo controlled, safety and tolerability study of intracerebroventricular administration of sNN0031 to patients with idiopathic Parkinson's disease (PD) of moderate severity, using an implanted catheter and a SynchroMed® II pump.	Idiopathic Parkinson's disease (PD) of moderate severity (modified Hoehn & Yahr Stage IIb - III)	Product Name: sNN0031 Product Code: sNN0031	NeuroNova AB	NULL	Not Recruiting			Female: yes Male: yes			Sweden
970	EUCTR2009-015833-66-IT (EUCTR)	20/01/2009	18/04/2012	Ropinirole 24h prolonged release and motor fluctuations: a study to control the wearing-off induced by dopamine agonists immediate release	Ropinirole 24h prolonged release and motor fluctuations: a study to control the wearing-off induced by dopamine agonists immediate release	Parkinson's Disease MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: REQUIP*28CPR 8MG R.P. INN or Proposed INN: ROPINIROLE Other descriptive name: NA Trade Name: REQUIP*21CPR 5MG INN or Proposed INN: ROPINIROLE Other descriptive name: NA Trade Name: MIRAPEXIN*30CPR 0,7MG INN or Proposed INN: PRAMIPEXOLE Other descriptive name: NA	CASA DI CURA PRIVATA S.RAFFAELE - PISANA	NULL	Not Recruiting			Female: yes Male: yes			Italy
971	EUCTR2007-002963-28-CZ (EUCTR)	19/01/2009	30/10/2007	A trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with early Parkinson's Disease treated with a single dopamine agonist.	A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist. - Safinamide in early IPD, as add-on to dopamine agonist	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Newron Pharmaceuticals SpA	NULL	Not Recruiting			Female: yes Male: yes	839	Phase 3	Portugal;United States;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;Bulgaria;South Africa;Germany
972	EUCTR2007-003035-22-PT (EUCTR)	09/01/2009	01/07/2008	A safety and tolerability study of ACP-103 in patients with Parkinson's Disease Psychosis	A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	MedDRA version: 18.0;Level: LLT;Classification code 10037241;Term: Psychosis NOS;System Organ Class: 100000004873 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Pimavanserin tartrate Product Code: pimavanserin (ACP-103) INN or Proposed INN: Pimavanserin tartrate Other descriptive name: N/A	ACADIA Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	400	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Portugal;United States;Ukraine;Austria;Russian Federation;United Kingdom;Italy;India;France;European Union;Canada;Belgium;Sweden
973	EUCTR2007-003035-22-IT (EUCTR)	07/01/2009	23/07/2008		A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease - ACP-103-015	Psychosis in Parkinson?s Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS	Product Name: primavanserin tartrate Product Code: ACP-103 INN or Proposed INN: primavanserin tartrate	ACADIA PHARMACEUTICALS INC.	NULL	Not Recruiting			Female: yes Male: yes	486		Portugal;United Kingdom;Belgium;France;Italy;Austria;Sweden
974	EUCTR2008-004906-15-FR (EUCTR)	05/01/2009	16/03/2009	EVALUATION DE LA CAPTATION D’UN RADIOLIGAND DES TRANSPORTEURS DE LA DOPAMINE CHEZ DES SUJETS ATTEINTS DE LA MALADIE DE PARKINSON ET PRESENTANT OU NON DES DOULEURS EN RAPPORT AVEC CETTE PATHOLOGIE - dénervation dopaminergique et douleur dans la maladie de Parkinson	EVALUATION DE LA CAPTATION D’UN RADIOLIGAND DES TRANSPORTEURS DE LA DOPAMINE CHEZ DES SUJETS ATTEINTS DE LA MALADIE DE PARKINSON ET PRESENTANT OU NON DES DOULEURS EN RAPPORT AVEC CETTE PATHOLOGIE - dénervation dopaminergique et douleur dans la maladie de Parkinson	Maladie de Parkinson MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Trade Name: DATSCAN	CHU Toulouse	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France
975	NCT00357994 (ClinicalTrials.gov)	January 2009	27/7/2006	Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects	A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations	Advanced Parkinson's Disease	Drug: Levodopa carbidopa intestinal gel (LCIG);Drug: Placebo gel;Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets;Drug: Placebo (PBO) oral capsules;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube	AbbVie (prior sponsor, Abbott)	Quintiles, Inc.	Completed	30 Years	N/A	All	36	Phase 3	United States;Germany
976	EUCTR2004-000148-26-AT (EUCTR)	31/12/2008	26/11/2008	A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A	A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A	Parkinson's Disease	Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol	Schwarz BioSciences Inc.	NULL	Not Recruiting			Female: yes Male: yes	360	Phase 3	Czech Republic;Hungary;Finland;Spain;Austria;Italy;Sweden
977	EUCTR2008-003966-25-DE (EUCTR)	23/12/2008	04/11/2008	Double-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to placebo. - DEPOPA	Double-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to placebo. - DEPOPA	Effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome MedDRA version: 9.1;Level: LLT;Classification code 10064016;Term: Nocturnal polyuria MedDRA version: 9.1;Classification code 10061536;Term: Parkinson's disease	Trade Name: Desmotabs® 0,2 mg Tabletten Product Name: Desmotabs® 0,2mg Tabletten INN or Proposed INN: Desmopressin Acetat	Universität Mainz, Klinik und Poliklinik für Neurologie	NULL	Not Recruiting			Female: no Male: yes	20		Germany
978	NCT00809302 (ClinicalTrials.gov)	December 2008	15/12/2008	Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1, 3, and 6 mg Twice Daily) in Patients With Early Parkinson Disease (APLIED)	Early Parkinson Disease	Drug: aplindore MR tablets or Placebo	Neurogen Corporation	NULL	Terminated	30 Years	N/A	Both	9	Phase 2	United States
979	EUCTR2008-004943-12-SK (EUCTR)	24/11/2008	10/10/2008	The Rubens Study:A Multicenter, Randomized, Double-blind, Parallel Group, Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration Schedules of Pardoprunox Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rubens Study	The Rubens Study:A Multicenter, Randomized, Double-blind, Parallel Group, Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration Schedules of Pardoprunox Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rubens Study	Early Stage Parkinson’s Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Other descriptive name: SLV308 hydrochloride Trade Name: Mirapex INN or Proposed INN: Pramipexole Other descriptive name: pramipexole dihydrochloride monohydrate	Solvay Pharmaceuticals B.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	320	Phase 2	Slovakia
980	EUCTR2007-003051-36-BE (EUCTR)	06/11/2008	21/05/2008	A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS	Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate	Acadia Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	280		Austria;Sweden;Portugal;Spain;Belgium
981	EUCTR2007-003035-22-GB (EUCTR)	05/11/2008	20/12/2007	A safety and tolerability study of ACP-103 in patients with Parkinson's Disease Psychosis	A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease - ACP-103-015	Psychosis in Parkinson's Disease MedDRA version: 20.0;Level: LLT;Classification code 10037241;Term: Psychosis NOS;System Organ Class: 100000004873 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Pimavanserin tartrate Product Code: pimavanserin (ACP-103) INN or Proposed INN: Pimavanserin tartrate Other descriptive name: N/a	ACADIA Pharmaceuticals Inc.	NULL	Not Recruiting			Female: yes Male: yes	400	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United States;Portugal;Ukraine;Austria;Russian Federation;United Kingdom;Italy;India;France;European Union;Canada;Belgium;Sweden
982	NCT00869791 (ClinicalTrials.gov)	November 2008	24/3/2009	A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa	A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa	Parkinson's Disease	Drug: IPX066;Drug: IR CD-LD	Impax Laboratories, LLC	NULL	Completed	30 Years	N/A	All	27	Phase 2	United States
983	EUCTR2008-003869-72-PT (EUCTR)	03/10/2008	25/06/2008	A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPONSE, AND ERYTHROCYTE SOLUBLE CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN PARKINSON'S DISEASE PATIENTS CONCOMITANTLY TREATED WITH LEVODOPA/DOPA-DECARBOXYLASE INHIBITOR	A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPONSE, AND ERYTHROCYTE SOLUBLE CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN PARKINSON'S DISEASE PATIENTS CONCOMITANTLY TREATED WITH LEVODOPA/DOPA-DECARBOXYLASE INHIBITOR	Parkinson MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Code: BIA 9-1067 Trade Name: SINEMET 25/100 INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Product Code: BIA 9-1067	Bial - Portela & Cª, S.A.	NULL	Not Recruiting			Female: yes Male: yes	12		Portugal
984	EUCTR2007-000350-31-IT (EUCTR)	02/10/2008	11/02/2008	A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson?s disease (PDD) - ND	A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson?s disease (PDD) - ND	mild to moderately severe dementia associated with Parkinson?s disease (PDD) MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Exelon path transdermal Product Code: ENA713B INN or Proposed INN: Rivastigmine Trade Name: EXELON INN or Proposed INN: Rivastigmine Trade Name: EXELON INN or Proposed INN: Rivastigmine Trade Name: EXELON INN or Proposed INN: Rivastigmine Trade Name: EXELON INN or Proposed INN: Rivastigmine Product Name: Exelon path transdermal Product Code: ENA713B INN or Proposed INN: Rivastigmine	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	550		France;Spain;Italy
985	NCT01048229 (ClinicalTrials.gov)	October 2008	12/1/2010	Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease	Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease	Early-stage Parkinson's Disease	Drug: Rasagiline;Drug: Pramipexole	Qualissima	H. Lundbeck A/S	Terminated	18 Years	70 Years	Both	112	Phase 4	NULL
986	NCT00906828 (ClinicalTrials.gov)	October 2008	19/5/2009	Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors	Pharmacokinetics of Levodopa in Patients With Parkinson's Disease Treated With Levodopa/Carbidopa Infusion With and Without Oral COMT Inhibitors	Parkinson Disease	Drug: levodopa/carbidopa;Drug: entacapone;Drug: tolcapone	Uppsala University	Swedish Parkinson's Disease Foundation;Swedish Society for Medical Research	Completed	30 Years	90 Years	Both	10	Phase 4	Sweden
987	EUCTR2008-003225-16-FI (EUCTR)	10/09/2008	30/05/2008	Aivostimulaattorin ja levodopainfuusion vaikutus elämänlaatuun ja autonomisen hermoston toimintaan Parkinsonin tautia sairastavilla potilailla	Aivostimulaattorin ja levodopainfuusion vaikutus elämänlaatuun ja autonomisen hermoston toimintaan Parkinsonin tautia sairastavilla potilailla	Vaikeahoitoinen Parkinsonin tauti potilailla, joille on aiemmin asetettu aivostimulaattori, tai on päädytty päivittäisten oireiden vuoksi aloittamaan Duodopa-infuusio. MedDRA version: 9.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS	Trade Name: Duodopa	Organisation name was not entered	NULL	Not Recruiting			Female: yes Male: yes			Finland
988	EUCTR2007-003051-36-AT (EUCTR)	10/09/2008	29/04/2008	A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS	Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate	Acadia Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	280		Portugal;Spain;Austria;Sweden
989	EUCTR2007-003051-36-PT (EUCTR)	05/09/2008	27/05/2008	A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS	Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate	Acadia Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	280		Portugal;Spain;Austria;Sweden
990	EUCTR2007-003035-22-BE (EUCTR)	02/09/2008	21/05/2008	A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS	Product Name: Pimavanserin tartrate Product Code: pimavanserin (ACP-103) INN or Proposed INN: Pimavanserin tartrate	Acadia Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	400	Phase 2;Phase 3	Portugal;France;Belgium;Austria;Italy;United Kingdom;Sweden
991	EUCTR2007-004235-37-GB (EUCTR)	19/08/2008	26/11/2007	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim	NULL	Not Recruiting			Female: yes Male: yes	390		Hungary;Czech Republic;United Kingdom;Spain;Italy;Poland;Austria;Sweden
992	EUCTR2004-005234-39-DE (EUCTR)	11/08/2008	02/12/2005	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Parkinson's disease MedDRA version: 7.0;Level: LLT;Classification code 10061536	Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa	Orion Corporation, ORION PHARMA, 02200 Espoo, Finland	NULL	Not Recruiting			Female: yes Male: yes	244		Finland;United Kingdom;Germany;Denmark;Ireland;Latvia;Lithuania;Sweden
993	NCT00643890 (ClinicalTrials.gov)	August 2008	24/3/2008	Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease	Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects With Advanced Parkinson's Disease	Parkinson's Disease	Genetic: Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus	Neurologix, Inc.	NULL	Terminated	30 Years	75 Years	Both	44	Phase 2	United States
994	EUCTR2004-000148-26-HU (EUCTR)	26/07/2008	19/07/2004	A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A	A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A	Parkinson's Disease	Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol	Schwarz BioSciences Inc.	NULL	Not Recruiting			Female: yes Male: yes	360	Phase 3	Finland;Hungary;Czech Republic;Spain;Italy;Sweden
995	EUCTR2008-003581-26-SE (EUCTR)	18/07/2008	30/05/2008	Pharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors - DuoCOMT	Pharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors - DuoCOMT	Parkinson's disease (G20.9), advanced, patients presently on Duodopa treatment. MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Trade Name: Duodopa INN or Proposed INN: levodopa INN or Proposed INN: carbidopa Trade Name: Comtess INN or Proposed INN: entacapone Trade Name: Tasmar INN or Proposed INN: tolcapone	Dept of Neuroscience, Uppsala University	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Sweden
996	EUCTR2007-003051-36-ES (EUCTR)	01/07/2008	05/05/2008	Ensayo multicéntrico, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de ACP-103 en el tratamiento de la psicosis en la enfermedad de Parkinson.A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	Ensayo multicéntrico, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de ACP-103 en el tratamiento de la psicosis en la enfermedad de Parkinson.A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	Psicosis en la enfermedad de Parkinson.Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS	Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate	Acadia Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	280		Portugal;Spain;Austria;Sweden
997	EUCTR2007-003051-36-SE (EUCTR)	30/06/2008	16/05/2008	A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS	Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate	Acadia Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	280		Portugal;Spain;Austria;Sweden
998	EUCTR2007-002963-28-IT (EUCTR)	30/06/2008	04/01/2008	A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson?s Disease treated with a stable dose of a single dopamine agonist. - Safinamide in early IPD, as add-on to dopamine agonist	A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson?s Disease treated with a stable dose of a single dopamine agonist. - Safinamide in early IPD, as add-on to dopamine agonist	Idiopathic Parkinson's Disease MedDRA version: 6.1;Level: PT;Classification code 10061536	Product Name: safinamide Product Name: safinamide	MERCK SERONO INTERNATIONAL SA	NULL	Not Recruiting			Female: yes Male: yes	666	Phase 3	Portugal;Czech Republic;Slovakia;Finland;Poland;Spain;Bulgaria;Germany;Italy
999	EUCTR2007-003035-22-SE (EUCTR)	11/06/2008	16/05/2008	A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS	Product Name: Pimavanserin tartrate Product Code: pimavanserin (ACP-103) INN or Proposed INN: Pimavanserin tartrate	Acadia Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	400	Phase 2;Phase 3	Portugal;France;Belgium;Austria;Italy;United Kingdom;Sweden
1000	EUCTR2007-002964-90-HU (EUCTR)	03/06/2008	15/11/2007	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono S.A.-Geneva	NULL	Not Recruiting			Female: yes Male: yes	1121	Phase 3	France;Czech Republic;Estonia;Hungary;Finland;Spain;Belgium;Austria;Germany;Netherlands;United Kingdom
1001	NCT00822913 (ClinicalTrials.gov)	June 2008	14/1/2009	Botulinum A Toxin in Patients With Parkinson's Disease	The Use of Toxin Botulinum A Toxin in Patients With Parkinson's Disease and Multiple System Disease, Affected by Refractory Detrusor Overactivity.	Parkinson's Disease;Multiple System Atrophy;Detrusor Overactivity	Drug: Intravesical injection of Botulinum A toxin	University Of Perugia	University of Roma La Sapienza	Enrolling by invitation	18 Years	80 Years	Both	20	Phase 4	NULL
1002	EUCTR2007-004235-37-PL (EUCTR)	29/05/2008	16/04/2008	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim Pharma Ges mbH	NULL	Not Recruiting			Female: yes Male: yes	390		Hungary;Czech Republic;United Kingdom;Spain;Italy;Austria;Poland;Sweden
1003	EUCTR2006-006752-35-DE (EUCTR)	06/05/2008	23/03/2007	RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINEPHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - RECOVER	RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINEPHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - RECOVER	Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro 2mg/24 h transdermal patch Product Code: ND1587 INN or Proposed INN: Rotigotine Trade Name: Neupro 4mg/24 h transdermal patch Product Code: ND1589 INN or Proposed INN: Rotigotine Trade Name: Neupro 6mg/24 h transdermal patch Product Code: ND1590 INN or Proposed INN: Rotigotine Trade Name: Neupro 8 mg/24 h transdermal patch Product Code: ND1702 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	400	Phase 3	Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy
1004	EUCTR2007-004235-37-SE (EUCTR)	23/04/2008	25/03/2008	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim AB	NULL	Not Recruiting			Female: yes Male: yes	390		Hungary;Czech Republic;United Kingdom;Spain;Italy;Poland;Austria;Sweden
1005	EUCTR2007-002906-23-BG (EUCTR)	16/04/2008	07/07/2008	A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease	A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease	Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS	Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate	Acadia Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	280		United Kingdom;France;Bulgaria
1006	EUCTR2007-001096-10-SK (EUCTR)	11/04/2008	09/04/2008	An Extension of the Van Gogh Study: An Open Label SLV308 Safety Extension to Study S308.3.004 in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - An Extension of the Van Gogh Study	An Extension of the Van Gogh Study: An Open Label SLV308 Safety Extension to Study S308.3.004 in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - An Extension of the Van Gogh Study	advanced stage of idiopathic PD with dose-dependent motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 3	Hungary;Slovakia
1007	NCT00753636 (ClinicalTrials.gov)	April 2008	13/9/2008	Parkinson's Disease Isradipine Safety Study	Phase II Safety and Tolerability of Isradipine (A Potential Neuroprotective Agent) in Patients With Parkinson's Disease- Stage II	Parkinson's Disease	Drug: Dynacirc CR (Isradipine)	Northwestern University	Northwestern Memorial Hospital	Completed	30 Years	75 Years	All	31	Phase 2	United States
1008	NCT02071810 (ClinicalTrials.gov)	April 2008	19/1/2012	Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067	A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Four Multiple Rising Dose Regimens of BIA 9-1067 in Healthy Male Volunteers	Parkinson's Disease (PD)	Drug: BIA 9-1067;Drug: Placebo	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	Male	34	Phase 1	France
1009	NCT00605553 (ClinicalTrials.gov)	April 2008	15/1/2008	Study to Evaluate SYN115 in Parkinson's Disease	A Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Study to Explore the Effects of 7 Days of Dosing With SYN115 20 mg p.o. BID or 60 mg p.o. BID on Clinical and fMRI Response to Intravenous Levodopa in Patients With Mild to Moderate Parkinson's Disease	Parkinson's Disease	Drug: Placebo;Drug: Tozadenant	Biotie Therapies Inc.	NULL	Completed	40 Years	75 Years	All	30	Phase 2	United States
1010	EUCTR2007-001095-36-HU (EUCTR)	27/03/2008	06/02/2008	The Van Gogh Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 as Adjunct Therapy to L-dopa in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - The Van Gogh Study	The Van Gogh Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 as Adjunct Therapy to L-dopa in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - The Van Gogh Study	advanced stage of idiopathic PD with dose-dependent motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	625		Hungary
1011	EUCTR2006-003732-30-PL (EUCTR)	27/03/2008	08/01/2008	Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1	Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1	Early Parkinson's Disease MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease	Product Name: Lisuride TTS 10cm² INN or Proposed INN: LISURIDE Trade Name: Sifrol 0,088 INN or Proposed INN: PRAMIPEXOLE Product Name: Lisuride TTS 20cm² INN or Proposed INN: LISURIDE Trade Name: Sifrol 0,18 INN or Proposed INN: PRAMIPEXOLE Trade Name: Sifrol 0,35 INN or Proposed INN: PRAMIPEXOLE Trade Name: Sifrol 0,7 INN or Proposed INN: PRAMIPEXOLE	NeuroBiotec Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350		Germany;Italy;Poland
1012	EUCTR2007-001096-10-HU (EUCTR)	27/03/2008	15/02/2008	An Extension of the Van Gogh Study: An Open Label SLV308 Safety Extension to Study S308.3.004 in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - An Extension of the Van Gogh Study	An Extension of the Van Gogh Study: An Open Label SLV308 Safety Extension to Study S308.3.004 in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - An Extension of the Van Gogh Study	advanced stage of idiopathic PD with dose-dependent motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308 INN or Proposed INN: Pardoprunox hydrochloride Product Name: Pardoprunox Product Code: SLV308	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	500		Hungary
1013	EUCTR2007-002964-90-GB (EUCTR)	20/03/2008	14/01/2009	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	Ideopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono S.A - Geneva	NULL	Not Recruiting			Female: yes Male: yes	605	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	France;Czech Republic;Estonia;Hungary;Slovakia;Finland;Spain;Belgium;Austria;Germany;Netherlands;United Kingdom
1014	EUCTR2007-004235-37-HU (EUCTR)	17/03/2008	17/01/2008	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim Pharma Ges mbH	NULL	Not Recruiting			Female: yes Male: yes	390	Phase 3	Czech Republic;Hungary;Slovakia;Spain;Poland;Austria;Italy;United Kingdom;Sweden
1015	NCT00727727 (ClinicalTrials.gov)	March 2008	31/7/2008	SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)	Stabilization on, or Change-Over to the Non-Ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Private Practices.	Parkinson's Disease	Drug: Piribedil	Desitin Arzneimittel GmbH	NULL	Completed	18 Years	N/A	Both	750	N/A	Germany
1016	NCT00607451 (ClinicalTrials.gov)	March 2008	22/1/2008	Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia	A Double-blind, Placebo Controlled, Crossover, Ascending Single Dose Safety Tolerability, Pharmacokinetic and Pharmacodynamic Study of Neu-120 in Patients With Advanced Phase Idiopathic Parkinson's Disease With Levodopa Induced Dyskinesia	Levodopa-induced Dyskinesia	Drug: Neu-120	Neurim Pharmaceuticals Ltd.	NULL	Terminated	30 Years	80 Years	All	8	Phase 1/Phase 2	Israel
1017	NCT00761137 (ClinicalTrials.gov)	March 2008	25/9/2008	Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients	A Two-Phase, Double Blind, Placebo-Controlled, Randomized, Crossover Study of the Safety and Efficacy of Intra-Oral NH004 Films for the Short-Term Relief of Sialorrhea Symptoms in Parkinson's Disease Patients	Sialorrhea Secondary to Parkinson's Disease	Drug: 0.3 mg tropicamide;Drug: 1 mg tropicamide;Drug: 3 mg tropicamide;Drug: 0 mg tropicamide	NeuroHealing Pharmaceuticals Inc.	Michael J. Fox Foundation for Parkinson's Research	Completed	50 Years	80 Years	All	19	Phase 2	Argentina
1018	EUCTR2007-003035-22-FR (EUCTR)	29/02/2008	15/02/2008	A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease	Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS	Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate	Acadia Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	486	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Portugal;France;Belgium;Austria;Italy;United Kingdom;Sweden
1019	EUCTR2007-002964-90-DE (EUCTR)	28/02/2008	17/12/2008	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	Idiopathic Parkinson's Disease MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	484	Phase 3	France;Czech Republic;Estonia;Hungary;Finland;Spain;Belgium;Austria;Netherlands;Germany;United Kingdom
1020	EUCTR2007-000350-31-ES (EUCTR)	13/02/2008	21/12/2007	Estudio prospectivo, multicéntrico y en condiciones abiertas de 76 semanas de duración para evaluar el efecto a largo plazo de Exelon® cápsula y parche transdérmico en el empeoramiento de los síntomas motores subyacentes de la EP en pacientes con demencia leve a moderadamente grave asociada a enfermedad de Parkinson (DEP)	Estudio prospectivo, multicéntrico y en condiciones abiertas de 76 semanas de duración para evaluar el efecto a largo plazo de Exelon® cápsula y parche transdérmico en el empeoramiento de los síntomas motores subyacentes de la EP en pacientes con demencia leve a moderadamente grave asociada a enfermedad de Parkinson (DEP)	Demencia leve a moderadamente grave asociada a enfermedad de Parkinson (DEP). MedDRA version: 9.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease	Trade Name: Exelon INN or Proposed INN: rivastigmine Trade Name: Exelon INN or Proposed INN: rivastigmine Trade Name: Exelon INN or Proposed INN: rivastigmine Trade Name: Exelon INN or Proposed INN: rivastigmine Trade Name: Exelon 4.6 mg/24 h transdermal patch INN or Proposed INN: rivastigmine Trade Name: Exelon 9.5 mg/24 h transdermal patch INN or Proposed INN: rivastigmine	Novartis Farmacéutica S.A	NULL	Not Recruiting			Female: yes Male: yes	550	Phase 3	France;Spain;Italy
1021	EUCTR2007-002964-90-EE (EUCTR)	13/02/2008	02/01/2008	A trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in patients with Parkinson’s Disease with motor fluctuations, treated with levodopa and who may be receiving a dopamine agonist, an anticholinergic and/or amantadine.	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Newron Pharmaceuticals SpA	NULL	Not Recruiting			Female: yes Male: yes	605	Phase 3	United States;Estonia;Taiwan;Finland;Spain;Thailand;Austria;Israel;United Kingdom;Switzerland;India;France;Czech Republic;Hungary;Canada;Malaysia;Belgium;Australia;Germany;Netherlands;New Zealand;Korea, Republic of
1022	NCT00888186 (ClinicalTrials.gov)	February 2008	24/4/2009	Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics	Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics	Parkinson Disease;Dyskinesias	Drug: levodopa/carbidopa	Uppsala University	Swedish Parkinson's Disease Foundation;Swedish Society for Medical Research	Completed	30 Years	90 Years	Both	5	Phase 4	Sweden
1023	NCT00624741 (ClinicalTrials.gov)	February 2008	15/2/2008	Compassionate Use Study of Pergolide in Patients With Parkinson's Disease	Compassionate Use of Pergolide as Adjunctive Therapy to Levodopa/Carbidopa for Treating Parkinson's Disease	Parkinson Disease	Drug: Pergolide	Valeant Pharmaceuticals International, Inc.	NULL	No longer available	N/A	N/A	Both		N/A	NULL
1024	EUCTR2007-004235-37-ES (EUCTR)	24/01/2008	08/03/2010	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD).Estudio abierto de seguridad a largo plazo de pramipexol de liberación prolongada (ER) en pacientes con enfermedad de Parkinson avanzada - Open label extension in advanced PD	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD).Estudio abierto de seguridad a largo plazo de pramipexol de liberación prolongada (ER) en pacientes con enfermedad de Parkinson avanzada - Open label extension in advanced PD	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim España, S.A.	NULL	Not Recruiting			Female: yes Male: yes	390	Phase 3	Hungary;Czech Republic;Slovakia;Poland;Spain;Austria;Italy;United Kingdom;Sweden
1025	EUCTR2007-002467-27-GB (EUCTR)	24/01/2008	26/11/2007	Antidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias - Antidyskinetic properties of topiramate	Antidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias - Antidyskinetic properties of topiramate	Patients with idiopathic Parkinson's disease and levodopa-induced dyskinesias MedDRA version: 13.1;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 13.1;Classification code 10061536;Term: Parkinson's disease;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 10029205 - Nervous system disorders	Product Name: Topiramate INN or Proposed INN: TOPIRAMATE	Salford Royal NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes			United Kingdom
1026	EUCTR2007-000350-31-FR (EUCTR)	22/01/2008	25/10/2007	A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD).	A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD).	Mild to moderately severe dementia associated with Parkinson’s disease (PDD). MedDRA version: 9.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease	Trade Name: Exelon INN or Proposed INN: rivastigmine Trade Name: Exelon INN or Proposed INN: rivastigmine Trade Name: Exelon INN or Proposed INN: rivastigmine Trade Name: Exelon INN or Proposed INN: rivastigmine Trade Name: Exelon 4.6 mg/24 h transdermal patch INN or Proposed INN: rivastigmine Trade Name: Exelon 9.5 mg/24 h transdermal patch INN or Proposed INN: rivastigmine	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	550		France;Spain;Italy
1027	EUCTR2006-006752-35-IT (EUCTR)	21/01/2008	24/04/2007	PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON S DISEASE - RECOVER	PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON S DISEASE - RECOVER	Idiopathic Parkinson Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro Trade Name: Neupro Trade Name: Neupro Trade Name: Neupro	SCHWARZ PHARMA	NULL	Not Recruiting			Female: yes Male: yes	336	Phase 3	Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy
1028	EUCTR2007-004235-37-CZ (EUCTR)	21/01/2008	18/12/2007	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim Pharma Ges mbH	NULL	Not Recruiting			Female: yes Male: yes	390		Hungary;United Kingdom;Czech Republic;Spain;Italy;Poland;Austria;Sweden
1029	EUCTR2007-002964-90-ES (EUCTR)	18/01/2008	30/11/2007	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.Ensayo fase III aleatorizado, doble ciego y controlado con placebo, para determinar la eficacia y la seguridad de un rango de dosis de 50 - 100 mg/día de safinamida, como terapia añadida, en pacientes con enfermedad de Parkinson idiopática con fluctuaciones motoras tratados con una dosis estable de levodopa y que podrían estar recibiendo tratamiento concomitante con dosis estables de un agonista de la dopamina, un anticolinérgico y/o amantadina. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.Ensayo fase III aleatorizado, doble ciego y controlado con placebo, para determinar la eficacia y la seguridad de un rango de dosis de 50 - 100 mg/día de safinamida, como terapia añadida, en pacientes con enfermedad de Parkinson idiopática con fluctuaciones motoras tratados con una dosis estable de levodopa y que podrían estar recibiendo tratamiento concomitante con dosis estables de un agonista de la dopamina, un anticolinérgico y/o amantadina. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	Ideopathic Parkinson's Disease Enfermedad de Parkinson Idiopática MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono International S.A.	NULL	Not Recruiting			Female: yes Male: yes	1121	Phase 3	France;Czech Republic;Estonia;Hungary;Slovakia;Finland;Belgium;Spain;Austria;Germany;Netherlands;United Kingdom
1030	EUCTR2007-002963-28-ES (EUCTR)	17/01/2008	16/11/2007	A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist.Ensayo en fase III aleatorizado, doble ciego y controlado con placebo, para determinar la eficacia y la seguridad de una dosis baja (50 mg/día) y una alta (100 mg/día) de safinamida, como terapia añadida en pacientes con enfermedad de Parkinson idiopática precoz tratados con una dosis estable de un único agonista de la dopamina. - Safinamide in early IPD, as add-on to dopamine agonist	A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist.Ensayo en fase III aleatorizado, doble ciego y controlado con placebo, para determinar la eficacia y la seguridad de una dosis baja (50 mg/día) y una alta (100 mg/día) de safinamida, como terapia añadida en pacientes con enfermedad de Parkinson idiopática precoz tratados con una dosis estable de un único agonista de la dopamina. - Safinamide in early IPD, as add-on to dopamine agonist	Idiopathic Parkinson's DiseaseEnfermedad de Parkinson Idiopática MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono International S.A.	NULL	Not Recruiting			Female: yes Male: yes	1036	Phase 3	Portugal;Czech Republic;Slovakia;Finland;Poland;Spain;Bulgaria;Germany;Italy
1031	EUCTR2007-004235-37-SK (EUCTR)	14/01/2008	16/04/2008	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Long-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PD	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim RCV GmbH & Co KG	NULL	Not Recruiting			Female: yes Male: yes	390	Phase 3	Hungary;Czech Republic;Slovakia;Spain;Poland;Austria;Italy;United Kingdom;Sweden
1032	NCT00623324 (ClinicalTrials.gov)	January 2008	14/2/2008	The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease	A Phase II, Dose Ranging, Randomized, Double Blind, Placebo-controlled, Multi-center, Pilot Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of Aplindore in Patients With Early Stage Parkinson's Disease	Early Stage Parkinson's Disease	Drug: Aplindore;Drug: Placebo	Ligand Pharmaceuticals	NULL	Completed	30 Years	N/A	Both	40	Phase 2	United States
1033	NCT00725478 (ClinicalTrials.gov)	January 2008	28/7/2008	SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease	Stabilization on, or Change-over to the Non-ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Parkinson Clinic Ambulances and Larger Private Practices.	Parkinson's Disease	Drug: Piribedil	Desitin Arzneimittel GmbH	NULL	Completed	18 Years	N/A	Both	250	N/A	NULL
1034	NCT00627588 (ClinicalTrials.gov)	January 2008	31/1/2008	Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease	A Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin®, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease.	Parkinson's Disease	Biological: ProSavin	Oxford BioMedica	NULL	Completed	48 Years	65 Years	Both	15	Phase 1/Phase 2	France;United Kingdom
1035	NCT00623103 (ClinicalTrials.gov)	January 2008	14/2/2008	Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)	A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)	Parkinson's Disease Dementia	Drug: Rivastigmine capsule;Drug: Rivastigmine transdermal patch	Novartis	NULL	Completed	50 Years	85 Years	All	583	Phase 3	United States;Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom
1036	EUCTR2006-003732-30-IT (EUCTR)	31/12/2007	13/02/2008	Transdermal Use of Lisuride in Early ParkinsonŽs Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - Tulep I	Transdermal Use of Lisuride in Early ParkinsonŽs Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - Tulep I	Diagnosys of Early-stage idiopathic Parkinson's Disease for longest 1 year MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: lisuride TTS INN or Proposed INN: Lisuride Trade Name: mirapexin INN or Proposed INN: Pramipexole	NEUROBIOTEC GMBH	NULL	Not Recruiting			Female: yes Male: yes	350		Germany;Italy;Poland
1037	EUCTR2007-004654-81-GB (EUCTR)	20/12/2007	16/10/2007	A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson’s disease patients	A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson’s disease patients	Sialorrhoea associated with Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10059812;Term: Sialorrhoea	Trade Name: Catapres ampoules INN or Proposed INN: Clonidine hydrochloride Trade Name: Ditropan elixir INN or Proposed INN: Oxybutynin hydrochloride	Summit (Cambridge) Ltd.	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	United Kingdom
1038	EUCTR2007-000801-30-HU (EUCTR)	20/12/2007	15/11/2007	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	726		Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania
1039	EUCTR2006-006907-35-IT (EUCTR)	19/12/2007	20/04/2007	A multicenter, multinational, phase 3b, open label extension trial, to evaluate the long term effect of the 24 hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non motor symptoms in subjects with idiopathic Parkinson disease. - SP915, Long term extension of RECOVER	A multicenter, multinational, phase 3b, open label extension trial, to evaluate the long term effect of the 24 hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non motor symptoms in subjects with idiopathic Parkinson disease. - SP915, Long term extension of RECOVER	Patient with Idiopathic Parkinson Diesease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: rotigotine INN or Proposed INN: rotigotine	SCHWARZ PHARMA	NULL	Not Recruiting			Female: yes Male: yes	270	Phase 3	Hungary;Finland;United Kingdom;Germany;Spain;Italy;Austria
1040	EUCTR2004-000185-12-GB (EUCTR)	13/12/2007	11/02/2005	A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PD	A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PD	Parkinson's disease MedDRA version: 7.0;Level: LLT;Classification code 10061536	Trade Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet INN or Proposed INN: Levodopa	Orion Corporation, ORION PHARMA, 02200 Espoo, Finland	NULL	Not Recruiting			Female: yes Male: yes	740	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Finland;Austria;Italy;United Kingdom;Sweden
1041	EUCTR2007-002963-28-FI (EUCTR)	12/12/2007	18/10/2007	A trial to determine the efficacy and safety of a low (50mg/day) and high (100mg/day) dose of safinamide, as add-on therapy, in patients with early Parkinson's Disease treated with a single dopamine agonist.	A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist. - Safinamide in early IPD, as add-on to dopamine agonist	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Newron Pharmaceuticals SpA	NULL	Not Recruiting			Female: yes Male: yes	839	Phase 3	Portugal;United States;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;South Africa;Germany
1042	EUCTR2007-002964-90-NL (EUCTR)	11/12/2007	11/12/2007	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	Ideopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono International S.A.	NULL	Not Recruiting			Female: yes Male: yes	1121	Phase 3	France;Czech Republic;Estonia;Hungary;Slovakia;Finland;Spain;Belgium;Austria;Germany;Netherlands;United Kingdom
1043	EUCTR2007-002963-28-SK (EUCTR)	06/12/2007	16/04/2008	A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist. - Safinamide in early IPD, as add-on to dopamine agonist	A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist. - Safinamide in early IPD, as add-on to dopamine agonist	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	839	Phase 3	Portugal;Czech Republic;Slovakia;Finland;Poland;Spain;Bulgaria;Germany;Italy
1044	EUCTR2007-002964-90-SK (EUCTR)	06/12/2007	16/04/2008	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	Idiopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono S.A. - Geneva	NULL	Not Recruiting			Female: yes Male: yes	540	Phase 3	France;Czech Republic;Estonia;Hungary;Slovakia;Finland;Spain;Belgium;Austria;Germany;Netherlands;United Kingdom
1045	EUCTR2007-002964-90-FI (EUCTR)	04/12/2007	18/10/2007	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopa	Ideopathic Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Merck Serono International S.A.	NULL	Not Recruiting			Female: yes Male: yes	1121	Phase 3	Hungary;Finland;Czech Republic;United Kingdom;Germany;Netherlands;Belgium;Estonia;France;Spain;Austria
1046	EUCTR2007-000801-30-ES (EUCTR)	29/11/2007	12/09/2007	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor FluctuationsEstudio de extensión abierto y multicéntrico para la evaluación a largo plazo de la seguridad, la tolerabilidad y la eficacia de E2007 como tratamiento complementario en pacientes con enfermedad de Parkinson tratados con levodopa que padecen fluctuaciones motoras	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor FluctuationsEstudio de extensión abierto y multicéntrico para la evaluación a largo plazo de la seguridad, la tolerabilidad y la eficacia de E2007 como tratamiento complementario en pacientes con enfermedad de Parkinson tratados con levodopa que padecen fluctuaciones motoras	Parkinson's DiseaseEnfermedad de Parkinson MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	726	Phase 3	France;Hungary;Estonia;Czech Republic;Poland;Spain;Lithuania;Latvia;Italy
1047	EUCTR2007-004985-41-SE (EUCTR)	29/11/2007	10/10/2007	Different dyskinesias in Parkinson's disease and their relation to levodopa pharmacokinetics - The dyskinesia study	Different dyskinesias in Parkinson's disease and their relation to levodopa pharmacokinetics - The dyskinesia study	Parkinson's disease, G20.9. Different dyskinesias related to advanced Parkinson's disease will be investigated.	Trade Name: Duodopa INN or Proposed INN: levodopa INN or Proposed INN: carbidopa	Department of Neuroscience, neurology	NULL	Not Recruiting			Female: yes Male: yes			Sweden
1048	EUCTR2007-002906-23-GB (EUCTR)	14/11/2007	15/08/2007	A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease	A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease	Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS	Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate	Acadia Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	280		United Kingdom;Bulgaria;France
1049	ChiCTR-TRC-07000027	2007-11-01	2007-11-09	A randomized controlled clinical study of Pramipexole for Parkinson's disease	A randomized controlled clinical study of Pramipexole for Parkinson's disease	Primary Parkinson's disease	Group 1:Artane oral 1-2mg, tid,+ Mirapexin, 0.25 mg/d at beginning, and add to 1.0 mg/d at the end of the second week; the dose will be added from the second weekend to the eighth week to 4. 5 mg/d(1.5 mg, tid); maintain the dose during 12 weeks and reduce the dose during 1-4weeks;Group 3:Artane oral 1-2mg, tid + Madopar, 62.5~500 mg, 2~4 times a day depends on the serious of disease + Mirapexin, the dose is same as group 1;Group 2:Artane oral 1-2mg, tid+ Benserazide-Levodopa (Madopar), oral 62.5~500 mg, 2~4 times a day depends on the serious of the disease;	First Affiliated Hospital of Xinjiang Medical University	NULL	Completed	30	80	Both	Group 1:45;Group 3:45;Group 2:45;		China
1050	NCT00605683 (ClinicalTrials.gov)	November 2007	19/12/2007	MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist	A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist	Idiopathic Parkinson's Disease	Drug: Safinamide (as add-on therapy)	Newron	NULL	Completed	30 Years	80 Years	Both	679	Phase 3	United States;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;Israel
1051	NCT00560508 (ClinicalTrials.gov)	November 2007	16/11/2007	A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period	A Double-blind, Double-dummy, Randomised, Parallel-group Study to Investigate the Safety, Tolerability, Trough Plasma Concentration, and Efficacy of Pramipexole ER Versus Pramipexole Immediate Release (IR) Administered Orally for 12 Weeks in Patients With Parkinson's Disease (PD) on L-dopa Therapy, Followed by a 52-week Open-label Long-term Treatment Period to Evaluate the Long-term Safety and Efficacy of Pramipexole ER	Parkinson Disease	Drug: Pramipexole Immediate Release;Drug: Pramipexole Extended Release	Boehringer Ingelheim	NULL	Completed	1 Year	N/A	All	112	Phase 2/Phase 3	Japan
1052	NCT00632762 (ClinicalTrials.gov)	November 2007	20/2/2008	Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK)	Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK.	Parkinson's Disease	Drug: mantadix	University Hospital, Toulouse	NULL	Completed	30 Years	80 Years	Both	80	Phase 4	France
1053	NCT00558337 (ClinicalTrials.gov)	November 2007	12/11/2007	Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease	An Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Relationship Study of L-Dopa/Carbidopa in a Novel Release Formulation in Parkinson's Disease Patients	Parkinson's Disease	Drug: levodopa-carbidopa	Osmotica Pharmaceutical Corp.	NULL	Completed	30 Years	80 Years	Both	78	Phase 2	Argentina
1054	EUCTR2007-002906-23-FR (EUCTR)	25/10/2007	21/08/2007	A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease	A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease	Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS	Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate	Acadia Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	280	Phase 2;Phase 3	France;Bulgaria;United Kingdom
1055	EUCTR2007-001717-42-FR (EUCTR)	25/10/2007	11/09/2007	A Phase 2, 36 Week, Open-Label, Uncontrolled Safety Follow-Up Study Assessing SCH 420814 5 mg BID - N/A	A Phase 2, 36 Week, Open-Label, Uncontrolled Safety Follow-Up Study Assessing SCH 420814 5 mg BID - N/A	Patients with Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias	Product Name: SCH 420814 Product Code: N/A	Schering Plough Research Institute	NULL	Not Recruiting			Female: yes Male: yes	200	Phase 2	France;Spain
1056	EUCTR2007-003353-90-NL (EUCTR)	23/10/2007	07/08/2007	A double-blind, double-dummy, randomized, parallel groups study toassess the Efficacy, Safety and Tolerability of switching patients withearly Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ERor Pramipexole IR.	A double-blind, double-dummy, randomized, parallel groups study toassess the Efficacy, Safety and Tolerability of switching patients withearly Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ERor Pramipexole IR.	Male or female patients with idiopathic Parkinson's disease diagnosed within 5 years, with a modified Hoehn and Yahr scale of 1 to 3. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim	NULL	Not Recruiting			Female: yes Male: yes	145	Phase 3	France;Germany;Netherlands
1057	EUCTR2007-000801-30-FR (EUCTR)	22/10/2007	23/07/2007	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	726	Phase 3	France;Hungary;Estonia;Czech Republic;Spain;Poland;Lithuania;Latvia;Italy
1058	EUCTR2007-003353-90-FR (EUCTR)	17/10/2007	27/08/2007	A double-blind, double-dummy, randomized, parallel groups study toassess the Efficacy, Safety and Tolerability of switching patients withearly Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ERor Pramipexole IR.	A double-blind, double-dummy, randomized, parallel groups study toassess the Efficacy, Safety and Tolerability of switching patients withearly Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ERor Pramipexole IR.	Male or female patients with idiopathic Parkinson's disease diagnosed within 5 years, with a modified Hoehn and Yahr scale of 1 to 3. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	BOEHRINGER INGELHEIM	NULL	Not Recruiting			Female: yes Male: yes	145	Phase 3	France;Germany;Netherlands
1059	EUCTR2006-006907-35-GB (EUCTR)	09/10/2007	26/04/2007	Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVER	Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVER	Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro 2mg/24h transdermal patch Product Code: ND1587 INN or Proposed INN: Rotigotine Trade Name: Neupro 4mg/24h transdermal patch Product Code: ND1589 INN or Proposed INN: Rotigotine Trade Name: Neupro 6mg/24h transdermal patch Product Code: ND1590 INN or Proposed INN: Rotigotine Trade Name: Neupro 8mg/24h transdermal patch Product Code: ND1702 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH, UCB Group	NULL	Not Recruiting			Female: yes Male: yes	270	Phase 3	Hungary;Finland;Spain;Austria;Germany;Italy;United Kingdom
1060	EUCTR2005-005791-32-SE (EUCTR)	04/10/2007	30/07/2007	Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.	Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.	HF0220 experimentally appears to exert its potential beneficial effects within the CNS and possibly other tissues by attenuating the adverse effects of oxidative stress. It is believed that this mechanism has the potential to reduce disease progression in a wide range of disorders of the nervous system, e.g. Alzheimer's and Parkinson's disease, and brain damage due to acute stroke and head injury. It may also apply to the protection of peripheral tissues, such as the heart and/or kidney. MedDRA version: 9.1;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes)	Product Name: HF0220 Product Code: HF0220 Other descriptive name: 7-beta-hydroxyepiandrosterone	Hunter-Fleming Ltd	NULL	Not Recruiting			Female: yes Male: yes	40		United Kingdom;Sweden
1061	EUCTR2007-002900-16-DE (EUCTR)	01/10/2007	21/08/2007	A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration study in patients with Parkinson’s disease to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias, and the safety and tolerability of AFQ056 in combination with L-dopa	A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration study in patients with Parkinson’s disease to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias, and the safety and tolerability of AFQ056 in combination with L-dopa	The main objective of this study is to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias.	Product Code: AFQ056 Product Code: AFQ056	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	34		Germany
1062	NCT00558025 (ClinicalTrials.gov)	October 2007	12/11/2007	Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease	A Double-blind, Double-dummy, Randomized, Parallel Groups Study to Assess the Efficacy, Safety and Tolerability of Switching Patients With Early Parkinson's Disease (PD) From Pramipexole IR to Pramipexole ER or Pramipexole IR	Parkinson Disease	Drug: Pramipexole Extended Release;Drug: Pramipexole Immediate Release	Boehringer Ingelheim	NULL	Completed	30 Years	N/A	All	156	Phase 3	France;Germany;Netherlands
1063	NCT01520727 (ClinicalTrials.gov)	October 2007	18/1/2012	A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects	A Single Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of BIA 9-1067 in Healthy Male Subjects	Parkinson Disease	Drug: BIA 9-1067;Drug: Placebo	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	Male	64	Phase 1	France
1064	NCT00559871 (ClinicalTrials.gov)	October 2007	15/11/2007	Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease	A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Efficacy, Safety and Tolerability of Fipamezole as an Oromucosal Fast Dissolving Tablet in the Treatment of Parkinson's Disease Patients.	Parkinson's Disease	Drug: fipamezole	Juvantia Pharma Ltd	Santhera Pharmaceuticals	Completed	30 Years	N/A	Both	180	Phase 2	United States;India
1065	NCT00642928 (ClinicalTrials.gov)	October 2007	21/3/2008	Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients	Randomized, Dose-finding Study of BF 2.649 5, 10 20 and 40 mg/d in Comparison to Placebo in Excessive Daytime Sleepiness in Parkinson's Disease Patients (PD)	Excessive Daytime Sleepiness;Parkinson's Disease	Drug: Placebo;Drug: BF 2.649 5 mg;Drug: BF 2.649 10 mg;Drug: BF 2.649 20 mg;Drug: BF 2.649 40 mg	Bioprojet	NULL	Completed	18 Years	N/A	Both	108	Phase 2	France
1066	NCT00582673 (ClinicalTrials.gov)	October 2007	21/12/2007	Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa	A Multi-centre, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multiple Oral Dose Titration Study in Patients With Parkinson's Disease to Assess the Efficacy of AFQ056 in Reducing L-dopa Induced Dyskinesias, and the Safety and Tolerability of AFQ056 in Combination With L-dopa	Parkinson's Disease	Drug: AFQ056;Drug: Placebo	Novartis	NULL	Completed	30 Years	85 Years	Both	31	Phase 2	Germany
1067	EUCTR2006-002937-20-HU (EUCTR)	20/09/2007	17/05/2007	A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Parkinson's Disease MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS Trade Name: Comtess Product Name: Entacapone	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	702		Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Lithuania
1068	EUCTR2007-002874-75-IT (EUCTR)	10/09/2007	14/01/2008	Safety and effectivness of Open- Label Melperone in the treatment of Patients with Psycosis Associated with Parkinson's Disease'' - OV-1005	Safety and effectivness of Open- Label Melperone in the treatment of Patients with Psycosis Associated with Parkinson's Disease'' - OV-1005	Psycosis associated to Parkinson's Disease MedDRA version: 9.1;Level: HLT;Classification code 10027361;Term: Mental disorders due to a general medical condition NEC	Product Name: Melperon	OVATION PHARMACEUTICALS INC	NULL	Not Recruiting			Female: yes Male: yes	90		Italy
1069	EUCTR2007-000801-30-LT (EUCTR)	07/09/2007	05/07/2007	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	726		Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania
1070	EUCTR2007-003353-90-DE (EUCTR)	05/09/2007	08/08/2007	A double-blind, double-dummy, randomized, parallel groups study toassess the Efficacy, Safety and Tolerability of switching patients withearly Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ERor Pramipexole IR.	A double-blind, double-dummy, randomized, parallel groups study toassess the Efficacy, Safety and Tolerability of switching patients withearly Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ERor Pramipexole IR.	Male or female patients with idiopathic Parkinson's disease diagnosed within 5 years, with a modified Hoehn and Yahr scale of 1 to 3. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Trade Name: Sifrol Product Name: Pramipexole Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim Pharma GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	132		Germany;Netherlands;France
1071	NCT00524914 (ClinicalTrials.gov)	September 2007	4/9/2007	Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study	Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study.	Parkinson's Disease	Drug: apomorphine;Drug: placebo	University Hospital, Toulouse	NULL	Completed	30 Years	70 Years	Both	16	N/A	France
1072	EUCTR2007-000801-30-PL (EUCTR)	29/08/2007	17/07/2007	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	726	Phase 3	Spain;Poland;Lithuania;Latvia;Italy;France;Hungary;Estonia;Czech Republic
1073	EUCTR2007-003512-57-FR (EUCTR)	24/08/2007	23/07/2007	Randomized, dose-finding study of BF 2.649 5, 10, 20 and 40 mg/d in comparison to placebo in Excessive Daytime Sleepiness in Parkinson’s Disease patients (PD)	Randomized, dose-finding study of BF 2.649 5, 10, 20 and 40 mg/d in comparison to placebo in Excessive Daytime Sleepiness in Parkinson’s Disease patients (PD)	Excessive daytime sleepiness associated to Parkinson disease MedDRA version: 9.1;Level: LLT;Classification code 10041014;Term: Sleepiness MedDRA version: 9.1;Classification code 10061536;Term: Parkinson's disease	Product Name: BF 2.649 Product Code: BF 2.649 Product Name: BF 2.649 Product Code: BF 2.649 Product Name: BF 2.649 Product Code: BF 2.649 Product Name: BF 2.649 Product Code: BF 2.649	Bioprojet	NULL	Not Recruiting			Female: yes Male: yes	130	Phase 2	France
1074	EUCTR2007-000801-30-EE (EUCTR)	22/08/2007	17/07/2007	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	726		Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania
1075	EUCTR2006-000859-18-DE (EUCTR)	13/08/2007	05/04/2007	An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study	An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study	Parkinson's Disease Early stage	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308	Solvay pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	225		Portugal;Czech Republic;Germany;Netherlands;Estonia;Italy;Lithuania
1076	EUCTR2007-000074-23-HU (EUCTR)	10/08/2007	01/06/2007	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Trade Name: SIFROL INN or Proposed INN: Pramipexole	Boehringer Ingelheim Pharma Ges mbH	NULL	Not Recruiting			Female: yes Male: yes	516	Phase 1	Hungary;United Kingdom;Spain;Italy;Austria;Sweden
1077	EUCTR2007-000801-30-CZ (EUCTR)	01/08/2007	15/06/2007	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	726		Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania
1078	NCT00335374 (ClinicalTrials.gov)	August 2007	8/6/2006	An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients	An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients	Early Stage Parkinson's Disease	Drug: Pardoprunox	Solvay Pharmaceuticals	NULL	Completed	30 Years	N/A	Both	202	Phase 3	United States;Australia;Czech Republic;Estonia;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Taiwan;Thailand;France;Spain;United Kingdom
1079	NCT00407095 (ClinicalTrials.gov)	August 2007	30/11/2006	An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.	An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.	Advanced Stage Parkinson's Disease	Drug: Pardoprunox	Solvay Pharmaceuticals	NULL	Completed	30 Years	N/A	Both	140	Phase 3	United States;Albania;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine
1080	EUCTR2007-000801-30-LV (EUCTR)	27/07/2007	05/07/2007	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations	Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	726		Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania
1081	EUCTR2006-006752-35-GB (EUCTR)	23/07/2007	13/01/2009	RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINE PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Recover	RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINE PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Recover	Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro 2mg/24 h transdermal patch Product Code: ND1587 INN or Proposed INN: Rotigotine Trade Name: Neupro 4mg/24 h transdermal patch Product Code: ND1589 INN or Proposed INN: Rotigotine Trade Name: Neupro 6mg/24 h transdermal patch Product Code: ND1590 INN or Proposed INN: Rotigotine Trade Name: Neupro 8 mg/24 h transdermal patch Product Code: ND1702 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH, UCB Group	NULL	Not Recruiting			Female: yes Male: yes	400	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Hungary;Finland;Spain;Austria;Germany;Italy;United Kingdom
1082	EUCTR2007-000801-30-IT (EUCTR)	17/07/2007	13/11/2007	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations - ND	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations - ND	Parkinson's Disease Subjects with Motor Fluctuations MedDRA version: 6.1;Level: PT;Classification code 10061536	Product Name: E2007	EISAI LTD UK	NULL	Not Recruiting			Female: yes Male: yes	726	Phase 3	France;Hungary;Estonia;Czech Republic;Spain;Poland;Lithuania;Latvia;Italy
1083	EUCTR2006-005318-11-FR (EUCTR)	06/07/2007	10/05/2007	Effet de l'apomorphine sur la perception douloureuse chez le patient parkinsonien : étude clinique et en tomographie par émission de positons.	Effet de l'apomorphine sur la perception douloureuse chez le patient parkinsonien : étude clinique et en tomographie par émission de positons.	maladie de Parkinson MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Trade Name: APOKINON	CHU Toulouse	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France
1084	NCT00519532 (ClinicalTrials.gov)	July 2007	21/8/2007	Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease	A Multicenter, Multinational, Phase 3b, Open-label Extension Trial to Evaluate the Long-term Effect of the 24-hour Transdermal Delivery of Rotigotine on Motor Function, Sleep Quality, and Nocturnal and Non-motor Symptoms in Subjects With Idiopathic Parkinson's Disease	Parkinson's Disease	Drug: Rotigotine	UCB Pharma	NULL	Terminated	18 Years	N/A	All	84	Phase 3	United States;Australia;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;Austria
1085	NCT00550238 (ClinicalTrials.gov)	July 2007	26/10/2007	A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease	Parkinson's Disease Psychosis	Drug: Pimavanserin tartrate (ACP-103)	ACADIA Pharmaceuticals Inc.	NULL	Completed	40 Years	N/A	All	459	Phase 3	United States;Austria;Belgium;Canada;France;India;Italy;Poland;Portugal;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom
1086	NCT00556764 (ClinicalTrials.gov)	July 2007	8/11/2007	Development of Cognitive Assessment Tools in Parkinson Disease	Development of Cognitive Assessment Tools in Parkinson Disease	Parkinson Disease	Drug: [123I] IBVM and SPECT imaging;Drug: Subjects will undergo the 123-I IBVM imaging visit	Institute for Neurodegenerative Disorders	Department of Defense;University of Oklahoma	Completed	30 Years	N/A	Both	75	Phase 0	United States
1087	NCT00515437 (ClinicalTrials.gov)	July 2007	10/8/2007	A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients	A Multi-Center, Randomized, Double-blind, Placebo-Controlled,Sequential Dose Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients	Drooling	Biological: Botulinum Toxin Type B (Myobloc);Biological: Matched placebo to Myobloc	Solstice Neurosciences	NULL	Completed	18 Years	85 Years	All	54	Phase 2	United States
1088	NCT00505622 (ClinicalTrials.gov)	July 2007	9/7/2007	Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations	Parkinson's Disease	Drug: Perampanel	Eisai Limited	NULL	Terminated	30 Years	N/A	All	328	Phase 3	France
1089	NCT00522379 (ClinicalTrials.gov)	July 2007	28/8/2007	Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch	A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects With Advanced-stage Parkinson's Disease	Parkinson's Disease	Drug: Rotigotine;Other: Placebo	UCB Pharma	NULL	Completed	30 Years	N/A	All	514	Phase 3	United States;Chile;India;Mexico;Peru
1090	NCT00593606 (ClinicalTrials.gov)	July 2007	21/12/2007	Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine	A Phase 3b, Open-Label, Multicenter Trial to Assess the Safety and Tolerability of Switching Korean Subjects From Ropinirole to the Rotigotine Transdermal System and Its Effect on Symptoms in Idiopathic Parkinson's Disease	Parkinson's Disease	Drug: Rotigotine	UCB Pharma	NULL	Completed	18 Years	N/A	All	124	Phase 3	NULL
1091	EUCTR2006-006752-35-HU (EUCTR)	22/06/2007	12/04/2007	RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINEPHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Recover	RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINEPHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Recover	Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro 2mg/24 h transdermal patch Product Code: ND1587 INN or Proposed INN: Rotigotine Trade Name: Neupro 4mg/24 h transdermal patch Product Code: ND1589 INN or Proposed INN: Rotigotine Trade Name: Neupro 6mg/24 h transdermal patch Product Code: ND1590 INN or Proposed INN: Rotigotine Trade Name: Neupro 8 mg/24 h transdermal patch Product Code: ND1702 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	400	Phase 3	Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy
1092	EUCTR2006-000678-57-CZ (EUCTR)	18/06/2007	02/08/2006	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	Parkinson 's Disease early stage MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochlori	Solvay pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	330		Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania
1093	EUCTR2007-000073-39-CZ (EUCTR)	18/06/2007	18/04/2007	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)	Male or female patients with idiopathic Parkinson’s disease (PD), diagnosed within 5 years, having Modified Hoehn and Yahr stage of 1 to 3. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet	Boehringer Ingelheim RCV GmbH & Co KG	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 1	Hungary;Finland;Czech Republic;Austria
1094	EUCTR2007-000074-23-CZ (EUCTR)	18/06/2007	31/05/2007	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Trade Name: SIFROL INN or Proposed INN: Pramipexole	Boehringer Ingelheim RCV GmbH & Co KG	NULL	Not Recruiting			Female: yes Male: yes	516	Phase 3	Hungary;Czech Republic;Spain;Austria;Italy;United Kingdom;Sweden
1095	EUCTR2007-000073-39-HU (EUCTR)	14/06/2007	31/05/2007	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)	Male or female patients with idiopathic Parkinson’s disease (PD), diagnosed within 5 years, having Modified Hoehn and Yahr stage of 1 to 3. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet	Boehringer Ingelheim Pharma Ges mbH	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 1	Finland;Hungary;Czech Republic;Austria
1096	EUCTR2007-000073-39-SK (EUCTR)	14/06/2007	09/04/2008	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)	Male or female patients with idiopathic Parkinson’s disease (PD), diagnosed within 5 years, having Modified Hoehn and Yahr stage of 1 to 3. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet	Boehringer Ingelheim Pharma Ges mbH	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 3	Hungary;Czech Republic;Slovakia;Finland;Austria;Germany
1097	EUCTR2007-000074-23-SK (EUCTR)	14/06/2007	09/04/2008	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Trade Name: SIFROL INN or Proposed INN: Pramipexole	Boehringer Ingelheim Pharma Ges mbH	NULL	Not Recruiting			Female: yes Male: yes	516	Phase 3	Hungary;Czech Republic;Slovakia;Spain;Austria;Italy;United Kingdom;Sweden
1098	EUCTR2006-005861-21-IT (EUCTR)	11/06/2007	05/01/2007	A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE LONG-TERM EFFICACY AND SAFETY OF A LOW (50 MG/DAY) AND HIGH (100 MG/DAY) DOSE OF SAFINAMIDE, AS ADD-ON THERAPY, IN PATIENTS WITH IDIOPATHIC PARKINSON`S DISEASE WITH MOTOR FLUCTUATIONS, TREATED WITH A STABLE DOSE OF LEVODOPA AND WHO MAY BE RECEIVING CONCOMITANT TREATMENT WITH STABLE DOSES OF A DOPAMINE AGONIST, AND/OR AN ANTICHOLINERGIC.	A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE LONG-TERM EFFICACY AND SAFETY OF A LOW (50 MG/DAY) AND HIGH (100 MG/DAY) DOSE OF SAFINAMIDE, AS ADD-ON THERAPY, IN PATIENTS WITH IDIOPATHIC PARKINSON`S DISEASE WITH MOTOR FLUCTUATIONS, TREATED WITH A STABLE DOSE OF LEVODOPA AND WHO MAY BE RECEIVING CONCOMITANT TREATMENT WITH STABLE DOSES OF A DOPAMINE AGONIST, AND/OR AN ANTICHOLINERGIC.	Patients with idiopathic Parkinson's disease with motor fluctuations MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Monoamine oxidase B inhibitors Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Monoamine oxidase B inhibitors	NEWRON PHARMACEUTICALS	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 3	Italy
1099	EUCTR2006-006684-22-FR (EUCTR)	08/06/2007	27/03/2007	Evaluation des effets à long terme de l’amantadine chez le parkinsonien souffrant de dyskinésies induites par la lévodopa : Etude randomisée en double-insu versus placebo de l’arrêt d’une prescription chronique. - AMANDYSK	Evaluation des effets à long terme de l’amantadine chez le parkinsonien souffrant de dyskinésies induites par la lévodopa : Etude randomisée en double-insu versus placebo de l’arrêt d’une prescription chronique. - AMANDYSK	maladie de parkinson MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's MedDRA version: 9.1;Classification code 10013916;Term: Dyskinesia	Trade Name: MANTADIX	CHU Toulouse	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France
1100	EUCTR2006-000858-45-SE (EUCTR)	05/06/2007	04/04/2007	An open label SLV308 safety extension to study S308.3.001 in early PD patients. - An extension of the Rembrandt study	An open label SLV308 safety extension to study S308.3.001 in early PD patients. - An extension of the Rembrandt study	Parkinson's Disease Early Stage	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	300		Finland;Sweden
1101	JPRN-UMIN000000780	2007/06/01	01/08/2007	A randomized, double-blind, placebo-controlled, cross-over, multi-center study concerning the efficacy and safety of amantadine hydrochloride in treatment of dyskinesias in Parkinson's disease	A randomized, double-blind, placebo-controlled, cross-over, multi-center study concerning the efficacy and safety of amantadine hydrochloride in treatment of dyskinesias in Parkinson's disease - The usefulness of amantadine hydrochloride in treatment of dyskinesias in Parkinson's disease	Parkinson's disease	An observation period (2 to 3 weeks) An administration of amantadine hydrochloride (27 days) A wash out period (15 days) An administration of placebo (27 days) An observation period (2 to 3 weeks) An administration of placebo (27 days) A wash out period (15 days) An administration of amantadine hydrochloride (27 days)	Comprehensive clinical study group concerning diagnosis, treatment, and prevention of the neurological disorders	Musashi Hospital, National Center of Neurology and Psychiatry, JapanEhime University Hospital	Complete: follow-up complete	20years-old	75years-old	Male and Female	60	Not applicable	Japan
1102	NCT00477672 (ClinicalTrials.gov)	June 2007	22/5/2007	A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease	Parkinson's Disease Psychosis	Drug: Pimavanserin tartrate (ACP-103);Drug: Placebo	ACADIA Pharmaceuticals Inc.	NULL	Completed	40 Years	N/A	All	298	Phase 3	United States;Bulgaria;France;India;Russian Federation;Ukraine;United Kingdom
1103	EUCTR2007-000073-39-AT (EUCTR)	30/05/2007	05/06/2007	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)	Male or female patients with idiopathic Parkinson’s disease (PD), diagnosed within 5 years, having Modified Hoehn and Yahr stage of 1 to 3. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet	Boehringer Ingelheim Pharma Ges mbH	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 1	Hungary;Finland;Czech Republic;Austria
1104	EUCTR2007-000074-23-AT (EUCTR)	30/05/2007	05/06/2007	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Trade Name: SIFROL INN or Proposed INN: Pramipexole	Boehringer Ingelheim Pharma GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	516	Phase 1	Hungary;United Kingdom;Spain;Italy;Austria;Sweden
1105	EUCTR2007-000073-39-DE (EUCTR)	29/05/2007	26/02/2007	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)	Male or female patients with idiopathic Parkinson’s disease (PD), diagnosed within 5 years, having Modified Hoehn and Yahr stage of 1 to 3. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet	Boehringer Ingelheim Pharma GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 1	Hungary;Czech Republic;Finland;Austria;Germany
1106	EUCTR2007-000074-23-ES (EUCTR)	29/05/2007	02/03/2010	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).Estudio aleatorizado, doble ciego, doble simulación, controlado con placebo de tres grupos paralelos que compara la eficacia, la seguridad y la tolerabilidad de pramipexol ER frente a placebo y frente a pramipexol IR administrados por vía oral durante una fase de mantenimiento de 26 semanas de duración en pacientes con enfermedad de Parkinson (EP) avanzada tratados con L-Dopa+.	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).Estudio aleatorizado, doble ciego, doble simulación, controlado con placebo de tres grupos paralelos que compara la eficacia, la seguridad y la tolerabilidad de pramipexol ER frente a placebo y frente a pramipexol IR administrados por vía oral durante una fase de mantenimiento de 26 semanas de duración en pacientes con enfermedad de Parkinson (EP) avanzada tratados con L-Dopa+.	Pacientes varones o mujeres, diagnosticados de enfermedad de Parkinson idiopática, al menos dos años antes, con 30 años o más de edad en el momento del diagnóstico, con un estadío entre 2 y 4 en la escala modificada de Hoehn y Yahr en el periodo on.Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim España, S.A.	NULL	Not Recruiting			Female: yes Male: yes	516	Phase 3	Hungary;Czech Republic;Slovakia;Spain;Austria;Italy;United Kingdom;Sweden
1107	EUCTR2006-006907-35-ES (EUCTR)	27/05/2007	27/03/2007	EXTENSIÓN A LARGO PLAZO DE RECOVER. ESTUDIO DE EXTENSIÓN MULTICÉNTRICO, MULTINACIONAL, DE FASE 3B, ABIERTO, PARA EVALUAR EL EFECTO A LARGO PLAZO DE LA ADMINISTRACIÓN TRANSDÉRMICA DURANTE 24 HORAS DE ROTIGOTINA SOBRE LA FUNCIÓN MOTORA, LA CALIDAD DEL SUEÑO Y LOS SÍNTOMAS NOCTURNOS Y SÍNTOMAS NO MOTORES EN SUJETOS CON ENFERMEDAD DE PARKINSON IDIOPÁTICA.(Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE) - Long-term extension of RECOVER	EXTENSIÓN A LARGO PLAZO DE RECOVER. ESTUDIO DE EXTENSIÓN MULTICÉNTRICO, MULTINACIONAL, DE FASE 3B, ABIERTO, PARA EVALUAR EL EFECTO A LARGO PLAZO DE LA ADMINISTRACIÓN TRANSDÉRMICA DURANTE 24 HORAS DE ROTIGOTINA SOBRE LA FUNCIÓN MOTORA, LA CALIDAD DEL SUEÑO Y LOS SÍNTOMAS NOCTURNOS Y SÍNTOMAS NO MOTORES EN SUJETOS CON ENFERMEDAD DE PARKINSON IDIOPÁTICA.(Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE) - Long-term extension of RECOVER	Enfermedad de Parkinson(Parkinson's disease) MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro 2mg/24h transdermal patch Product Code: ND1587 INN or Proposed INN: Rotigotine Trade Name: Neupro 4mg/24h transdermal patch Product Code: ND1589 INN or Proposed INN: Rotigotine Trade Name: Neupro 6mg/24h transdermal patch Product Code: ND1590 INN or Proposed INN: Rotigotine Trade Name: Neupro 8mg/24h transdermal patch Product Code: ND1702 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	270	Phase 3	Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy
1108	EUCTR2006-006752-35-ES (EUCTR)	27/05/2007	27/03/2007	RECOVER: EVALUACIÓN ALEATORIZADA DE LA COBERTURA 24 HORAS: EFICACIA DE ROTIGOTINA. ESTUDIO DE FASE 3B, MULTICÉNTRICO, MULTINACIONAL, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE 2 BRAZOS PARA EVALUAR EL EFECTO DE LA ADMINISTRACIÓN TRANSDÉRMICA 24 HORAS DE ROTIGOTINA SOBRE EL CONTROL DE LA FUNCIÓN MOTORA A PRIMERA HORA DE LA MAÑANA, LA CALIDAD DEL SUEÑO, LOS SÍNTOMAS NOCTURNOS Y LOS SÍNTOMAS NO MOTORES EN SUJETOS CON ENFERMEDAD DE PARKINSON IDIOPÁTICA.(RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINEPHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE) - Recover	RECOVER: EVALUACIÓN ALEATORIZADA DE LA COBERTURA 24 HORAS: EFICACIA DE ROTIGOTINA. ESTUDIO DE FASE 3B, MULTICÉNTRICO, MULTINACIONAL, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE 2 BRAZOS PARA EVALUAR EL EFECTO DE LA ADMINISTRACIÓN TRANSDÉRMICA 24 HORAS DE ROTIGOTINA SOBRE EL CONTROL DE LA FUNCIÓN MOTORA A PRIMERA HORA DE LA MAÑANA, LA CALIDAD DEL SUEÑO, LOS SÍNTOMAS NOCTURNOS Y LOS SÍNTOMAS NO MOTORES EN SUJETOS CON ENFERMEDAD DE PARKINSON IDIOPÁTICA.(RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINEPHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE) - Recover	Enfermedad de Parkinson(Parkinson's disease) MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro 2mg/24 h transdermal patch Product Code: ND1587 INN or Proposed INN: Rotigotine Trade Name: Neupro 4mg/24 h transdermal patch Product Code: ND1589 INN or Proposed INN: Rotigotine Trade Name: Neupro 6mg/24 h transdermal patch Product Code: ND1590 INN or Proposed INN: Rotigotine Trade Name: Neupro 8 mg/24 h transdermal patch Product Code: ND1702 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	400	Phase 3	Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy
1109	EUCTR2007-000074-23-IT (EUCTR)	17/05/2007	06/04/2007	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa treated patients with advanced Parkinson s disease PD . - ND	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa treated patients with advanced Parkinson s disease PD . - ND	Patients with advanced idiopathic Parkinson s disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: pramipexole ER Product Code: SND 919 CL2Y Product Name: Pramipexole ER Product Code: SND 919 CL2Y Product Name: Pramipexole ER Product Code: SND 919 CL2Y Product Name: Pramipexole ER Product Code: SND 919 CL2Y Product Name: Pramipexole ER Product Code: SND 919 CL2Y Trade Name: Sifrol Trade Name: Sifrol	BOEHRINGER ING.	NULL	Not Recruiting			Female: yes Male: yes	645	Phase 1	Hungary;United Kingdom;Spain;Italy;Austria;Sweden
1110	EUCTR2006-006907-35-HU (EUCTR)	17/05/2007	12/04/2007	Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVER	Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVER	Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro 2mg/24h transdermal patch Product Code: ND1587 INN or Proposed INN: Rotigotine Trade Name: Neupro 4mg/24h transdermal patch Product Code: ND1589 INN or Proposed INN: Rotigotine Trade Name: Neupro 6mg/24h transdermal patch Product Code: ND1590 INN or Proposed INN: Rotigotine Trade Name: Neupro 8mg/24h transdermal patch Product Code: ND1702 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	270	Phase 3	Finland;Hungary;United Kingdom;Germany;Spain;Italy;Austria
1111	EUCTR2007-000074-23-GB (EUCTR)	11/05/2007	29/03/2007	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Trade Name: SIFROL INN or Proposed INN: Pramipexole	Boehringer Ingelheim Limited	NULL	Not Recruiting			Female: yes Male: yes	516	Phase 1	Hungary;United Kingdom;Spain;Italy;Austria;Sweden
1112	EUCTR2006-006907-35-FI (EUCTR)	09/05/2007	21/03/2007	Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVER	Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVER	Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro 2mg/24h transdermal patch Product Code: ND1587 INN or Proposed INN: Rotigotine Trade Name: Neupro 4mg/24h transdermal patch Product Code: ND1589 INN or Proposed INN: Rotigotine Trade Name: Neupro 6mg/24h transdermal patch Product Code: ND1590 INN or Proposed INN: Rotigotine Trade Name: Neupro 8mg/24h transdermal patch Product Code: ND1702 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	270	Phase 3	Hungary;Finland;United Kingdom;Germany;Spain;Italy;Austria
1113	EUCTR2006-006752-35-FI (EUCTR)	09/05/2007	21/03/2007	RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINEPHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Recover	RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINEPHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Recover	Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro 2mg/24 h transdermal patch Product Code: ND1587 INN or Proposed INN: Rotigotine Trade Name: Neupro 4mg/24 h transdermal patch Product Code: ND1589 INN or Proposed INN: Rotigotine Trade Name: Neupro 6mg/24 h transdermal patch Product Code: ND1590 INN or Proposed INN: Rotigotine Trade Name: Neupro 8 mg/24 h transdermal patch Product Code: ND1702 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	400	Phase 3	Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy
1114	EUCTR2007-000074-23-SE (EUCTR)	02/05/2007	02/04/2007	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).	Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Product Name: Pramipexole ER Product Code: SND 919 CL2Y INN or Proposed INN: Pramipexole Trade Name: SIFROL INN or Proposed INN: Pramipexole	Boehringer Ingelheim AB	NULL	Not Recruiting			Female: yes Male: yes	516	Phase 1	Hungary;United Kingdom;Spain;Italy;Austria;Sweden
1115	NCT00489255 (ClinicalTrials.gov)	May 2007	20/6/2007	Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment	A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Trimethobenzamide (Tigan®) in the Control of Nausea and Vomiting During Initiation and Continued Treatment With Subcutaneous Apomorphine (Apokyn®) in Apomorphine-naïve Subjects With Parkinson's Disease Suffering From Acute Intermittent Off Episodes, With Phased Withdrawal of Subjects From Tigan® to Placebo	Parkinson's Disease	Drug: Tigan®;Drug: Placebo	Ipsen	INC Research Limited	Completed	18 Years	N/A	All	117	Phase 4	United States
1116	NCT00479401 (ClinicalTrials.gov)	May 2007	25/5/2007	Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients	A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD).	Early Parkinson Disease (Early PD)	Drug: Pramipexol Extended Release;Drug: Pramipexol Immediate Release;Drug: Placebo	Boehringer Ingelheim	NULL	Completed	30 Years	N/A	All	539	Phase 3	United States;Argentina;Austria;Czech Republic;Finland;Germany;Hungary;India;Japan;Malaysia;Russian Federation;Slovakia;Taiwan;Ukraine;Brazil
1117	NCT00477802 (ClinicalTrials.gov)	May 2007	22/5/2007	Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease	Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study	Parkinson Disease	Biological: Botulinum Toxin Type A;Biological: Placebo	University of Cincinnati	Allergan	Terminated	35 Years	75 Years	Both	8	Phase 4	United States
1118	NCT00505843 (ClinicalTrials.gov)	May 2007	24/7/2007	A Study of MK0657 in Parkinson's Disease Patients (0657-006)	A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate Effectiveness of Single-Dose MK0657 in Combination With Levodopa on Motor Symptoms and Dyskinesias in Patients With Parkinson's Disease	Parkinson's Disease	Drug: MK0657;Drug: Comparator: Placebo (unspecified);Drug: Comparator: levodopa;Drug: Comparator: carbidopa	Merck Sharp & Dohme Corp.	NULL	Completed	40 Years	80 Years	Both	18	Phase 1	United States
1119	NCT00474058 (ClinicalTrials.gov)	May 2007	14/5/2007	Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine	Phase 3B, Multicenter, Multinational, Double-Blind, Placebo Controlled, 2-Arm Trial to Evaluate the Effect of the 24-Hour Transdermal Delivery of Rotigotine on the Control of Early Morning Motor Function, Sleep Quality, Nocturnal Symptoms, and Non-Motor Symptoms in Subjects With Idiopathic Parkinson's Disease	Parkinson's Disease	Drug: Rotigotine;Other: Placebo	UCB Pharma	NULL	Completed	18 Years	N/A	All	287	Phase 3	United States;Australia;Austria;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom
1120	EUCTR2006-002937-20-ES (EUCTR)	27/04/2007	26/04/2007	Estudio Multicéntrico, Randomizado, Doble ciego, Controlado con Placebo y Entacapona, de Grupos Paralelos, para evaluar la eficacia, Seguridad y Tolerabilidad de E2007 en Pacientes con Enfermedad de Parkinson Tratados con Levodopa, y Fluctuaciones Motoras	Estudio Multicéntrico, Randomizado, Doble ciego, Controlado con Placebo y Entacapona, de Grupos Paralelos, para evaluar la eficacia, Seguridad y Tolerabilidad de E2007 en Pacientes con Enfermedad de Parkinson Tratados con Levodopa, y Fluctuaciones Motoras	Enfermedad de Parkinson MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS Trade Name: Comtess Product Name: Entacapone	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	702		Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Lithuania
1121	EUCTR2006-002339-26-PT (EUCTR)	27/04/2007	07/03/2007	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	Levodopa treated Parkinson's disease patients with motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1400		Hungary;Portugal;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania
1122	EUCTR2006-000577-29-DE (EUCTR)	27/04/2007	12/10/2006	Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects	A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects Receiving Optimized Treatments with Parkinson Medicinal Products who Continue toExperience Persistent Motor Fluctuations	Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations. MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: DUODOPA®Intestinal Gel INN or Proposed INN: Levodopa Other descriptive name: 3-(3,4-Dihydroxyphenyl)-L-alanine; L-3-(3,4-Dihydroxyphenyl)alanine; L-DOPA INN or Proposed INN: Carbidopa Monohydrate Other descriptive name: (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate Trade Name: Sinemet®25-100 INN or Proposed INN: Levodopa Other descriptive name: 3-(3,4-Dihydroxyphenyl)-L-alanine; L-3-(3,4-Dihydroxyphenyl)alanine; L-DOPA INN or Proposed INN: Carbidopa Monohydrate Other descriptive name: (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate	Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)	NULL	Not Recruiting			Female: yes Male: yes	31		United States;Germany
1123	EUCTR2007-000073-39-FI (EUCTR)	25/04/2007	06/03/2007	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)	A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)	Male or female patients with idiopathic Parkinson’s disease (PD), diagnosed within 5 years, having Modified Hoehn and Yahr stage of 1 to 3. MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet Product Name: Pramipexole ER Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Other descriptive name: Prolonged release tablet	Boehringer Ingelheim Finland Ky	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 1	Hungary;Finland;Czech Republic;Austria
1124	EUCTR2006-002339-26-ES (EUCTR)	19/04/2007	30/01/2007	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.Estudio de extensión abierto, multicéntrico para evaluar la seguridad, tolerabilidad y eficacia a largo plazo de E2007 como terapia complementaria en pacientes con enfermedad de Parkinson tratados con Levodopa y fluctuaciones motoras.	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.Estudio de extensión abierto, multicéntrico para evaluar la seguridad, tolerabilidad y eficacia a largo plazo de E2007 como terapia complementaria en pacientes con enfermedad de Parkinson tratados con Levodopa y fluctuaciones motoras.	Levodopa treated Parkinson's disease patients with motor fluctuations.Pacientes con enfermedad de Parkinson tratados con Levodopa y fluctuaciones motoras MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1400		Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania
1125	EUCTR2006-006752-35-AT (EUCTR)	17/04/2007	21/05/2007	RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINEPHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Recover	RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINEPHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Recover	Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro 2mg/24 h transdermal patch Product Code: ND1587 INN or Proposed INN: Rotigotine Trade Name: Neupro 4mg/24 h transdermal patch Product Code: ND1589 INN or Proposed INN: Rotigotine Trade Name: Neupro 6mg/24 h transdermal patch Product Code: ND1590 INN or Proposed INN: Rotigotine Trade Name: Neupro 8 mg/24 h transdermal patch Product Code: ND1702 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	400	Phase 3	Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy
1126	EUCTR2006-006907-35-AT (EUCTR)	17/04/2007	21/05/2007	Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVER	Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVER	Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro 2mg/24h transdermal patch Product Code: ND1587 INN or Proposed INN: Rotigotine Trade Name: Neupro 4mg/24h transdermal patch Product Code: ND1589 INN or Proposed INN: Rotigotine Trade Name: Neupro 6mg/24h transdermal patch Product Code: ND1590 INN or Proposed INN: Rotigotine Trade Name: Neupro 8mg/24h transdermal patch Product Code: ND1702 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	270	Phase 3	Hungary;Finland;United Kingdom;Germany;Spain;Italy;Austria
1127	EUCTR2006-002339-26-DE (EUCTR)	10/04/2007	22/12/2006	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	Levodopa treated Parkinson's disease patients with motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1400		Portugal;Hungary;United Kingdom;Czech Republic;Germany;Estonia;Spain;Italy;Austria;Sweden;Lithuania
1128	NCT00438607 (ClinicalTrials.gov)	April 2007	20/2/2007	Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects With Moderate to Late Stage Parkinson's Disease Who Are Also Receiving Treatment With Levodopa	Parkinson's Disease	Drug: BIIB014;Drug: Placebo	Biogen Idec	NULL	Completed	30 Years	N/A	Both	83	Phase 2	India;Israel;United Kingdom
1129	NCT00466167 (ClinicalTrials.gov)	April 2007	25/4/2007	Pivotal Study in Advanced Parkinsons Disease Patients	A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD).	Parkinson Disease	Drug: Pramipexol Extended Release;Drug: Pramipexol Immediate Release;Drug: Placebo	Boehringer Ingelheim	NULL	Completed	32 Years	N/A	All	517	Phase 3	Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom
1130	NCT00460148 (ClinicalTrials.gov)	April 2007	11/4/2007	Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole	An Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets.	Parkinson Disease	Drug: Ropinirole	GlaxoSmithKline	NULL	Completed	30 Years	85 Years	Both	28	Phase 2	Germany;South Africa
1131	NCT00459420 (ClinicalTrials.gov)	April 2007	11/4/2007	Caffeine for Excessive Daytime Somnolence in Parkinson's Disease	Caffeine for Excessive Daytime Somnolence in Parkinson's Disease	Parkinson's Disease;Excessive Daytime Somnolence	Drug: Caffeine 100-200 mg BID;Drug: placebo	Ron Postuma	Canadian Institutes of Health Research (CIHR);University of Toronto	Completed	18 Years	N/A	Both	58	Phase 2/Phase 3	Canada
1132	EUCTR2006-006209-94-DE (EUCTR)	15/03/2007	26/01/2007	An open label, repeat dose, dose escalation study conducted in Parkinson’s Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets.	An open label, repeat dose, dose escalation study conducted in Parkinson’s Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets.	Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Requip-Modutab Product Name: Requip-Modutab Product Code: SK&F101468 INN or Proposed INN: Ropinirole Trade Name: Requip-Modutab Product Name: Requip-Modutab Product Code: SK&F101468 INN or Proposed INN: Ropinirole Trade Name: Requip-Modutab Product Name: Requip-Modutab Product Code: SK&F101468 INN or Proposed INN: Ropinirole Product Name: Ropinirole Product Code: SK&F101468 INN or Proposed INN: Ropinirole	GlaxoSmithKline Research & Development Limited	NULL	Not Recruiting			Female: yes Male: yes	36		Germany
1133	EUCTR2006-002937-20-FR (EUCTR)	12/03/2007	12/02/2007	A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Parkinson's Disease MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS Trade Name: Comtess Product Name: Entacapone INN or Proposed INN: entacapone	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	702	Phase 3	France;Hungary;Czech Republic;Estonia;Spain;Lithuania;Latvia;Italy
1134	NCT00443872 (ClinicalTrials.gov)	March 2007	3/3/2007	Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists	Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications	Parkinson's Disease	Drug: orally disintegrating selegiline (Zelapar)	Parkinson's Disease and Movement Disorder Center of Boca Raton	Valeant Pharmaceuticals International, Inc.	Completed	30 Years	90 Years	All	77	Phase 4	United States
1135	NCT00437125 (ClinicalTrials.gov)	March 2007	16/2/2007	Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease	An Open Label Pilot Study on the Tolerability of Duloxetine in the Treatment of Depressed Patients With Parkinson's Disease	Major Depressive Disorder;Idiopathic Parkinson Disease	Drug: Duloxetine hydrochloride	Eli Lilly and Company	NULL	Completed	30 Years	75 Years	All	151	Phase 4	Italy
1136	NCT00451633 (ClinicalTrials.gov)	March 2007	21/3/2007	The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations	A Randomized, Double Blind, Placebo-Controlled Study To Investigate The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations	Parkinson's Disease	Drug: E2007	Eisai Inc.	NULL	Withdrawn	30 Years	80 Years	Both	0	Phase 2	Germany;Italy
1137	NCT00406588 (ClinicalTrials.gov)	March 2007	30/11/2006	SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients With Parkinson's Disease Experiencing Motor Fluctuations.	Advanced Stage Parkinson's Disease	Drug: Pardoprunox;Drug: Placebo Comparator	Solvay Pharmaceuticals	NULL	Completed	30 Years	N/A	Both	295	Phase 3	United States;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine
1138	NCT01693081 (ClinicalTrials.gov)	March 2007	21/9/2012	Phase IIa Multicentre Study Investigating of VR040 in Parkinson's Disease	A Clinic-Based, Phase IIa, Double-Blind, Placebo- Controlled, Ascending-Dose, Multicentre Study of Safety, Tolerability, Efficacy and Pharmacokinetics of VR040 in Parkinson's Disease	Parkinson's Disease	Drug: VR040/Aspirair® inhaler;Drug: placebo	South Glasgow University Hospitals NHS Trust	Vectura Limited	Completed	30 Years	90 Years	Both	47	Phase 2	Serbia;United Kingdom
1139	EUCTR2006-005714-12-IT (EUCTR)	27/02/2007	03/08/2007	A randomized, double blind, placebo-controlled study to investigate the effect of E2007 on pharmacodynamic responses to levodopa among patients with Parkinson's disease who experience dyskinesia and motor fluctuations. - E2007-E044-213	A randomized, double blind, placebo-controlled study to investigate the effect of E2007 on pharmacodynamic responses to levodopa among patients with Parkinson's disease who experience dyskinesia and motor fluctuations. - E2007-E044-213	Patients with idiopathic Parkinson's disease who respond to levodopa treatment but who experience peak-effect levodopa-induced dyskinesia and end-of-dose 'wearing-off' motor fluctuations MedDRA version: 6.1;Level: HLT;Classification code 10034005	Product Name: E2007 Product Code: E2007 INN or Proposed INN: OTHER NERVOUS SYSTEM DRUGS Trade Name: SINEMET INN or Proposed INN: levodopa-carbidopa	EISAI LTD UK	NULL	Not Recruiting			Female: yes Male: yes	24		Italy
1140	EUCTR2005-002038-36-GR (EUCTR)	27/02/2007	09/10/2006	A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies	A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies	Patients with Parkinson’s disease dementia or dementia with Lewy Bodies MedDRA version: 8.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease	Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE	H. Lundbeck A/S	NULL	Not Recruiting			Female: yes Male: yes	200	Phase 3	France;Greece;Spain;Austria;Germany;Italy;United Kingdom
1141	EUCTR2006-005183-91-LT (EUCTR)	14/02/2007	20/12/2006	An open label SLV308 safety extension to study S308.3.002 in patients with Parkinson’s disease experiencing motor fluctuations. - An extension of the Mondrian study	An open label SLV308 safety extension to study S308.3.002 in patients with Parkinson’s disease experiencing motor fluctuations. - An extension of the Mondrian study	Advanced stage Parkinson's disease with motor fluctuations. MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	220		Latvia;Lithuania
1142	EUCTR2006-005182-20-LT (EUCTR)	13/02/2007	20/12/2006	A multicenter, randomized, double-blind, placebo-controlled, parallel group study of SLV308 as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations. - The Mondriaan study	A multicenter, randomized, double-blind, placebo-controlled, parallel group study of SLV308 as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations. - The Mondriaan study	Advanced stage Parkinson's disease with motor fluctuations. MedDRA version: 9.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS	Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	280		Latvia;Lithuania
1143	EUCTR2006-005182-20-LV (EUCTR)	02/02/2007	28/12/2006	A multicenter, randomized, double-blind, placebo-controlled, parallel group study of SLV308 as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations. - The Mondriaan study	A multicenter, randomized, double-blind, placebo-controlled, parallel group study of SLV308 as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations. - The Mondriaan study	Advanced stage Parkinson's disease with motor fluctuations.	Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	280		Latvia;Lithuania
1144	EUCTR2006-005183-91-LV (EUCTR)	02/02/2007	11/01/2007	An open label SLV308 safety extension to study S308.3.002 in patients with Parkinson’s disease experiencing motor fluctuations. - An extension of the Mondriaan study	An open label SLV308 safety extension to study S308.3.002 in patients with Parkinson’s disease experiencing motor fluctuations. - An extension of the Mondriaan study	Advanced stage Parkinson's disease with motor fluctuations.	Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride Product Name: SLV308(mono)hydrochloride Product Code: SLV308(mono)hydrochloride	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	140		Latvia;Lithuania
1145	NCT00332917 (ClinicalTrials.gov)	February 2007	1/6/2006	An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients	An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients	Early Stage Parkinson's Disease	Drug: Pardoprunox	Solvay Pharmaceuticals	NULL	Completed	30 Years	N/A	Both	224	Phase 3	United States;Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;Former Serbia and Montenegro
1146	NCT00427011 (ClinicalTrials.gov)	February 2007	24/1/2007	A Study of E2007 In Patients With Parkinson's Disease	A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing-Off Motor Fluctuations	Parkinson's Disease	Drug: E2007	Eisai Inc.	NULL	Terminated	18 Years	N/A	All	25	Phase 2	United States
1147	EUCTR2006-003732-30-DE (EUCTR)	31/01/2007	29/11/2006	Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1	Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1	Early Parkinson's Disease MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease	Product Name: Lisuride TTS 10cm² INN or Proposed INN: LISURIDE Trade Name: Sifrol 0,088 INN or Proposed INN: PRAMIPEXOLE Product Name: Lisuride TTS 20cm² INN or Proposed INN: LISURIDE Trade Name: Sifrol 0,18 INN or Proposed INN: PRAMIPEXOLE Trade Name: Sifrol 0,35 INN or Proposed INN: PRAMIPEXOLE Trade Name: Sifrol 0,7 INN or Proposed INN: PRAMIPEXOLE	Axxonis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350		Germany;Italy;Poland
1148	EUCTR2006-000859-18-NL (EUCTR)	25/01/2007	05/04/2007	An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study	An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study	Parkinson's Disease Early stage	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochlori	Solvay pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	247		Portugal;Germany;Czech Republic;Netherlands;Estonia;Italy;Lithuania
1149	EUCTR2006-002339-26-HU (EUCTR)	24/01/2007	24/08/2006	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	Levodopa treated Parkinson's disease patients with motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1400		Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania
1150	EUCTR2006-000678-57-FR (EUCTR)	09/01/2007	10/10/2006	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	Parkinson 's Disease early stage MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride	Solvay pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	330	Phase 3	Portugal;France;Estonia;Czech Republic;Lithuania;Netherlands;Germany;Italy;United Kingdom
1151	EUCTR2006-000859-18-PT (EUCTR)	04/01/2007	18/09/2006	An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study	An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study	Parkinson's Disease Early stage	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochlori	Solvay pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	225		Portugal;Germany;Czech Republic;Netherlands;Estonia;Italy;Lithuania
1152	NCT00465452 (ClinicalTrials.gov)	January 2007	24/4/2007	Impact of Switching to Continuous Release Dopamine Agonists	The Impact of Switching to Continuous Release Dopamine Agonists on Non-Motor Side Effects	Parkinson Disease	Drug: Continuous Release Dopamine Agonists	University of Toledo Health Science Campus	NULL	Completed	55 Years	N/A	Both	15	Phase 3	United States
1153	NCT00640159 (ClinicalTrials.gov)	January 2007	18/3/2008	Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease	Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease.	Parkinson's Disease	Drug: Zelapar	Baylor College of Medicine	NULL	Completed	30 Years	90 Years	Both	55	Phase 4	United States
1154	NCT01187966 (ClinicalTrials.gov)	January 2007	31/5/2010	Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease	A Phase III, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Patients With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, and/or an Anticholinergic	Parkinson's Disease	Drug: Safinamide;Drug: Placebo	Newron	NULL	Completed	30 Years	80 Years	Both	669	Phase 3	NULL
1155	EUCTR2006-000678-57-PT (EUCTR)	29/12/2006	10/08/2006	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	Parkinson 's Disease early stage MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochlori	Solvay pharmaceuticals B.V.	NULL	Not Recruiting			Female: yes Male: yes	330		Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania
1156	EUCTR2006-002339-26-GB (EUCTR)	28/12/2006	16/10/2006	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	Levodopa treated Parkinson's disease patients with motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1400		Portugal;Hungary;Germany;Czech Republic;United Kingdom;Estonia;Spain;Italy;Austria;Sweden;Lithuania
1157	EUCTR2006-000678-57-DE (EUCTR)	22/12/2006	06/10/2006	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	Parkinson 's Disease early stage MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochlori	Solvay pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	376		Portugal;United Kingdom;Czech Republic;Germany;Netherlands;France;Estonia;Italy;Lithuania
1158	EUCTR2006-005509-79-GB (EUCTR)	21/12/2006	07/12/2006	A Clinic-Based, Phase IIa, Randomised, Double-Blind, Placebo-Controlled, Ascending-Dose, Multicentre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040 in Patients with Established Idiopathic Parkinson’s Disease	A Clinic-Based, Phase IIa, Randomised, Double-Blind, Placebo-Controlled, Ascending-Dose, Multicentre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040 in Patients with Established Idiopathic Parkinson’s Disease	Idiopathic Parkinson's Disease patients who have motor fluctuations with recognisable motor off” periods	Product Name: apomorphine hydrochloride Product Code: VR040 INN or Proposed INN: apomorphine hydrochloride	Vectura Group plc	NULL	Not Recruiting			Female: yes Male: yes	42	Phase 2	United Kingdom
1159	EUCTR2006-003490-27-GB (EUCTR)	19/12/2006	29/09/2006	A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are Also Receiving Treatment with Levodopa	A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are Also Receiving Treatment with Levodopa	Parkinson's disease MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease	Product Code: BIIB014 Product Code: BIIB014 Product Code: BIIB014	BIOGEN IDEC LTD	NULL	Not Recruiting			Female: yes Male: yes	137	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
1160	EUCTR2006-005860-14-IT (EUCTR)	19/12/2006	17/03/2009	A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic parkinson?s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist and/or an anticholinergic - ND	A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic parkinson?s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist and/or an anticholinergic - ND	PATIENTS WITH IDIOPATHIC PARKINSON?S DISEASE WITH MOTOR FLUCTUATIONS MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Safinamide Product Code: NW-1015 Product Name: Safinamide Product Code: NW-1015	NEWRON PHARMACEUTICALS	NULL	Not Recruiting			Female: yes Male: yes	600	Phase 3	Italy
1161	EUCTR2006-000858-45-FI (EUCTR)	18/12/2006	26/06/2006	An open label SLV308 safety extension to study S308.3.001 in early PD patients. - An extension of the Rembrandt study	An open label SLV308 safety extension to study S308.3.001 in early PD patients. - An extension of the Rembrandt study	Parkinson's Disease Early Stage	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	300		Finland;Sweden
1162	EUCTR2006-002339-26-IT (EUCTR)	16/12/2006	05/06/2007	Studio di Estensione Multi-centrico, in Aperto per Valutare Sicurezza, Tollerabilita' ed Efficacia a Lungo Termine di E2007 come Terapia Aggiuntiva in Pazienti affetti da Morbo di Parkinson con Fluttuazioni Motorie Trattati con Levodopa. - E2007-G000-303	Studio di Estensione Multi-centrico, in Aperto per Valutare Sicurezza, Tollerabilita' ed Efficacia a Lungo Termine di E2007 come Terapia Aggiuntiva in Pazienti affetti da Morbo di Parkinson con Fluttuazioni Motorie Trattati con Levodopa. - E2007-G000-303	Levodopa treated Parkinson's Disease Patients with Motor Fluctuations MedDRA version: 6.1;Level: PT;Classification code 10061536	Product Name: E2007	EISAI LTD UK	NULL	Not Recruiting			Female: yes Male: yes	1400	Phase 3	Portugal;Hungary;Czech Republic;Estonia;Spain;Belgium;Lithuania;Austria;Germany;United Kingdom;Italy;Sweden
1163	EUCTR2006-002937-20-CZ (EUCTR)	14/12/2006	24/10/2006	A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Parkinson's Disease MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS Trade Name: Comtess Product Name: Entacapone	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	702		Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Lithuania
1164	EUCTR2006-005140-89-NL (EUCTR)	11/12/2006	01/12/2006	A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge study	A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge study	This postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson's Disease (PD). MedDRA version: 9.1;Level: PT;Classification code 10061536	Trade Name: Selegiline HCl 5 PCH Trade Name: Nardil Product Name: Rasagiline 1mg tablet Product Code: TVP-1012 INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesilate Product Name: Rasagiline 2 mg tablet Product Code: TVP-1012 INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesilate	TEVA Pharmaceuticals Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	160	Phase 4	Netherlands
1165	EUCTR2006-002937-20-EE (EUCTR)	11/12/2006	19/10/2006	A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Parkinson's Disease MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS Trade Name: Comtess Product Name: Entacapone	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	702		Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Lithuania
1166	EUCTR2006-002937-20-LT (EUCTR)	04/12/2006	02/11/2006	A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Parkinson's Disease MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS Trade Name: Comtess Product Name: Entacapone INN or Proposed INN: entacapone	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	702		Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Lithuania
1167	NCT01964573 (ClinicalTrials.gov)	December 2006	14/10/2013	Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects	A Single-site, Randomized, Double-blind, Placebo-controlled, Repeated-dose Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in 2 Different Dosages (2 mg / 24 Hours [10 cm2], 4 mg / 24 Hours [20 cm2]) in Healthy Korean Subjects	Parkinson's Disease	Drug: Rotigotine;Other: Placebo	UCB Pharma	NULL	Completed	19 Years	45 Years	Both	48	Phase 1	Korea, Republic of
1168	NCT00406029 (ClinicalTrials.gov)	November 20, 2006	30/11/2006	Dyskinesia in Parkinson's Disease (Study P04501)	A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias	Parkinson Disease;Movement Disorders;Central Nervous System Diseases;Neurodegenerative Diseases;Brain Diseases	Drug: Preladenant;Drug: Placebo;Drug: L-dopa;Drug: Other Parkinson's Disease treatments	Merck Sharp & Dohme Corp.	NULL	Completed	30 Years	N/A	All	253	Phase 2	Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States
1169	EUCTR2006-001755-36-GB (EUCTR)	20/11/2006	29/09/2006	Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients - SENSE	Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients - SENSE	Parkinson’s disease MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone	Orion Corporation Orion Pharma	NULL	Not Recruiting			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Germany;United Kingdom;Sweden
1170	EUCTR2006-004112-51-IT (EUCTR)	14/11/2006	04/12/2006	A randomised, double-blind, double-dummy, two-period, cross-over study to determine the pharmacokinetics, pharmacodynamics and safety of multiple doses of V1512 effervescent tablets in Parkinson s Disease PD patients compared to standard levodopa/carbidopa Sinemet oral tablets - ND	A randomised, double-blind, double-dummy, two-period, cross-over study to determine the pharmacokinetics, pharmacodynamics and safety of multiple doses of V1512 effervescent tablets in Parkinson s Disease PD patients compared to standard levodopa/carbidopa Sinemet oral tablets - ND	Parkinson s disease MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: SIRIO*30CPR EFF 25MG+100MG INN or Proposed INN: Melevodopa and decarboxylase inhibitor Trade Name: SINEMET*50CPR 100MG+25MG INN or Proposed INN: LEVODOPA DC.IT FU INN or Proposed INN: CARBIDOPA FU	VERNALIS DEVELOPMENT LIMITED	NULL	Not Recruiting			Female: yes Male: yes			Italy
1171	EUCTR2006-000678-57-GB (EUCTR)	14/11/2006	30/05/2007	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	Parkinson 's Disease early stage MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydro	Solvay pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	330	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	France;Portugal;Estonia;Czech Republic;Lithuania;Netherlands;Germany;Italy;United Kingdom
1172	EUCTR2006-001793-24-PT (EUCTR)	07/11/2006	31/07/2006	A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA/CARBIDOPA OR LEVODOPA/BENSERAZIDE - not available	A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA/CARBIDOPA OR LEVODOPA/BENSERAZIDE - not available	Patients with idiopathic Parkinson’s disease (PD) and with end-of-dose deterioration (wearing-off) phenomenon although currently treated with levodopa/DDCI. MedDRA version: 7;Level: LLT;Classification code 10061536	Product Name: Nebicapone Product Code: BIA 3-202 Trade Name: COMTAN® Product Name: Entacapone INN or Proposed INN: Entacapone Product Name: Nebicapone Product Code: BIA 3-202 Product Name: Nebicapone Product Code: BIA 3-202	BIAL - Portela & Cª, SA	NULL	Not Recruiting			Female: yes Male: yes	250		Portugal;Austria
1173	EUCTR2006-000678-57-LT (EUCTR)	07/11/2006	07/09/2006	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	Parkinson 's Disease early stage MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochlori	Solvay pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	330		Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania
1174	EUCTR2006-000859-18-LT (EUCTR)	07/11/2006	07/09/2006	An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study	An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study	Parkinson's Disease Early stage	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochlori	Solvay pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	225		Portugal;Germany;Czech Republic;Netherlands;Estonia;Italy;Lithuania
1175	EUCTR2006-000678-57-EE (EUCTR)	03/11/2006	01/09/2006	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	Parkinson 's Disease early stage MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochlori	Solvay pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	330		Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania
1176	EUCTR2006-000859-18-EE (EUCTR)	03/11/2006	01/09/2006	An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study	An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study	Parkinson's Disease Early stage	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochlori	Solvay pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	225		Portugal;Germany;Czech Republic;Netherlands;Estonia;Italy;Lithuania
1177	EUCTR2006-002339-26-CZ (EUCTR)	01/11/2006	21/08/2006	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	Levodopa treated Parkinson's disease patients with motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1400		Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania
1178	EUCTR2006-002937-20-LV (EUCTR)	01/11/2006	02/11/2006	A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Parkinson's Disease MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: E2007 Product Code: MARS Trade Name: Comtess Product Name: Entacapone	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	702		Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Lithuania
1179	NCT00400634 (ClinicalTrials.gov)	November 2006	15/11/2006	Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease	Multicenter, Randomized, Double-Blind, Sham Surgery-Controlled Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) to Assess the Efficacy and Safety of Bilateral Intraputaminal (IPu) Delivery in Subjects With Idiopathic Parkinson's Disease	Idiopathic Parkinson's Disease	Drug: CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]);Procedure: Sham Surgery	Sangamo Therapeutics	Ceregene	Completed	35 Years	75 Years	All	58	Phase 2	United States
1180	NCT00387075 (ClinicalTrials.gov)	November 2006	10/10/2006	A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease	Parkinson Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson Disease	Parkinson Disease	Procedure: [123I]ß-CIT and SPECT imaging;Drug: [123I]ß-CIT	Institute for Neurodegenerative Disorders	United States Department of Defense;Molecular NeuroImaging	Active, not recruiting	50 Years	N/A	All	3000	Phase 2	United States
1181	NCT00360308 (ClinicalTrials.gov)	November 2006	2/8/2006	Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo and Entacapone Controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations	Parkinson's Disease	Drug: Placebo;Drug: E2007	Eisai Limited	NULL	Terminated	30 Years	N/A	All	723	Phase 3	France
1182	NCT00335166 (ClinicalTrials.gov)	November 2006	8/6/2006	SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease	A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.	Early Stage Parkinson Disease	Drug: Pardaprunox;Drug: pramipexole;Drug: Placebo Comparator	Solvay Pharmaceuticals	NULL	Completed	30 Years	N/A	Both	330	Phase 3	United States;Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom
1183	NCT00491998 (ClinicalTrials.gov)	November 2006	26/6/2007	PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets	Randomised, Double-blind, Double-dummy, Two-period, Cross-over Study to Determine the PK, PD and Safety of Multiple Doses of V1512 Effervescent Tablets in Parkinson's Disease Patients Compared to Sinemet® Oral Tablets	Parkinson's Disease	Drug: V1512;Drug: V1512 and Entacapone	Vernalis (R&D) Ltd	Cita NeuroPharmaceuticals;INC Research	Completed	30 Years	N/A	Both	27	Phase 1/Phase 2	Italy
1184	NCT00468078 (ClinicalTrials.gov)	November 2006	30/4/2007	Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients	The Single Center, Phase III Clinical Trial to Evaluate the Efficacy and the Safety of [18F]FPCIT Positron Emission Tomography in Parkinson's Disease and Essential Tremor Patients	Parkinson's Disease	Procedure: PET/CT;Drug: F-18 FPCIT	Asan Medical Center	NULL	Completed	40 Years	N/A	Both	78	Phase 3	Korea, Republic of
1185	EUCTR2005-002038-36-GB (EUCTR)	31/10/2006	09/10/2006	A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies	A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies	Patients with Parkinson’s disease dementia or dementia with Lewy Bodies MedDRA version: 8.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease	Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE Product Code: Lu 00-800 INN or Proposed INN: memantine hydrochloride	H. Lundbeck A/S	NULL	Not Recruiting			Female: yes Male: yes	200	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	France;Greece;Spain;Austria;Germany;Italy;United Kingdom
1186	EUCTR2006-002339-26-EE (EUCTR)	20/10/2006	15/08/2006	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	Levodopa treated Parkinson's disease patients with motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1400		Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania
1187	EUCTR2006-002339-26-SE (EUCTR)	19/10/2006	22/09/2006	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	Levodopa treated Parkinson's disease patients with motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1400		Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Lithuania;Sweden
1188	EUCTR2006-002339-26-BE (EUCTR)	16/10/2006	24/08/2006	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	Levodopa treated Parkinson's disease patients with motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1400		Portugal;Hungary;Czech Republic;Estonia;Spain;Belgium;Lithuania;Austria;Germany;Italy;United Kingdom;Sweden
1189	EUCTR2006-000858-45-SK (EUCTR)	11/10/2006	28/09/2006	An open label SLV308 safety extension to study S308.3.001 in early PD patients. - An extension of the Rembrandt study	An open label SLV308 safety extension to study S308.3.001 in early PD patients. - An extension of the Rembrandt study	Parkinson's Disease Early Stage	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochlo	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 3	Slovakia;Finland;Sweden
1190	EUCTR2006-002339-26-LT (EUCTR)	05/10/2006	07/08/2006	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	Levodopa treated Parkinson's disease patients with motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1400		Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania
1191	NCT00590122 (ClinicalTrials.gov)	October 2006	28/12/2007	Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study	COMPARISON OF ORALLY DISSOLVING LEVODOPA (PARCOPA®) TO CONVENTIONAL ORAL LEVODOPA: A SINGLE DOSE, DOUBLE-BLIND, PLACEBO CONTROLLED, CROSS-OVER TRIAL	Parkinson's Disease	Drug: Parcopa;Drug: carbidopa-levodopa	Baylor College of Medicine	UCB Pharma	Completed	31 Years	80 Years	Both	20	Phase 4	United States
1192	NCT00391898 (ClinicalTrials.gov)	October 2006	24/10/2006	Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off	A 3-month, Multi-center, Double-blind, Randomized Study to Evaluate the Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Impairment of Activities of Daily Living and Early Wearing-off With Levodopa	Parkinson's Disease	Drug: Levodopa/carbidopa/entacapone;Drug: Levodopa/carbidopa	Novartis	NULL	Completed	30 Years	80 Years	All	95	Phase 4	Spain
1193	NCT00360412 (ClinicalTrials.gov)	October 2006	2/8/2006	A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations	Parkinson's Disease	Drug: E2007	Eisai Inc.	NULL	Terminated	30 Years	N/A	Male	997	Phase 3	Germany
1194	NCT03103399 (ClinicalTrials.gov)	September 26, 2006	28/3/2017	Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon	A Multicentre, Double-blind, Randomised, Active- and Placebo-controlled Trial to Investigate the Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon Treated With Levodopa/Carbidopa or Levodopa/Benserazide	Parkinson Disease	Drug: Comtan®;Drug: Nebicapone;Drug: Levodopa/DDCI;Drug: Placebo	Bial - Portela C S.A.	NULL	Completed	30 Years	80 Years	All	254	Phase 2	NULL
1195	EUCTR2006-002339-26-AT (EUCTR)	25/09/2006	18/10/2006	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	Levodopa treated Parkinson's disease patients with motor fluctuations. MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1400		Portugal;Hungary;Germany;United Kingdom;Czech Republic;Estonia;Spain;Italy;Austria;Sweden;Lithuania
1196	EUCTR2006-000678-57-IT (EUCTR)	14/09/2006	26/06/2007	A multicenter, randomized, double-blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson's Disease. - ND	A multicenter, randomized, double-blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson's Disease. - ND	Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: SLV308 (mono)hydrochloride Product Code: SLV308 Product Name: Pramipexole INN or Proposed INN: Pramipexole Product Name: SLV308 (mono)hydrochloride Product Code: SLV308 Product Name: SLV308 (mono)hydrochloride Product Code: SLV308 Product Name: SLV308 (mono)hydrochloride Product Code: SLV308 Product Name: SLV308 (mono)hydrochloride Product Code: SLV308 Product Name: SLV308 (mono)hydrochloride Product Code: SLV308	SOLVAY PHARMACEUTICALS B.V.	NULL	Not Recruiting			Female: yes Male: yes	390		Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania
1197	EUCTR2005-005146-39-IT (EUCTR)	14/09/2006	06/12/2006	A Phase-2, 12-week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a range of SCH 420814 Doses 1 mg BID, 2 mg BID, 5 mg BID and Possibly 10 mg BID in Subjects With Moderate to Severe Parkinson s Disease Experiencing Motor Fluctuations and Dyskinesias. - ND	A Phase-2, 12-week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a range of SCH 420814 Doses 1 mg BID, 2 mg BID, 5 mg BID and Possibly 10 mg BID in Subjects With Moderate to Severe Parkinson s Disease Experiencing Motor Fluctuations and Dyskinesias. - ND	Moderate to severe Parkinson s disease with motor fluctuation and dyskinesias. MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Code: SCH 420814 Product Code: SCH 420814	Schering Plough Research Institute	NULL	Not Recruiting			Female: yes Male: yes	160		Italy
1198	EUCTR2006-000859-18-CZ (EUCTR)	11/09/2006	02/08/2006	An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study	An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study	Parkinson's Disease Early stage	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochlori	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	225		Portugal;Germany;Czech Republic;Netherlands;Estonia;Italy;Lithuania
1199	EUCTR2004-005234-39-LV (EUCTR)	06/09/2006	29/09/2006	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Parkinson's disease MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa	Orion Corporation, ORION PHARMA, 02200 Espoo, Finland	NULL	Not Recruiting			Female: yes Male: yes	244		Finland;Germany;United Kingdom;Denmark;Ireland;Latvia;Lithuania;Sweden
1200	EUCTR2005-001006-12-CZ (EUCTR)	06/09/2006	24/08/2006	Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO	Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO	Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to conventional treatment. MedDRA version: 9.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated	Product Name: Lisparin INN or Proposed INN: Lisuride Hydrogenmaleate Other descriptive name: 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate Product Name: Pramipexol INN or Proposed INN: Pramipexol Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Product Name: Pramipexol INN or Proposed INN: Pramipexol Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Product Name: Cabergoline INN or Proposed INN: Cabergoline Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea Product Name: Cabergoline INN or Proposed INN: Cabergoline Other descriptive name: 1[(6- Allyl- 8ß- erg	Axxonis Pharma GmbH	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2;Phase 3	Czech Republic;Austria;Germany;Italy
1201	EUCTR2005-004949-34-SE (EUCTR)	06/09/2006	27/03/2006	A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study	A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study	Parkinson's disease MedDRA version: 6.1;Level: pref;Classification code 10061536	Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim AB	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 4	Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden
1202	NCT00462007 (ClinicalTrials.gov)	September 2006	17/4/2007	Study to Evaluate Initiation of Stalevo in Early Wearing-off	Efficacy and Safety of Stalevo® in Subjects With Early Wearing-off Identified Using a Screening Tool WOQ-9; an Open, Non-randomised, Multinational, Multicentre 6-week Direct Switch Study in Levodopa-treated Parkinson's Disease Patients	Parkinson's Disease	Drug: Stalevo	Orion Corporation, Orion Pharma	NULL	Completed	35 Years	N/A	Both	115	Phase 4	Germany;Sweden;United Kingdom
1203	NCT00507715 (ClinicalTrials.gov)	September 2006	25/7/2007	Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk	Clinical Trial to Study the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk	Parkinson's Disease, Idiopathic	Drug: Plantago ovata husk;Other: hemicellulose crystalline	Rottapharm Spain	NULL	Completed	60 Years	80 Years	Both	18	Phase 1	Spain
1204	NCT00208611 (ClinicalTrials.gov)	September 2006	13/9/2005	Vitamin B12 Status and Response to Vitamin B12 Supplementation in Patients With Parkinson's Disease	Assessment of Cobalamin Status and Responses to Supplementation in Patients With Parkinson's Disease : a Pilot Study	Parkinson's Disease	Dietary Supplement: Vitamin B12 Supplementation	Emory University	National Institutes of Health (NIH)	Terminated	21 Years	N/A	Both	57	Phase 2/Phase 3	United States
1205	EUCTR2005-006033-32-SE (EUCTR)	15/08/2006	22/06/2006	A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rembrandt study	A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rembrandt study	Parkinson's Disease Early Stage	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	440		Finland;Slovakia;Sweden
1206	EUCTR2005-004314-33-PT (EUCTR)	09/08/2006	10/05/2006	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Levodopa treated Parkinson's disease patients with motor fluctuations MedDRA version: 8.1;Classification code 10061536	Product Name: MARS Product Code: E2007 Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1260		Hungary;Portugal;Germany;United Kingdom;Estonia;Spain;Italy;Lithuania;Sweden
1207	EUCTR2006-001755-36-SE (EUCTR)	09/08/2006	30/06/2006	Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients - SENSE	Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients - SENSE	Parkinson’s disease MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone	Orion Corporation Orion Pharma, FI-02200 Espoo, Finland	NULL	Not Recruiting			Female: yes Male: yes	100		United Kingdom;Germany;Sweden
1208	EUCTR2005-004949-34-DE (EUCTR)	04/08/2006	30/03/2006	A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study	A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study	Parkinson's disease MedDRA version: 6.1;Level: pref;Classification code 10061536	Trade Name: Sifrol Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Trade Name: Sifrol Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Trade Name: SIFROL Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim Pharma GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	500		Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden
1209	EUCTR2006-000678-57-NL (EUCTR)	03/08/2006	04/04/2007	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer study	Parkinson 's Disease early stage MedDRA version: 8.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochlori	Solvay pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	330		Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania
1210	NCT00368108 (ClinicalTrials.gov)	August 2006	22/8/2006	Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations	Parkinson's Disease	Drug: 2 mg perampanel;Drug: 4 mg perampanel;Drug: placebo comparator	Eisai Inc.	NULL	Completed	30 Years	N/A	All	752	Phase 3	United States;Canada
1211	EUCTR2006-001793-24-AT (EUCTR)	31/07/2006	24/07/2006	A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA/CARBIDOPA OR LEVODOPA/BENSERAZIDE - not available	A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA/CARBIDOPA OR LEVODOPA/BENSERAZIDE - not available	Patients with idiopathic Parkinson’s disease (PD) and with end-of-dose deterioration (wearing-off) phenomenon although currently treated with levodopa/DDCI. MedDRA version: 7;Level: LLT;Classification code 10061536	Product Name: Nebicapone Product Code: BIA 3-202 Product Name: Entacapone INN or Proposed INN: Entacapone Product Name: Nebicapone Product Code: BIA 3-202 Product Name: Nebicapone Product Code: BIA 3-202	BIAL - Portela & Cª, SA	NULL	Not Recruiting			Female: yes Male: yes	250		Portugal;Austria
1212	EUCTR2006-000391-32-NL (EUCTR)	18/07/2006	10/05/2006	A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, Active, Efficacy, safety and Tolerability Assessment of APO Nasal Powder (2 and 4 mg) in the Alleviation of Acute Episodes of Motor Symptoms Associated with PD, Followed by Period 2 Comprising a 36-Week Open, Active Treatment, Safety Assessment of APO Nasal Powder (2 and 4 mg), in Subjects with PD. - Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Subjects with Parkinson's Disease	A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, Active, Efficacy, safety and Tolerability Assessment of APO Nasal Powder (2 and 4 mg) in the Alleviation of Acute Episodes of Motor Symptoms Associated with PD, Followed by Period 2 Comprising a 36-Week Open, Active Treatment, Safety Assessment of APO Nasal Powder (2 and 4 mg), in Subjects with PD. - Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Subjects with Parkinson's Disease	Alleviation of acute episodes of motor symptoms associated with Parkinson's Disease MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Apomorphine Nasal Powder Other descriptive name: 6aß - apomorphine-10,11-diol hydrochloride hemihydrate	Britannia Pharmaceuticals Limited	NULL	Not Recruiting			Female: yes Male: yes	130	Phase 3	Germany;Netherlands;United Kingdom
1213	NCT03097211 (ClinicalTrials.gov)	July 17, 2006	27/3/2017	Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg	A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg	Parkinson Disease	Drug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: Nebicapone	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	38	Phase 1	Portugal
1214	EUCTR2006-003717-41-IT (EUCTR)	13/07/2006	12/07/2007	EVALUATE THE TOLERABILITY AND EFFICACY OF OMEGA 3 ON MOOD ANDMOTOR SYMPTOMS OF PATIENTS SUFFERING FROM PARKINSON DISEASE - ND	EVALUATE THE TOLERABILITY AND EFFICACY OF OMEGA 3 ON MOOD ANDMOTOR SYMPTOMS OF PATIENTS SUFFERING FROM PARKINSON DISEASE - ND	MOOD DEPRESSION MedDRA version: 6.1;Level: PT;Classification code 10012374		POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI	NULL	Not Recruiting			Female: yes Male: yes			Italy
1215	EUCTR2006-000680-28-ES (EUCTR)	07/07/2006	22/05/2006	Estudio multicéntrico, doble ciego, aleatorizado y de tres meses de seguimiento para evaluar la eficacia de levodopa/carbidopa/entacapona frente a levodopa/carbidopa en pacientes con enfermedad de Parkinson y wearing-off”A 3-months, multicenter, double-blind, randomized study to evaluate the efficacy of levodopa/carbidopa/entacapone vs. levodopa/carbidopa in Parkinson's disease patients with 'wearing-off' - DERBI	Estudio multicéntrico, doble ciego, aleatorizado y de tres meses de seguimiento para evaluar la eficacia de levodopa/carbidopa/entacapona frente a levodopa/carbidopa en pacientes con enfermedad de Parkinson y wearing-off”A 3-months, multicenter, double-blind, randomized study to evaluate the efficacy of levodopa/carbidopa/entacapone vs. levodopa/carbidopa in Parkinson's disease patients with 'wearing-off' - DERBI	Enfermedad de Parkinson (Parkinson Disease)	Trade Name: Stalevo 100 Product Name: Stalevo (levodopa/carbidopa/entacapona) INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA INN or Proposed INN: ENTACAPONA Trade Name: Sinemet plus Product Name: Sinemet plus (levodopa/carbidopa) INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA Trade Name: Stalevo 150 Product Name: Stalevo (levodopa/carbidopa/entacapona) INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA INN or Proposed INN: ENTACAPONA	NOVARTIS FARMACEUTICA, S.A	NULL	Not Recruiting			Female: yes Male: yes	200		Spain
1216	EUCTR2006-000391-32-DE (EUCTR)	04/07/2006	27/04/2006	A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, Active, Efficacy, safety and Tolerability Assessment of APO Nasal Powder (2 and 4 mg) in the Alleviation of Acute Episodes of Motor Symptoms Associated with PD, Followed by Period 2 Comprising a 36-Week Open, Active Treatment, Safety Assessment of APO Nasal Powder (2 and 4 mg), in Subjects with PD. - Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Subjects with Parkinson's Disease	A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, Active, Efficacy, safety and Tolerability Assessment of APO Nasal Powder (2 and 4 mg) in the Alleviation of Acute Episodes of Motor Symptoms Associated with PD, Followed by Period 2 Comprising a 36-Week Open, Active Treatment, Safety Assessment of APO Nasal Powder (2 and 4 mg), in Subjects with PD. - Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Subjects with Parkinson's Disease	Alleviation of acute episodes of motor symptoms associated with Parkinson's Disease	Product Name: Apomorphine Nasal Powder Other descriptive name: 6aß - apomorphine-10,11-diol hydrochloride hemihydrate	Britannia Pharmaceuticals Limited	NULL	Not Recruiting			Female: yes Male: yes	130		United Kingdom;Germany;Netherlands
1217	NCT00354133 (ClinicalTrials.gov)	July 2006	19/7/2006	Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's Disease	The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study)	Parkinson Disease	Device: Kinetra and Soletra (neurostimulator, Medtronic);Drug: Best Medical Treatment	German Parkinson Study Group (GPS)	University Hospital Schleswig-Holstein;Assistance Publique - Hôpitaux de Paris;KKS Netzwerk	Active, not recruiting	18 Years	60 Years	All	251	Phase 4	France;Germany
1218	NCT00408915 (ClinicalTrials.gov)	July 2006	5/12/2006	Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion	Double-blind, Placebo-controlled, Randomized, Multicentre Phase II/III Study to Evaluate the Efficacy and Safety of Lisuride, Applied Subcutaneously by Means of a Minipump in Patients With Advanced Parkinson's Disease Refractory to Conventional Oral Therapy	Parkinson's Disease	Drug: Continuous Subcutaneous Lisuride Infusion	Axxonis Pharma AG	NULL	Completed	18 Years	75 Years	Both	60	Phase 3	Germany
1219	EUCTR2006-000361-11-GB (EUCTR)	23/06/2006	01/02/2006	A Proof of Concept Study to Determine the Minimum Effective Dose and to Assess the Efficacy and Safety of Subcutaneous Injections of FPFS-1169 in Parkinson's Disease Patients - Parkinson's Disease FPFS-1169 Proof of Concept Study (RD639/24201)	A Proof of Concept Study to Determine the Minimum Effective Dose and to Assess the Efficacy and Safety of Subcutaneous Injections of FPFS-1169 in Parkinson's Disease Patients - Parkinson's Disease FPFS-1169 Proof of Concept Study (RD639/24201)	Treatment of Parkinson's Disease MedDRA version: 8.0;Classification code 10029205	Product Name: FPFS-1169 INN or Proposed INN: R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride	Fujimoto Pharmaceutical Corporation	NULL	Not Recruiting			Female: yes Male: yes	10	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
1220	EUCTR2005-004314-33-DE (EUCTR)	21/06/2006	01/12/2005	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Levodopa treated Parkinson's disease patients with motor fluctuations MedDRA version: 8.1;Classification code 10061536	Product Name: MARS Product Code: E2007 Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1260		Portugal;Hungary;United Kingdom;Germany;Estonia;Spain;Italy;Lithuania;Sweden
1221	EUCTR2005-004949-34-GB (EUCTR)	19/06/2006	24/03/2006	A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease The main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study	A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease The main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study	Parkinson's disease MedDRA version: 6.1;Level: pref;Classification code 10061536	Trade Name: Sifrol Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Trade Name: Sifrol Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Trade Name: Sifrol Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim Ltd	NULL	Not Recruiting			Female: yes Male: yes	500	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden
1222	EUCTR2005-006033-32-SK (EUCTR)	13/06/2006	02/05/2006	A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rembrandt study	A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rembrandt study	Parkinson's Disease Early Stage	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	440		Finland;Slovakia;Sweden
1223	EUCTR2006-000391-32-GB (EUCTR)	06/06/2006	21/04/2006	A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, Active, Efficacy, safety and Tolerability Assessment of APO Nasal Powder (2 and 4 mg) in the Alleviation of Acute Episodes of Motor Symptoms Associated with PD, Followed by Period 2 Comprising a 36-Week Open, Active Treatment, Safety Assessment of APO Nasal Powder (2 and 4 mg), in Subjects with PD. - Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Subjects with Parkinson's Disease	A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, Active, Efficacy, safety and Tolerability Assessment of APO Nasal Powder (2 and 4 mg) in the Alleviation of Acute Episodes of Motor Symptoms Associated with PD, Followed by Period 2 Comprising a 36-Week Open, Active Treatment, Safety Assessment of APO Nasal Powder (2 and 4 mg), in Subjects with PD. - Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Subjects with Parkinson's Disease	Alleviation of acute episodes of motor symptoms associated with Parkinson's Disease MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: Apomorphine Nasal Powder Other descriptive name: 6aß - apomorphine-10,11-diol hydrochloride hemihydrate	Britannia Pharmaceuticals Limited	NULL	Not Recruiting			Female: yes Male: yes	130	Phase 3	Netherlands;Germany;United Kingdom
1224	NCT00269516 (ClinicalTrials.gov)	June 2006	22/12/2005	SLV308 for Treatment of Patients With Early Parkinson's Disease	A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease	Early Stage Parkinson's Disease	Drug: pardoprunox;Drug: Pardoprunox;Drug: Placebo	Solvay Pharmaceuticals	NULL	Completed	30 Years	N/A	Both	468	Phase 3	United States;Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;Former Serbia and Montenegro
1225	EUCTR2005-004949-34-ES (EUCTR)	29/05/2006	21/04/2006	A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease. Protocol includes DAT SPECT of a sub-set of patients Estudio aleatorizado, doble ciego, controlado con placebo, para examinar la eficacia y seguridad del tratamiento temprano frente al tratamiento retrasado con pramipexol en pacientes con inicio de Parkinson - Pramipexole Early Start Study	A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease. Protocol includes DAT SPECT of a sub-set of patients Estudio aleatorizado, doble ciego, controlado con placebo, para examinar la eficacia y seguridad del tratamiento temprano frente al tratamiento retrasado con pramipexol en pacientes con inicio de Parkinson - Pramipexole Early Start Study	Parkinson's disease MedDRA version: 6.1;Level: pref;Classification code 10061536	Trade Name: Sifrol, Mirapexin Product Name: Sifrol, Mirapexin Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Trade Name: Sifrol, Mirapexin Product Name: Sifrol, Mirapexin Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Trade Name: Sifrol, Mirapexin Product Name: Sifrol, Mirapexin Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim España, S.A.	NULL	Not Recruiting			Female: yes Male: yes	500		Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden
1226	NCT00302146 (ClinicalTrials.gov)	May 23, 2006	11/3/2006	Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations	Functional Imaging in Subjects With Glucocerebrosidase Mutations	Parkinson Disease;Gaucher Disease	Drug: 15-0 H20	National Human Genome Research Institute (NHGRI)	NULL	Completed	18 Years	N/A	All	64		United States
1227	EUCTR2005-004314-33-ES (EUCTR)	19/05/2006	15/03/2006	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Levodopa treated Parkinson's disease patients with motor fluctuations MedDRA version: 8.1;Classification code 10061536	Product Name: MARS Product Code: E2007 Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1260	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Portugal;Czech Republic;Hungary;Estonia;Belgium;Spain;Lithuania;Austria;Germany;Italy;United Kingdom;Sweden
1228	EUCTR2005-004949-34-FI (EUCTR)	17/05/2006	21/04/2006	A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study	A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study	Parkinson's disease MedDRA version: 6.1;Level: pref;Classification code 10061536	Trade Name: Sifrol Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Trade Name: Sifrol Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Trade Name: Sifrol Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim	Boehringer Ingelheim Finland Ky	Not Recruiting			Female: yes Male: yes	500	Phase 4	Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden
1229	EUCTR2004-005234-39-LT (EUCTR)	09/05/2006	24/03/2006	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Parkinson's disease MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa	Orion Corporation, ORION PHARMA, 02200 Espoo, Finland	NULL	Not Recruiting			Female: yes Male: yes	244		Finland;Germany;United Kingdom;Denmark;Ireland;Latvia;Sweden;Lithuania
1230	NCT00321854 (ClinicalTrials.gov)	May 2006	3/5/2006	Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)	A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease.	Parkinson Disease	Drug: pramipexole	Boehringer Ingelheim	NULL	Completed	30 Years	79 Years	All	535	Phase 4	United States;Austria;Finland;France;Germany;Italy;Japan;Spain;Sweden;United Kingdom
1231	NCT03094156 (ClinicalTrials.gov)	April 26, 2006	23/3/2017	Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics	A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Entacapone 200 mg	Parkinson Disease	Drug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: Comtan®	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	39	Phase 1	Portugal
1232	EUCTR2005-005791-32-GB (EUCTR)	24/04/2006	17/02/2006	Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.	Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.	HF0220 experimentally appears to exert its potential beneficial effects within the CNS and possibly other tissues by attenuating the adverse effects of oxidative stress. It is believed that this mechanism has the potential to reduce disease progression in a wide range of disorders of the nervous system, e.g. Alzheimer's and Parkinson's disease, and brain damage due to acute stroke and head injury. It may also apply to the protection of peripheral tissues, such as the heart and/or kidney. MedDRA version: 9.1;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes)	Product Name: HF0220 Product Code: HF0220 Other descriptive name: 7-beta-hydroxyepiandrosterone	Hunter-Fleming Ltd	NULL	Not Recruiting			Female: yes Male: yes	40	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4):	United Kingdom;Sweden
1233	EUCTR2005-006033-32-FI (EUCTR)	20/04/2006	06/03/2006	A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rembrandt study	A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rembrandt study	Parkinson's Disease Early Stage	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Other descriptive name: SLV308 (mono) hydrochloride	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	440		Finland;Slovakia;Sweden
1234	EUCTR2005-004949-34-AT (EUCTR)	18/04/2006	21/03/2006	A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study	A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study	Parkinson's disease MedDRA version: 6.1;Level: pref;Classification code 10061536	Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole Product Name: Sifrol Product Code: SND 919 CL2 Y INN or Proposed INN: Pramipexole	Boehringer Ingelheim Austria GmbH	NULL	Not Recruiting			Female: yes Male: yes	500		Finland;Germany;United Kingdom;Spain;Italy;Austria;Sweden
1235	EUCTR2005-001006-12-AT (EUCTR)	02/04/2006	28/02/2006	Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO	Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO	Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to conventional treatment.	Product Name: Lisparin INN or Proposed INN: Lisuride Hydrogenmaleate Other descriptive name: 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate Trade Name: Sifrol, 0,35 mg Tablette Product Name: Pramipexol INN or Proposed INN: Pramipexol Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Trade Name: Sifrol, 0,70 mg Tablette Product Name: Pramipexol INN or Proposed INN: Pramipexol Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Trade Name: Cabaseril, 1,0 mg Tablette Product Name: Cabergoline INN or Proposed INN: Cabergoline Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea Trade Name: Cabaseril, 2,0 mg Tablette Product Name: Cabergoline INN or Proposed INN: Cabergoline Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-	Axxonis Pharma GmbH	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	Germany;Czech Republic;Italy;Austria
1236	NCT00461942 (ClinicalTrials.gov)	April 2006	17/4/2007	Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson's Disease Patients	A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Neuroprotection Effect of Green Tea Polyphenol in De Novo Parkinson's Disease Patients	Parkinson's Disease	Drug: Green Tea Polyphenols (EGCG/ECG)	Xuanwu Hospital, Beijing	Ministry of Health, China;Michael J. Fox Foundation for Parkinson's Research	Completed	30 Years	N/A	Both	480	Phase 2	China
1237	EUCTR2005-001032-72-PT (EUCTR)	23/03/2006	11/11/2005	A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step	A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step	Parkinson disease	Trade Name: Stalevo Product Code: ELC200 INN or Proposed INN: levodopa/carbidopa/entacapone Trade Name: SINEMET Product Name: sinemet INN or Proposed INN: levodopa/carbidopa	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	424		Portugal;Czech Republic;Italy
1238	EUCTR2005-001006-12-DE (EUCTR)	09/03/2006	05/09/2006	Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO	Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO	Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to conventional treatment. MedDRA version: 9.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated	Product Name: Lisparin INN or Proposed INN: Lisuride Hydrogenmaleate Other descriptive name: 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate Product Name: Pramipexol INN or Proposed INN: Pramipexol Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Product Name: Pramipexol INN or Proposed INN: Pramipexol Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol Product Name: Cabergoline INN or Proposed INN: Cabergoline Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea Product Name: Cabergoline INN or Proposed INN: Cabergoline Other descriptive name: 1[(6- Allyl- 8ß- erg	Axxonis Pharma GmbH	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2;Phase 3	Czech Republic;Austria;Germany;Italy
1239	EUCTR2005-004314-33-HU (EUCTR)	01/03/2006	20/12/2005	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Levodopa treated Parkinson's disease patients with motor fluctuations MedDRA version: 8.1;Classification code 10061536	Product Name: MARS Product Code: E2007 Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1260		Portugal;Hungary;Germany;United Kingdom;Estonia;Spain;Italy;Lithuania;Sweden
1240	EUCTR2005-004314-33-GB (EUCTR)	01/03/2006	29/11/2005	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Levodopa treated Parkinson's disease patients with motor fluctuations MedDRA version: 8.1;Classification code 10061536	Product Name: MARS Product Code: E2007 Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1260	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Portugal;Czech Republic;Hungary;Estonia;Spain;Belgium;Lithuania;Austria;Germany;Italy;United Kingdom;Sweden
1241	NCT00282152 (ClinicalTrials.gov)	March 2006	23/1/2006	Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)	Safety and Tolerability of Neurostimulation in Early Stage Parkinson's Disease	Parkinson's Disease	Device: B-STN DBS;Drug: Optimal drug therapy	Vanderbilt University Medical Center	NULL	Completed	50 Years	75 Years	All	37	N/A	United States
1242	NCT00305331 (ClinicalTrials.gov)	March 2006	20/3/2006	Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease	Phase II Clinical Trial of Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease	Parkinson's Disease;Peripheral Edema	Drug: Domperidone (drug)	University Health Network, Toronto	NULL	Terminated	30 Years	90 Years	Both	25	Phase 2	Canada
1243	EUCTR2005-001032-72-CZ (EUCTR)	16/02/2006	12/01/2006	A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step	A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step		Trade Name: Stalevo 100 mg/25 mg / 200 mg Product Code: ELC200 Trade Name: SINEMET CR Product Name: SINEMET CR	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	424		Portugal;Czech Republic;Italy
1244	EUCTR2005-004290-19-GB (EUCTR)	03/02/2006	09/01/2006	A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's disease	A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's disease	advanced-stage, idiopathic Parkinson's disease MedDRA version: 8.1;Level: LLT;Classification code 10061536	Product Name: Rotigotine Nasal Spray Product Code: ND1421 INN or Proposed INN: Rotigotine hydrochloride	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Spain;Austria;Germany;United Kingdom
1245	EUCTR2005-004314-33-SE (EUCTR)	03/02/2006	13/12/2005	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Levodopa treated Parkinson's disease patients with motor fluctuations MedDRA version: 8.1;Classification code 10061536	Product Name: MARS Product Code: E2007 Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1260		Portugal;Hungary;Germany;United Kingdom;Estonia;Spain;Italy;Lithuania;Sweden
1246	EUCTR2005-004314-33-BE (EUCTR)	02/02/2006	24/11/2005	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Levodopa treated Parkinson's disease patients with motor fluctuations MedDRA version: 8.1;Classification code 10061536	Product Name: MARS Product Code: E2007 Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1260		Portugal;Hungary;Estonia;Spain;Belgium;Lithuania;Austria;Germany;Italy;United Kingdom;Sweden
1247	EUCTR2005-004314-33-CZ (EUCTR)	01/02/2006	11/01/2006	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Levodopa treated Parkinson's disease patients with motor fluctuations MedDRA version: 8.1;Classification code 10061536	Product Name: MARS Product Code: E2007 Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1260		Portugal;Hungary;Estonia;Czech Republic;Spain;Belgium;Lithuania;Austria;Germany;Italy;United Kingdom;Sweden
1248	EUCTR2005-004314-33-LT (EUCTR)	01/02/2006	03/01/2006	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Levodopa treated Parkinson's disease patients with motor fluctuations MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Product Name: MARS Product Code: E2007 Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1260		Portugal;Hungary;Germany;United Kingdom;Estonia;Spain;Italy;Sweden;Lithuania
1249	NCT00296192 (ClinicalTrials.gov)	February 2006	22/2/2006	Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms	A Double-Blind, Placebo-Controlled, Parallel-Group, Proof of Concept Trial to Assess the Tolerability, Safety, and Efficacy of Rotigotine Nasal Spray for the Acute Treatment of OFF Symptoms in Subjects With Advanced-Stage, Idiopathic Parkinson Disease	Parkinson's Disease	Drug: Rotigotine nasal spray;Other: Placebo	UCB Pharma	NULL	Completed	30 Years	N/A	All	82	Phase 2	Germany
1250	NCT00286897 (ClinicalTrials.gov)	February 2006	3/2/2006	The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations	Parkinson's Disease	Drug: E2007	Eisai Limited	NULL	Completed	30 Years	N/A	Both	702	Phase 3	Austria;Belgium;Czech Republic;Estonia;France;Germany;Hungary;Israel;Italy;Lithuania;Poland;Portugal;Serbia;South Africa;Spain;Sweden;United Kingdom;Former Serbia and Montenegro
1251	EUCTR2005-004314-33-IT (EUCTR)	31/01/2006	07/09/2007	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations. - ND	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations. - ND	Parkinson's Desease patients with Motor Fluctuations who are on optimised and stabilised therapy with Levodopa. MedDRA version: 6.1;Level: PT;Classification code 10061536	Product Name: E2007 Product Name: E2007	EISAI LTD UK	NULL	Not Recruiting			Female: yes Male: yes	900		Portugal;Hungary;Germany;United Kingdom;Estonia;Spain;Italy;Lithuania;Sweden
1252	EUCTR2005-004290-19-DE (EUCTR)	25/01/2006	05/12/2005	A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's disease	A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's disease	advanced-stage, idiopathic Parkinson's disease MedDRA version: 8.1;Level: LLT;Classification code 10061536	Product Name: Rotigotine Nasal Spray Product Code: ND1421 INN or Proposed INN: Rotigotine hydrochloride	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	100		United Kingdom;Germany;Spain
1253	NCT03095105 (ClinicalTrials.gov)	January 24, 2006	23/3/2017	Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects	An Open-label, Parallel-group Study to Compare the Pharmacokinetic Profile in Healthy Elderly Subjects Versus Healthy Young Subjects After Single and Repeated Oral Administration of BIA 6-512 (Trans-resveratrol)	Parkinson Disease	Drug: 200 mg BIA 6-512	Bial - Portela C S.A.	NULL	Completed	18 Years	N/A	All	25	Phase 1	Germany
1254	EUCTR2005-004314-33-EE (EUCTR)	17/01/2006	24/11/2005	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Levodopa treated Parkinson's disease patients with motor fluctuations MedDRA version: 8.1;Classification code 10061536	Product Name: MARS Product Code: E2007 Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1260		Portugal;Hungary;Germany;United Kingdom;Estonia;Spain;Italy;Lithuania;Sweden
1255	NCT01683292 (ClinicalTrials.gov)	January 2006	7/9/2012	Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease	An Ascending-Dose, Single-Centre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040(Inhaled Apomorphine)in Parkinson's Disease	Parkinson's Disease	Drug: Inhaled VR040;Drug: Placebo for VR040	South Glasgow University Hospitals NHS Trust	Vectura Limited	Completed	30 Years	N/A	Both	29	Phase 2	United Kingdom
1256	NCT00292227 (ClinicalTrials.gov)	January 2006	14/2/2006	Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease	Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial.	Parkinson's Disease	Drug: Rotigotine;Other: Placebo;Drug: Moxifloxacin infusion;Other: Placebo infusion	UCB Pharma	NULL	Completed	18 Years	N/A	All	130	Phase 1	South Africa
1257	NCT02772614 (ClinicalTrials.gov)	January 2006	12/5/2016	Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites	An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites Following a Single-dose Oral Administration	Parkinson's Disease	Drug: BIA 3-202 (200 mg)	Bial - Portela C S.A.	NULL	Completed	40 Years	55 Years	Male	4	Phase 1	Switzerland
1258	NCT00279825 (ClinicalTrials.gov)	January 2006	18/1/2006	Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Compare IPX054 200 mg and 250 mg to CD-LD IR 200 (2x100) mg Tablets and CD-LD CR 200 mg Tablet in Subjects With Parkinson's Disease	Idiopathic Parkinson's Disease	Drug: IPX054 200 mg;Drug: IPX054 250 mg;Drug: CD-LD IR;Drug: CD-LD CR;Drug: IPX054 200 mg Placebo;Drug: IPX054 250 mg Placebo;Drug: CD-LD IR Placebo;Drug: CD-LD CR Placebo	Impax Laboratories, LLC	NULL	Completed	30 Years	N/A	All	16	Phase 2	United States
1259	NCT00275275 (ClinicalTrials.gov)	January 2006	9/1/2006	Pramipexole Conversion to Ropinirole Controlled Release (CR)	An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease.	Parkinson Disease	Drug: Requip PR;Drug: Mirapex	Rajesh Pahwa, MD	GlaxoSmithKline	Completed	18 Years	N/A	All	61	Phase 3	United States
1260	NCT00273351 (ClinicalTrials.gov)	January 2006	4/1/2006	Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families	Assessment of Pre-symptomatic and Symptomatic Patients With Parkinson Disease to Identify and Characterize Genetic and Phenotypic Biomarkers for Disease Onset and Progression.	Parkinson Disease;Parkinsonian Syndrome	Drug: [123I]B-CIT	Institute for Neurodegenerative Disorders	Department of Defense;Molecular NeuroImaging	Completed	21 Years	N/A	Both	62	Phase 2	United States
1261	EUCTR2005-005120-13-GB (EUCTR)	21/12/2005	02/11/2005	A clinic based, Phase IIa, randomised, double-blind, placebo-controlled, ascending dose, single centre study investigating the safety, tolerability, efficacy, and pharmacokinetics of VR040 in patients with established idiopathic Parkinson’s Disease	A clinic based, Phase IIa, randomised, double-blind, placebo-controlled, ascending dose, single centre study investigating the safety, tolerability, efficacy, and pharmacokinetics of VR040 in patients with established idiopathic Parkinson’s Disease	Hypomobility (off” or freezing”) episodes associated with advanced Parkinson’s disease	Product Name: Apomorphine hydrochloride Product Code: VR040 INN or Proposed INN: apomorphine hydrochloride	Vectura Group plc	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 2	United Kingdom
1262	EUCTR2005-001032-72-IT (EUCTR)	25/11/2005	26/03/2007	A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 t.i.d. vs. immediate release carbidopa/levodopa t.i.d. in Parkinsons disease patients requiring levodopa.	A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 t.i.d. vs. immediate release carbidopa/levodopa t.i.d. in Parkinsons disease patients requiring levodopa.	Parkinson s Disease MedDRA version: 6.1;Level: PT;Classification code 10061536	Trade Name: Stalevo INN or Proposed INN: ENTACAPONE INN INN or Proposed INN: LEVODOPA INN INN or Proposed INN: CARBIDOPA INN Trade Name: Sinemet INN or Proposed INN: LEVODOPA INN or Proposed INN: CARBIDOPA ANIDRA	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	424		Portugal;Czech Republic;Italy
1263	EUCTR2005-002432-10-MT (EUCTR)	25/11/2005	10/10/2005	A multicenter, randomized, double-blind, placebo-controlled, ascending dose, parallel group study exploring effects of SLV308 up to 42 mg/day administered as an adjunctive therapy to l-dopa in patients with advanced stage Parkinson’s disease	A multicenter, randomized, double-blind, placebo-controlled, ascending dose, parallel group study exploring effects of SLV308 up to 42 mg/day administered as an adjunctive therapy to l-dopa in patients with advanced stage Parkinson’s disease	Parkinson Disease late stage	Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride Product Name: SLV308 (mono) hydrochloride Product Code: SLV308 (mono) hydrochloride	Solvay Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	60		Malta
1264	EUCTR2005-000444-84-GB (EUCTR)	23/11/2005	13/09/2005	An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY-O	An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY-O	Treatment-Associated Dyskinesia in Parkinson's Disease	Product Code: EMD128130 INN or Proposed INN: Sarizotan hydrochloride	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	800	Phase 3	Finland;Spain;Austria;Italy;United Kingdom
1265	EUCTR2005-002010-38-DE (EUCTR)	21/11/2005	10/02/2006	Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Disease patients with motor fluctuations: a 4-week open label pilot study	Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Disease patients with motor fluctuations: a 4-week open label pilot study	Advanced Parkinson´s Disease	Product Name: Trivastal Product Code: S 90049 INN or Proposed INN: Piribedil	Institut de Recherches Internationales Servier (I.R.I.S.)	NULL	Not Recruiting			Female: yes Male: yes	80		Germany
1266	EUCTR2005-001416-42-PT (EUCTR)	07/11/2005	25/08/2005	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO	Parkinson's Disease MedDRA version: 7.1;Level: PT;Classification code 10061536	Trade Name: AZILECT Product Name: rasagiline tablets Product Code: TVP-1012 INN or Proposed INN: rasagiline Other descriptive name: rasagiline mesilate	Teva Pharmaceuticals Industries LtD	NULL	Not Recruiting			Female: yes Male: yes	1100		Hungary;Portugal;Germany;United Kingdom;Spain;Italy
1267	NCT00253084 (ClinicalTrials.gov)	November 2005	11/11/2005	Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease	A Randomized, Double-Blind, Cross-Over Study to Compare IPX054 to Carbidopa-Levodopa Immediate-Release Tablets in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: IPX054 200 mg;Drug: CD-LD IR;Drug: IPX054 Placebo;Drug: CD-LD IR Placebo	Impax Laboratories, LLC	NULL	Completed	30 Years	N/A	All	12	Phase 2	United States
1268	NCT00256204 (ClinicalTrials.gov)	November 2005	16/11/2005	A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease	A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects	Parkinson's Disease	Drug: Rasagiline Mesylate;Other: Placebo	Teva Pharmaceutical Industries	NULL	Completed	30 Years	80 Years	All	1174	Phase 3	Argentina;Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States
1269	EUCTR2004-005234-39-IE (EUCTR)	20/10/2005	16/08/2005	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Parkinson's disease MedDRA version: 7.0;Level: LLT;Classification code 10061536	Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa	Orion Corporation, ORION PHARMA, 02200 Espoo, Finland	NULL	Not Recruiting			Female: yes Male: yes	240	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Finland;Ireland;Lithuania;Denmark;Latvia;Germany;United Kingdom;Sweden
1270	NCT00134251 (ClinicalTrials.gov)	October 2005	22/8/2005	Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Parallel Group Study Exploring Effects of SLV308 up to 42 mg/Day Administered as an Adjunctive Therapy to L-Dopa in Patients With Advanced Stage Parkinson's Disease	Parkinson's Disease	Drug: SLV308	Solvay Pharmaceuticals	NULL	Completed	30 Years	N/A	Both		Phase 3	Bulgaria;Malta;Serbia;Former Serbia and Montenegro
1271	NCT00517842 (ClinicalTrials.gov)	October 2005	15/8/2007	A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's Disease	A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's Disease	Parkinson Disease	Drug: ViNeuro	Hospital Authority, Hong Kong	Vigconic (International) Ltd.	Completed	30 Years	N/A	Both	160	N/A	China
1272	NCT00239564 (ClinicalTrials.gov)	October 2005	13/10/2005	Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease	An Open-Label Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease	Idiopathic Parkinson's Disease	Drug: IPX054 100 mg;Drug: IPX054 150 mg;Drug: IPX054 200 mg;Drug: IPX054 250 mg;Drug: IPX054 300 mg	Impax Laboratories, LLC	NULL	Completed	30 Years	N/A	All	12	Phase 1/Phase 2	United States
1273	EUCTR2005-001416-42-HU (EUCTR)	27/09/2005	20/06/2005	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO	Parkinson's Disease MedDRA version: 7.1;Level: PT;Classification code 10061536	Trade Name: AZILECT Product Name: rasagiline tablets Product Code: TVP-1012 INN or Proposed INN: rasagiline Other descriptive name: rasagiline mesilate	Teva Pharmaceuticals Industries LtD	NULL	Not Recruiting			Female: yes Male: yes	1100		Portugal;Hungary;Germany;United Kingdom;Spain;Italy
1274	EUCTR2004-005234-39-FI (EUCTR)	22/09/2005	03/06/2005	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Parkinson's disease MedDRA version: 7.0;Level: LLT;Classification code 10061536	Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa	Orion Corporation, ORION PHARMA	NULL	Not Recruiting			Female: yes Male: yes	240		Finland;Germany;United Kingdom;Denmark;Ireland;Latvia;Lithuania;Sweden
1275	EUCTR2005-001416-42-GB (EUCTR)	15/09/2005	13/06/2005	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO	Parkinson's Disease MedDRA version: 7.1;Level: PT;Classification code 10061536	Trade Name: Azilect Product Name: rasagiline tablets Product Code: TVP-1012 INN or Proposed INN: rasagiline Other descriptive name: rasagiline mesilate Product Name: Rasagiline Product Code: TVP-1012	Teva Pharmaceuticals Industries LtD	NULL	Not Recruiting			Female: yes Male: yes	1100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Portugal;Hungary;Spain;Austria;Germany;Italy;United Kingdom
1276	EUCTR2005-000444-84-FI (EUCTR)	08/09/2005	26/07/2005	An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY-O	An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY-O	Treatment-Associated Dyskinesia in Parkinson's Disease	Product Code: EMD128130 INN or Proposed INN: Sarizotan hydrochloride	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	800	Phase 3	Finland;United Kingdom;Spain;Italy
1277	EUCTR2005-001416-42-DE (EUCTR)	01/09/2005	17/10/2005	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO	Parkinson's Disease MedDRA version: 7.1;Level: PT;Classification code 10061536	Product Name: rasagiline tablets Product Code: TVP-1012 INN or Proposed INN: rasagiline Other descriptive name: rasagiline mesilate Product Name: rasagiline tablets Product Code: TVP-1012 INN or Proposed INN: rasagiline Other descriptive name: rasagiline mesilate Product Name: rasagiline tablets Product Code: TVP-1012 INN or Proposed INN: rasagiline Other descriptive name: rasagiline mesilate	Teva Pharmaceuticals Industries LtD	NULL	Not Recruiting			Female: yes Male: yes	1100		Portugal;Hungary;United Kingdom;Germany;Spain;Italy
1278	NCT00165789 (ClinicalTrials.gov)	September 2005	12/9/2005	A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations	A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations	Parkinson's Disease	Drug: E2007	Eisai Inc.	NULL	Completed	18 Years	N/A	All	75	Phase 2	United States
1279	NCT00224263 (ClinicalTrials.gov)	September 2005	20/9/2005	Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease Receiving Stable L-dopa/DCI	Parkinson's Disease	Drug: Lingzhi (Ganoderma)	Xuanwu Hospital, Beijing	NULL	Completed	30 Years	80 Years	Both	360	Phase 2	China
1280	EUCTR2005-001416-42-AT (EUCTR)	24/08/2005	20/07/2005	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO	Parkinson's Disease MedDRA version: 7.1;Level: PT;Classification code 10061536	Trade Name: AZILECT Product Name: rasagiline tablets Product Code: TVP-1012 INN or Proposed INN: rasagiline Other descriptive name: rasagiline mesilate	Teva Pharmaceuticals Industries LtD	NULL	Not Recruiting			Female: yes Male: yes	1100		Portugal;Hungary;Spain;Austria;Germany;Italy;United Kingdom
1281	EUCTR2004-005234-39-DK (EUCTR)	04/08/2005	31/05/2005	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Parkinson's disease MedDRA version: 7.0;Level: LLT;Classification code 10061536	Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa	Orion Corporation, ORION PHARMA, 02200 Espoo, Finland	NULL	Not Recruiting			Female: yes Male: yes	240		Finland;Germany;United Kingdom;Denmark;Ireland;Latvia;Lithuania;Sweden
1282	NCT00125567 (ClinicalTrials.gov)	August 2005	29/7/2005	Stalevo in Early Wearing-Off Patients	Multicentre, Randomised, Double-Blind Study to Compare Stalevo to Levodopa/Carbidopa in Patients With Parkinson's Disease Experiencing Symptoms of Early Wearing-Off	Idiopathic Parkinson's Disease	Drug: Stalevo (levodopa/carbidopa/entacapone);Drug: Levodopa/carbidopa	Orion Corporation, Orion Pharma	NULL	Completed	30 Years	N/A	Both	223	Phase 4	Denmark;Finland;Germany;Ireland;Sweden;United Kingdom
1283	NCT00134966 (ClinicalTrials.gov)	August 2005	23/8/2005	A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa	A 39 Week Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Effect of Fixed Dose Carbidopa/Levodopa/Entacapone 100 mg t.i.d. vs. Immediate Release Carbidopa/Levodopa 25/100 mg (t.i.d.) in Parkinson's Disease Patients Requiring Levodopa	Parkinson's Disease	Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)	Novartis	NULL	Completed	30 Years	80 Years	All	493	Phase 3	United States;Canada;Czechia;Israel;Italy;Poland;Portugal;Turkey;Czech Republic
1284	EUCTR2005-001416-42-ES (EUCTR)	28/07/2005	28/06/2005	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects. Estudio multicéntrico, doble ciego, de inicio randomizado, controlado con placebo, de grupos paralelos, para valorar Rasagilina como una terapia que modifica la enfermedad de Parkinson en pacientes con enfermedad de Parkinson en fase temprana - ADAGIO	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects. Estudio multicéntrico, doble ciego, de inicio randomizado, controlado con placebo, de grupos paralelos, para valorar Rasagilina como una terapia que modifica la enfermedad de Parkinson en pacientes con enfermedad de Parkinson en fase temprana - ADAGIO	Parkinson's Disease MedDRA version: 7.1;Level: PT;Classification code 10061536	Trade Name: AZILECT Product Name: rasagiline tablets Product Code: TVP-1012 INN or Proposed INN: rasagiline Other descriptive name: rasagiline mesilate Trade Name: AZILECT Product Name: rasagiline tablets Product Code: TVP-1012 INN or Proposed INN: rasagiline Other descriptive name: rasagiline mesilate Trade Name: AZILECT Product Name: rasagiline tablets Product Code: TVP-1012 INN or Proposed INN: rasagiline Other descriptive name: rasagiline mesilate	Teva Pharmaceuticals Industries LtD	NULL	Not Recruiting			Female: yes Male: yes	1100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Portugal;Hungary;Spain;Austria;Germany;Italy;United Kingdom
1285	EUCTR2004-000835-27-ES (EUCTR)	18/07/2005	23/05/2006	A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A DOSE RANGE OF SAFINAMIDE OF 50-200 MG/DAY, AS ADD-ON THERAPY IN PATIENTS WITH EARLY IDIOPATHIC PARKINSON’S DISEASE TREATED WITH A STABLE DOSE OF A SINGLE DOPAMINE AGONIST.	A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A DOSE RANGE OF SAFINAMIDE OF 50-200 MG/DAY, AS ADD-ON THERAPY IN PATIENTS WITH EARLY IDIOPATHIC PARKINSON’S DISEASE TREATED WITH A STABLE DOSE OF A SINGLE DOPAMINE AGONIST.	Early idiopathic Parkinson's disease MedDRA version: 7.0;Level: LLT;Classification code 10013113	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Newron Pharmaceuticals S.P.A	NULL	Not Recruiting			Female: yes Male: yes	212	Phase 3	Spain;Italy
1286	EUCTR2005-004290-19-AT (EUCTR)	17/07/2005	06/12/2005	A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's disease	A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's disease	advanced-stage, idiopathic Parkinson's disease MedDRA version: 8.1;Level: LLT;Classification code 10061536	Product Name: Rotigotine Nasal Spray Product Code: ND1421 INN or Proposed INN: Rotigotine hydrochloride	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	100		Spain;Austria;Germany;United Kingdom
1287	EUCTR2005-001416-42-IT (EUCTR)	14/07/2005	21/06/2005	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects	A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects	Neuroprotective early treatment of Parkinson's disease subjects MedDRA version: 6.1;Level: PT;Classification code 10061536	Product Name: NA Product Code: NA Other descriptive name: NA Product Name: rasagiline Product Code: TVP-1012	TEVA	NULL	Not Recruiting			Female: yes Male: yes			Portugal;Hungary;Germany;United Kingdom;Spain;Italy
1288	EUCTR2005-000444-84-ES (EUCTR)	12/07/2005	22/05/2006	An open-label, multicenter, multinational Phase IIIfollow-up study to investigate the long-term safetyand efficacy of Sarizotan HCl 1 mg b.i.d. inpatients with Parkinson's disease suffering fromtreatment-associated dyskinesia (PADDY-O) - PADDY-O	An open-label, multicenter, multinational Phase IIIfollow-up study to investigate the long-term safetyand efficacy of Sarizotan HCl 1 mg b.i.d. inpatients with Parkinson's disease suffering fromtreatment-associated dyskinesia (PADDY-O) - PADDY-O	Treatment- Associated Dyskinesia in Parkinson´s Disease	Product Code: EMD128130 INN or Proposed INN: Sarizotan hydrochloride	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	800	Phase 3	Finland;Spain;Austria;Italy;United Kingdom
1289	NCT00143026 (ClinicalTrials.gov)	July 2005	31/8/2005	Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States	Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease.	Parkinson's Disease	Drug: carbidopa, levodopa, entacapone	Novartis	NULL	Completed	30 Years	N/A	All	184	Phase 4	Australia;Philippines;Taiwan;Thailand
1290	EUCTR2005-000444-84-AT (EUCTR)	22/06/2005	18/05/2005	An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY-O	An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY-O	Treatment-Associated Dyskinesia in Parkinson's Disease	Product Code: EMD128130 INN or Proposed INN: Sarizotan hydrochloride	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	800	Phase 3	Finland;Spain;Austria;Italy;United Kingdom
1291	EUCTR2005-004314-33-AT (EUCTR)	16/06/2005	05/12/2005	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Levodopa treated Parkinson's disease patients with motor fluctuations MedDRA version: 8.1;Classification code 10061536	Product Name: MARS Product Code: E2007 Product Name: MARS Product Code: E2007	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	1260		Portugal;Hungary;Estonia;Spain;Lithuania;Austria;Germany;Italy;United Kingdom;Sweden
1292	EUCTR2004-005234-39-SE (EUCTR)	08/06/2005	02/05/2005	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Parkinson's disease MedDRA version: 7.0;Level: LLT;Classification code 10061536	Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa	Orion Corporation, ORION PHARMA, 02200 Espoo, Finland	NULL	Not Recruiting			Female: yes Male: yes	240		Finland;Germany;United Kingdom;Denmark;Ireland;Latvia;Lithuania;Sweden
1293	NCT00642889 (ClinicalTrials.gov)	June 2005	21/3/2008	Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)	A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A DOSE RANGE OF SAFINAMIDE OF 50-200 MG/DAY, AS ADD-ON THERAPY IN PATIENTS WITH EARLY IDIOPATHIC PARKINSON'S DISEASE TREATED WITH A STABLE DOSE OF A SINGLE DOPAMINE AGONIST.	Parkinson's Disease	Drug: Safinamide;Drug: Placebo	Newron	NULL	Completed	30 Years	80 Years	Both	227	Phase 3	NULL
1294	NCT00252850 (ClinicalTrials.gov)	June 2005	11/11/2005	Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease	A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease	Parkinson's Disease	Genetic: CERE-120: AAV2-NTN	Sangamo Therapeutics	Ceregene	Completed	35 Years	75 Years	All	12	Phase 1	United States
1295	EUCTR2004-005234-39-GB (EUCTR)	27/05/2005	22/03/2005	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOP	Parkinson's disease MedDRA version: 7.0;Level: LLT;Classification code 10061536	Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet Product Name: Sinemet	Orion Corporation, ORION PHARMA, Finland	NULL	Not Recruiting			Female: yes Male: yes	240	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Finland;Ireland;Lithuania;Denmark;Latvia;Germany;United Kingdom;Sweden
1296	EUCTR2004-002641-12-GB (EUCTR)	16/05/2005	30/06/2005	A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease	A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease	Parkinson's disease	Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	220	Phase 3	Spain;Austria;Italy;United Kingdom
1297	NCT03093389 (ClinicalTrials.gov)	May 11, 2005	22/3/2017	Tolerability and Steady-state Pharmacokinetics of BIA 6-512	A Double-blind, Randomised, Placebo-controlled, Rising Multiple-dose Study to Investigate the Tolerability and Steady-state Pharmacokinetics of BIA 6-512 (Trans-resveratrol) in Healthy Volunteers	Parkinson Disease	Drug: BIA 6-512;Drug: Placebo	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	40	Phase 1	Portugal
1298	NCT00199433 (ClinicalTrials.gov)	May 2005	12/9/2005	A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients	A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) as Monotherapy in Subjects With Parkinson's Disease	Parkinson's Disease;Movement Disorder Syndrome	Drug: Istradefylline (KW-6002)	Kyowa Kirin Pharmaceutical Development, Inc.	NULL	Completed	30 Years	N/A	Both	160	Phase 2	United States
1299	NCT00163085 (ClinicalTrials.gov)	May 2005	9/9/2005	The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Explore The Efficacy And Safety Of The NR2B NMDA Antagonist CP-101,606 In Patients With Idiopathic Parkinson's Disease	Parkinson's Disease	Drug: NR2B NMDA Antagonist CP-101,606 (traxoprodil)	Pfizer	NULL	Completed	30 Years	80 Years	Both	12	Phase 2	United States
1300	EUCTR2004-002641-12-ES (EUCTR)	25/04/2005	10/07/2006	A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease	A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease	Parkinson's disease	Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	220	Phase 3	Spain;Austria;Italy;United Kingdom
1301	EUCTR2004-000817-20-IT (EUCTR)	06/04/2005	13/04/2005	A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (Istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy	A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (Istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy	Parkinson's Disease MedDRA version: 6.1;Level: PT;Classification code 10061536	Product Name: istradefylline Product Code: KW-6002 Other descriptive name: NA Trade Name: COMTAN 200* 60 CPR 200 MG Product Name: NA Product Code: NA INN or Proposed INN: Entacapone	KYOWA HAKKO UK LTD	NULL	Not Recruiting			Female: yes Male: yes	405		Spain;Italy;Latvia;Lithuania
1302	NCT00375778 (ClinicalTrials.gov)	April 2005	12/9/2006	Parkinson's Disease Evaluated by PET and the Effect of Memantine	Parkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist Memantine	Parkinson's Disease	Drug: memantine (drug)	University of Aarhus	Lundbeck Foundation	Completed	50 Years	70 Years	Both	12	N/A	Denmark
1303	NCT00108667 (ClinicalTrials.gov)	April 2005	15/4/2005	Talampanel to Treat Parkinson's Disease	AMPA Receptor Antagonist Treatment of Parkinson's Disease	Parkinson Disease	Drug: IV Levodopa;Drug: Talampanel	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	40	Phase 2	United States
1304	NCT00199355 (ClinicalTrials.gov)	April 2005	12/9/2005	A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa	Placebo-Controlled , Double-Blind , Exploratory Study of KW-6002(Istradefylline) in the Treatment of Parkinson's Disease. [Adjunctive Therapy to Levodopa]	Parkinson's Disease	Drug: Istradefylline (KW-6002)	Kyowa Hakko Kirin Company, Limited	NULL	Completed	30 Years	N/A	Both	75	Phase 2	Japan
1305	EUCTR2004-001593-10-GB (EUCTR)	21/03/2005	25/08/2005	A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1) - PADDY 1	A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1) - PADDY 1	Treatment-Associated Dyskinesia in Parkinson's Disease	Product Name: SARIZOTAN Product Code: EMD128130	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	600	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Italy;United Kingdom
1306	EUCTR2004-002598-21-GB (EUCTR)	02/03/2005	07/07/2005	A phase 3b, open-label. multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's disease	A phase 3b, open-label. multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's disease	Idiopathic Parkinson's disease	Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 3	Austria;United Kingdom
1307	NCT02834507 (ClinicalTrials.gov)	March 2005	13/7/2016	Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients	A Double-blind, Randomised, Placebo- and Active-controlled, Cross-over Study to Investigate the Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients	Parkinson's Disease (PD)	Drug: Placebo;Drug: BIA 3-202;Drug: Comtan®;Drug: Sinemet®	Bial - Portela C S.A.	NULL	Completed	30 Years	75 Years	Both	19	Phase 2	NULL
1308	EUCTR2004-002650-59-GB (EUCTR)	03/02/2005	30/06/2005	A phase 3b, open-label, multicentre, multinational trial to assess the tolerability of switching subjects from ropinerole, pramipexole or cabergoline to the rotigotine transdermal system and its effect on symptoms with idiopathic Parkinson's disease - n/a	A phase 3b, open-label, multicentre, multinational trial to assess the tolerability of switching subjects from ropinerole, pramipexole or cabergoline to the rotigotine transdermal system and its effect on symptoms with idiopathic Parkinson's disease - n/a	Idiopathic Parkinson's disease	Product Name: rotigotine Product Code: SPM 962 INN or Proposed INN: rotigotine	SCHWARZ BIOSCIENCES	NULL	Not Recruiting			Female: yes Male: yes	130	Phase 3	United Kingdom
1309	EUCTR2004-001594-25-AT (EUCTR)	02/02/2005	29/12/2004	A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY 2	A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY 2	Treatment-Associated Dyskinesia in Parkinson's Disease	Product Code: EMD128130 INN or Proposed INN: Sarizotan hydrochloride	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	600	Phase 3	Finland;Spain;Austria
1310	EUCTR2004-000817-20-AT (EUCTR)	02/02/2005	29/12/2004	A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.	A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.	Parkinson's Disease	Product Name: Istradefylline Product Code: KW-6002 INN or Proposed INN: Istradefylline Trade Name: Comtess Product Name: Comtess INN or Proposed INN: Entacapone	Kyowa Hakko U.K. Limited	NULL	Not Recruiting			Female: yes Male: yes	405		Spain;Lithuania;Austria;Latvia;Italy
1311	NCT00505687 (ClinicalTrials.gov)	February 2005	20/7/2007	An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease	A Multicenter, Multinational, Phase 3b, Open-Label Extension Trial to Assess the Safety and Tolerability of Long-Term Treatment of Rotigotine Patch in Subjects With Idiopathic Parkinson's Disease	Idiopathic Parkinson's Disease	Drug: Rotigotine	UCB Pharma	NULL	Completed	31 Years	N/A	All	186	Phase 3	United States;Austria;Germany;Israel;Italy;South Africa;Spain;United Kingdom
1312	EUCTR2004-002641-12-AT (EUCTR)	21/01/2005	17/12/2004	A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease	A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease	Parkinson's disease	Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	220	Phase 3	Spain;Austria;Italy;United Kingdom
1313	NCT00219284 (ClinicalTrials.gov)	January 2005	30/6/2005	Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease	A Prospective, Multi-center, Randomized, Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off	Parkinson's Disease With End of Dose Wearing Off	Drug: Carbidopa/levodopa/entacapone	Novartis Pharmaceuticals	NULL	Completed	30 Years	85 Years	All	359	Phase 4	United States;Puerto Rico
1314	EUCTR2004-001594-25-FI (EUCTR)	30/12/2004	26/10/2004	A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY 2	A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY 2	Treatment-Associated Dyskinesia in Parkinson's Disease	Product Code: EMD128130 INN or Proposed INN: Sarizotan hydrochloride	Merck KGaA	NULL	Not Recruiting			Female: yes Male: yes	600	Phase 3	Finland;Spain
1315	EUCTR2004-002598-21-AT (EUCTR)	22/12/2004	17/11/2004	A phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's disease	A phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's disease	Parkinson's Disease	Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 3	Austria;United Kingdom
1316	EUCTR2004-002609-66-IT (EUCTR)	21/12/2004	03/03/2006	A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson s disease	A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson s disease	Idiopathic Parkinson Disease in early stage MedDRA version: 6.1;Level: PT;Classification code 10061536	Product Name: rotigotine Product Code: SPM 926 Trade Name: REQUIP 21 CPR 0,25 MG INN or Proposed INN: Ropinirole Product Name: rotigotine Product Code: SPM 962 Trade Name: REQUIP 21 CPR 0,5 MG INN or Proposed INN: Ropinirole Product Name: rotigotine Product Code: SPM 962 Product Name: rotigotine Product Code: SPM 962 Trade Name: REQUIP 21 CPR 1 MG INN or Proposed INN: Ropinirole Trade Name: REQUIP 21 CPR 2 MG INN or Proposed INN: Ropinirole	SCHWARZ PHARMA	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 3	Germany;Italy
1317	EUCTR2004-000817-20-ES (EUCTR)	10/12/2004	04/05/2005	A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.	A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.	Parkinson's Disease	Product Name: Istradefylline Product Code: KW-6002 INN or Proposed INN: Istradefylline Trade Name: Comtan Product Name: Comtess INN or Proposed INN: Entacapone	Kyowa Hakko U.K. Limited	NULL	Not Recruiting			Female: yes Male: yes	405		Spain;Italy;Latvia;Lithuania
1318	EUCTR2004-002609-66-DE (EUCTR)	06/12/2004	22/04/2005	A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson's disease	A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson's disease	Parkinson's Disease	Product Name: Rotigotine Product Code: SPM962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM962 INN or Proposed INN: Rotigotine Product Name: Rotigotine Product Code: SPM962 INN or Proposed INN: Rotigotine Trade Name: Requip Product Name: Requip INN or Proposed INN: Ropinirole Trade Name: Requip Product Name: Requip INN or Proposed INN: Ropinirole Trade Name: Requip Product Name: Requip INN or Proposed INN: Ropinirole Trade Name: Requip Product Name: Requip INN or Proposed INN: Ropinirole	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 3	Germany;Italy
1319	EUCTR2004-000835-27-IT (EUCTR)	03/12/2004	21/07/2005	A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the efficacy and safety of a dose range of safinamide of 50-200 mg/day, as add-on therapy in patients with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonist	A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the efficacy and safety of a dose range of safinamide of 50-200 mg/day, as add-on therapy in patients with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonist	Parkinson's Disease MedDRA version: 6.1;Level: PT;Classification code 10061536	Product Name: Safinamide Product Code: NW-1015	NEWRON PHARMACEUTICALS	NULL	Not Recruiting			Female: yes Male: yes		Phase 3	Spain;Italy
1320	EUCTR2004-001593-10-IT (EUCTR)	02/12/2004	03/01/2005	A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1)	A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1)	Treatment-Associated Dyskinesia in Parkinson's Disease	Product Name: Sarizotan hydrochloride Product Code: EMD 128130 INN or Proposed INN: Sarizotan hydrochloride	MERCK S.P.A.	NULL	Not Recruiting			Female: yes Male: yes		Phase 3	United Kingdom;Italy
1321	EUCTR2004-000185-12-IT (EUCTR)	02/12/2004	27/06/2005	A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo in patients with Parkinson's disease	A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo in patients with Parkinson's disease	Parkinson's Disease MedDRA version: 6.1;Level: PT;Classification code 10061536	Trade Name: Stalevo Product Name: NA Product Code: NA INN or Proposed INN: carbidopa INN or Proposed INN: levodopa INN or Proposed INN: entecapone Trade Name: Sinemet Product Name: NA Product Code: NA INN or Proposed INN: LEVODOPA (DC.IT) (FU) INN or Proposed INN: CARBIDOPA (FU) Trade Name: Stalevo Product Name: NA Product Code: NA INN or Proposed INN: carbidopa INN or Proposed INN: levodopa INN or Proposed INN: entecapone Trade Name: Sinemet Product Name: NA Product Code: NA INN or Proposed INN: LEVODOPA (DC.IT) (FU) INN or Proposed INN: CARBIDOPA (FU) Trade Name: Sinemet Product Name: NA Product Code: NA INN or Proposed INN: LEVODOPA (DC.IT) (FU) INN or Proposed INN: CARBIDOPA (FU)	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	740		Finland;United Kingdom;Italy;Sweden
1322	EUCTR2004-000833-12-IT (EUCTR)	02/12/2004	15/03/2005	A Phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonist	A Phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonist	Parkinson's Disease MedDRA version: 6.1;Level: PT;Classification code 10061536	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Monoamine oxidase B inhibitors	NEWRON PHARMACEUTICALS	NULL	Not Recruiting			Female: yes Male: yes		Phase 3	Spain;Italy
1323	EUCTR2004-000833-12-ES (EUCTR)	02/12/2004	23/11/2004	A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic parkinson’s disease treated with a stable dose of a single dopamine agonist.	A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic parkinson’s disease treated with a stable dose of a single dopamine agonist.	Early idiopathic Parkinson’s disease MedDRA version: 7.0;Level: LLT;Classification code 10013113	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: Safinamide	Newron Pharmaceuticals S.p.A.	NULL	Not Recruiting			Female: yes Male: yes	250	Phase 3	Spain;Italy
1324	NCT00242008 (ClinicalTrials.gov)	December 2004	18/10/2005	A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease	A Phase 3b, Open-Label, Multicenter, Multinational Trial To Assess The Tolerability Of Switching Subjects From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System And Its Effect On Symptoms In Subjects With Idiopathic Parkinson's Disease	Parkinson's Disease	Drug: Rotigotine	UCB Pharma	NULL	Completed	18 Years	N/A	Both		Phase 3	United States
1325	NCT00243945 (ClinicalTrials.gov)	December 2004	24/10/2005	A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease	A Phase 3b, Open-Label, Multicenter, Multinational Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders in Patients With Idiopathic Parkinson's Disease	IDIOPATHIC PARKINSON'S DISEASE	Drug: Rotigotine	UCB Pharma	NULL	Completed	18 Years	N/A	Both	58	Phase 3	Germany
1326	NCT00643045 (ClinicalTrials.gov)	December 2004	21/3/2008	Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist	A Phase III, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of a Low (50 100 mg/Day) and High (150 200 mg/Day) Dose Range of Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist	Idiopathic Parkinson's Disease	Drug: Safinamide;Drug: Placebo	Newron	NULL	Completed	30 Years	80 Years	Both	269	Phase 3	NULL
1327	EUCTR2004-000185-12-AT (EUCTR)	25/11/2004	21/10/2004	A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PD	A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PD	Parkinson's disease MedDRA version: 7.0;Level: LLT;Classification code 10061536	Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet Product Name:	Orion Corporation, ORION PHARMA, 02200 Espoo, Finland	NULL	Not Recruiting			Female: yes Male: yes	740		Finland;Austria;Italy;United Kingdom;Sweden
1328	EUCTR2004-001594-25-ES (EUCTR)	24/11/2004	02/11/2004	A double-blind, placebo controlled, multicenter, multinational, phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d in patients with Parkinson' s disease suffering from treatment-associated dyskinesia. - PADDY-2	A double-blind, placebo controlled, multicenter, multinational, phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d in patients with Parkinson' s disease suffering from treatment-associated dyskinesia. - PADDY-2	Treatment-Associated Dyskinesia in Parkinson's Disease	Product Name: Sarizotan Product Code: EMD 128130 INN or Proposed INN: Sarizotan Hydrochloride	MERCK KGaA	NULL	Not Recruiting			Female: yes Male: yes	600	Phase 3	Finland;Spain;Austria
1329	EUCTR2004-000185-12-SE (EUCTR)	11/11/2004	03/09/2004	A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PD	A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PD	Parkinson's disease MedDRA version: 7.0;Level: LLT;Classification code 10061536	Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet Product Name:	Orion Corporation, ORION PHARMA, 02200 Espoo, Finland	NULL	Not Recruiting			Female: yes Male: yes	740		Finland;United Kingdom;Italy;Sweden
1330	EUCTR2004-000817-20-GB (EUCTR)	08/11/2004	11/02/2005	A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.	A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.	Parkinson's Disease	Product Name: Istradefylline Product Code: KW-6002 INN or Proposed INN: Istradefylline Trade Name: Comtess Product Name: Comtess INN or Proposed INN: Entacapone	Kyowa Hakko U.K. Limited	NULL	Not Recruiting			Female: yes Male: yes	405	Phase 3	Spain;Lithuania;Austria;Latvia;Italy;United Kingdom
1331	NCT03091868 (ClinicalTrials.gov)	November 3, 2004	21/3/2017	Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics	A Double-blind, Randomised, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability and Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Carbidopa 100/25 mg or With a Single-dose of Levodopa/Carbidopa 100/25 mg Plus a Single-dose of Entacapone 200 mg	Parkinson Disease	Drug: Placebo oral capsule;Drug: Sinemet® 100/25;Drug: Comtan®;Drug: BIA 6-512 25 mg;Drug: BIA 6-512 100 mg	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	80	Phase 1	Portugal
1332	NCT00243971 (ClinicalTrials.gov)	November 2004	24/10/2005	A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease	A Phase 3, Randomized, Open-Label, Two-Arm, Parallel-Group, Multicenter, Multinational Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease	Parkinson's Disease	Drug: SPM 962	UCB Pharma	NULL	Completed	18 Years	N/A	Both		Phase 3	Germany
1333	NCT00296946 (ClinicalTrials.gov)	November 2004	23/2/2006	Ipratropium Spray for Drooling Saliva in Parkinson's Disease	Phase II Clinical Trial of Ipratropium Bromide Spray as a Treatment for Sialorrhea in Patients With Parkinson's Disease	Parkinson's Disease	Drug: ipratropium bromide (drug)	University Health Network, Toronto	Parkinson's Disease Foundation	Completed	30 Years	N/A	All	20	Phase 2	Canada
1334	NCT00199394 (ClinicalTrials.gov)	November 2004	12/9/2005	A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease	A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.	Parkinson's Disease	Drug: Istradefylline (KW-6002)	Kyowa Hakko Kirin UK, Ltd.	NULL	Completed	30 Years	N/A	Both	405	Phase 3	United Kingdom
1335	NCT01634360 (ClinicalTrials.gov)	November 2004	3/7/2012	Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations	A 48-month Open Label Multi-centered Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 in Patients With Parkinson's Disease With Wearing Off Motor Fluctuations and on Period Dyskinesias	Parkinson's Disease	Drug: Perampanel	Eisai Inc.	NULL	Terminated	N/A	N/A	All	185	Phase 2	NULL
1336	EUCTR2004-000817-20-LV (EUCTR)	22/10/2004	27/10/2004	A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.	A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.	Parkinson's Disease	Product Name: Istradefylline Product Code: KW-6002 INN or Proposed INN: Istradefylline Trade Name: Comtess Product Name: Comtess INN or Proposed INN: Entacapone	Kyowa Hakko U.K. Limited	NULL	Not Recruiting			Female: yes Male: yes	405		Spain;Italy;Latvia;Lithuania
1337	EUCTR2004-000361-35-IT (EUCTR)	22/10/2004	23/05/2005	A 12-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON'S DISEASE WITH WEARING OFF MOTOR FLUCTUATIONS AND ON PERIOD DYSKINESIAS.	A 12-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON'S DISEASE WITH WEARING OFF MOTOR FLUCTUATIONS AND ON PERIOD DYSKINESIAS.	Parkinson's disease. MedDRA version: 6.1;Level: PT;Classification code 10061536	Product Name: NA Product Code: E2007 Other descriptive name: NA	EISAI LTD UK	NULL	Not Recruiting			Female: yes Male: yes			Czech Republic;Italy
1338	EUCTR2004-000361-35-CZ (EUCTR)	18/10/2004	22/10/2004	A 48-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON’S DISEASE WITH WEARING OFF” MOTOR FLUCTUATIONS AND ON” PERIOD DYSKINESIAS.	A 48-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON’S DISEASE WITH WEARING OFF” MOTOR FLUCTUATIONS AND ON” PERIOD DYSKINESIAS.	Parkinson's Disease	Product Name: MARS Product Code: E2007 Other descriptive name: MARS Other descriptive name: MARS Other descriptive name: MARS	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	225		Czech Republic;Italy
1339	EUCTR2004-000148-26-ES (EUCTR)	13/10/2004	16/09/2004	A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A	A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A	Parkinson's Disease	Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol	Schwarz BioSciences Inc.	NULL	Not Recruiting			Female: yes Male: yes	360	Phase 3	Czech Republic;Hungary;Finland;Spain;Austria;Italy;Sweden
1340	EUCTR2004-000148-26-CZ (EUCTR)	12/10/2004	11/10/2004	A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A	A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A	Parkinson's Disease	Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol	Schwarz BioSciences Inc.	NULL	Not Recruiting			Female: yes Male: yes	360	Phase 3	Hungary;Finland;Czech Republic;Spain;Italy;Sweden
1341	NCT00105508 (ClinicalTrials.gov)	September 30, 2004	15/3/2005	Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia	A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia	Parkinson's Disease;Dyskinesia	Drug: Sarizotan;Drug: Placebo	EMD Serono	NULL	Completed	30 Years	N/A	All	506	Phase 3	United States
1342	EUCTR2004-000148-26-SE (EUCTR)	29/09/2004	05/07/2004	A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A	A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A	Parkinson's Disease	Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol	Schwarz BioSciences Inc.	NULL	Not Recruiting			Female: yes Male: yes	360	Phase 3	Hungary;Finland;Czech Republic;Spain;Italy;Sweden
1343	EUCTR2004-000185-12-FI (EUCTR)	21/09/2004	23/07/2004	A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PD	A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PD	Parkinson's disease MedDRA version: 7.0;Level: LLT;Classification code 10061536	Trade Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa	Orion Corporation, ORION PHARMA	NULL	Not Recruiting			Female: yes Male: yes	740		Finland;United Kingdom;Italy;Sweden
1344	EUCTR2004-000817-20-LT (EUCTR)	16/09/2004	07/01/2005	A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.	A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.	Parkinson's Disease	Product Name: Istradefylline Product Code: KW-6002 INN or Proposed INN: Istradefylline Trade Name: Comtess Product Name: Comtess INN or Proposed INN: Entacapone	Kyowa Hakko U.K. Limited	NULL	Not Recruiting			Female: yes Male: yes	405		Spain;Italy;Latvia;Lithuania
1345	EUCTR2004-003355-39-AT (EUCTR)	14/09/2004	08/10/2004	A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia.	A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia.	Dementia associated with Parkinson's disease	Trade Name: Aricept 5 mg-Filmtabletten Product Name: Aricept 5mg-Filmtabletten	Eisai Limited	NULL	Not Recruiting			Female: yes Male: yes	468		Austria
1346	NCT00296959 (ClinicalTrials.gov)	September 2004	23/2/2006	Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease	Anti-Dyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients With Parkinson's Disease and Levodopa-Induced Dyskinesias	Parkinson's Disease	Drug: topiramate (drug)	University Health Network, Toronto	NULL	Terminated	30 Years	75 Years	Both	20	Phase 2	Canada
1347	NCT00641186 (ClinicalTrials.gov)	September 2004	18/3/2008	Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)	A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's Disease	Parkinson Disease	Drug: sodium oxybate	Baylor College of Medicine	Jazz Pharmaceuticals	Completed	30 Years	75 Years	All	30	Phase 2	NULL
1348	NCT00099268 (ClinicalTrials.gov)	September 2004	10/12/2004	Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy	A Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy	Parkinson's Disease	Drug: Carbidopa/levodopa/entacapone;Drug: Immediate release carbidopa/levodopa	Novartis Pharmaceuticals	Orion Corporation, Orion Pharma	Completed	30 Years	70 Years	All	747	Phase 3	United States;Austria;Belgium;Canada;Finland;France;Germany;Greece;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom
1349	NCT00105521 (ClinicalTrials.gov)	September 2004	15/3/2005	Sarizotan HCl in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia	A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia	Parkinson's Disease;Dyskinesia	Drug: Sarizotan HC1	EMD Serono	NULL	Completed	30 Years	N/A	All	594	Phase 3	United States
1350	NCT00089622 (ClinicalTrials.gov)	August 4, 2004	6/8/2004	Lisuride Patch to Treat Parkinson's Disease	Transcutaneous Lisuride Therapy of Parkinson's Disease	Parkinson Disease	Drug: Intravenous Levodopa;Drug: Lisuride Transdermal System	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	40 Years	80 Years	All	40	Phase 2	United States
1351	NCT00501969 (ClinicalTrials.gov)	August 2004	16/7/2007	An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease	An Open-Label Extension to the Double-Blind SP515 (NCT00244387) Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease Who Are Not Well Controlled on L-Dopa	Advanced Stage Parkinson's Disease	Drug: Rotigotine	UCB Pharma	NULL	Completed	31 Years	N/A	All	395	Phase 3	Australia;Austria;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;New Zealand;Norway;Poland;South Africa;Spain;Sweden;United Kingdom
1352	EUCTR2004-000148-26-FI (EUCTR)	30/07/2004	28/06/2004	A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A	A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A	Parkinson's Disease	Product Name: Rotigotine Product Code: SPM 962 INN or Proposed INN: Rotigotine Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol	Schwarz BioSciences Inc.	NULL	Not Recruiting			Female: yes Male: yes	360	Phase 3	Czech Republic;Hungary;Finland;Spain;Italy;Sweden
1353	NCT00199420 (ClinicalTrials.gov)	July 2004	12/9/2005	A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa	A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.	Parkinson's Disease	Drug: Istradefylline (KW-6002)	Kyowa Kirin Pharmaceutical Development, Inc.	NULL	Completed	30 Years	N/A	Both	580	Phase 3	United States
1354	NCT00086294 (ClinicalTrials.gov)	June 25, 2004	29/6/2004	ACP-103 to Treat Parkinson's Disease	5HT2A/C Serotonin Blockade in Parkinson's Disease	Parkinson's Disease;Dyskinesias	Drug: Intravenous Levodopa;Drug: ACP-103	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	30 Years	80 Years	All	40	Phase 2	United States
1355	EUCTR2004-000148-26-IT (EUCTR)	14/06/2004	26/07/2007	A multi-center, multinational, phase 3, open-label extension trial to assess the safety of long term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinsons disease who are not well controlled on levodopa	A multi-center, multinational, phase 3, open-label extension trial to assess the safety of long term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinsons disease who are not well controlled on levodopa	Advanced stage Parkinson's Disease	INN or Proposed INN: rotigotine	SCHWARZ PHARMA	NULL	Not Recruiting			Female: yes Male: yes	360	Phase 3	Hungary;Finland;Czech Republic;Spain;Italy;Sweden
1356	NCT00203138 (ClinicalTrials.gov)	June 2004	13/9/2005	Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease	A Multicenter, Open-Label, Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline Mesylate in Patients With Parkinson's Disease	Parkinson's Disease	Drug: rasagiline mesylate	Teva Pharmaceutical Industries	NULL	Completed	35 Years	N/A	Both	306	Phase 3	United States
1357	NCT00199407 (ClinicalTrials.gov)	June 2004	12/9/2005	A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa	A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.	Parkinson's Disease	Drug: Istradefylline (KW-6002)	Kyowa Kirin Pharmaceutical Development, Inc.	NULL	Completed	30 Years	N/A	Both	230	Phase 3	United States
1358	NCT03091543 (ClinicalTrials.gov)	May 4, 2004	21/3/2017	Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics	A Double-blind, Randomised, Crossover, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 100/25 mg	Parkinson Disease	Drug: Madopar® HBS 125;Drug: Placebo;Drug: BIA 6-512 25 mg dose;Drug: BIA 6-512 50 mg dose;Drug: BIA 6-512 100 mg dose;Drug: BIA 6-512 200 mg dose	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	20	Phase 1	Portugal
1359	NCT01172379 (ClinicalTrials.gov)	May 2004	26/7/2010	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With Wearing Off Motor Fluctuations and On Period Dyskinesias	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With Wearing Off Motor Fluctuations and On Period Dyskinesias	Parkinson's Disease	Drug: E2007;Other: Placebo Comparator	Eisai Limited	NULL	Completed	30 Years	75 Years	Both	2	Phase 2	Czech Republic;France;Germany;Italy;Serbia;Spain
1360	NCT00139867 (ClinicalTrials.gov)	January 2004	29/8/2005	A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease	A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease	Parkinson's Disease	Drug: PARCOPA	UCB Pharma	NULL	Completed	18 Years	N/A	Both		Phase 3	United States
1361	NCT02231905 (ClinicalTrials.gov)	January 2004	3/9/2014	Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease	Open Label, Exploratory Clinical Trial to Assess the Safety, Tolerability and Effectiveness of a Switching From Talipexole to Pramipexole	Parkinson Disease	Drug: BI-Sifrol®	Boehringer Ingelheim	NULL	Completed	20 Years	N/A	Both	29	Phase 4	NULL
1362	NCT00363727 (ClinicalTrials.gov)	December 2003	7/8/2006	Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's	A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects.	Parkinson's Disease;Parkinson Disease;Dyskinesias	Drug: ropinirole controlled-release (REQUIP CR) for RLS	GlaxoSmithKline	NULL	Completed	30 Years	70 Years	All	209	Phase 3	United States
1363	NCT00111982 (ClinicalTrials.gov)	December 2003	27/5/2005	Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin	Multi-Center, Open-Label Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin (Protocol 20020168)	Parkinson's Disease	Biological: Liatermin	Amgen	Medtronic	Completed	35 Years	70 Years	Both	34	Phase 1/Phase 2	United States
1364	NCT01941732 (ClinicalTrials.gov)	November 2003	10/9/2013	Motor Response to Sildenafil in PD	Motor Response to Acute Challenge to Sildenafil in Parkinsons Disease	Parkinsons Disease;Erectile Dysfunction	Drug: Sildenafil	Bispebjerg Hospital	NULL	Completed	18 Years	80 Years	Male	8	Phase 4	Denmark
1365	NCT00234676 (ClinicalTrials.gov)	October 2003	5/10/2005	POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease	A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study for the Safety, Tolerability and Efficacy of Estrogen Replacement Therapy (Conjugated Equine Estrogens 0.625 mg Daily) in Post Menopausal Women With Parkinson's Disease	Parkinson's Disease	Drug: Premarin ®	The Parkinson Study Group	Wyeth is now a wholly owned subsidiary of Pfizer;Joseph and Rosalyn Newman Foundation	Completed	N/A	75 Years	Female	23	Phase 2	United States
1366	NCT00160576 (ClinicalTrials.gov)	July 2003	8/9/2005	Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias	A Therapeutic Exploratory, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Levetiracetam up to 4000 mg/Day (500mg Oral Tablets) on Levodopa Induced Dyskinesias in Adults With Idiopathic Parkinson's Disease	Idiopathic Parkinson Disease	Drug: Levetiracetam	UCB Pharma	NULL	Completed	30 Years	N/A	Both	30	Phase 2	NULL
1367	NCT00095810 (ClinicalTrials.gov)	July 2003	9/11/2004	Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease	An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease	Parkinson's Disease;Psychoses	Drug: aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	Otsuka America Pharmaceutical	Completed	50 Years	N/A	Both	50	Phase 4	United States
1368	NCT00228150 (ClinicalTrials.gov)	July 2003	26/9/2005	Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease	A Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Outpatients With Early Parkinson's Disease	Parkinson Disease	Drug: SR57667B	Sanofi	NULL	Completed	35 Years	N/A	Both	564	Phase 2	Austria;Canada;Denmark;France;Germany;Morocco;Netherlands;Portugal;South Africa;Spain;Sweden;Tunisia;United Kingdom
1369	NCT00058721 (ClinicalTrials.gov)	April 2003	11/4/2003	Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease	SPECT Evaluation of Nicotinic Cholinergic Receptors in Parkinson's Disease	Parkinson Disease	Drug: I-123-5-IA85380	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	60	N/A	United States
1370	NCT01327859 (ClinicalTrials.gov)	March 2003	30/3/2011	Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia	A 52-week, Multicentre Open Label Extension Study of the Safety Tolerability and Efficacy of Donepezil (Aricept) in Parkinson's Disease (PD) Patients With Dementia	Parkinson's Disease;Dementia	Drug: Prior Donepezil 5mg;Drug: Prior Donzepezil 10mg;Drug: Prior Placebo	Eisai Inc.	NULL	Completed	40 Years	N/A	Both	357	Phase 3	United Kingdom
1371	NCT00115427 (ClinicalTrials.gov)	March 2003	22/6/2005	Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease	Idiopathic Parkinson's Disease	Drug: Liatermin (r-metHuGDNF)	Amgen	NULL	Completed	35 Years	70 Years	Both		Phase 1	United States
1372	NCT00056524 (ClinicalTrials.gov)	February 2003	15/3/2003	Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)	An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.	Alzheimer's Disease;Stroke;Parkinson's Disease;Traumatic Brain Injury	Drug: AVP-923	Avanir Pharmaceuticals	NULL	Completed	18 Years	80 Years	Both	600	Phase 3	United States
1373	NCT00237263 (ClinicalTrials.gov)	February 2003	7/10/2005	An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States	An Extension Study to Phase IIb Dose-finding Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off	Parkinson's Disease	Drug: Entacapone	Novartis	NULL	Completed	20 Years	N/A	All	285	Phase 2	United States
1374	NCT00206687 (ClinicalTrials.gov)	January 2003	13/9/2005	STEPS Trial - Spheramine Safety and Efficacy Study	Study of the Safety, Tolerability and Efficacy of Spheramine Implanted Bilaterally Into the Postcommissural Putamen of Patients With Advanced Parkinson's Disease	Parkinson Disease	Biological: Spheramine (BAY86-5280);Procedure: Placebo	Bayer	Titan Pharmaceuticals	Terminated	30 Years	70 Years	Both	71	Phase 2	United States;Germany;Spain;Austria;France
1375	NCT02248207 (ClinicalTrials.gov)	January 2003	22/9/2014	Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease	Management of Parkinson's Disease Patients at Their First Visits in a Neurological Practice	Parkinson Disease	Drug: Pramipexole	Boehringer Ingelheim	NULL	Completed	N/A	N/A	Both	1293	N/A	NULL
1376	NCT00247247 (ClinicalTrials.gov)	December 2002	31/10/2005	Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.	Efficacy and Tolerability of Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing-Off Phenomenon	Parkinson's Disease	Drug: Comtess®	Orion Corporation, Orion Pharma	NULL	Completed	60 Years	N/A	Both	300	Phase 4	Germany
1377	NCT00209508 (ClinicalTrials.gov)	November 2002	13/9/2005	2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy.	Parkinson's Disease	Drug: GPI 1485	Eisai Inc.	Symphony Neuro Development Company	Completed	40 Years	80 Years	Both	200	Phase 2	NULL
1378	NCT00165815 (ClinicalTrials.gov)	August 2002	13/9/2005	The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia		Dementia With Parkinson's Disease	Drug: ARICEPT	Eisai Limited	NULL	Completed	40 Years	N/A	Both		Phase 3	Germany;Ireland
1379	NCT00599196 (ClinicalTrials.gov)	August 2002	24/12/2007	An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease	An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease	Early Stage Parkinson's Disease	Drug: Rotigotine	UCB Pharma	NULL	Completed	30 Years	N/A	All	381	Phase 3	Australia;Austria;Belgium;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;South Africa;Spain;Sweden;Switzerland;United Kingdom
1380	NCT00594386 (ClinicalTrials.gov)	August 2002	24/12/2007	An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease	An Open-Label Extension to the Double-Blind SP650 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease.	Parkinson's Disease	Drug: Rotigotine	UCB Pharma	NULL	Completed	31 Years	N/A	All	258	Phase 3	United States;Canada
1381	NCT00314288 (ClinicalTrials.gov)	July 2002	12/4/2006	Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia	A Multicenter, Multinational, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Investigate the Anti-dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia	Parkinson's Disease;Dyskinesia	Drug: Sarizotan HCl	EMD Serono	NULL	Completed	30 Years	N/A	All	360	Phase 2	United States;Belgium;Bulgaria;Canada;France;Germany;Hungary;Portugal;Romania;South Africa;United Kingdom
1382	NCT00594165 (ClinicalTrials.gov)	June 2002	24/12/2007	An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.	An Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease.	Early-Stage Parkinson's Disease	Drug: Rotigotine	UCB Pharma	NULL	Completed	31 Years	N/A	All	217	Phase 3	United States;Canada
1383	NCT00040209 (ClinicalTrials.gov)	June 2002	21/6/2002	JP-1730 to Treat Parkinson's Disease	Alpha-2 Adrenergic Antagonist Treatment of Parkinson's Disease	Parkinson Disease	Drug: JP 1730;Drug: IV Levodopa;Drug: IV Apomorphine	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	30	Phase 2	United States
1384	NCT01044992 (ClinicalTrials.gov)	May 2002	6/1/2010	Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study	Motor Activation in Patients With Multi Systemic Atrophy and Comparison With Parkinson Disease and Dopaminergic Challenge	Multisystemic Atrophy	Radiation: H215O PET;Drug: Levodopa	University Hospital, Toulouse	NULL	Completed	40 Years	75 Years	Both	38	N/A	France
1385	NCT00650104 (ClinicalTrials.gov)	May 2002	27/3/2008	Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164	101648/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients With Parkinson's Disease Who Completed the Previous Ropinirole CR Studies 167 or 164	Parkinson Disease	Drug: Ropinirole XL (formerly CR)	GlaxoSmithKline	NULL	Completed	30 Years	N/A	All	76	Phase 3	United States;Belgium;France;Netherlands;Norway
1386	NCT00203164 (ClinicalTrials.gov)	May 2002	13/9/2005	Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients	A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy	Parkinson's Disease	Drug: rasagiline mesylate	Teva Pharmaceutical Industries	NULL	Completed	30 Years	N/A	Both	254	Phase 3	United States
1387	NCT00024622 (ClinicalTrials.gov)	March 15, 2002	23/9/2001	PET Scanning in Parkinson s Disease	Positron Emission Tomography (PET) Scanning in Dopamine Disorders: Parkinson's Disease and Schizophrenia	Schizophrenia;Parkinson's Disease	Drug: 18F-Fluoro-L-dopa;Drug: O-15 Water	National Institute of Mental Health (NIMH)	NULL	Recruiting	18 Years	90 Years	All	580		United States
1388	NCT00040404 (ClinicalTrials.gov)	March 2002	26/6/2002	Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's Disease	Parkinson Disease	Drug: CEP-1347 10mg;Drug: CEP1347 25mg;Drug: CEP-1347 50mg;Other: Placebo Comparator	Cephalon	H. Lundbeck A/S;The Parkinson Study Group	Terminated	30 Years	N/A	Both	806	Phase 2/Phase 3	United States;Canada;Puerto Rico
1389	NCT00030979 (ClinicalTrials.gov)	February 2002	15/2/2002	Donepezil to Treat Dementia in Parkinson's Disease	Donepezil for Dementia in Parkinson's Disease: A Randomized, Double Blinded Placebo Controlled Crossover Trial	Parkinson Disease	Drug: Donepezil	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	28	Phase 4	United States
1390	NCT00407212 (ClinicalTrials.gov)	January 2002	30/11/2006	A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging, Efficacy and Safety Study of Three Doses of TCH346 (1mg, 5mg and 20mg Daily) in Patients With Early Parkinson's Disease	Parkinson's Disease	Drug: TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)	Novartis	NULL	Completed	30 Years	80 Years	Both	301	Phase 1/Phase 2	United States;Brazil;Canada;France;Germany;Italy;Netherlands;Portugal;United Kingdom
1391	NCT00036218 (ClinicalTrials.gov)	December 2001	8/5/2002	Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.	A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease.	Parkinson Disease	Drug: sumanirole;Drug: ropinirole	Pfizer	NULL	Completed	30 Years	N/A	Both	600	Phase 3	United States;Argentina;Mexico;Puerto Rico
1392	NCT00203177 (ClinicalTrials.gov)	October 2001	13/9/2005	Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.	A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy.	Parkinson's Disease	Drug: rasagiline mesylate;Drug: rasagiline mesylate 1.0 mg	Teva Pharmaceutical Industries	NULL	Completed	30 Years	N/A	Both	254	Phase 3	United States;Canada
1393	NCT02772627 (ClinicalTrials.gov)	September 2001	12/5/2016	Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202	A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202 in Healthy Volunteers.	Parkinson's Disease	Drug: Nebicapone;Drug: Placebo	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	Both	22	Phase 1	Portugal
1394	NCT00013624 (ClinicalTrials.gov)	March 2001	24/3/2001	Riluzole to Treat Parkinson's Disease	Effect of Antiglutamatergic Treatment in Parkinson's Disease	Parkinson's Disease	Drug: IV Levodopa	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	20	Phase 2	United States
1395	NCT00145171 (ClinicalTrials.gov)	February 2001	2/9/2005	A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.	Study of Orthostatic Changes Upon Apomorphine Dose Initiation in Late Stage Parkinson’s Disease Patients. A Dose Escalation Study With a Double-Blind Placebo-Controlled Efficacy Determination at 4 Mg.	Parkinson Disease	Drug: apomorphine HCl injection	Mylan Bertek Pharmaceuticals	NULL	Completed	18 Years	N/A	Both	56	Phase 3	NULL
1396	NCT00006337 (ClinicalTrials.gov)	October 2000	4/10/2000	KW-6002 to Treat Parkinson's Disease	Adenosine A2A Blockade With KW-6002 in Parkinson's Disease	Parkinson's Disease	Drug: KW-6002;Drug: IV Levodopa	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	16	Phase 2	United States
1397	NCT00203125 (ClinicalTrials.gov)	October 2000	13/9/2005	A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.	Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133)	Parkinson's Disease	Drug: rasagiline mesylate;Other: tyramine	Teva Pharmaceutical Industries	NULL	Completed	N/A	N/A	Both	55	Phase 3	United States
1398	NCT02763800 (ClinicalTrials.gov)	September 2000	4/5/2016	Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202	Double-Blind, Randomised, Placebo-Controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202, in Young Healthy Volunteers	Parkinson's Disease	Drug: BIA 3-202;Drug: Placebo	Bial - Portela C S.A.	NULL	Completed	18 Years	35 Years	Male	33	Phase 1	United Kingdom
1399	NCT00070928 (ClinicalTrials.gov)	September 2000	9/10/2003	Valerian to Improve Sleep in Patients With Parkinson's Disease	Polysomnographic Assessment of Alternative Treatments for Sleep Disturbance in Parkinson's Disease	Insomnia;Parkinson's Disease	Drug: valerian	National Center for Complementary and Integrative Health (NCCIH)	NULL	Completed	30 Years	80 Years	Both	80	Phase 2	United States
1400	NCT00036205 (ClinicalTrials.gov)	August 2000	8/5/2002	Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease	Open-Label, Long Term, Flexible Dose Study Of Safety, Tolerability, And Therapeutic Response In Patients With Parkinson's Disease.	Parkinson Disease	Drug: sumanirole	Pfizer	NULL	Terminated	30 Years	N/A	Both	984	Phase 3	United States;Argentina;Colombia;Puerto Rico
1401	NCT00203034 (ClinicalTrials.gov)	May 2000	13/9/2005	Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations	A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations	Parkinson's Disease	Drug: rasagiline mesylate;Drug: 1.0 mg rasagiline mesylate;Other: Placebo	Teva Pharmaceutical Industries	NULL	Completed	30 Years	N/A	Both	472	Phase 3	United States
1402	NCT02763787 (ClinicalTrials.gov)	April 2000	4/5/2016	Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202	A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Single Doses of BIA 3-202 in Healthy Volunteers.	Parkinson's Disease	Drug: BIA 3-202;Drug: Placebo	Bial - Portela C S.A.	NULL	Completed	18 Years	35 Years	Male	71	Phase 1	United Kingdom
1403	NCT00761436 (ClinicalTrials.gov)	February 29, 2000	26/9/2008	Pilot Study of Safety and Efficacy of Spheramine	Stereotactic Intrastriatal Implantation of Spheramine in Advanced Parkinson's Disease Patients: A Pilot Study of Tolerability and Efficacy.	Parkinson''s Disease	Biological: Spheramine (BAY86-5280)	Bayer	Titan Pharmaceuticals	Terminated	40 Years	70 Years	All	6	Phase 2	United States
1404	NCT02172573 (ClinicalTrials.gov)	April 1999	20/6/2014	Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease	A Double-blind, Placebo-controlled, Randomised, Multicenter Trial to Compare the Safety and Efficacy of Oral Administration of Pramipexole up to 4.5mg and Bromocriptine up to 22.5mg Combined With L-dopa in Advanced Parkinson's Disease	Parkinson Disease	Drug: Pramipexole;Drug: Bromocriptine;Drug: Placebo pramipexole;Drug: Placebo bromocriptine	Boehringer Ingelheim	NULL	Completed	20 Years	N/A	Both	315	Phase 3	NULL
1405	NCT02177357 (ClinicalTrials.gov)	November 1998	24/6/2014	Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients	Pramipexole: Efficacy, Safety and Tolerability Study in Untreated and Levodopa-Treated Parkinson's Disease Patients, a Multinational Study	Parkinson Disease	Drug: Pramipexole;Drug: Placebo	Boehringer Ingelheim	NULL	Completed	30 Years	N/A	Both	150	Phase 3	NULL
1406	NCT02248220 (ClinicalTrials.gov)	October 1998	22/9/2014	Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease	Observation of the Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease	Parkinson Disease	Drug: Pramipexole	Boehringer Ingelheim	NULL	Completed	N/A	N/A	Both	657	N/A	NULL
1407	NCT02233023 (ClinicalTrials.gov)	June 1998	4/9/2014	Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease	Matched Pair, Assessor Blinded, Open Label Clinical Trial to Assess the Ophthalmologic Safety of Long Term Oral Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease	Parkinson Disease	Drug: Pramipexole;Drug: Bromocriptine and other dopamine agonists	Boehringer Ingelheim	NULL	Completed	N/A	N/A	Both	705	Phase 4	NULL
1408	NCT00203060 (ClinicalTrials.gov)	July 1997	13/9/2005	Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa	A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial For The Efficacy, Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinson's Disease (PD) Patients Not Treated With Levodopa	Parkinson's Disease	Drug: Rasagiline Mesylate;Drug: placebo	Teva Neuroscience, Inc.	NULL	Completed	35 Years	N/A	Both	404	Phase 3	United States
1409	NCT00001258 (ClinicalTrials.gov)	November 26, 1993	3/11/1999	Studies of Frontal Lobe Brain Functioning in Schizophrenia	Studies of Frontal Lobe Function During Cognitive Stimulation as Measured With Oxygen-15 Water Positron Emission Tomography in Normal Subjects and Patients With Neuropsychiatric Disorders	Healthy Subjects;Schizophrenia;Parkinson Disease	Drug: Oxygen-15 Water	National Institute of Mental Health (NIMH)	NULL	Completed	18 Years	90 Years	All	1039		United States
1410	EUCTR2008-005492-94-DE (EUCTR)		11/08/2009	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients	Idiopathic Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide Product Name: Safinamide Product Code: NW-1015 INN or Proposed INN: safinamide	Newron Pharmaceuticals	NULL	Not Recruiting			Female: yes Male: yes	1285		United States;Portugal;Taiwan;Estonia;Slovakia;Spain;Thailand;Chile;Colombia;Italy;India;France;Malaysia;Peru;South Africa;Netherlands;Korea, Republic of;Finland;Austria;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Croatia;Bulgaria;Germany;New Zealand
1411	EUCTR2006-006907-35-DE (EUCTR)		30/01/2007	Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVER	Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVER	Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro 2mg/24h transdermal patch Product Code: ND1587 INN or Proposed INN: Rotigotine Trade Name: Neupro 4mg/24h transdermal patch Product Code: ND1589 INN or Proposed INN: Rotigotine Trade Name: Neupro 6mg/24h transdermal patch Product Code: ND1590 INN or Proposed INN: Rotigotine Trade Name: Neupro 8mg/24h transdermal patch Product Code: ND1702 INN or Proposed INN: Rotigotine	Schwarz Biosciences GmbH	NULL	Not Recruiting			Female: yes Male: yes	270	Phase 3	Hungary;Finland;United Kingdom;Germany;Spain;Italy;Austria
1412	EUCTR2009-014341-84-DE (EUCTR)		07/10/2009	Non-GI: A multi site, open-label, interventional Pilot study assessing the switch from oral treatment to rotigotine transdermal patch (Neupro) in Parkinson's disease patients with identified gastrointestinal symptoms.	Non-GI: A multi site, open-label, interventional Pilot study assessing the switch from oral treatment to rotigotine transdermal patch (Neupro) in Parkinson's disease patients with identified gastrointestinal symptoms.	idiopathic Parkinson's disease MedDRA version: 12.0;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Neupro 2 mg/24 h transdermal patch Product Name: Rotigotine transdermal patch 2mg/24h(10cm2) INN or Proposed INN: Rotigotine Trade Name: Neupro 4 mg/24 h transdermal patch Product Name: Rotigotine transdermal patch 4mg/24h (20cm2) INN or Proposed INN: Rotigotine Trade Name: Neupro 6 mg/24 h transdermal patch Product Name: Rotigotine transdermal patch 6mg/24h (30cm2) INN or Proposed INN: Rotigotine Trade Name: Neupro 8 mg/24 h transdermal patch Product Name: Rotigotine transdermal patch 8mg/24h (40cm2) INN or Proposed INN: rotigotine	Schwarz Pharma Deutschland GmbH, UCB Group	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Germany
1413	EUCTR2010-022200-46-DE (EUCTR)		13/04/2011	Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®) in patients with Pakinson’s disease.	Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover, proof of concept study in patients with Parkinson’s disease and end-of-dose motor fluctuations. - PARPOC	Parkinson's disease MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ODM-101 Product Code: 75 INN or Proposed INN: LEVODOPA Other descriptive name: na INN or Proposed INN: CARBIDOPA Other descriptive name: na INN or Proposed INN: ENTACAPONE Other descriptive name: na Product Name: ODM-101 Product Code: 100 INN or Proposed INN: LEVODOPA Other descriptive name: na INN or Proposed INN: CARBIDOPA Other descriptive name: na INN or Proposed INN: ENTACAPONE Other descriptive name: na Product Name: ODM-101 Product Code: 125 INN or Proposed INN: LEVODOPA Other descriptive name: na INN or Proposed INN: CARBIDOPA Other descriptive name: na	Orion Corporation	NULL	Not Recruiting			Female: yes Male: yes	100		Finland;Lithuania;Latvia;Germany
1414	EUCTR2011-002073-30-DE (EUCTR)		20/09/2011	Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	12-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease	L-dopa induced dyskinesias in patients with Parkinson’s disease MedDRA version: 14.1;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056 Product Name: AFQ056 Product Code: AFQ056	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	63		France;United States;Hungary;Canada;Spain;Germany;Italy
1415	EUCTR2006-001755-36-DE (EUCTR)		15/08/2006	Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients - SENSE	Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients - SENSE	Parkinson’s disease MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease	Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone Trade Name: Stalevo Product Name: Stalevo INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa INN or Proposed INN: Entacapone	Orion Corporation Orion Pharma	NULL	Not Recruiting			Female: yes Male: yes	100		United Kingdom;Germany;Sweden
1416	EUCTR2020-006067-28-BE (EUCTR)		18/11/2021	A study to investigate if CST-103 and CST-107 has an effect on the brain in patients with progressive disease of the nervous system.	A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 co-administered with CST-107 on the Central Nervous System in Subjects with Neurodegenerative Disorders - PD Effects of CST-103/CST-107 on CNS in Neurodegenerative Disorders	Patients with Parkinson’s Disease with REM sleep behaviour disorder, Mild Cognitive Impairment, Dementia with Lewy Bodies and Parkinson’s Disease Dementia. MedDRA version: 24.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 21.1;Classification code 10009846;Term: Cognitive impairment;Classification code 10067889;Term: Dementia with Lewy bodies;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Spiropent Product Name: Spiropent Product Code: CST-103 INN or Proposed INN: Clenbuterol Hydrochloride Product Name: Nadolol Product Code: CST-107 INN or Proposed INN: Nadolol	CuraSen Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	Belgium;Australia;United Kingdom;New Zealand
1417	JPRN-JapicCTI-111699		22/11/2011	Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease	An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects with Advanced Parkinson's Disease	Advanced Parkinson's disease	Intervention name : ABT-SLV187 Dosage And administration of the intervention : Usually 2-6 ml/hour (40-120 mg levodopa/hour), dose will be individually optimized for each subject based on the subject's symptoms Control intervention name : null	Abbott Japan Co., Ltd.	NULL		30		BOTH	8	Phase 2	NULL

先頭へ